Conditions: Carcinoma, Non-Small-Cell Lung
Keywords: CC-486 Azacitidine Oral azacitidine Methyltransferase inhibitor Hypomethylation Hypomethylating agent Epigenetic MK-3475 Pembrolizumab Keytruda PD-1 PD-L1 ImmunotherapyAdvanced non-small cell lung cancer Metastatic non-small cell lung cancer Non-small cell lung cancer NSCLC Merck Pembrolizumab (Keynote-117)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 100
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether the combination therapy of CC-486 (oral azacitidine) and pembrolizumab provides improved patient outcomes compared to pembrolizumab alone in patients with previously treated locally advanced or metastatic non-small cell lung cancer.

Detailed description:
This is a Phase 2, multicenter, international, randomized, placebo controlled, double-blind study to assess the safety and efficacy of CC-486 and pembrolizumab combination therapy versus pembrolizumab plus placebo in previously treated patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had received one prior platinum-based chemotherapy regimen.

Approximately 100 participants will be randomized 1:1 to receive CC-486 plus pembrolizumab or placebo plus pembrolizumab as follows:

* Arm A: CC-486 300 mg administered orally daily on days 1 to 14 plus pembrolizumab 200 mg administered as a 30-minute IV infusion on day 1 of a 21-day cycle
* Arm B: Placebo administered orally daily on days 1-14 plus pembrolizumab 200 mg administered as a 30-minute IV infusion on day 1 of a 21-day cycle

Randomization will be stratified between treatment arms by histology (non-squamous versus squamous).

The decision to discontinue a patient, which will not be delayed or refused by the Sponsor, remains the responsibility of the treating physician. However, prior to discontinuing a patient, the Investigator may contact the medical monitor and forward appropriate supporting documents for review and discussion.

In the follow-up phase, anticancer treatment administered following the last dose of investigational product (IP) and survival will be followed every 8 weeks until death, withdrawal of consent, or lost-to follow-up, whichever occurs first, or the End of Trial.

The study will be conducted in compliance with the International Council on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good Clinical Practice (GCP) and applicable regulatory requirements.

Primary analysis will be conducted when 70 Progression Free Survival (PFS) events have occurred.

Arms:
arm 1: In the experimental arm, participants will receive a combination of two investigational drugs, CC-486 and pembrolizumab every 21-days. arm 2: In this control arm, participants will receive pembrolizumab as a 30 minute IV infusion on day 1 of each 21-day cycle and placebo will be administered by mouth daily on days 1 to 14 of each 21 day cycle. Placebo will also be administered in order to allow blinding of the study.

Interventions: intervention 1: CC-486 intervention 2: Pembrolizumab intervention 3: Placebo
Intervention descriptions: intervention 1: CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle. intervention 2: Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle. intervention 3: Placebo will be administered orally daily on days 1-14 of each 21-day cycle.

Protocol document:
SAP_002.pdf: 
 
 
 
 
 
Protocol Title: A Phase 2 Multicenter, Randomized, 
Placebo Controlled, Double-Blind Study To Assess 
The Safety And Efficacy Of CC-486 (Oral Azacitidine) 
In Combination With Pembrolizumab (Mk-3475) 
Versus Pembrolizumab Plus Placebo In Subjects 
With Previously Treated Locally Advanced Or 
Metastatic Non-Small Cell Lung Cancer 
 
NCT Number:  NCT02546986 
Final Statistical Analysis Plan:  28 June 2017 


',6&/2685(
5('$&7('67$7,67,&$/$1$/<6,63/$1
&&16&/
$3+$6(08/7,&(17(55$1'20,=('3/$&(%2&21752//(''28%/(
%/,1'678'<72$66(667+(6$)(7<$1'()),&$&<2)&&25$/
$=$&,7,',1(,1&20%,1$7,21:,7+3(0%52/,=80$%0.9(5686
3(0%52/,=80$%3/863/$&(%2,168%-(&76:,7+35(9,286/<75($7('
/2&$//<$'9$1&('250(7$67$7,&12160$//&(///81*&$1&(5
㻌
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW\RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG

&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFDOWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH/DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHUKDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RUUHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV

7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFHUWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HOJHQH¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLSOHV

x
5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQLQJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x
$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGXDOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x
$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLRQDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQIRUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOFRPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\VHV
x
&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFWOLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNVLQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x
,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFWHGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQVSUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVSURWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQH¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODELOLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFDOWULDOVFOLQLFDOWULDOVGDWDVKDULQJ


&(/*(1(35235,(7$5<,1)250$7,21
(
5686
5686
5($7('
5($7('
&$1&(5
&$1&(5
OGQRWEHVKD
OGQRWEHVK
HDUFKHUVDQG
HDUFKHUVDQ
GUHJXO
GUHJXODWLRQ
DWLR
OHJDORUF
JDORUFRQ
RQ
WHGWRFHUWDL
WHGWRFHU
FHUWDLQLQIRU
HUWDLQLQIRU
WHFW&HOJHQH
WHFW&HOJHQ
QJSULQFLSOH
QJSULQFLSOH
JUH\
JUH\ VSDFH
VSDFH
HQWLIL
HQWLILFDWLRQ
FDWL
QWDLQFRQILGH
DLQFRQILG
RQWDLQLGHQ
RQWDLQLGHQ
\DOVRPD\
\DOVRPD\
WKHVLVJHQHU
KHVLVJHQH
HVHDWWDFKPH
HVHDWWDFKP
RG\RIWKHU
RG\RIWKH
O
ERXW&HOJHQ
ERXW&HOJHQ
RIWKDWLQIRU
IWKDWLQIR
LRQDERXWR
LRQDERXWR
PDWLRQDERXW
PDWLRQDERXW
IRXQGDWKWWS
RXQGDWKWWS


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
1
STATISTICAL ANALYSIS PLAN
A PHASE 2 MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED, DOUBLE-
BLIND STUDY TO ASSESS THE SAFETY AND EFFICACY OF CC-486 (ORAL 
AZACITIDINE) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) VERSUS 
PEMBROLIZUMAB PLUS PLACEBO IN SUBJECTS WITH PREVIOUSLY TREATED 
LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
STUDY DRUG:
CC-486
PROTOCOL NUMBER:
CC-486-NSCL-001
DATE FINAL:
28 June 2017
Prepared by:
on behalf of
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
CONFIDENTIAL
The information contained in this document is regarded as confidential 
and, except to the extent necessary to obtain informed consent, may not be 
disclosed to another party unless such disclosure is required by law or 
regulations.  Persons to whom the information is disclosed must be 
informed that the information is confidential and may not be further 
disclosed by them.
&(/*(1(35235,(7$5<,1)250$7,21
S 
TED 
CER
ER
y:
n behalf o
n behalf of
elelgene Cor
gene C
86 Mo
6 Mo
S
The info
The info
and, ex
nd, ex
d
1(
1(
(/
(/
(7


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
2
TABLE OF CONTENTS
SIGNATURE PAGE...................................................................................................................6
1.
LIST OF ABBREVIATIONS...................................................................................7
2.
INTRODUCTION....................................................................................................9
3.
STUDY OBJECTIVES...........................................................................................10
3.1.
Primary Objective...................................................................................................10
3.2.
Secondary Objectives .............................................................................................10
3.3.
Exploratory Objectives ...........................................................................................10
4.
INVESTIGATIONAL PLAN .................................................................................11
4.1.
Overall Study Design and Plan ...............................................................................11
4.2.
Study Endpoints .....................................................................................................12
4.2.1.
Primary Efficacy Endpoint......................................................................................12
4.2.2.
Secondary Efficacy Endpoints ................................................................................12
4.2.3.
Exploratory Efficacy Endpoints ..............................................................................12
4.3.
Stratification, Randomization, and Blinding............................................................12
4.4.
Sample Size Determination.....................................................................................13
5.
GENERAL STATISTICAL CONSIDERATIONS .................................................14
5.1.
Reporting Conventions ...........................................................................................14
5.2.
Calculation of Treatment Start Dates, Cycles, and Treatment End date ...................15
5.3.
Analysis Populations ..............................................................................................15
5.3.1.
Intent-to-Treat Population/Full Analysis Set ...........................................................15
5.3.2.
Safety Population....................................................................................................16
5.3.3.
Efficacy Evaluable Population................................................................................16
5.3.4.
PK Population ........................................................................................................16
5.3.5.
Biomarker Population.............................................................................................16
6.
SUBJECT DISPOSITION......................................................................................17
7.
PROTOCOL DEVIATIONS/VIOLATIONS ..........................................................19
8.
DEMOGRAPHICS AND BASELINE CHARACTERISTICS................................20
8.1.
Demographics.........................................................................................................20
8.2.
Baseline Characteristics..........................................................................................20
8.3.
Cancer History and Baseline Lesion Status.............................................................20
8.4.
Medical History......................................................................................................21
&(/*(1
m
1(35235,(7$5<,1)250$7,21
10
10
........10
10
............
............10
1
..............
.............
.............
.........
.............
.....
..............
..........
.............
...........
....
.............
........
..............
..........
..........
.............
DERATION
ERATIO
..............
.............
rt Dates, C
rt Dates, C
..............
...........
ati
ation/Full
on/Full
n............
..........
aluab
alu
le Pop
le P
ulatatioion ......
arker Pop
arker Pop
SUBJECT 
SUBJECT
PROTO
PROT
DE
DE
8.1.
.1.
2


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
3
8.5.
Prior Therapy..........................................................................................................21
8.5.1.
Prior Anti-Cancer Therapy......................................................................................21
8.6.
Prior and Concomitant Medications........................................................................21
8.6.1.
Prior Medications ...................................................................................................21
8.6.2.
Concomitant Medications .......................................................................................21
9.
STUDY TREATMENTS AND EXTENT OF EXPOSURE....................................23
9.1.
Treatment Duration.................................................................................................23
9.2.
Cumulative Dose ....................................................................................................23
9.3.
Dose Intensity.........................................................................................................23
9.4.
Relative Dose Intensity...........................................................................................24
9.5.
Dose Reduction/Interruption...................................................................................24
10.
EFFICACY ANALYSIS ........................................................................................25
10.1.
Multiplicity.............................................................................................................25
10.2.
Analysis of Primary Efficacy Endpoint...................................................................25
10.3.
Analyses of Secondary Efficacy Endpoints.............................................................27
10.3.1.
Overall Survival (OS).............................................................................................27
10.3.2.
Overall Response Rate (ORR) ................................................................................28
10.3.3.
Disease Control Rate (DCR)...................................................................................28
10.3.4.
Time to response.....................................................................................................28
10.3.5.
Duration of response...............................................................................................28
10.4.
Analyses of Exploratory Efficacy Endpoint ............................................................29
10.5.
Assessing Study Center Effect and Treatment-by-Center Interaction.......................29
11.
SAFETY ANALYSIS ............................................................................................30
11.1.
Adverse Events.......................................................................................................30
11.2.
Adverse Events of Special Interest..........................................................................31
11.3.
Clinical Laboratory Evaluations..............................................................................32
11.3.1.
Hematology............................................................................................................32
11.3.2.
Clinical Chemistry..................................................................................................33
11.4.
Vital Sign Measurements........................................................................................33
11.5.
Physical Examination .............................................................................................33
11.6.
Electrocardiograms.................................................................................................33
11.7.
ECOG Performance Status......................................................................................34
11.8.
Pregnancy test ........................................................................................................34
&(/*(1(35235,(7$5<,1)250$7,21
3
......23
.2
..........
.... 23
2
..............
...........
..............
............
.............
.............
..............
............
.............
.............
.............
.....
..............
...........
.............
.............
.............
............
..............
..........
...........
..... ....
.............
....
ory Efficacy
Efficacy
y
Center Effe
enter Effe
ALYSIS
LYSI
Events
vents......
rse Events 
rse Events 
Clinical Lab
linical Lab
Hem
Hemato
ato
2.2.
Clin
Cli
1.4.
1.4.
11.5.
1.5.


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
12.
PHARMACOKINETIC ANALYSES.....................................................................35
12.1.
Plasma concentrations.............................................................................................35
12.2.
PK Parameter..........................................................................................................36
12.3.
PK Analyses...........................................................................................................37
13.
BIOMARKER ANALYSES...................................................................................38
14.
INTERIM ANALYSIS...........................................................................................39
14.1.
General Information................................................................................................39
15.
CHANGES TO THE STATISTICAL ANALYSES SECTION OF THE 
PROTOCOL...........................................................................................................40
16.
REFERENCES.......................................................................................................41
17.
APPENDICES........................................................................................................42
17.1.
Study Schematic .....................................................................................................42
17.2.
Table of Events.......................................................................................................43
17.3.
Handling of Dates...................................................................................................48
17.3.1.
Calculation Using Dates .........................................................................................48
17.4.
Date Imputation Guideline......................................................................................49
17.4.1.
Impute Missing Adverse Events/ Prior or Concomitant Medications.......................49
17.4.1.
Adverse Events.......................................................................................................50
17.4.2.
Prior/Concomitant Medications/Procedures ............................................................50
17.4.3.
Medical History......................................................................................................51
17.4.4.
Tumor Response Visit Window ..............................................................................52
&(/*(1(35235,(7$5<,1)250$7,21
9
.......39
3
..............
............ 4
.............
.......
.............
.............
..............
.......
.............
.......
...........
..
..
..............
........
...............
.......
or Conc
or Concomi
om
..............
............
/Procedure
Procedure
..............
.............
Window
Window .


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
LIST OF TABLES
Table 1:
Abbreviations and Specialist Terms..........................................................................7
Table 2:
Hypothetical Power and Resulting Two-sided 90% CI of Hazard Ratio ..................13
Table 3:
Censoring Rules for PFS.........................................................................................26
&(/*(1(35235,(7$5<,1)250$7,21


0$7


235
( 35


1




CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
1.
LIST OF ABBREVIATIONS
Table 1:
Abbreviations and Specialist Terms
ALT
Alanine aminotransferase (SGPT)
ANC
Absolute neutrophil count
ANOVA
Analysis of variance
ANCOVA
Analysis of covariance
AST
Aspartate aminotransferase (SGOT)
AUC
Area under the curve
BLQ
Below the limit of quantitation
CI
Confidence interval
CMH
Cochran-Mantel-Haenszel
CSR
Clinical study report
CR
Complete response
CRF
Case report form
CT
Computerized tomography
CTCAE
Common Terminology Criteria for Adverse Events
DCR
Disease control rate
DMC
Data Monitoring Committee
ECOG
Eastern Cooperative Oncology Group
ECI
Events of clinical interest
EE
Efficacy evaluable
EOS
End of study
Hgb
Hemoglobin
HR
Hazard ratio
ir
Immune-related
irDCR
Immune-related Disease control rate
irPFS
Immune-related Progression-free survival
&(/*(1(35235,(7$5<,1)250$7,21
hy
hy
ogy Criteria 
ogy Crite
rate
rate
itoring Com
itoring C
rn Cooperat
rn Cooper
Events of cl
ents of cl
Efficac
Effic
En
En
R


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
irORR
Immune-related Overall response rate
irRECIST
Immune-related Response Evaluation Criteria in Solid Tumors
IP
Investigational product
ITT
Intent-to-treat
IV
Intravenous
LDH
Lactic dehydrogenase
MRI
Magnetic resonance imaging
NA
Not applicable
ORR
Overall response rate
OS
Overall survival
PD
Progressive disease
PD-LI
Programmed death-ligand 1
PFS
Progression-free survival
PK
Pharmacokinetic
PS
Performance Status
PR
Partial response
RECIST
Response Evaluation Criteria in Solid Tumors
RMP
Risk Management Plan
SAP
Statistical Analysis Plan
SD
Stable disease
STDEV
Standard deviation
SE
Standard error 
SGOT
Serum glutamic oxaloacetic transaminase (AST)
SGPT
Serum glutamic pyruvic transaminase (ALT)
TIL
Tumor-infiltrating lymphocytes
TTP
Time to progression
ULN
Upper limit of normal
US
United States
ria in Solid T
ia in Solid T
n
is Plan
Plan
e
d deviation
deviation
ndard error
ndard err
Serum glu
Serum gl
Seru
Seru
ULN
UL


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
2.
INTRODUCTION
This statistical analysis plan (SAP) describes the analyses and data presentations for Celgene’s 
protocol CC-486-NSCL-001 “A PHASE 2 MULTICENTER, RANDOMIZED, PLACEBO 
CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS THE SAFETY AND EFFICACY OF 
CC-486 (ORAL AZACITIDINE) IN COMBINATION WITH PEMBROLIZUMAB (MK-3475) 
VERSUS PEMBROLIZUMAB PLUS PLACEBO IN SUBJECTS WITH PREVIOUSLY 
TREATED LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG 
CANCER” which was issued on 15 May 2015 and amended on 14 December 2015. It contains 
definitions of analysis populations, derived variables and statistical methods for the analysis of 
efficacy and safety.
These analyses include 3 Data Monitoring Committee (DMC) interim analyses and one final 
analysis. Throughout this SAP, the treatment arms will be referred to as “CC-486 plus 
pembrolizumab” and “pembrolizumab plus placebo”. The purpose of the SAP is to ensure the 
credibility of the study findings by pre-specifying the statistical approaches to the analysis of 
study data prior to database lock and any data analysis for the final analysis. This SAP is 
developed after the finalization of the protocol and will be finalized and signed prior to the 
clinical database lock for the final analysis. All statistical analyses detailed in this SAP will be
conducted using SAS® Version 9.2 or higher. The final database lock will occur after 70 
progression-free survival events are achieved.
&(/*(1(35235,(7$5<,1)250$7,21
ntains
ntains
alysis o
alysis of f 
and one fin
and one fin
486 pl
486 us 
us
l
SAP is to e
SAP is to e
ches to the 
ches to th
analysis.
alysis. Th
Th
ed and sign
d and sign
yses detaile
yses deta
abase l
base lock 
ock


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
3.
STUDY OBJECTIVES
3.1.
Primary Objective
The primary objective is:
!
To estimate the efficacy of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo based on progression-free survival (PFS) as measured using RECIST 1.1 criteria
3.2.
Secondary Objectives
The secondary objectives of the study are:
!
To estimate disease control rate (DCR) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To estimate overall survival (OS) of CC-486 plus pembrolizumab versus pembrolizumab 
plus placebo
!
To estimate overall response rate (ORR) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To evaluate safety and tolerability of CC-486 plus pembrolizumab versus pembrolizumab 
plus placebo
!
To evaluate the impact of pembrolizumab on the pharmacokinetics of CC-486
3.3.
Exploratory Objectives
The exploratory objectives of the study are:
!
To determine the preliminary efficacy (immune-related [ir] PFS, irDCR, irORR) of CC-
486 plus pembrolizumab versus pembrolizumab plus placebo based on irRECIST criteria
(see Appendix B of the protocol for details on irRECIST). 
!
To explore mechanism and biomarkers associated with efficacy of CC-486 plus 
pembrolizumab versus pembrolizumab plus placebo,
 
&(/*(1(35235,(7$5<,1)250$7,21
eriaia
b versus 
versus
ab
ab versus 
ersus p
pembro
pem
liz
s pembro
pembroli
on the pha
on the ph
y are:
y are:
ary efficacy
ary efficacy
b versus
b versus pe
pe
he protoco
he protoc
anism and 
anism an
ab
ab versus
versus p
(1(


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
4.
INVESTIGATIONAL PLAN
4.1.
Overall Study Design and Plan
This is a Phase 2, multicenter, international, randomized, placebo controlled double-blind study 
to assess the safety and efficacy of the combination therapy of CC-486 plus pembrolizumab 
versus pembrolizumab plus placebo in previously treated subjects with locally advanced or 
metastatic NSCLC who have received one prior platinum-based chemotherapy regimen.
Approximately 90 subjects meeting the inclusion criteria will be randomized 1:1 to one of the 2 
treatment arms:
!
Arm A: CC-486 300 mg administered orally daily on days 1-14 plus pembrolizumab 200 
mg administered as a 30-minute IV infusion on day 1 of a 21-day cycle, or
!
Arm B: Placebo administered orally daily on days 1-14 plus pembrolizumab 200 mg 
administered as a 30-minute IV infusion on day 1 of a 21-day cycle. 
The randomization will be stratified by histology (non-squamous versus squamous).
Subjects may remain on treatment until radiologic disease progression, unacceptable toxicity,
and initiation of a new anticancer therapy, withdrawal of consent, subject refusal, physician 
decision, or death.
The study consists of a 3-week screening period, a treatment period consisting of 21-day cycles, 
and a follow-up period. The subjects will be seen at Day 1 and Day 14 for the first 2 cycles, and 
only on Day 1 for subsequent cycles. Tumor evaluation (i.e. efficacy follow-up period) will be 
assessed by the Investigator according to RECIST 1.1 guidelines at screening and every 6 weeks 
(± 5 days) from randomization for the first 24 weeks, and every 9 weeks thereafter until disease 
progression, start of a new anticancer treatment or withdrawal consent. Subjects will also be 
evaluated according to irRECIST guidelines in cases of progressive disease (PD) per RECIST 
1.1.
In the follow-up phase, anticancer treatment administered following the last dose of 
investigational product (IP) and survival will be followed every 8 weeks (± 5 days) until death, 
withdrawal of consent, or lost-to-follow-up, whichever occurs first, or the End of Trial.
A safety analysis will be performed in the first 10 subjects in each arm after the completion of at 
least 1 cycle of treatment. An independent Data Monitoring Committee will be established to 
evaluate safety. Following the initial DMC data review meeting, the DMC will meet 
approximately every 6 months per DMC charter (or more often if requested by the DMC 
Chairman) to assess safety data. Details are outlined in the DMC charter.
The study schematic is presented in Section 17.1 while the table of events is presented in Section 
17.2.
&(/*(1(35235,(7$5<,1)250$7,21
of the 2
the 2
mbro
mbrolizumab
lizuma
e, or
e, o
brolizumab
rolizum
cycle
ycle. . 
versu
er
s squa
s squ
gressi
gression, 
on u
onsent, subj
nsent, su
reatment pe
reatment 
n at Day
at Da 1 a
1 a
y
valaluati
uati
l
on (
on (
ECIST 1.1
ECIST 1.
rst 24 week
rst 24 we
treatment 
treatme
guidelines i
guidelines 
cancer trea
ancer tre
IP) and sur
IP) and s
t, or l
t, or lost
ost-to
will be per
will be per
f treatm
treatment
en
fety
fety. Foll
. Follow
ow
mately
ely ever
eve
y
man) to
an) to ass
as
he study
he study
&
sc
sc
y
17.2.
&


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
4.2.
Study Endpoints
4.2.1.
Primary Efficacy Endpoint
The primary endpoint is:
!
PFS measured as time from randomization to progression according to RECIST 1.1 
(based on Investigator assessment) or death due to any cause, whichever occurs first.
4.2.2.
Secondary Efficacy Endpoints
The secondary endpoints are:
!
Number (%) of subjects with Stable Disease (SD) for ≥ 18 weeks, complete response 
(CR) or partial response (PR) (DCR).
!
Overall survival.
!
Number (%) of subjects who achieve an objective CR or PR (ORR).
!
Safety endpoints include the incidence of treatment-emergent adverse events (TEAEs), 
serious TEAEs, Grade 3-4 TEAEs, TEAEs of special interest, and laboratory 
abnormalities and other safety parameters.
4.2.3.
Exploratory Efficacy Endpoints
The exploratory efficacy endpoints are:
!
Exploratory efficacy as measured by irPFS, irDCR, and irORR based on Investigator 
assessment using irRECIST.
!
Measures of the tumor-associated immune state,
 
!
 
!
DNA analyses, gene expression and soluble factors in blood.
4.3.
Stratification, Randomization, and Blinding
Once the subject has met all eligibility criteria during the Screening Period, they will be 
randomized to one of two treatment arms to enter the Treatment Period. Randomization will be 
centralized using an Interactive Response Technology (IRT) system and stratified by histology 
(non-squamous vs squamous). Approximately 90 subjects will be randomized to one of two 
treatment arms in a 1:1 ratio. A permuted-block randomization method will be employed.
Subjects will receive one of the following treatments based on the randomization assignment:
!
Arm A: CC-486 300 mg administered orally daily on days 1-14 plus pembrolizumab 200 
mg administered as a 30-minute IV infusion on day 1 of a 21-day cycle, or
&(/*(1(3
, gene expr
gene expr
Stratificat
Stratificat
he subject h
e subject h
omized to 
mized to 
entralized u
entralized 
(non
no -squa
squa
eatm
eatm
5235,(7$5<,1)250$7,21
response 
response 
RR
RR).).
nt adverse 
nt advers
erest, and la
erest, and l
PFS, i
FS, irDCR
rDCR
i
d immune 
d immun
23
352
35


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
13
!
Arm B: Placebo administered orally daily on days 1-14 plus pembrolizumab 200 mg 
administered as a 30-minute IV infusion on day 1 of a 21-day cycle
CC-486 and matching placebo will be double blind whereas pembrolizumab will be open-label. 
CC-486 and pembrolizumab are designated as IPs.
4.4.
Sample Size Determination
The primary goal of this study is to provide estimates of the difference in efficacy and safety 
between CC-486 plus pembrolizumab and pembrolizumab plus placebo.
Approximately 90 subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or 
pembrolizumab plus placebo. The primary analysis will be conducted when 70 PFS events occur.
Selected hypothetical scenarios are presented in Table 2 with confidence interval and power 
estimates, when approximately 70 PFS events have occurred.
Table 2 demonstrates the hypothetical power of testing the null hypothesis H0: λT/ λC=1, against 
the two sided alternative HA: λT / λC ≠1, assuming that time to PFS events in both treatment arms 
follow exponential distributions, and λC is the monthly hazard rate of the survival distribution in 
the control arm, and λT is the monthly hazard rate of the survival distribution in the experimental 
arm (CC-486+pembrolizumab).
Table 2:
Hypothetical Power and Resulting Two-sided 90% CI of Hazard Ratio
Combo Treatment Median PFS (month)
5.5
5.0
4.6
Total PFS events
74
75
76
Power (%) w/two-sided α=0.101
82.4
71.7
59.4
HR with [two-sided 90% CI]
0.55 [0.38,0.81]
0.60 [0.41,0.88]
0.65 [0.45,0.95]
1
These calculations assume the median PFS in pembrolizumab alone is 3.0 months (Garon, 2014). And lost to follow-up (to 
assess PFS events) rate is 10% at the end of study
The power calculations are conducted with East 5.4.
&(/*(1(35235,(7$5<,1)250$7,21
ab or 
or
vents occur
ents occu
and power
nd power
 H0: λT/ λ
/ λC
nts in both t
in bot
f the surviv
the surviv
distribut
stributioio
wo
wo-sided 9
sided 9
5.5
5.5
(7
74
74
,(
5,
35
0
35
35
35
235
FS in 
FS in pembro
pembr
of study
f study
are condu
are condu


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
14
5.
GENERAL STATISTICAL CONSIDERATIONS
Programming, statistical analysis, and reporting will be conducted according to the following 
conventions.
5.1.
Reporting Conventions
The following reporting conventions apply generally to tables, listings, and figures:
!
Listings will include both the randomized treatment and actual treatment;
!
Data from all study centers will be combined for analysis;
!
All stratified efficacy analyses will use the stratification factors including histology 
(non-squamous vs squamous);  
!
P-values will be rounded to 4 decimal places. P-values <0.00005 will be presented as 
‘<0.0001’ and p-values ≥0.9995will be presented as ‘>0.9999’; 
!
Confidence intervals (CIs) will be presented as 2-sided 90% CIs unless otherwise 
specified;
!
Summary statistics will consist of the number and percentage of subjects (or cycles, if 
appropriate) in each category for discrete variables, and the sample size, mean, 
median, Standard Deviation (STDEV), minimum, and maximum for continuous 
variables;
!
All mean and median values will be formatted to one more decimal place than the 
measured value. Standard deviation values will be formatted to two more decimal 
places than the measured value;
!
All percentages will be rounded to one decimal place. The number and percentage of 
responses will be presented in the form XX (XX%), where the percentage is in the 
parentheses;
!
All laboratory data will be reported using standard international (SI) units;
!
All listings will be sorted for presentation in order of randomized treatment arm, 
study center, subject, and date of procedure or event. Subjects who are enrolled but 
not randomized will be listed as a non-randomized group before randomized subjects;
!
All analysis and summary tables will have the analysis population sample size (i.e., 
number of subjects);
!
The day of the first dose of any study drug will be defined as Day 1; 
!
Baseline is defined as the last non-missing value on or before the first dose date of 
administration of CC-486/placebo, unless specified otherwise. If multiple values are 
present for the same date, the average of these values will be used as the baseline, 
with the exception of lab data where the value with the worst CTC grade will be used 
as the baseline. For lab values with equal or missing CTC grade on the same date, the 
average of these values will be used as the baseline. For subjects who were not 
&(/*(1(35235,(7$5<,1)250$7,21
ding 
ding histol
histol
05 will be 
05 will be 
99’; 
99 ;
90% CIs u
 CIs 
nd percenta
d percen
riables, and
iables, an
inimum, an
inimum,
be formatted
e formatte
tioion values
n value
ue;
ue;
rounded to
unded to
sented in th
sented in th
data will b
ta wi
s will be so
s will be 
enter, subj
enter, subj
andomized
andomized
All
All analysi
analysi
number
numbe
!
The
The
!


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
15
treated, the baseline will be the last non-missing assessment value taken on the day of 
or before the randomization or Cycle 1 Day 1, whichever is later. 
!
SAS Version 9.2 (or higher) will be the statistical software package used to produce 
all other data summaries, listings, graphs, and statistical analyses.
5.2.
Calculation of Treatment Start Dates, Cycles, and Treatment End 
date
The treatment start date will be calculated as follows:
!
The day of the first dose of any study drug will be defined as Day 1. 
The treatment end date will be calculated as follows:
!
For subjects who discontinue prior to the clinical cutoff date, treatment end date of 
individual drug is the date of treatment discontinuation from treatment disposition 
form in the eCRF. 
!
For subjects who are still on treatment at the time of study closure or clinical cutoff,
treatment end date of CC-486 is the last non-missing dose date of CC-486+7.
!
Treatment end date of pembrolizumab is the last non-missing dose date of 
pembrolizumab+20.
!
The treatment end date of the investigational product (IP) would be the latest of the 
two individual drug end dates.
Cycle dates will be calculated as follows:
!
Each cycle starts with the date of the first dose date of the cycle, and the last day of 
the cycle is the day before the first dose date of subsequent cycle. In by-cycle 
analyses, assessments taken pre-dose on Day 1 of a given cycle (e.g., laboratory 
measures) will be grouped with the previous cycle.
!
For the last cycle, the last day of the cycle is 21 days after Day 1 of the last cycle, the 
treatment discontinuation date on the electronic case report form (eCRF) EOT page, 
or study cut-off date, whichever is earlier.
!
The cycle number and the day with a cycle for each date of interest, e.g., AE start 
date, will be calculated based on the cycle window set by the start and end dates of 
the study medication.
5.3.
Analysis Populations
5.3.1.
Intent-to-Treat Population/Full Analysis Set
The Intent-to-Treat (ITT) population includes all subjects who are randomized. All efficacy 
analyses will be based on the ITT population, unless otherwise specified. The efficacy analyses 
will be performed according to treatment assigned at randomization.
&(/*(1(35235,(7$5<,1)250$7,21
nt end date
nt end date
ment dispos
ment dispo
clo
closure or 
sure or
se date of C
se date of
n-missing d
miss
l product (I
l product (
f the first do
f the first do
first dose d
first dose d
n pre
n pre-dose 
dose 
ed with the
d with th
he last day
e last day o
y
inuat
inuatioion da
n
ff date, whi
ff date, 
number an
number a
will be calcu
ll be calcu
study
study m
y
edi
e
An
Ana
&
5.3.1.
5.3
I


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
16
5.3.2.
Safety Population
The safety population includes all subjects who are randomized and receive at least one dose of 
study drug. If a subject receives study drug other than the subject’s randomized treatment 
assignment, then the subject is assigned to the treatment arm reflecting the treatment that the 
subject actually received during the study. All safety analyses will be based on the Safety 
population, unless otherwise specified. 
5.3.3.
Efficacy Evaluable Population
The efficacy evaluable (EE) population is defined as ITT subjects who meet protocol 
requirements (meet eligibility criteria and have at least one valid tumor assessment at baseline) 
and are evaluated for tumor assessment after receiving at least one dose of study treatment. 
Selected efficacy analysis (e.g., PFS, OS, and ORR) will be performed using the EE population.
5.3.4.
PK Population
The pharmacokinetic population will include all randomized subjects who have evaluable 
concentration data to determine the pharmacokinetic parameters from at least one dose of 
CC-486. The evaluable subjects in the pharmacokinetic population will be included in the 
pharmacokinetic data analysis.
5.3.5.
Biomarker Population
The biomarker analysis population will include all randomized subjects who received at least 1 
dose of IP, provided consent for exploratory biomarker studies, and had at least 1 predose 
biomarker tissue collected and deemed of adequate quality for biomarker analysis. 
&(/*(1(35235,(7$5<,1)250$7,21
aseline
aseline) ) 
atm
atment.
ent.
EE populat
popula
who have ev
who have 
m at l
at least o
east o
on will be i
will be 
ando
andomized
mize
marker stud
arker stud
quate quali
quate quali


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
17
6.
SUBJECT DISPOSITION
The total number of subjects screened will be presented, and subjects with screen failure and 
reasons for screen failure will be summarized by frequency and percentage.
Subject disposition (analysis of population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent for both treatment 
and follow-up phases for ITT population. 
Reasons for treatment discontinuation will be summarized for the study drug (CC-486 or 
Placebo) and pembrolizumab separately, for all subjects with the following categories. The 
number and percentage of subjects who are in the survival follow-up, lost to survival follow-up, 
or died at the time of analysis will also be presented.
!
Death 
!
Adverse events
!
Pregnancy
!
Progressive disease 
!
Withdrawal by Subject 
!
Non-compliance with study drug
!
Lost to follow-up 
!
Study terminated by sponsor
!
Transition to commercially available treatment
!
Physician Decision
!
Symptomatic deterioration 
!
Protocol violation
!
Other
Reasons for study discontinuation will be summarized for all subjects who discontinue study 
with the following categories:
!
Screen failure
!
Death 
!
Adverse event 
!
Pregnancy
!
Progressive disease 
!
Withdrawal by Subject
!
Non-compliance with study drug
&(/*(1(35235,(7$5<,1)250$7,21
The
fo
follo
llow-
w-up
u
le treatmen
e treatmen
cont
continuat
inuatio
categories
categories
failure
failur
athth
Ad
Adverse 
vers
!
Preg
Preg
!


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
!
Lost to follow-up 
!
Study terminated by sponsor
!
Transition to commercially available treatment
!
Physician Decision
!
Symptomatic deterioration 
!
Protocol violation 
!
Other 
Number of subjects randomized by strata and number of subjects randomized by country and site 
will be summarized. Listings will be provided for subjects who are screened but not enrolled, 
randomized but not treated, and for discontinued subjects with reason for treatment 
discontinuation.
&(/*(1(35235,(7$5<,1)250$7,21
try
ry and site
and sit
y
t enrolled,
t enrolled,
ent 
ent 


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
7.
PROTOCOL DEVIATIONS/VIOLATIONS
The protocol deviations/violations will be identified and assessed by clinical research physician 
or designee following company standard operational procedure. Protocol deviations and 
violations will be reviewed before database lock to determine the efficacy evaluable population. 
Events that could trigger exclusion from the EE population include inclusion/exclusion criteria 
violations, failure to take any study drug as assigned, randomization errors, and prohibited 
concomitant medications and procedures. 
The protocol deviations/violations will be summarized separately by treatment arm for the ITT 
population. A by-subject listing of subjects with protocol deviations/violations in the ITT 
population will be provided. 
&(/*(1(35235,(7$5<,1)250$7,21
e ITT
 ITT
TT
TT


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
8.
DEMOGRAPHICS AND BASELINE CHARACTERISTICS
The demographics and baseline characteristics will be summarized for the ITT population. 
Individual subject listings will be provided to support the summary tables.
8.1.
Demographics
Subject’s age (years), height (cm), weight (kg), Body Mass Index (BMI) and Body Surface Area 
(BSA) at baseline will be summarized descriptively. Sex, race, ethnicity and reproductive status
will be summarized by frequency counts.
Age will be calculated as follows: age = Integer ∀[(Date of informed consent – Date of Birth + 
1) / 365.25]. 
BMI will be calculated as follows: BMI (kg/m2) = weight in kg / (height in m)2.
BSA will be calculated as follows: BSA (m2) = 0.007184 × (Weight in kg)0.425 × (Height in 
cm)0.725.
8.2.
Baseline Characteristics
The following baseline characteristic will be summarized by frequency counts, by treatment arm 
and overall:
!
ECOG performance status at baseline (0, 1);
!
Disease stage at primary diagnosis (Ia, Ib, IIa, IIb, IIIa, IIIb, IV, Unknown); 
!
Disease stage at baseline (Ia, Ib, IIa, IIb, IIIa, IIIb, IVa, IVb, Unknown);
!
Histology (squamous cell carcinoma, adenocarcinoma);
!
Current sites of metastasis;
!
Number of metastatic sites.
8.3.
Cancer History and Baseline Lesion Status
The following items will be summarized for cancer diagnosis:
!
The time from specimen collection date to first dose date in months, defined as (first 
dose date – specimen collection date + 1)/ 30.4375
!
Tissue type (archival tissue, fresh tumor biopsy [surgical, core needle, other])
!
Most current recurrence/progression (month) as defined as (first dose date – most 
recent recurrence/progression specimen collection date + 1)/ 30.4375
!
Number of target/non-target lesions
!
Method of assessment for target/non-target lesions
!
Sum of target lesion diameters
&(/*(1(35235,(7$5<,1)250$7,21
rea
ea
status
status
e of Birth +
e of Birth 
m)
m)2.
kg)0.425
0.425 × (H
by frequenc
by frequen
;
Ib, IIa, IIb,
b, IIa, IIb
a, IIb, IIIa, 
a, IIb, IIIa, 
noma, ade
ma, ade
;
sites.
sites.
istory
istory an
and
 will
will b
l e su
e su
time fro
time from
ose date
ose date –
Tissue t
Tissue 
!
Mo
Mo


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
Subject listings will be provided for all of the above, as well as date of specimen collection.
8.4.
Medical History
A summary of medical and surgical history will be presented by MedDRA (Version 19.0) system 
and organ class (SOC) and preferred term (PT). 
8.5.
Prior Therapy
8.5.1.
Prior Anti-Cancer Therapy
8.5.1.1.
Prior Systemic Anti-Cancer Therapy
Prior systemic therapies (e.g. chemotherapy) will be coded to therapeutic drug classes and 
generic drug names using the World Health Organization (WHO) drug dictionary. The duration, 
the number of cycles (if known), and the best response will all be presented in a listing. A 
summary table will also be provided.
8.5.1.2.
Prior Radiation Therapy
The number and percentage of subjects who had any prior radiation therapy will be presented. 
For subjects with prior radiation therapy, the number and percentage of subjects with each type 
of radiotherapy (External Beam Location, Radio-Immuno Therapy, Brachytherapy, Other) and 
each site of radiation therapy will be presented.
8.5.1.3.
Prior Surgeries
The number and percentage of subjects who had any prior surgery will be presented. Prior 
surgeries will be listed.
8.6.
Prior and Concomitant Medications
Medications reported on the Prior and Concomitant medications eCRF pages will be coded to 
therapeutic drug classes and generic drug names using the WHO drug dictionary version 
WHODRUG ENHANCED 01 MARCH 2016. 
8.6.1.
Prior Medications
Prior medications are defined as all medications that were started before Day 1 of Treatment. A 
summary showing the number and percentage of subjects who took prior medications will be 
presented by WHO drug dictionary therapeutic drug class and generic drug name. This summary 
will be presented for the ITT population.
8.6.2.
Concomitant Medications
Concomitant medications for the Treatment Period are defined as medications that were initiated 
before the first dose of study drug and continued during the study treatment, or initiated on/after 
the date of the first dose of study drug and within 28 days after the date of treatment 
discontinuation. 
&(/*(1(35235,(7$5<,1)250$7,21
asses and 
asses and 
nary
ry. The du
. The d
d in a list
in a listing
in
atatioion therap
n th
rcentage of
rcentage o
o Therapy
Therap
had any pr
had any pr
ant 
ant Medi
Me
rior and Co
or and Co
d generic dr
generic 
ED 01 MAR
D 01 M
edications
dications
ons are def
ns are de
howing the 
owing the 
d by WHO 
y WHO
e presented
e presented
8.6.2.
.6.2
onco
onco


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
Summaries showing the number and percentage of subjects who took concomitant medications 
will be presented by WHO therapeutic drug class and generic drug name for the ITT population.
&(/*(1(35235,(7$5<,1)250$7,21


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
9.
STUDY TREATMENTS AND EXTENT OF EXPOSURE
Study treatment and extent of exposure summaries will be provided based on the safety 
population. Descriptive statistics will be provided for treatment duration, number of cycles, 
cumulative dose, dose intensity, and relative dose intensity by treatment arm. Dose 
reduction/interruption will also be summarized.
9.1.
Treatment Duration
For a given study drug, treatment duration (in weeks, rounded to one decimal) is defined as: 
Treatment Duration = [(Treatment end date) – (Day 1 of Treatment) + 1]/ 7. 
Each cycle starts with the date of the first dose date of the cycle and the last day of the cycle is 
the day before the first dose date of subsequent cycle.  
For clinical cutoff, the last day of pembrolizumab will be Day 1 of the last cycle plus 20 days or 
last dose of treatment plus 20 days, whichever comes first. For CC-486, the last day will be Day 
1 of the last cycle plus 20 days or last dose of treatment plus 7 days, whichever comes first.
Treatment duration specific to a drug will follow the rules described above, respectively for each 
drug. Treatment duration specific to a treatment arm combination will be the maximum of the 
two end dates from the same arm. 
Descriptive statistics will be provided for treatment duration and total number of cycles for each 
arm, i.e. the CC-486 plus pembrolizumab and the pembrolizumab plus placebo arms.  
Descriptive statistics will also be provided for number of doses received for both CC-486 and 
pembrolizumab separately.
9.2.
Cumulative Dose
Cumulative dose will be computed separately for CC-486, pembrolizumab and placebo. 
Cumulative dose for pembrolizumab is defined as the sum of all actual doses, defined as the 
values entered on the dose assigned field on the dosing eCRF, taken across the Treatment Period 
in mg/m2. Cumulative dose for CC-486 is defined as the sum of all actual doses, defined as the 
values entered on the actual dose administered field on the dosing eCRF, taken across the 
Treatment Period in mg. Similarly, the cumulative dose for placebo is defined as the sum of all 
actual doses, defined as the values entered on the actual dose administered field on the dosing 
eCRF, taken across the Treatment Period in mg. Descriptive statistics will be presented for 
cumulative dose for the safety subjects. 
9.3.
Dose Intensity
Dose intensity during the treatment is defined as the cumulative dose divided by the treatment 
duration in weeks. Dose intensity will be calculated separately for CC-486 and pembrolizumab.
Dose intensities will be calculated as follows:
!
Dose intensity for pembrolizumab (mg/m2/wk) = [cumulative dose for pembrolizumab in 
mg/m2] / [treatment duration in weeks].
&(/*(1(35235,(7$5<,1)250$7,21
d as:s: 
y of
of the cy
the c
f
c
ast cy
t cycle plu
cle
86, the last 
6, the last 
s, whichev
s, whichev
ribed above
ibed above
atatioion will
n will b
l
uration and
uration and
pembro
pembrolizu
lizu
number of d
umber of
d separately
d separate
zumab
umab is de
is de
ssigned fie
ssigned f
se for CC
se for C
actual dose
ctual dose
n mg. 
n mg. Si
Simil
mi
fined as the
fined as the
across the T
cross the 
e dose for th
dose for t
Dos
Do
Dose inten
Dose inten
durati
uration
o


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
!
Dose intensity for CC-486 (mg/ wk) = [cumulative dose for CC-486 in mg] / [treatment 
duration in weeks].
Dose intensity will be presented by drug for the Treatment Period of the study for the treated 
population.  
9.4.
Relative Dose Intensity
Relative dose intensity by week is the dose intensity divided by the protocol weekly dose, 
expressed as a percentage. Relative dose intensity will be calculated separately for CC-486 and 
pembrolizumab.
!
Percentage of protocol dose = (dose intensity / protocol weekly dose) * 100%
The original protocol weekly doses for CC-486:
!
CC-486: 1400 mg /wk (300 mg each day on days 1 to 14 of each 21 day cycle)
The original protocol weekly doses for pembrolizumab:
!
Pembrolizumab: 66.67 mg/wk (200 mg on day 1 of a 21-day cycle).
Percentage of protocol dose CC-486 and pembrolizumab will be categorized into <70%, ≥70% to 
< 80%, and ≥80 to <90% and ≥90%, and frequency counts will be provided for the treated 
population.
9.5.
Dose Reduction/Interruption
Dose reduction is defined as when the dose administered after Cycle 1 Day 1 is at a lower dose 
level than the dose the subject receives at the previous dosing visit.
In addition, for CC-486, dose interruption is defined as a zero dose given on one or more days on 
which the protocol -specified dose is non-zero. Consecutive zeros are counted as one 
interruption. Dose interruption for pembrolizumab will be defined similarly. 
Treatment exposure and dose reductions will be summarized as follows (separately for each 
investigational drug):
!
Number of cycles and doses administered;
!
Number and percentage of subjects with at least 1 dose reduction, number of dose 
reductions, and reasons (Per Protocol, adverse event, or other) for reduction;
Number and percentage of subjects with at least one dose interruption, number of dose 
interruptions will be presented.
&(/*(1(35235,(7$5<,1)250$7,21
nd 
nd
0%
0%
21 day
21 da cycl
cyc
y
day
ay cycle).
cycle)
y
e categori
cate
ze
ze
ill be provi
ill be prov
ministered a
inistered
e previous d
e previous d
n is define
n is defin
non-
non-zero. C
zer
pembrolizu
embrolizu
reductions w
eductions
cycles and 
cycles and
r and perce
r and perce
ctitions, and 
ons, and
d percentag
d percentag
ons s will
will b
l


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
10.
EFFICACY ANALYSIS
All efficacy evaluations will be conducted using the ITT population. Supportive analysis of the 
primary and key secondary efficacy endpoints using the EE population will be conducted for the 
final analysis. Data listings will be provided for all endpoints.
10.1.
Multiplicity
There is no multiplicity adjustment on the efficacy endpoints. The statistical tests will not be 
formally performed.
10.2.
Analysis of Primary Efficacy Endpoint
The primary efficacy endpoint is progression-free survival (PFS), which is defined as the time in 
months from the date of randomization to the date of disease progression according to RECIST 
1.1 criteria (documented by CT-scan result, not including symptomatic deterioration) or death 
(any cause) on or prior to the clinical cutoff date, whichever occurs earlier. 
Subjects who do not have disease progression or have not died as of the data cutoff date will be 
censored at the time of the last radiologic assessment where the subject was documented to be 
progression-free prior to the data cutoff date.  In the event that a new anti-cancer therapy is
initiated for a subject prior to documented progression (or death), the subject will be censored at 
the time of the last radiologic assessment where the subject was documented to be progression-
free prior to the new anti-cancer therapy. Subjects with a single missing radiologic assessment 
prior to a visit with documented disease progression (or death) will be analyzed as a PFS event at 
the time of the radiologic assessment that shows progression or death (whichever is earlier). 
Subjects with two or more consecutive missing radiologic assessments prior to a visit with 
documented disease progression (or death) will be censored at the time of the last radiologic 
assessment where the subject was documented to be progression-free prior to the first of the two 
or more consecutive missing visits. The PFS censoring rule is further illustrated in Table 3.
An additional analysis of PFS will be performed using the European Medicines Agency 
methodology for analysis of a PFS endpoint.  Similar to the approach described above, PFS will 
be defined as the time from the randomization to the date of disease progression according to 
RECIST 1.1 criteria (documented by CT-scan result, not including symptomatic deterioration) 
or death (any cause) on or prior to the clinical cutoff date, whichever occurs earlier. Subjects 
who do not have disease progression or have not died will be censored at the last known time 
that the subject is progression free (i.e. the last tumor assessment).  However, occasional missing 
observations or initiation of subsequent new anticancer therapy will not result in censoring for 
this analysis. 
&(/*(1(35235,(7$5<,1)250$7,21
be
efined as th
fined as th
according t
according t
deteriorati
deteriora
earlier.
arlier.
as o
as of f the da
d
the subject 
he subjec
that a
at a new
new
(or death), 
(or death),
subject was
subject w
s wi
s with
th
i
a sin
si
h
ession (or d
ession (or d
hows 
ows progr
progr
missing radi
missing ra
eath) will b
eath) w
documente
cumente
sits.
its. The PF
The PF
FS will be p
S will be
s of a PFS e
s of a PF
from
from th
the r
a (documen
a (docume
use) on or 
use) on or 
ave disease
ave disease
ubject is
ect is pro
pro
tioi ns or in
s or in
analysis.
analysis.


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
Table 3:
Censoring Rules for PFS
Value of Progression-
free Survival Date 
(ADT)
Censored 
(Y,N) 
Derivation
ADT = min(death date, 
progression date) 
N
If a subject died or had disease progression, and the 
time interval between the death date/progression date 
and the previous tumor assessment date with 
progression-free response or the randomization date is 
less than or equal to 91 days. 
ADT = the last 
progression-free 
assessment date/ 
randomization date
Y
If a subject died or had disease progression, and the 
time interval between the death date/progression date 
and the previous tumor assessment date with 
progression-free response or the randomization date is 
greater than 91 days.
ADT = the last tumor 
assessment 
date/randomization date 
Y
If a subject did not die or have progression, and did not 
receive any subsequent anticancer chemotherapy. 
If there was no post-baseline tumor assessment, then 
ADT = the randomization date.
ADT = the last tumor 
assessment date on or 
prior to start of 
subsequent 
chemotherapy/randomiz
ation date
Y
If a subject did not die or have progression on or prior 
to start of subsequent anticancer chemotherapy, or a 
subject died/progressed after the start of sequent 
anticancer chemotherapy. 
If there was no post-baseline tumor assessment, then 
ADT = the randomization date.
ADT = the last tumor 
assessment date on or 
prior to date of surgery 
or start of 
radiotherapy/randomizat
ion date
Y
If a subject did not die or have progression on or prior 
to date of surgery or start of curative radiotherapy, or a 
subject died/progressed after the date of surgery or start 
of radiotherapy. 
If there was no post-baseline tumor assessment, then 
ADT = the randomization date.
ADT = the last tumor 
assessment date on or 
prior to treatment 
discontinuation 
date/randomization date
Y
If a subject did not die or have progression on or prior 
to the date of treatment discontinuation due to 
symptomatic deterioration, or a subject died/progressed 
after the date of treatment discontinuation due to 
symptomatic deterioration. 
If there was no post-baseline tumor assessment, then 
ADT = the randomization date.
ADT = analysis date; N = no; Y = yes.
Note: Progression-free response refers to a response that was neither progressive disease (PD) nor un-evaluable 
(UE). 
he last tum
last tum
ment date 
ment date 
or to treatm
or to treatm
didiscontinua
scontinu
(1(
omizat
mizat
(35235,(7$5<,1)250$7,21
te i
e is s
$7
on, and the
n, and th
rogression 
rogressio
date with
date with
randomiza
randomiza
0$
or have
ha
pro
pro
ent anticanc
ent antica
st-baseline
baselin
domizat
omizatioion
1
ct did not d
ct did not d
t of subsequ
of subse
ject died/pr
ject died/pr
ntnticancer c
icancer 
If there w
If there 
ADT
ADT
7$
2
Y
2
(
2
date/ran
date/ran
(1


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
The final analysis for PFS will be conducted when a total of approximately 70 PFS events occur, 
all disease progression and death events that occurred on or prior to the projected clinical cutoff 
date will be included. 
The survival distribution of PFS will be estimated using the Kaplan-Meier method, the median 
PFS including two-sided 90% confidence interval (CI) for each treatment arm will be provided. 
The survival distributions for two treatment arms will be compared using the stratified log-rank 
test, and the p-value will be provided. The stratification factors will be histology (non-squamous
vs squamous). The associated hazard ratio (HR) and two-sided 90% confidence interval will be 
estimated by using stratified Cox proportional hazard model with treatment, and strata (i.e. 
histology) as model covariate. Kaplan-Meier curves will be provided by treatment arm and 
strata. 
The number and percent of subjects surviving without progression will be provided for every 8 
weeks relative to randomization. The denominator for percentages at each time point will be the 
number of subjects at risk at each time point.
The following analyses will be conducted as supporting or sensitivity analyses using the same 
methods (i.e. HR and two-sided 90% confidence interval from the Cox model with stratification 
factors):
!
Sensitivity analyses to address the impact of measurability of endpoints and 
adherence to protocol will be done by performing the PFS analyses mentioned above 
on the efficacy evaluable population.
10.3.
Analyses of Secondary Efficacy Endpoints
The secondary efficacy endpoints will be analyzed based on ITT population except otherwise 
specified.
10.3.1.
Overall Survival (OS)
Overall survival (OS) is defined as the duration (in months) between randomization and death 
from any cause:
OS = (Date of Death – Date of Randomization + 1) / 30.4375
Subjects who are still alive at the end of the study will be censored at the last contact date or 
clinical cutoff, whichever is earlier. The last contact date is the date of the last record in the 
database for that subject, or if the subject is dead, the last known date the subject was alive from 
the follow-up assessment, AE record or date of discontinuation record.  The OS analysis may 
also be conducted at the time when 70 deaths occur, in addition to when the primary analysis is 
performed. 
Median of overall survival including two-sided 90% CI for each treatment group will be 
calculated. The hazard ratio and a two-sided 90% CI will be estimated using Cox proportional 
hazard model with treatment, and all stratification factors in the model. The Kaplan-Meier curve 
for survival will be presented for each strata and treatment group. Median time to censoring for 
&(/*(1(35235,(7$5<,1)250$7,21
ous
us
ll be
be
.e.
m and 
and 
vided for e
vided for e
time point w
ime point 
y analyses 
analyses 
e Cox mod
Cox mo
measurabilit
measurabilit
rming the P
rming the 
fficacy
fficacy E
ll be analyz
ll be ana
l (OS)
l (OS)
s defined as
 defined a
f Death
Death
f
– D
o are still a
o are still a
utoff, which
off, whic
se fo
e f r that 
that 
fo
follo
llow-
w-up 
up 
also be cond
lso be con
perform
perform
d


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
those who are still alive at the cutoff date will also be provided. The analysis will be based on the 
ITT population.
10.3.2.
Overall Response Rate (ORR)
The number and percentage of those with a tumor response of partial response (PR), or complete 
response (CR) will be presented, as well as the number and percentage with each of progressive 
disease (PD), SD, PR, CR, and un-evaluable (UE). This analysis will be presented for each 
protocol-specified CT as defined in Section 17.4.4. If there is more than one CT scan within a 
relative day range, the best response will be counted. 
Overall response rate (ORR) is the percentage of subjects who achieved best response of PR or 
CR compared with baseline among all tumor assessments, where baseline is the last CT-scan 
obtained prior to or on Day 1 of Treatment. The ORR will be presented for each treatment group 
and strata. The 90% Clopper-Pearson confidence interval of the response rates will be provided. 
A two-sided 90% CI of the Response rate differences between CC-486 plus pembrolizumab and 
pembrolizumab plus placebo, with each stratum and overall will be provided. The p-value from a 
CMH test with stratification factors, if cell size is sufficiently large, will be reported to indicate 
the strength of association of the relative treatment effect.
The analysis will be based on the ITT population and will be repeated based on the EE 
population as a sensitivity analysis.
10.3.3.
Disease Control Rate (DCR)
Disease Control rate (i.e., percent of subjects who have stable disease (SD) or complete response 
(CR) or partial response (PR) compared with baseline, where baseline is the last CT scan 
obtained prior to or on Day 1 of Treatment) over the Treatment Period is a secondary efficacy 
endpoint. When SD is believed to be best response, it must meet the minimum duration of 18 
weeks from randomization. The DCR will be presented for each treatment group and strata. The 
90% Clopper-Pearson confidence interval of the response rates will be provided. A two-sided 
90% CI of the Response rate differences between CC-486 plus pembrolizumab and 
pembrolizumab plus placebo arm, with each stratum and overall will be provided. The analysis 
will be based on the ITT population.
10.3.4.
Time to response
Time to response is defined as the time from the first dose date to the first occurrence of 
confirmed response (CR or PR). Time to response will be summarized with descriptive statistics.
Only subjects with a CR or PR as a best overall confirmed response will be included in this 
analysis. The analysis will be based on the ITT population.
10.3.5.
Duration of response
For subjects who had a confirmed CR or PR, the duration of overall response is measured from 
the time measurement criteria are first met for CR/PR (whichever is first recorded) until the first 
date that recurrent or progressive disease is radiologically documented (taking as reference for 
progressive disease the smallest measurements recorded on study). 
&(/*(1(35235,(7$5<,1)250$7,21
of PR or 
of PR or 
CT-
CT-scan 
scan 
reatme
eatmentnt g
will be pro
will be pr
pembrolizu
pembroliz
ded
ded. The p
Th
ill be repor
ill be repo
epeated bas
peated
have stabl
have stab
aseline, wh
seline, w
over the T
over the T
t response, 
t response, 
will be pre
will be pre
nterval of t
erval of 
ferences
ferences be
be
arm, with e
arm, with 
opulation.
pulation.
response
esponse
e is defined
e is define
sponse (CR
sponse (CR
jects with a
ts with a
sisis. The ana
The ana
0.3.5.
0.3.5.
or sub
or sub


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
Subjects who are non-responders (i.e., do not achieve at least a PR) will be excluded from this 
analysis. Subjects who do not have PD after the response will be censored on the date of last 
tumor assessment. If a subject died before PD, then the subject will be censored on the date of 
death. 
The duration of response will be analyzed using the Kaplan-Meier method. The median time 
(including 2-sided 90% CI) will be summarized for each treatment arm; the associated hazard 
ratio with two-sided 90% confidence interval may be estimated using Cox proportional hazard 
model (Cox, 1972). The analysis will be based on the ITT population.
10.4.
Analyses of Exploratory Efficacy Endpoint
Exploratory endpoint, irORR, assessed by Investigator according to irRECIST will be analyzed 
in a manner similar to the analysis described in Section 10.3.
10.5.
Assessing Study Center Effect and Treatment-by-Center Interaction
This study is a multicenter study and has approximately 40 study sites to enroll approximately 90 
subjects. However, since the site is not part of the efficacy model, no site effect will be assessed.
&(/*(1(35235,(7$5<,1)250$7,21
be analyzed
be analyze
enter Int
enter Int
to enroll
o enroll ap
a
l
no site effec
no site eff


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
11.
SAFETY ANALYSIS
The purpose of this section is to describe the safety analyses for the Treatment Period of the 
study. Adverse events and laboratory values will be analyzed based on the safety population, per 
treatment arm and for treatment-related TEAEs or TEAEs with action taken, also by specific 
drug. 
11.1.
Adverse Events
Adverse events will be analyzed in terms of treatment-emergent adverse events (TEAEs) which 
are defined as any AEs that begin or worsen on or after the start of study drug through 30 days 
after the last dose of study drug. In addition, any serious AE with an onset date more than 30
days after the last dose of study drug that is assessed by the investigator as related to study drug 
will be considered a TEAE. All AEs will be coded using the Medical Dictionary for Regulatory 
Affairs® (MedDRA) dictionary Version 19.0. 
Treatment-related TEAE will be summarized for each treatment arm. If a subject experiences 
multiple occurrences of the same AE with different relationship to study medication categories, 
the subject will be counted once, as a relationship category of treatment-related. TEAEs with a 
missing relationship will be presented in the summary table as a relationship category of 
“treatment-related”.
The incidence of TEAEs will be summarized for each treatment arm by MedDRA SOC and PT 
in a descending order of frequency of SOC and PT within each SOC based on the combination 
arm. If a subject experiences multiple AEs under the same SOC or PT, then the subject will be 
counted only once for that SOC or PT.
The toxicity of AEs will be graded 1 to 5 according to the Common Terminology Criteria for 
Adverse Events (CTCAE) Version 4.0. For all other AEs not described in the CTCAE criteria, 
the toxicity will be assessed by the investigator as mild (grade 1), moderate (grade 2), severe 
(grade 3), life-threatening (grade 4) or death (grade 5). If a subject experiences the same AE 
more than once with different toxicity grade, then the event with the highest grade will be 
tabulated in “by grade” tables. If a subject experiences multiple AEs under the same preferred 
term (system organ class), then the subject will be counted only once for that preferred term 
(system organ class). In addition, AEs with a missing intensity will be presented in the summary 
table as an intensity category of “Missing.” 
Deaths during the study will be summarized by cause categories. AEs regarded as primary cause 
of deaths, as reported on CRF, will also be summarized by SOC and PT, For both types of 
summaries, on-treatment (within 30 days after the last dose of study treatment) and post-
treatment deaths will be summarized separately.
Tables summarizing the incidence of TEAEs will be generated for each of the following:
!
All TEAEs;
!
TEAEs reported as treatment-related; 
!
Serious TEAEs;
&(/
m
(/*(1(35235,(7$5<,1)250$7,21
) which
which
30
30 days 
days 
re than
re than 30
30
ed to study
ed to study
nary
nary f
y or Reg
Re
f
If a subject
If a subjec
study
study m
y
edi
e
eatm
eatment-rel
s a rel
s a r atatioion
treatm
treatment 
ent
within eac
within eac
r the same
r the sam
according 
according 
. Fo
For all ot
r all ot
invest
nvestigato
igat
e 4
e 4) or deat
) or deat
toxicit
toxicity gr
g
bles.
es. If a su
If a su
ss), then the
s), then th
In addit
In additioio
ty y category
category
g the study
g the study
as reported
s reported
ries, on
ries, on-tre
tre
ent deat
ent death
Tables sum
Tables sum


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
!
Treatment-related serious TEAEs;
!
All TEAEs with grade 3-4; 
!
Treatment-related grade 3-4 TEAEs;
!
TEAEs leading to death;
!
Treatment-related TEAEs leading to death;
!
TEAEs leading to dose discontinuation;
!
All TEAEs by CTCAE grade as well as grade 1-2 vs. grade 3-4 ;
!
All death within 30 days of last dose with cause of death.
Listings for the corresponding summary tables will be presented separately. Non-treatment-
emergent AEs will also be listed. 
11.2.
Adverse Events of Special Interest
The following TEAEs of special interest for CC-486 based on risk definitions (search criteria) as 
outlined in the Vidaza RMP (risk management plan) currently approved at the time of data cut-
off will be summarized by treatment arm: 
!
Myelosuppression (neutropenia, thrombocytopenia, anemia, general 
myelosuppression);
!
Hemorrhagic events;
!
Infections;
!
Renal failure;
!
Hepatic failure;
!
Ischemic colitis;
!
Interstitial lung disease;
!
Cardiac events (cardiac failure, cardiac arrhythmias, and myocardial infarction);
!
Anxiety, confusional state, insomnia;
!
Other psychiatric disorders;
!
Tumor lysis syndrome.
The following TEAEs of special interest for pembrolizumab based on risk definitions (search 
criteria) as outlined in the pembrolizumab IB will be summarized by treatment arm: 
!
Adrenal insufficiency
!
Colitis
!
Hematologic
&(/*(1(35235,(7$5<,1)250$7,21
reatm
eatment
ent-
efinit
finitioions (
ns (
proved at th
oved at th
eni
enia, anem
a, anem
sease
sease;
s (cardi
s (cardiac f
confusio
onfusiona
n
r psy
r psychiatri
chiatr
um
umor lysis
or lysis
fo
follo
llowing 
wing 
ririteria) as o
teria) as 
i


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
!
Hepatic
!
Hyperthyroidism
!
Hypophysitis
!
Hypothyroidism
!
Infusion reactions
!
Myasthenic syndrome
!
Myositis
!
Pancreatitis
!
Pericarditis
!
Pneumonitis
!
Nephritis
!
Skin
!
Thyroiditis
!
Type 1 diabetes mellitus
!
Uveitis
!
Vasculitis
The AE of special interest may be reviewed during the study at each MedDRA upgrade or 
protocol.
11.3.
Clinical Laboratory Evaluations
Clinical laboratory values from the central laboratories will be graded according to NCI CTCAE
version 4.0 for applicable tests. The worst grade during the treatment period will be summarized 
by treatment arm.  Frequency distributions for shift from baseline to the worst grade during 
treatment period will be presented by treatment arm. Normal ranges will be used to determine the 
categories of High, Low, and Normal for lab tests that have no severity grade. 
Listings of clinical laboratory data from central laboratory with abnormal flags will be provided 
by subjects and tests. Listings will also be provided for the local laboratory data. 
11.3.1.
Hematology
Hemoglobin, hematocrit, red blood cell count and morphology, mean corpuscular volume, mean 
corpuscular hemoglobin, mean corpuscular hemoglobin concentration, white blood cell count 
with absolute and differential and percent (neutrophils, lymphocytes, monocytes, eosinophils, 
basophils, and bands), platelet count, reticulocytes, erythrocyte sedimentation rate, international 
normalized ratio, prothrombin time, partial thromboplastin time will be collected in hematology 
panel. Additional laboratory samples may be collected as clinically indicated.
&(/*(1(35235,(7$5<,1)250$7,21
ring the stu
ing the st
valuation
aluatio
e central
e central ll a
The worst
The worst
cy distribu
y distributi
presented b
presente
ow, and No
w, and No
l la
l laboratory
boratory
d tests. 
tests. List
Li
Hematol
Hematol
ogl
oglobin, hem
obin, he
rpuscular h
puscular h
wi
with
th
i
abso
abso
h
l
basophi
asoph


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
In order to investigate the maximal degree of myelosuppression, the NCI CTCAE grade for 
hemoglobin, leukocytes, lymphocytes, neutrophils and platelets will be summarized by the worst 
grade in each treatment cycle and by the worst grade overall (i.e., any time after first dose of 
study drug). The number and percentage of subjects with each NCI CTCAE grade will be 
presented. A shift table representing the shift from the baseline grade to the worst grade will be 
provided for each of these laboratory tests.
Treatment group differences in each laboratory parameter with respect to the NCI CTCAE 
grades will be summarized by the frequency distribution of subjects with the grades.  
All laboratory parameters will be summarized by descriptive statistics within each treatment arm, 
as appropriate.
11.3.2.
Clinical Chemistry
Serum chemistry panel includes sodium, potassium, bicarbonate, calcium, magnesium, 
phosphorus, blood urea nitrogen, serum creatinine and clearance, uric acid, glucose, lactic 
dehydrogenase, total protein, albumin, alkaline phosphatase, aspartate aminotransferase, alanine 
aminotransferase, gamma glutamyl transferase, total, direct and indirect bilirubin, fibrinogen, 
ferritin. Additional laboratory samples may be collected as clinically indicated.
Hepatic and renal function will be summarized using the NCI CTCAE grade for ALT (SGPT), 
AST (SGOT), albumin, total bilirubin, creatinine, potassium, and sodium. The number and 
percentage of subjects that have each NCI CTCAE grade will be summarized using the worst 
grade for each cycle and overall. A shift table representing the shift from the baseline grade to 
the worst grade will be provided for each of these laboratory tests.
Treatment group differences in each laboratory parameter with respect to the NCI CTCAE 
grades will be summarized by the frequency distribution of subjects with the grades.  
All laboratory parameters will be summarized by descriptive statistics within each treatment arm, 
as appropriate.
11.4.
Vital Sign Measurements
Vital signs (Weight, Temperature, Systolic and Diastolic Blood Pressure, Pulse and Respiratory 
rate) will be recorded at screening and on Day 1 of each cycle and EOT. Vital sign data will be 
listed.
11.5.
Physical Examination
Physical Examination will be recorded in source documentation (i.e. not collected on CRF) only 
and hence no table and listings will be produced.
11.6.
Electrocardiograms
Triplicate 12-lead ECGs will be recorded at screening and EOT and will be assessed locally. The 
12-lead ECGs (12-lead at 25 mm/sec reporting rhythm, ventricular rate, PR-interval, QRS 
complex, QT interval, and QTc interval) will be performed after the subject has been in the 
supine position for at least 5 minutes. Shift from baseline to most abnormal post-baseline 
nt arm,
nt arm,
gnesium
nesium, 
glucose, la
glucose, la
minotra
inotransfe
ect bilirubin
ct bilirubin
lly indicate
ly indicat
CTCAE gr
CTCAE
m, and sodi
, and sodi
e will be su
will be 
ntnting the sh
ing the sh
laboratory
laboratory
y param
param
y
eter
ete
y distribut
distribut
y
i
marized by
arized by d
y
surements
urement
perature, S
perature, S
at screening
at screening
hysical Ex
ysical E
Examinat
aminatio
nce
nce no tab
tab
11.6.
11.6.
iplic
li
i


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
qualitative assessment of ECG abnormality (i.e., ‘Normal’, ‘Abnormal, not clinically 
significant’, and ‘Abnormal, clinically significant’) will be displayed in cross–tabulations by 
treatment. 
11.7.
ECOG Performance Status
The Eastern Cooperative Oncology Group (ECOG) score runs from 0 to 5, with 0 denoting 
perfect health and 5 death. ECOG performance status (PS) scores will be assessed and reported 
on the appropriate eCRF at screening, Day 1 of each cycle and at EOT. A shift table representing 
the shift from the baseline to the worst post-baseline ECOG PS scores will be provided for each 
treatment cycle and overall.
11.8.
Pregnancy test
A by-subject listing of pregnancy test and results will be provided for all female subjects of 
childbearing potential.
&(/*(1(35235,(7$5<,1)250$7,21
ing 
ng
each
ach
ale subjects
ale subject


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
12.
PHARMACOKINETIC ANALYSES
For the first 10-12 subjects randomized to each Arm, blood samples for CC-486 PK assessment 
will be collected on Day 1 of Cycle 1 and Cycle 2 prior to the dose administration of CC-
486/placebo, known as predose, and over the 8-hour period following each dose administration 
of CC-486/placebo at 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose.
Validated high-performance liquid chromatography/tandem mass spectrometric method (LC-
MS/MS) will be used for azacitidine plasma concentration analysis.
12.1.
Plasma concentrations
By-subject listing of pharmacokinetic blood sample collection times as well as derived sampling 
time deviations will be provided.  CC-486 plasma concentrations will be summarized using 
descriptive statistics (N, arithmetic mean, standard deviation, standard error, minimum, median, 
maximum, percent coefficient of variation, geometric mean, and geometric percent coefficient of 
variation) for each cycle, if/when appropriate.  Concentrations that are below the limit of 
quantitation (BLQ) will be treated as zero for the computation of descriptive statistics. Missing 
concentrations and concentrations from blood samples collected more than ± 10% of nominal 
time will be omitted from the calculation of descriptive statistics.
Individual subject concentration-time data and mean concentration-time data for each cycle will 
be graphically presented on linear and semi-logarithmic scales.
Following single dose administration, predose samples that are BLQ or missing will be assigned 
a numerical value of zero for the calculation of AUC.  Any anomalous concentration values 
observed at predose will be identified in the clinical study report (CSR) and used for the 
computation of AUC.  Pharmacokinetic parameters will be computed if the anomalous value is 
not greater than 5% of the Cmax.  If the anomalous value is greater than 5% of Cmax, the computed 
pharmacokinetic parameters for the given subject will be dropped from the pharmacokinetic 
analysis.  
Any other BLQ concentrations will be assigned a value of zero if they precede quantifiable 
samples in the initial portion of the profile.  A BLQ value that occurs between quantifiable data 
points, especially prior to Cmax, will be evaluated to determine if an assigned concentration of 
zero makes sense, or if reanalysis or exclusion of the data is warranted.  Following Cmax, BLQ 
values embedded between 2 quantifiable data points will be treated as missing when calculating 
AUC.  BLQ values occurring at the end of the collection interval (after the last quantifiable 
concentration) will be treated as missing data.  If consecutive BLQ concentrations are followed 
by quantifiable concentrations in the terminal portion of the concentration curve, these quantified 
values will be excluded from the pharmacokinetic analysis by assigning them a value of missing, 
unless otherwise warranted by the concentration-time profile.  For the purpose of analysis, these 
trailing BLQ values may be designated as zero in the dataset if the pharmacokinetic program 
used to do the analysis (such as WinNonlin®) will treat trailing zero values as missing when 
calculating AUC.
Actual sampling times will be used in the calculations of pharmacokinetic parameters that will be 
derived using noncompartmental (NCA) methods with Phoenix™ WinNonlin® Professional 
&(/*(1(35235,(7$5<,1)250$7,21
rived sampl
ved samp
arized usin
arized us
minimum,
minimum
c percent c
c percent c
below the 
below the
script
riptive st
ive st
more than 
ore than
cs.s.
entration-
entration-t
c scales.
c scales.
mples that a
mples that a
of
of A
f
UC. 
UC.
A
th
the clinica
clinica
parameters
parameters
anom
nomala ous
ou
e given
given su
s
ns will be a
ns will be a
on of
n of the p
 the p
f
toto Cmax
m , wi
w
r if reanaly
if reanaly
between 2
between 2
alues occur
lues occu
on) will be 
on) will be
tifiable con
ble con
s will be ex
s will be ex
less otherw
ss otherw
trailing BL
railing BL
used to 
sed to


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
Version 6.3, or higher, 
  Graphics may
be prepared with SAS Version 9.1, or higher; or Excel 2007, or higher; Phoenix™ WinNonlin®
Professional 6.3, or higher; or S-Plus 8.2., or higher 
.
12.2.
PK Parameter
The following PK parameters will be calculated for CC-486:
AUCinf
Area under the plasma concentration-time curve from Time 0 extrapolated to 
infinity, calculated as [AUCt + Ct/#z].  Ct is the last quantifiable concentration. 
No AUC extrapolation will be performed with unreliable #z.  If AUC %Extrap is 
≥25%, AUCinf will not be reported
AUCt
Area under the plasma concentration-time curve from Time 0 to the time of the 
last quantifiable concentration, calculated by linear trapezoidal method when 
concentrations are increasing and the logarithmic trapezoidal method when 
concentrations are decreasing.
Cmax
Maximum observed plasma concentration, obtained directly from the observed 
concentration versus time data.
Tmax
Time to Cmax, obtained directly from the observed concentration versus time data.
t1/2
Terminal phase half-life in plasma, calculated as [(ln 2)/#z].  t1/2 will only be 
calculated when a reliable estimate for #z can be obtained.  
CL/F
Apparent total clearance, calculated as [Dose/AUCinf]. 
Vz/F
Apparent volume of distribution, calculated as [(CL/F)/#z]. 
&(/*(1(35235,(7$5<,1)250$7,21
s s
time of the
ime of the
ethod whe
thod whe
method wh
method wh
irect
rectly 
ly fro
from
rved conce
ed conc
ulated as [(
ulated as
or 
or #z can be
an b
lated as [Do
ated as [Do
bututioion, cal
n, cal


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
12.3.
PK Analyses
By-subject listing of pharmacokinetic parameters will be provided.  The pharmacokinetic 
parameters will also be summarized using descriptive statistics (N, arithmetic mean, standard 
deviation, standard error, minimum, median, maximum, percent coefficient of variation, 
geometric mean, and geometric percent coefficient of variation) for each treatment.  Also, when 
appropriate, graphical representations (i.e., scatter plots, box plots, etc) may be used to visualized 
the results. In addition, two-sided 90% confidence intervals (CIs) for the geometric means will 
also be provided.
A linear mixed effects model will be performed on the log-transformed PK parameters AUCinf
and Cmax (ANOVA). Other PK parameters, such as AUCt, may also be tested. Included in the 
model will be cycle of visit as fixed effects and subject as the random effect. The 90% CIs for 
the mean of the difference (test - reference) on the log-scale will be calculated, and the back-
transformed 90% CIs for the geometric mean of the ratio (test/reference) will be provided.  Note: 
test = CC-486 co-administered with pembrolizumab during Cycle 2; reference = CC-486 alone
during Cycle 1 (see Protocol Section 5 for details). For Tmax, a non-parametric statistical method 
will be used to compare the median Tmax between treatments. Tlag (lag time in absorption) will 
also be tested, if observed.
As a sensitivity analysis, a paired T-test on the PK parameters of the same patient between cycles 
of visit will also be conducted. 
&(/*(1(35235,(7$5<,1)250$7,21
Cinf
nf
in th
the
% CIs for 
% CIs for
d the back
the back
be provided
e provide
nce = CC
nce = CC-4
metri
etric statis
c s
time in ab
time in ab
of the same
of the s


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
13.
BIOMARKER ANALYSES
Tumor, blood and serum will be collected to explore the hypothesized mechanism of CC-486 
priming to pembrolizumab efficacy, and potentially identify biomarkers to predict patients that 
would benefit from this therapeutic regimen. Fresh tumor biopsy is the preferred tissue for these 
analyses; however archival formalin fixed, paraffin embedded (FFPE) blocks may be provided 
instead. Blood, serum and saliva will also be collected at time point detailed in the schedule of 
events. Biomarker analyses will be performed separately. Details of these analyses will be 
outlined in a separate document. 
&(/*(1(35235,(7$5<,1)250$7,21


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
14.
INTERIM ANALYSIS
14.1.
General Information
An independent Data Monitoring Committee will be established and will include medical 
oncologists and a statistician, all of whom are not otherwise involved in the study conduct. 
During the course of the study, the DMC will review the safety data regularly. The DMC will 
offer recommendations based on periodic evaluations of comparative safety data, in accordance 
with criteria outlined in the DMC Charter. An independent statistician will prepare the reports to 
the DMC members for each scheduled meeting. Details will be provided in the DMC charter.  
&(/*(1(35235,(7$5<,1)250$7,21
ance
nce
ports to 
orts to 
charter. 
harter. 


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
15.
CHANGES TO THE STATISTICAL ANALYSES SECTION OF 
THE PROTOCOL
An efficacy evaluable population was added to examine the effect of adherence to protocol 
requirement. The efficacy evaluable (EE) population is defined as ITT subjects who meet 
protocol requirements (either meet eligibility criteria and/or have at least one valid tumor 
assessment at baseline) and are evaluated after receiving at least one dose of study treatment.
The protocol states that exploratory endpoints such as irPFS, irORR, and irDCR assessed by 
Investigator according to irRECIST will be analyzed. In this SAP, irORR is the only exploratory 
endpoint that will be analyzed using statistical methods described for similar secondary endpoint.
In Protocol Section 10.6.3, subgroup analyses on the efficacy variables OS, PFS, and DCR were 
described. These subgroup analyses will not be performed in this SAP. 
&(/*(1(35235,(7$5<,1)250$7,21
by
by
xplora
ploratory
tory
ary endpo
ary endpoini
, and DCR 
, and DCR


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
16.
REFERENCES
Cox, DR. Regression Models and Life-Tables. Journal of the Royal Statistical Society. Series B 
Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of pembrolizumab in 
previously treated patients (pts) with non-small cell lung cancer (NSCLC) [abstract]. In:
Proceedings of the 2014 ASCO Annual Meeting; 2014 May 30-Jun 3; Chicago, IL. J Clin Oncol. 
32:5s, 2014 (suppl; abstr 8020).
&(/*(1(35235,(7$5<,1)250$7,21


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
17.
APPENDICES
17.1.
Study Schematic
&(/*(1(35235,(7$5<,1)250$7,21


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
17.2.
Table of Events
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-
up 
Period
Day
-21 to -1
1b
14
1
14
1
EOT
Disease 
Progressi
on/ 
Survival
Informed consent 
X
Demographics
X
Prior cancer history
X
Prior cancer therapiesc
X
Complete medical history
X
Prior/ concomitant 
medication evaluationd
X (≤ 28d 
from 
screening)
Continuous, until 28 days after last dose 
Prior/ concomitant 
procedures evaluatione
X (≤ 28d 
from 
screening)
Continuous, until 28 days after last dose 
Inclusion/exclusion criteria
X
IRT registration
X
IRT randomization
Xf
Adverse event evaluation
Continuous after informed consent signature. See Section Error! Reference source not 
found. for additional details on AE reporting timeframe
Physical examination 
(source documented only)
X
X
X
X
X
&(/*(1(35235,(7$5<,1)250$7,21
ivalal
0$
0$
0$
0$
50
50
25
25
25
25
)25
)2
)2
)2
)2
ys after last do
s after last d
1)
until 28 days a
until 28 days
<
$5
$5
$5
$5
7$
( $
(7
,(
ormed consent
med consen
und.
und. for addi
for a
5,(
,(
X
35
35
35
52
52
52
5235


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-
up 
Period
Day
-21 to -1
1b
14
1
14
1
EOT
Disease 
Progressi
on/ 
Survival
Weight
X
X
X
X
X
Height
X
Vital signs
X
X
X
X
X
ECOG performance status
X
X
X
X
X
Hematology laboratoryg
X
X
X
X
X
X
X
Coagulationh
X
HBV and HCV serologies 
(HBsAg, HBeAg, HBsAb, 
HBeAb, HBcAb, HCVAb)
X
X
Chemistry laboratoryi
X
X
X
X
X
X
X
Lipid panelj
X
Every 4th
cycle
X
Thyroid test
X
X
Cycle 3 Day 
1 then every 
6 weeks
Urinalysisk
X
X
X
X
X
&(/*(1(35235,(7$5<,1)250$7,21
alal
$
0$
0$
0$
50$
X
50
25
X
25
25
25
)25
X
)2
)2
)2
)2
1)
,1
5<
X
5<
5<
5<
$5<
$5
$5
$5
$5
7$
5,( $
X
5
35
3


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-
up 
Period
Day
-21 to -1
1b
14
1
14
1
EOT
Disease 
Progressi
on/ 
Survival
Serum β-hCG (for all 
FCBP)l
X
Serum or Urine β-hCG (for 
all FCBP)l
X
(w/in72 
hours)
X
X
X
X
PK blood draws sampling 
(See Section Error! 
Reference source not 
found. for timepoints) 
X
X
Tumor biopsy for Biomarker 
Analyses
X
(Mandatory –
archival or 
fresh tumor 
collection)
X
(Optio
nal)
Blood for Biomarker DNA 
Analyses
X 
X
Blood for Biomarker RNA 
Analyses
X
X
X
Serum for Biomarker 
Analyses
X 
X
Xm
X
Saliva for Germline DNA 
Analysis
X
&(/*(1(35235,(7$5<,1)250$7,21
alal
$
50$
50
)25
)2
)2
)2
)2
Optio
Optio
nal)
nal)
,1
$5<
X
7$
( $
X
(7
,(
5,(
,(
35,(
X
35
35
35
235
3


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-
up 
Period
Day
-21 to -1
1b
14
1
14
1
EOT
Disease 
Progressi
on/ 
Survival
Tumor evaluation (CT/MRI)
X 
RECIST 1.1 algorithm: Every 6 weeks (± 5 days) from randomization for 
the first 24 weeks then every 9 weeks until disease progression (for 
exceptions refer to Section Error! Reference source not found.) or start 
of a new anticancer treatment, or withdrawal of consent
The irRECIST will be evaluated as exploratory efficacy assessment. For 
additional details, see Sections Error! Reference source not found. , 
Error! Reference source not found. and Appendix B, Section Error! 
Reference source not found.
Bone Scan
Only if clinically indicated
CT Scan of the Head or 
Brain MRI
X
Only if clinically indicated
Administer                    CC-
486/placebo
Daily on Days 1-14
Administer pembrolizumab
Xn
X
On Day 1 
only
IP accountability
X
X
X
X
Survival follow-up
Every 8 
weeks 
(+/- 5 
days)
Anticancer therapy since IP 
discontinuation
At every 
survival 
follow-up 
visit
Abbreviations: β-hCG = beta human chorionic gonadotropin; C1D1 = Cycle 1 Day 1; CT = 
computed tomography; ECOG = Eastern Cooperative Oncology Group; EOT = End of 
Treatment; FCBP = females of child bearing potential; IP = investigational product; irRECIST =
immune-related Response Evaluation Criteria in Solid Tumors; IRT = interactive response 
technology; MRI = magnetic resonance imaging; PK = pharmacokinetic; RECIST = Response 
Evaluation Criteria in Solid Tumors
a All visits have a ± 2-day window, except Cycle 1 Day 1 which must occur within 21 days from 
Informed Consent Form signature, and survival follow-up which has a ±5-day window.
b Cycle 1 Day 1 evaluations can be omitted if Screening evaluations are performed within 72 
hours of Cycle 1 Day 1.
c Prior cancer therapies include surgery, radiation, systemic or any other therapy (eg, hormonal, 
locoregional) for the subject's cancer
&(/*(1(35235,(7$5<,1)250$7,21
alal
$
tion for 
on fo
on (for 
on (for 
und.
und.) or start 
) or star
onsent
onsent
cy assessmen
cy assessm
source not f
source no
endix
endix B, Secti
Secti
)2
ound.
und.
$
0$
1)
ndicated
dic
,1
ays 1
ys 1-14
14
5<
X
$5
$5
$5
$5
X
(7$
(7
35,(
23
3523
G = beta hu
G = beta h
aphy; ECO
aphy; ECO
BP = femal
BP = fem
ated Respo
ated Respo
gy; MRI = 
MRI =
atatioion Cri
n Criter
ti
All
All visits ha
visits h
Inform
nformed 
ed
Cyc


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
d Prior/concomitant medication evaluation ≤ 28 days before screening through 28 days after last 
dose.
e Prior/concomitant procedures evaluation ≤ 28 days before screening through 28 days after last 
dose.
f Prior to receiving first dose.
g Hematology includes complete blood count (CBC) with differential, including but not limited 
to red blood cell (RBC) count, hemoglobin, hematocrit, white blood cell (WBC) count with 
differential (neutrophil count including lymphocyte, monocyte, eosinophil, basophil counts and 
bands), absolute neutrophil count (ANC), and platelet count. ANC should be measured with 
automated count where available.
h Coagulation tests, including prothrombin time (PT), partial thromboplastin time (PTT), 
activated partial thromboplastin time (aPTT) and international normalized ration (INR)
i Chemistry includes (but is not limited to) sodium, potassium, calcium, phosphorus, chloride, 
magnesium, bicarbonate, blood urea nitrogen (BUN) or urea, serum creatinine, fasting glucose, 
uric acid, albumin, total protein, alkaline phosphatase, lactate dehydrogenase, total bilirubin 
(indirect and direct), aspartate aminotransferase/serum glutamic oxaloacetic transaminase 
(AST/SGOT), alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)
j Lipid Panel parameters include total cholesterol, high-density lipoprotein, low-density 
lipoprotein, triglycerides
k Urinalysis (a urine dipstick may be used) at screening and D1 of each cycle if abnormal at 
baseline.
l Serum β-hCG (for all FCPB) performed at screening; remaining pregnancy tests may be serum 
or urine at the Investigator’s discretion. Pregnancy testing (for all FCPB) must be done within 72 
hours prior to the first administration of IP and prior to dosing on Day 1 of every cycle. If the 
serum screening pregnancy test is performed > 72 hours before first dose, a serum or urine 
pregnancy test should be performed (Investigator’s discretion). The subject may not receive IP 
until the Investigator has verified that the result of the pregnancy test is negative.
m Day 1 of Cycle 3 and every third cycle thereafter (C6D1, C9D1, C12D1)
n On Cycle 1 Day 1, pembrolizumab will be administered after the 6 hour CC-486 PK sample 
collection. For all subsequent pembrolizumab administration, pembrolizumab will be co-
administered with CC-486.
&(/*(1(35235,(7$5<,1)250$7,21
and 
nd 
ithth
(PTT), 
PTT), 
n (INR)
n (INR)
osphoru
osphorus, c
s, c
atinine, fast
nine, 
ogenase, to
ogenase, to
ala oacet
cetic t
ic
c transamin
transamin
ity y lipopro
lipopro
ing and D1
ing and D
creening; r
creening; r
egnancy te
egnancy te
f IP and pri
IP and pr
erform
rformed > 
ed 
ed (Invest
ed (Investi
ied that the 
d that the
ery third cy
y third cy
embrolizum
mbrolizum
ubsequent 
ubsequent 
h CC
h CC-486.
-486


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
17.3.
Handling of Dates
Dates will be stored as numeric variables in the SAS analysis files and reported in 
DDMMMYYYY format (i.e., the Date9. datetime format in SAS).  Dates in the clinical database 
are classified into the categories of procedure dates, log dates, milestone dates, outcome dates, 
and special dates.
!
Procedure Dates are the dates on which given protocol-specified procedure are 
performed.  They include the dates of laboratory testing, physical examinations, 
tumor scans, etc.  They should be present whenever data for a protocol-specified 
procedure are present and should only be missing when a procedure are marked as 
NOT DONE in the database.  Procedure dates will not be imputed.
!
Log Dates are dates recorded in CRF data logs.  Specifically, they are the start and 
end dates for adverse events and concomitant medications/procedures.  They should 
not be missing unless an event or medication is marked as ongoing in the database.  
Otherwise, incomplete log dates will be imputed according to the rules in Appendix 
16.2 (eg, for duration or cycle assignment, etc). However, in listings, log dates will be 
shown as recorded without imputation.
!
Milestone Dates are dates of protocol milestones such as randomization, study drug 
start date, study drug termination date, study closure date, etc.  They should not be 
missing if the milestone occurs for a subject.  They will not be imputed.
!
Outcome Dates are dates corresponding to study endpoints such as survival, 
progression, etc.  In most cases they are derived either from a milestone (eg, the 
survival date is derived from the death date), or a procedure date (eg, the progression 
date is derived from the date of the tumor scan that was used to determine 
progression).  They may be subject to endpoint-specific censoring rules if the 
outcome did not occur, but are not otherwise subject to imputation.
!
Special Dates cannot be classified in any of the above categories and they include the 
date of birth.  They may be subject to variable-specific censoring and imputation 
rules. 
Dates recorded in comment fields will not be imputed or reported in any specific format. 
17.3.1.
Calculation Using Dates 
Calculations using dates (e.g., subject’s age or relative day after the first dose of study drug) will 
adhere to the following conventions: 
!
Study days after the start day of study drug will be calculated as the difference 
between the date of interest and the first date of dosing of study drug (e.g, CC-486) 
plus 1 day. The generalized calculation algorithm for relative day is the following: 
o
If TARGET DATE >= DRUG START DATE then STUDY DAY = 
(TARGET DATE – DRUG START DATE) + 1; 
&(/*(1(35235,(7$5<,1)250$7,21
s, 
s, 
cified 
ified 
marked as
marked as
y are the st
y are the 
cedures.  T
cedures.  T
ongoing
ngoing in t
in
ng to the ru
g to the ru
ever, in list
er, in lis i
nes such as
nes such as
y clc
y
osure d
osure d
ject.  They 
ject.  The
ding to stud
ding to st
hey are deri
hey are deri
he death da
e death da
e of the tum
of the tum
be subject 
e subjec
r, but are n
r, but are n
nnot be
nnot be cla
They
They m
y
ay b
comment fi
comment fi
alculation 
culation 
ions using 
s using
e to the fo
e to the fol
!
S


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
o
Else use STUDY DAY = TARGET DATE – DRUG START DATE.
Note that Study Day 1 is the first day of treatment of study drug. Negative study days 
are reflective of observations obtained during the baseline/screening period.  Note: 
Partial dates for the first study drug are not imputed in general. All effort should be 
made to avoid incomplete study drug start dates. 
!
Age (expressed in days) is calculated: AGE = CONSENT – DATE of BIRTH + 1.  In 
practice, age will be transformed to years by dividing the difference by 365.25 days, 
then truncating.
∃
Preference is for using calculated age from clinical database. When not available, 
calculated age from CRF or IVRS may be used
∃
Partial birth date: impute missing day as 15th of the month; impute as 01-July for 
missing month; set missing age for missing year
!
Intervals that are presented in weeks will be transformed from days to weeks by using 
(without truncation) the following conversion formula:
WEEKS = DAYS /7
!
Intervals that are presented in months will be transformed from days to months by 
using (without truncation) the following conversion formula:
MONTHS = DAYS /30.4375
17.4.
Date Imputation Guideline
17.4.1.
Impute Missing Adverse Events/ Prior or Concomitant Medications 
Incomplete Start Date:
Missing day and month
!
If the year is the same as the year of the first dosing date, then the day and month of 
the first doing date will be assigned to the missing fields.
!
If the year is prior to the year of first dosing date, then December 31 will be assigned 
to the missing fields.
!
If the year is after the year of first dosing, then January 1 will be assigned to the 
missing fields.
Missing day only 
!
If the month and year are the same as the year and month of first dosing date, then the 
first doing date will be assigned to the missing day.
!
If either the year of the partial date is before the year of the first dosing date or the 
years of the partial date and the first dosing date are the same but the month of partial 
date is before the month of the first dosing date, then the last day of the month will be 
assigned to the missing day.
&(/*(1(35235,(7$5<,1)250$7,21
ailable,
ilable,
as 01
s 01-July 
July
days to wee
ays to wee
rmed fro
rmed
m
on formula
on formul
s/ Prior or
/ Prior or
me
me as the y
as the y
atete will be a
will be
pr
prior to
to th
ssing fields
sing field
e year is
 year is aft
af
issing field
issing field
day only
y only
!
If th
If th
f


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
!
If either the year of the partial date is after the year of the first dosing date or the 
years of the partial date and the first dose date are the same but the month of partial 
date is after the month of the first dosing date, then the first day of the month will be 
assigned to the missing day.
!
If the stop date is not missing, and the imputed start date is after the stop date, the 
start date will be imputed by the stop date. 
Missing day, month, and year
!
No imputation is needed; the corresponding AE will be included as TEAE. 
Incomplete Stop Date: If the imputed stop date is before the start date, then the imputed stop 
date will be equal to the start date.
Missing day and month
!
If the year of the incomplete stop date is the same as the year of the last dosing date, 
then the day and month of the last dosing date will be assigned to the missing fields. 
!
If the year of the incomplete stop date is prior to the year of the last dosing date or 
prior to the year of the first dosing date, then December 31 will be assigned to the 
missing fields. 
!
If the year of the incomplete stop date is prior to the year of the last dosing date but 
is the same as the year of the first dosing date, then the first dosing date will be 
assigned to the missing date. 
!
If the year of the incomplete stop date is after the year of the last dosing date, then
January 1 will be assigned to the missing fields.
Missing day only 
!
If the month and year of the incomplete stop date are the same as the month and year 
of the last dosing date, then the day of the last dosing date will be assigned to the 
missing day. 
!
If either the year of the partial date is not equal to the year of the last dosing date or 
the years of the partial date and the last dosing date are the same but the month of 
partial date is not equal to the month of the last dosing date, then the last day of the 
month will be assigned to the missing day. 
17.4.1.
Adverse Events
Partially missing AE start dates will be imputed in the ADaM dataset for AEs, but partially 
missing AE end dates will not be imputed in the same dataset. If the AE end date is complete 
with no missing year, month, or day, and the partially missing start date imputed by the rules 
below is after the AE end date, then the start date will be imputed by the AE end date.
17.4.2.
Prior/Concomitant Medications/Procedures
Partially missing start/stop dates for prior/concomitant medications and partially missing start 
dates for prior/concomitant procedures will be imputed in the ADaM dataset for 
&(/*(1(35235,(7$5<,1)250$7,21
d stop 
d stop 
the l
the last dos
ast do
d to the mi
to the
r of the last
of the las
er 31 will b
31 will b
to the year
the yea
te, then the 
te, then the
e is
e is after
after th
missing fiel
missing fiel
the incomp
he incom
, then the d
, then the 
ar of the pa
of the pa
the partial 
the partial
te i
e is s not eq
not e
h will be as
h will be as
Adverse Ev
Adverse E
ly missing A
y missing A
sing AE en
sing AE en
wi
with
th
i
no mis
no mis
h
below is 
below is 


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
prior/concomitant medications/procedures. For prior/concomitant medications, if the stop date is 
complete with no missing year, month, or day, and the partially missing start date imputed by the 
rule below is after the stop date, then the start date will be imputed by the stop date.
Partially missing prior/concomitant medication/procedure start dates will be imputed by the 
earliest possible date given the non-missing field(s) of the date.
Partially missing prior/concomitant medication stop dates will be imputed by the latest possible 
date given the non-missing field(s) of the date.
17.4.3.
Medical History
Partially missing medical history start dates will be imputed in the ADaM dataset for medical 
history (for the purposes of calculating durations of PsA and psoriasis). The 16th of the month 
will be used to impute a partially missing start date that has only the day missing, and July 1st 
will be used to impute a partially missing start date that has both the month and day missing.
&(/*(1(35235,(7$5<,1)250$7,21
medical
medical
f the month
f the month
g, and July 
g, and July 
nd day miss
nd day mis


CC-486
Statistical Analysis Plan. Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
17.4.4.
Tumor Response Visit Window
Relative Day Ranges for the CT-Scans
Study Week
Relative Weeks From Randomization
Relative Days  From Randomization
6
6
2 - 63
12
12
64 - 105
18
18
106 - 147
24
24
148 - 203
33
33
204 - 266
42
42
267 - 329
51
51
330 - 392
60
60
393 - 455
69
69
456 - 518
78
78
519 - 581
87
87
582 - 644
96
96
645 - 707
105
105
708 - 770
114
114
770 - 833
&(/*(1(35235,(7$5<,1)250$7,21
$7
$7
$7
$7
0$
50
392
392
25
93 - 455
3 - 45
)2
456 - 51
456 - 5
1)
519
19
,1
5<
$5
7$
(7
(7
(7
(7
5,(7

Prot_001.pdf: 
 
 
 
 
 
Protocol Title: A Phase 2 Multicenter, Randomized, 
Placebo Controlled, Double-Blind Study To Assess 
The Safety And Efficacy Of CC-486 (Oral Azacitidine) 
In Combination With Pembrolizumab (Mk-3475) 
Versus Pembrolizumab Plus Placebo In Subjects 
With Previously Treated Locally Advanced Or 
Metastatic Non-Small Cell Lung Cancer 
 
NCT Number:  NCT02546986 
Protocol Amendment 1 Date:  14 December 2015 


',6&/2685(
5('$&7('35272&2/$0(1'0(17
&&16&/
$3+$6(08/7,&(17(55$1'20,=('3/$&(%2&21752//(''28%/(
%/,1'678'<72$66(667+(6$)(7<$1'()),&$&<2)&&25$/
$=$&,7,',1(,1&20%,1$7,21:,7+3(0%52/,=80$%0.9(5686
3(0%52/,=80$%3/863/$&(%2,168%-(&76:,7+35(9,286/<75($7('
/2&$//<$'9$1&('250(7$67$7,&12160$//&(///81*&$1&(5
㻌
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW\RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG

&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFDOWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH/DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHUKDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RUUHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV

7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFHUWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HOJHQH¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLSOHV

x
5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQLQJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x
$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGXDOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x
$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLRQDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQIRUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOFRPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\VHV
x
&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFWOLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNVLQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x
,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFWHGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQVSUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVSURWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQH¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODELOLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFDOWULDOVFOLQLFDOWULDOVGDWDVKDULQJ


&(/*(1(35235,(7$5<,1)250$7,21
(
5686
5686
5($7('
5($7('
&$1&(5
&$1&(5
OGQRWEHVKD
OGQRWEHVK
HDUFKHUVDQG
HDUFKHUVDQ
GUHJXO
GUHJXODWLRQ
DWLR
OHJDORUF
JDORUFRQ
RQ
WHGWRFHUWDL
WHGWRFHU
FHUWDLQLQIRU
HUWDLQLQIRU
WHFW&HOJHQH
WHFW&HOJHQ
QJSULQFLSOH
QJSULQFLSOH
JUH\
JUH\ VSDFH
VSDFH
HQWLIL
HQWLILFDWLRQ
FDWL
QWDLQFRQILGH
DLQFRQILG
RQWDLQLGHQ
RQWDLQLGHQ
\DOVRPD\
\DOVRPD\
WKHVLVJHQHU
KHVLVJHQH
HVHDWWDFKPH
HVHDWWDFKP
RG\RIWKHU
RG\RIWKH
O
ERXW&HOJHQ
ERXW&HOJHQ
RIWKDWLQIRU
IWKDWLQIR
LRQDERXWR
LRQDERXWR
PDWLRQDERXW
PDWLRQDERXW
IRXQGDWKWWS
RXQGDWKWWS


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
1
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
TITLE PAGE
A PHASE 2 MULTICENTER, RANDOMIZED, PLACEBO 
CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS 
THE SAFETY AND EFFICACY OF CC-486 (ORAL 
AZACITIDINE) IN COMBINATION WITH 
PEMBROLIZUMAB (MK-3475) VERSUS 
PEMBROLIZUMAB PLUS PLACEBO IN SUBJECTS 
WITH PREVIOUSLY TREATED LOCALLY ADVANCED 
OR METASTATIC NON-SMALL CELL LUNG CANCER
PROTOCOL NUMBER:
CC-486-NSCL-001
DATE FINAL:
15 May 2015
DATE AMENDMENT 1 FINAL:
14 Dec 2015
EudraCT NUMBER:
2014-005614-29
IND NUMBER:
123160
SPONSOR NAME / ADDRESS:
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
United States
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
you, your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by law or regulations.  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by them.
&(/*(1(35
s provided to y
s provided to
staff, and eth
taff, and eth
ent is regarde
ent is regar
may not be di
may not be di
Persons to w
ersons to w
35235,(7$5<,1)250$7,21
CTS 
CTS 
VANCE
VANCE
G CANC
CAN
NSCL
C -001
01
ay
ay 2015
20
4 Dec 2015
Dec 20
2014
2014-00
-0
123
23
35
35
(/
(/
(/
(/
(/
(/
(/


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
2
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION 
Contact Information:
Name:
Title:
Address: Route de Perreux 1, 
Boudry, Switzerland  2017
Phone:
E-mail:
Note: The back-up 24-hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.
Back-up 24-hour Global Emergency Contact Call Center: 
&(/*(1(35235,(7$5<,1)250$7,21
0
50
2
1)
should only
should onl
dical Moni
ical Mon
er: 
5<
$5
$5<


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
3
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE
{See appended electronic signature page}
Signature of Celgene Therapeutic Area Head
dd mmm yyyy
Printed Name of Celgene Therapeutic Area Head and Title
By my signature, I indicate I have reviewed this protocol and find its content to be 
acceptable.  
&(/*(1(35235,(7$5<,1
,1
,1)250$7,21
0$
0$
50
content to 
content to
,1


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaration of Helsinki, International Conference on 
Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations 
governing the conduct of clinical studies.
&(/*(1(35235,(7$5<,1)250$7,21
0$
0$
50
s study
s study at m
at
y
, informed 
nformed
ocedures, in
edures, i
national C
nationa
nes, and loc
s, and lo
7$
7$


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator
dd mmm yyyy
Printed Name of Coordinating Principal Investigator
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
&(/*(1(35235,(7$5<
5<
5<,1)
wi
wi
1)250$7,21
0$
0$
50
th
th
i
ICH G
ICH 
h
ghout the st
out the st
5<


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
PROTOCOL SUMMARY
Study Title
A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety 
and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus 
pembrolizumab plus placebo in subjects with previously treated locally advanced or metastatic 
non-small cell lung cancer
Indication  
Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). 
Objectives
Primary Objective:
!
To estimate the efficacy of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo based on progression-free survival (PFS) as measured using Response 
Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Secondary Objectives:
!
To estimate disease control rate (DCR) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To estimate overall survival (OS) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To estimate overall response rate (ORR) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To evaluate safety and tolerability of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To evaluate the impact of pembrolizumab on the pharmacokinetics of CC-486 
Exploratory Objectives:
!
To determine the preliminary efficacy (immune-related [ir] PFS, irDCR, irORR) of 
CC-486 in combination with pembrolizumab versus pembrolizumab plus placebo
based on irRECIST criteria 
!
To explore mechanism and biomarkers associated with efficacy of CC-486 in 
combination with pembrolizumab versus pembrolizumab plus placebo,
Study Design
This is a Phase 2, multicenter, international, randomized, placebo controlled double-blind study 
to assess the safety and efficacy of the combination therapy of CC-486 plus pembrolizumab
versus placebo plus pembrolizumab in previously treated subjects with locally advanced or 
metastatic NSCLC who have received only one prior platinum-based chemotherapy regimen. 
&(/*(1(35235,(7$5<,1)250$7,21
SCLC
SCLC).
us s pembrol
pemb
ured using
red using R
ia
486 pl
6 plus 
us
l
pe
p
486 pl
486 plus
l
p
(ORR)
(ORR) of
of
erabilit
erability of
acebo
eb
mpact of pem
act of pe
mine the pre
ine the p
6 in combin
in combin
d on i
d on irREC
rREC
i
To expl
To explore
ore
combina
combin
Study De
Study D
(/*
(/


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Approximately 90 subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or 
placebo plus pembrolizumab. A safety analysis will be performed in the first 10 subjects in each 
arm after the completion of at least 1 cycle of treatment.
The randomization will be stratified by histology (non-squamous versus squamous).
An independent Data Monitoring Committee (iDMC) will be established to evaluate safety. 
Following the initial iDMC data review meeting, the iDMC will meet approximately every 6 
months per DMC charter (or more often if requested by the DMC Chairman) to assess safety 
data.  Details are outlined in the DMC charter.
The conduct of this trial will be overseen by a Steering Committee which will serve in an 
advisory capacity to the Sponsor.  
The study will be conducted in compliance with International Conference on Harmonisation 
(ICH) Good Clinical Practices (GCPs).
Study Population
Adult subjects with histologically confirmed diagnosis of locally advanced or metastatic 
NSCLC, lacking or with unknown anaplastic lymphoma kinase (ALK) or epidermal growth 
factor receptor (EGFR) mutations, who have been treated with only 1 prior platinum-based 
chemotherapy regimen for locally advanced or metastatic disease.
Length of Study
Enrollment is expected to take approximately 12 months to complete.  The total length of this 
Phase 2 study with follow-up is estimated to be approximately 2 years. The primary analysis will 
be conducted when 70 PFS events have occurred. 
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol,
whichever is the later date.  
Study Treatments
CC-486/placebo will be administered at a dose of 300 mg orally daily on days 1-14 of a 21-day 
cycle. Pembrolizumab will be administered as a 30-minute intravenous (IV) infusion at a dose of 
200 mg (4 x 50 mg vials) on day 1 of a 21-day cycle. 
Subjects may remain on treatment until radiologic disease progression (for exceptions refer to 
Section 6.4.3), unacceptable toxicity, initiation of a new anticancer therapy, withdrawal of 
consent, subject refusal, physician decision, or death.
Overview of Efficacy Assessments
All subjects will be evaluated for tumor response and progression by Investigator assessment
according to RECIST 1.1 guidelines at screening and every 6 weeks (± 5 days) from 
randomization for the first 24 weeks, and every 9 weeks thereafter until documented disease 
progression (for exceptions refer to Section 6.4.3), start of new anticancer therapy, or withdrawal 
of consent. Subjects will also be evaluated according to irRECIST guidelines in cases of 
progressive disease (PD) per RECIST 1.1.
&(/*(1(35235,(7$5<,1)250$7,21
monisat
onisatioion n
nced 
ced or 
or met
m
K)
K or 
or epi
epide
de
nly 1 prior p
or p
ase
se.
ths to comp
ths to comp
proximately
proximatel
d.
e of the last
e of the last
eceipt of th
eceipt of th
r explorato
r explorato
ministered 
ministered
will be adm
will be adm
ials)
als) on day
on d
main on trea
main on tre
, unaccepta
unaccept
bject refusa
bject refus
iew of Effi
iew of Effi
subjects w
subjects w
acco
cc rding 
ding 
ando
andom


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Response assessments will include computed tomography (CT) scan or magnetic resonance 
imaging (MRI) of the chest, upper abdomen, including whole liver and kidney and, if clinically 
indicated, pelvis. Pelvis scan should be performed only with MRI unless CT is local standard of 
care at the site. Bone scans will only be performed at baseline if clinically indicated. If the 
baseline bone scan is suggestive of metastasis, a CT or MRI should be performed and further 
follow-up of these lesions will follow the protocol schedule. Bone scans during the trial will only 
be performed if clinically indicated.  If suggestive of new lesions, a CT or MRI will be 
performed to confirm progression.
In the follow-up phase, anticancer treatment administered following the last dose of 
investigational product [(IP), also referred to as investigational medicinal product (IMP)] and 
survival will be followed every 8 weeks (± 5 days) until death, withdrawal of consent, or lost-to-
follow-up, whichever occurs first, or the End of Trial.
Overview of Safety Assessments
All subjects will be monitored for adverse events, starting from the time the subject signs the 
informed consent form (ICF) until 30 days after the last dose of either study drug. A thorough 
evaluation of medical conditions will be conducted during screening for eligibility. Documented
physical examination (PE), vital signs, laboratory assessments, (eg, serum chemistry, 
hematology), 12-lead electrocardiogram (ECG), urinalysis, and Eastern Cooperative Oncology 
Group (ECOG) performance status will be monitored regularly. Preventative measures will be 
taken to avoid pregnancy in study subjects or their partners, and females of child-bearing 
potential will have regular pregnancy testing performed. The full schedule of assessments is 
described in Table 2 and Section 6.
Overview of Statistical Methods
This is a double-blind, placebo-controlled, randomized, phase 2 trial designed to evaluate the 
efficacy and safety/tolerability of  CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo, in subjects with previously treated locally advanced or metastatic non-small cell lung 
cancer. The primary endpoint is PFS based on Investigator review.
Sample Size
The primary goal of this study is to provide estimates of the difference in efficacy and safety 
between CC-486 + pembrolizumab and placebo + pembrolizumab. Approximately 90 subjects 
will be randomized 1:1 to receive CC-486 plus pembrolizumab or placebo plus pembrolizumab. 
Primary analysis will be conducted when 70 PFS events occur. In this particular setting, a formal 
power calculation was not conducted.
Efficacy Analysis
Efficacy analyses will be performed using the intent-to-treat (ITT) population.
The median PFS in each stratum and treatment arm will be calculated based on Kaplan-Meier 
estimates along with corresponding two-sided 90% confidence interval (CI).  In addition, the 
Cox proportional hazards regression model with treatment and any stratification factors will be 
performed to obtain the point estimate of hazard ratio (HR) and two-sided 90% CI.  
The secondary efficacy endpoint of OS will be analyzed similarly to PFS.  Other secondary 
endpoints of overall response rate (ORR), and disease control rate (DCR) will be evaluated as 
&(/*(1(35235,(7$5<,1)250$7,21
and 
and
or 
or lolostst-toto
e subject si
e subject si
tudy
dy drug
drug
y
A
for eligibil
for eligibi
g, serum ch
 serum ch
Eastern
Easte
C
rly
rly. Preven
Preven
rs, and fem
rs, and fem
d. The full 
d. The full
randomized
andomize
86 pl
86 plus
us
l
pem
p
reated
reated lol ca
FS based on
based on
tudy
dy i
y s to p
s to p
mbrolizuma
mbrolizuma
1:1 to recei
1 to rece
will be con
will be con
ion was no
n was n
Analysis
nalysis
cy analyses
cy analyse
he m
he median P
edian 
estimates 
stimates 
ox pr
ox pr


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
well. A two-sided 90% CI of the difference in ORR and DCR between the two treatment arms 
will be provided. 
Safety Analysis
Safety analysis will be performed using the safety population. Safety and tolerability will be 
monitored through continuous reporting of adverse events (AEs) and serious adverse events 
(SAEs), laboratory abnormalities, and incidence of subjects experiencing adverse events 
resulting in dose reductions, dose interruptions, and/or premature discontinuation of study drugs. 
Treatment-emergent adverse events (TEAEs), TEAEs leading to death or discontinuation from 
treatment, events assessed as Grade 3 or Grade 4,  vital signs, weight, clinical laboratory 
information, and concomitant medications/procedures will be tabulated and summarized.
All AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA). 
All TEAEs will be summarized by system organ class and preferred term, frequency, severity 
grade based on the Common Terminology Criteria for Adverse Events (CTCAE) (Version 4.0) 
and relationship to treatment. Serious TEAEs, TEAEs of interest, and TEAEs leading to 
discontinuation, dose reduction, or interruption,  or death will be summarized/ listed separately.
&(/*(1(35235,(7$5<,1)250$7,21
m 
d.
s (MedDR
s (MedDR
ency, severi
ncy, sever
AE) (Versio
AE) (Versi
AEs leading
Es leading
arized/ liste
zed/ li


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1.
INTRODUCTION..................................................................................................17
1.1.
Disease Background ...............................................................................................17
1.2.
Treatment Options in Second-line Metastatic NSCLC ............................................17
1.3.
Overview of CC-486...............................................................................................19
1.3.1.
CC-486 Experience in Solid Tumors.......................................................................21
1.4.
Overview of Pembrolizumab ..................................................................................22
1.4.1.
Pembrolizumab Experience in Solid Tumors and Safety.........................................22
1.5.
Study Rationale ......................................................................................................23
2.
STUDY OBJECTIVES...........................................................................................25
2.1.
Primary Objective...................................................................................................25
2.2.
Secondary Objectives .............................................................................................25
2.3.
Exploratory Objectives ...........................................................................................25
3.
STUDY ENDPOINTS............................................................................................26
3.1.
Primary Endpoint....................................................................................................26
3.2.
Secondary Endpoints ..............................................................................................26
3.3.
Exploratory Endpoint(s)..........................................................................................26
4.
OVERALL STUDY DESIGN ................................................................................27
4.1.
Study Design ..........................................................................................................27
4.2.
Study Duration .......................................................................................................28
4.3.
End of Trial ............................................................................................................28
5.
TABLE OF EVENTS.............................................................................................29
6.
PROCEDURES......................................................................................................34
6.1.
Screening Period.....................................................................................................34
6.2.
Treatment Period ....................................................................................................35
6.2.1.
End of Treatment....................................................................................................36
6.3.
Follow-up Period....................................................................................................37
6.3.1.
Efficacy Follow-up.................................................................................................37
6.3.2.
Survival Follow-up.................................................................................................37
6.4.
Response Assessments............................................................................................37
&(/*(1(35235,(7$5<,1)250$7,21
7
....... 19
19
...........
.......... 21
2
.............
............
..............
............
.............
............
.............
.............
........
..
......
.....
.............
.........
..............
...
................
........
.............
.............
.............
.............
..............
........
IGN
IGN ......
..
..............
.............
..............
.........
.............
.........
OF EVENT
OF EVEN
CEDURES
CEDURES
Screening P
Screening P
Treatme
Treatm
.
End
En
.3.
.3.
.3.1.
.3.1.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
6.4.1.
Assessment of Response According to RECIST Version 1.1...................................38
6.4.2.
Assessment of Response According to irRECIST ...................................................38
6.4.3.
Assessment of Disease and Treatment after Initial Radiologic Progression .............38
6.5.
Pharmacokinetics....................................................................................................39
6.6.
Biomarkers .............................................................................................................40
6.7.
12-lead Electrocardiogram......................................................................................40
7.
STUDY POPULATION.........................................................................................41
7.1.
Number of Subjects and Sites .................................................................................41
7.2.
Inclusion Criteria....................................................................................................41
7.3.
Exclusion Criteria...................................................................................................42
8.
DESCRIPTION OF STUDY TREATMENTS........................................................45
8.1.
Description of Investigational Products...................................................................45
8.1.1.
CC-486 (Oral Azacitidine)/Placebo.........................................................................45
8.1.2.
Pembrolizumab.......................................................................................................45
8.2.
Treatment Administration and Schedule .................................................................45
8.2.1.
Dose Adjustment Guidelines...................................................................................46
8.2.1.1.
CC-486 (oral azacitidine)/Placebo ..........................................................................46
8.2.1.2.
Pembrolizumab.......................................................................................................48
8.2.2.
Overdose ................................................................................................................50
8.3.
Method of Treatment Assignment...........................................................................51
8.4.
Packaging and Labeling..........................................................................................51
8.5.
Investigational Product Accountability and Disposal ..............................................51
8.6.
Investigational Product Compliance........................................................................51
9.
CONCOMITANT MEDICATIONS AND PROCEDURES....................................52
9.1.
Permitted Concomitant Medications and Procedures...............................................52
9.1.1.
CC-486 (oral azacitidine)........................................................................................52
9.1.2.
Pembrolizumab Supportive Care.............................................................................52
9.1.2.1.
Management of pneumonitis...................................................................................53
9.1.2.2.
Management of Diarrhea/Colitis.............................................................................53
9.1.2.3.
Management of type 1 diabetes mellitus (if new onset, including diabetic 
ketoacidosis [DKA]) or ≥ Grade 3 Hyperglycemia, if associated with ketosis 
(ketonuria) or metabolic acidosis (DKA) ................................................................53
9.1.2.4.
Management of hypophysitis ..................................................................................53
&(/*(1(35235,(7$5<,1)250$7,21
0
.......41
4
..........
.... 41
4
..............
...........
..............
............
.............
.............
..............
............
.............
......
.........
..... ....
..............
...........
..........
.............
.............
............
..............
..........
.............
..........
ignment
gnmen ..
ng...........
.........
oduct Acco
oduct Acc
al Product C
al Product C
MITANT M
ITANT
tted Conco
tted Conco
C-486 (ora
486 (ora
Pembrol
Pembro
1.1.
Man
Ma
.1.2.2.
.1.2.2.
9.1.2.3.
.1.2.3


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
9.1.2.5.
Management of hyperthyroidism or hypothyroidism...............................................54
9.1.2.6.
Management of hepatic abnormalities.....................................................................54
9.1.2.7.
Management of renal failure or nephritis.................................................................54
9.1.2.8.
Management of infusion reactions ..........................................................................54
9.2.
Prohibited Concomitant Medications and Procedures..............................................56
9.3.
Required Concomitant Medications and Procedures................................................57
10.
STATISTICAL ANALYSES..................................................................................58
10.1.
Overview................................................................................................................58
10.2.
Study Population Definitions ..................................................................................58
10.2.1.
Intent-To-Treat Population .....................................................................................58
10.2.2.
Safety Population....................................................................................................58
10.2.3.
PK Population ........................................................................................................58
10.2.4.
Biomarker Population.............................................................................................58
10.3.
Sample Size and Power Considerations...................................................................58
10.4.
Background and Demographic Characteristics........................................................59
10.5.
Subject Disposition.................................................................................................59
10.6.
Efficacy Analysis....................................................................................................59
10.6.1.
Primary Efficacy Endpoint......................................................................................59
10.6.2.
Secondary Endpoints ..............................................................................................60
10.6.2.1.
Overall Survival .....................................................................................................60
10.6.2.2.
Overall Response Rate (ORR) ................................................................................60
10.6.2.3.
Disease Control Rate (DCR)...................................................................................60
10.6.2.4.
irPFS, irORR and irDCR per irRECIST..................................................................60
10.6.3.
Subgroup Analysis..................................................................................................60
10.7.
Safety Analysis.......................................................................................................60
10.8.
Pharmacokinetic Analysis.......................................................................................61
10.8.1.
Plasma Concentrations............................................................................................61
10.8.2.
Pharmacokinetic Parameters...................................................................................62
10.8.3.
PK Analyses...........................................................................................................63
10.9.
Interim Analysis .....................................................................................................63
10.10.
Other Topics...........................................................................................................63
10.10.1.
Data Monitoring Committee ...................................................................................63
10.10.2.
Steering Committee ................................................................................................63
7
.......58
5
..........
.... 58
5
..............
...........
..............
............
.............
.............
..............
............
.............
.............
.............
.....
..............
...........
.............
.............
.............
............
..............
..........
.............
..........
.............
....
e (ORR)
e (ORR) .
Rate (DCR)
Rate (DCR
and i
nd irDCR
rDCR
i
Analysis
Analysi
y y Analysis
Analysis
harmacokin
armacoki
Pl
P asma 
asma 
2.2.
Phar
Ph
0.8.3.
0.8.3.
10.9.
0.9.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
13
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
11.
ADVERSE EVENTS..............................................................................................65
11.1.
Monitoring, Recording and Reporting of Adverse Events .......................................65
11.2.
Evaluation of Adverse Events.................................................................................66
11.2.1.
Seriousness.............................................................................................................66
11.2.2.
Severity / Intensity..................................................................................................67
11.2.3.
Causality ................................................................................................................67
11.2.4.
Duration .................................................................................................................68
11.2.5.
Action Taken..........................................................................................................68
11.2.6.
Outcome.................................................................................................................68
11.3.
Abnormal Laboratory Values..................................................................................68
11.4.
Pregnancy...............................................................................................................68
11.4.1.
Females of Childbearing Potential ..........................................................................69
11.4.2.
Male Subjects.........................................................................................................69
11.5.
Reporting of Serious Adverse Events......................................................................69
11.5.1.
Safety Queries ........................................................................................................70
11.6.
Expedited Reporting of Adverse Events..................................................................70
11.7.
Pembrolizumab Events of Clinical Interest .............................................................71
12.
DISCONTINUATIONS .........................................................................................73
12.1.
Treatment Discontinuations ....................................................................................73
12.2.
Study Discontinuation ............................................................................................73
13.
EMERGENCY PROCEDURES.............................................................................74
13.1.
Emergency Contact.................................................................................................74
13.2.
Emergency Identification of Investigational Products .............................................74
14.
REGULATORY CONSIDERATIONS...................................................................75
14.1.
Good Clinical Practice............................................................................................75
14.2.
Investigator Responsibilities ...................................................................................75
14.3.
Subject Information and Informed Consent.............................................................76
14.4.
Confidentiality........................................................................................................76
14.5.
Protocol Amendments.............................................................................................76
14.6.
Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................76
14.7.
Ongoing Information for Institutional Review Board / Ethics Committee................77
14.8.
Termination of the Study ........................................................................................77
&(/*(1(35235,(7$5<,1)250$7,21
7
.......68
6
..........
.... 68
6
..............
...........
..............
............
.............
.............
..............
............
.............
......
..........
..... ...
..............
...........
.............
.............
rest
rest .......
...
..............
..........
.............
..........
.............
....
EDURES
DURE
ctct...........
......
entificati
tifica on
TORY CO
TORY C
Clinical Pr
Clinical P
nvest
estigator 
igator
Subject 
Subject 
Con
Co
4.5.
4.5.
14.6.
4.6.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
14
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
15.
DATA HANDLING AND RECORDKEEPING.....................................................78
15.1.
Data/Documents .....................................................................................................78
15.2.
Data Management...................................................................................................78
15.3.
Record Retention....................................................................................................78
16.
QUALITY CONTROL AND QUALITY ASSURANCE........................................80
16.1.
Study Monitoring and Source Data Verification......................................................80
16.2.
Audits and Inspections............................................................................................80
17.
PUBLICATIONS ...................................................................................................81
18.
REFERENCES.......................................................................................................82
19.
APPENDICES........................................................................................................85
19.1.
Appendix A: RECIST 1.1.......................................................................................85
19.1.1.
Definitions..............................................................................................................85
19.1.1.1.
Measurable Disease ................................................................................................85
19.1.2.
Tumor Response Evaluation ...................................................................................85
19.1.2.1.
Target Lesions........................................................................................................85
19.1.2.2.
Non-target Lesions .................................................................................................86
19.1.2.3.
Response Criteria....................................................................................................86
19.1.2.4.
Symptomatic Deterioration.....................................................................................88
19.2.
Appendix B: irRECIST...........................................................................................89
19.3.
Appendix C: Table of Abbreviations.......................................................................99
&(/*(1(35235,(7$5<,1)250$7,21
0
.......80
8
..........
.... 81
8
..............
...........
..............
............
.............
.............
..............
............
..........
......... .....
.............
.....
..............
...........
.............
.............
.............
............
..............
..........
.............
..........
breviat
breviatioi ns


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
15
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
LIST OF TABLES
Table 1:
Main Data in Pretreated NSCLC Subjects...............................................................18
Table 2:
Table of Events.......................................................................................................29
Table 3:
Imaging and Treatment after Site-Assessed 1st Radiologic Evidence of PD............39
Table 4:
Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase..........................................................................................40
Table 5:
CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity ...........................47
Table 6:
Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events.....................................................................................................................49
Table 7:
Infusion Reactions..................................................................................................55
Table 8:
Hypothetical Power and Resulting Two-sided 90% CI of Hazard Ratio ..................59
Table 9:
Time Point Response: Subjects With Target (± Non-target) Disease .......................87
Table 10:
Time Point Response: Subjects With Non-target Disease Only ...............................88
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) 
RECIST..................................................................................................................89
Table 12:
Abbreviations and Specialist Terms........................................................................99
&(/*(1(35235,(7$5<,1)250$7,21
0
......47
.............
.......
4
..............
...
Ratio
Rati .......
Disease
sease ...
 Only
Only .....
mune-
un relat
lat
..............
............
.............
..........


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
16
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
LIST OF FIGURES
Figure 1:
Overall Study Design..............................................................................................28
&(/*(1(35235,(7$5<,1)250$7,21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
17
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
1.
INTRODUCTION
1.1.
Disease Background
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in both men 
and women. Globally, approximately 1,825,000 new cases of lung cancer were diagnosed in
2012, and 1,590,000 deaths occurred due to this disease (Globocan, 2012). The World Health
Organization (WHO) divides lung cancer into 2 major classes based on its biology, therapy, and 
prognosis: NSCLC and small cell lung cancer. NSCLC accounts for more than 85% of all lung 
cancer cases and includes 2 major types: (1) non-squamous carcinoma (including 
adenocarcinoma, large-cell carcinoma, other cell types); and (2) squamous cell (epidermoid) 
carcinoma. Adenocarcinoma (40% of lung cancers) is the most common type of lung cancer seen 
in the United States (US) and is also the most frequently occurring cell type in nonsmokers 
(Speicher, 2000).
Cigarette smoking remains the most important risk factor for lung cancer, although 
approximately 15% of all lung cancers are diagnosed in patients who never smoked.
One reason for the high mortality rate of lung cancer is the advanced stage at diagnosis; only 25-
30% of new NSCLC cases are diagnosed with localized disease that is potentially curable with 
surgery (Fossella, 2000; Lang-Lazdunski, 2013). The majority of patients are diagnosed with 
locally advanced or metastatic disease and are not candidates for surgery.
1.2.
Treatment Options in Second-line Metastatic NSCLC
In patients with metastatic NSCLC who have experienced disease progression either during or 
after first-line therapy and have an Eastern Cooperative Oncology Group (ECOG) performance 
score of 0-2, single agent docetaxel, gemcitabine, or erlotinib is recommended if not previously 
given. Pemetrexed is another option for the non-squamous subtype of NSCLC (NCCN, 2014, 
ESMO, 2014).  
Docetaxel was shown to be superior to best supportive care (BSC), vinorelbine and ifosfamide; 
nevertheless, using either the weekly or three-weekly schedule in multiple randomized studies 
the observed response rate with docetaxel ranged from 3% to 12%, progression-free survival 
(PFS) from 1.9 to 3.4 months, and overall survival (OS) from 5.4 to 9.2 months (Shepherd, 2000; 
Fossella, 2000; Bria, 2006).
Recently, nintedanib, a triple angiokinase inhibitor, was approved in the European Union (EU) in 
combination with docetaxel as second-line therapy for NSCLC. The results showed that 
compared to docetaxel alone, nintedanib plus docetaxel significantly extended the median OS
from 10.3 to 12.6 months for patients with advanced adenocarcinoma, after first-line 
chemotherapy (P=0.0359; hazard ratio [HR]: 0.83) (Reck, 2014). In addition, ramucirumab was 
approved in the US in combination with docetaxel as second-line therapy. The phase 3 REVEL 
trial compared ramucirumab, a vascular endothelial growth factor (VEGFR)-2 antagonist, plus 
docetaxel with placebo plus docetaxel in NSCLC patients who experienced disease progression 
after treatment with platinum-based chemotherapy for locally advanced or metastatic disease.
Median OS was better in the ramucirumab group than in the placebo group (10.5 vs 9.1 months; 
&(/*(1(35235,(7$5<,1)250$7,21
nd
lung 
lung 
ermo
ermoid) 
id) 
ung cancer 
ng cancer
nonsm
nonsmoker
ok
er, although
althou
never smo
never sm
nced stage a
ed stage 
se that is po
se that is 
rity
ty
i
of
of
y
pat
pat
f
ie
dates for su
dates for 
ne Metas
Metas
experience
experience
Cooperativ
Cooperati
mcicitabine
tabine
i
, o
fofor the non
r the 
perior to be
perior to b
he weekly o
weekly
ate w
ate ith doc
h d
months, an
months, 
a, 2006
, 2006).).
edanib
danib, a tr
a 
n wi
n with
th
i
doce
doce
h
d to doceta
o docet
10.3 to 12.
10.3 to 12
emotherapy
motherapy
approved i
pproved i
ririalal co
co
l


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
HR, 0.857; P = .0235), as was median PFS (4.5 vs 3.0 months; HR, 0.762; P < .0001) (Perol,
2014).
Gemcitabine showed modest activity in a phase II study with a 6.2% partial response and 17 
weeks median duration of survival in advanced NSCLC subjects who progressed on first-line 
cisplatin-containing therapy (Sculier, 2000).  Another phase II study found a partial response in
19% of subjects treated with gemcitabine as a second-line agent, and a median duration of 
response of 29 weeks (Crino, 1999).  In a third trial evaluating gemcitabine plus BSC versus 
BSC alone, tumor response was seen in 19% of gemcitabine-treated subjects while response was 
not measured in subjects treated with BSC alone (Anderson, 2000).  There was no difference in 
OS (5.7 versus 5.9 months, respectively).   The difference in the results between the trials may be 
due to the percentage of stage III versus stage IV subjects included in the trials.  In the study by 
Sculier et al. 96% of subjects had stage IV disease compared to 59% and 40% in Crino et al. and 
Anderson et al., respectively.
Erlotinib has been proven to be superior to BSC with significantly improved survival (6.7 vs. 4.7 
months), PFS (2.2 vs. 1.8 months), and delayed time to symptom deterioration (Shepherd, 2005).
Gefitinib is approved in the EU for the treatment of advanced and metastatic NSCLC with 
activating mutations of epidermal growth factor receptor (EGFR) only. Although a higher 
response rate was in favor of gefitinib compared to placebo (8% vs. 1%), median time to 
progression (TTP) (3.0 vs. 2.6 months) and survival (5.6 vs. 5.1 months) were similar in the 2
groups (Thatcher, 2005). A non-inferiority trial compared gefitinib to docetaxel in NSCLC 
patients after 1 or 2 lines of chemotherapy (Kim, 2008). A similar median survival (7.6 vs. 8 
months) and TTP (2.2 vs. 2.7 months) were observed, but less toxicity and better quality of life 
favored the gefitinib arm.
Pemetrexed showed clinically equivalent efficacy outcomes but better tolerability when 
compared to docetaxel in patients with the non-squamous subtype of NSCLC (Hanna, 2004; 
Peterson, 2007). 
An overview of the published data with the above described agents are summarized in Table 1.
Table 1:
Main Data in Pretreated NSCLC Subjects
Compound
Line of 
treatment
Histology
N
RR (%)
Median 
TTP/PFS 
(months)
OS 
(months)
Docetaxel
2nd
All
2557
2.7-12.6
1.9-3.4
5.4-9.2
Gemcitabine
2nd
All
65
6.21
--
4.22
Erlotinib
2nd 3rd
All
806
6.2-9
1.7-2.2
6.7-9.2
Gefitinib
2nd 3rd
All
1862
8.0-9.1
2.2-3.0
5.6-7.6
Pemetrexed
2nd
All3
871
4.3-9.1
2.6-2.9
6.7-8.3
1 This value represents partial response.
2 This value represents median duration of survival.
3 A retrospective analysis found that pemetrexed only showed significantly higher survival when compared to docetaxel in the 
non-squamous subgroup.  Docetaxel had statistically better survival in the squamous cell subgroup
&(/*(1(35235,(7$5<,1)250$7,21
as 
as 
e inin
may 
may be
be
e study
study by
by
y
ino et al. a
ino et al. a
d survival (6
d survival 
ati
ation (
on (Shep
etastatic NS
tastatic N
only
n . Alt
Altho
h
% vs. 1%), m
vs. 1
5.1
5.1 mo
m nth
d gefit
gefitinib t
inib t
). A simila
). A simila
ed, but less 
ed, but les
ficacy
ficacy ou
ou
y
tctc
u
e non
e non-squa
squa
a with the ab
with the a
Pretreated
retreate
f f 
ment
ment
H
35
(
2nd
nd
1(
2nd
(1
*
2n
*(
/*
inib
inib
/*
/*
/*
/*
Pemetrexed
emetrexed
&(
&
This va
This va
i


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Personalized treatment based on molecular characteristics of the tumor has also become the 
standard of care.  In addition to the above guidelines, patients whose tumors are positive for the 
EGFR and/or anaplastic lymphoma kinase (ALK) mutation(s) should receive targeted therapy.  
The EGFR mutation which results in the activation of the EGFR tyrosine kinase domain has 
been reported in about 20-25% of non-squamous NSCLC cases and less than 5% in tumors with 
squamous histology.  Erlotinib and afatinib are EGFR tyrosine kinase inhibitors (TKIs) indicated 
for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 
deletions or exon 21 (L858R) substitution mutations, the most commonly found mutations in 
NSCLC (Tarceva® Package Insert; Gilotrif® Package Insert; NCCN, 2014).  Patients who 
progress after first-line therapy are still recommended to be continued on erlotinib or afatinib as 
part of second-line therapy (NCCN, 2014).  Anaplastic lymphoma kinase translocation, another 
key driver mutation, occurs in roughly 5% of NSCLC cases (Shaw, 2013), and it is mostly 
associated with the adenocarcinoma subtype (Bang, 2011; Xalkori Package Insert).  Tumors with 
this mutation are amenable to treatment with crizotinib, an ALK, MET, and ROS1 tyrosine 
kinase inhibitor, and thus, crizotinib is used in first-line therapy for metastatic ALK-positive 
NSCLC patients.  For patients who progress after first-line therapy, crizotinib or the recently 
approved ALK inhibitor, ceritinib, is recommended as part of second-line therapy (NCCN, 
2014).  This trial will focus on second-line therapy for subjects who do not possess these 2 driver 
mutations.  Thus, EGFR-positive and ALK-positive subjects will be excluded from this trial.  
The reported response rate to second-line therapy has generally been less than 10% (NCCN, 
2014), and many patients who respond to second-line therapy eventually develop resistance.  The 
limited effective second-line therapy options available call for the investigation of novel 
approaches to drug therapy in advanced NSCLC.
1.3.
Overview of CC-486
CC-486 is an orally bioavailable formulation of azacitidine (AZA).  Azacitidine, an analog of the 
pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and 
deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
Vidaza® (azacitidine injection) is approved by the US Food and Drug Administration (FDA) for 
five subtypes of the French American British (FAB) classification system of myelodysplastic 
syndrome (MDS) and chronic myelomonocytic leukemia (CMMoL). Vidaza is also approved by 
the European Commission for the treatment of adult MDS, acute myeloid leukemia (AML) and 
CMMoL patients who are not eligible for hematopoietic stem cell transplantation.  Vidaza can be 
administered by intravenous (IV) or subcutaneous (SC) routes as designated by country 
approval.
After its incorporation into a cell’s DNA during the S-phase of the cell cycle, AZA forms 
covalent adducts with DNA methyltransferase 1 (DNMT1) and depletes this enzyme required for 
the maintenance of DNA methylation patterns, thereby altering the epigenetic status of the cell.   
Epigenetic changes are covalent modifications of chromatin (DNA and histone proteins) that 
mediate the stable transmission of a gene’s transcriptional status through cell division.  One of 
the first recognized epigenetic alterations in cancer was DNA methylation.  The addition of a 
methyl group to cytosine in the dinucleotide CpG is catalyzed by DNA methyltransferases 
(DNMTs) and is associated with transcriptional suppresion of genes (Miranda, 2007).  Genomic 
methylation patterns are precisely regulated during normal embryonic development and 
&(/*(1(35235,(7$5<,1)250$7,21
nib as 
nib as 
another 
another 
mostly
ostly
).  Tumors 
 Tumors
OS1 ty
S1 tyrosin
ros
y
tic ALK
tic ALK-po
p
tinib or the
inib or
line therap
line therap
o do not po
o do not p
ll be exclud
ll be exclud
ally been le
ally been le
erapy event
rapy eve
call for th
call for th
ioion of a
n of aza
fects on ce
fects on ce
hesis and m
sis and m
) is approve
s approve
American B
American
ronic myelo
ronic my
sion for the
sion for the
who are not 
who are not 
intntravenou
ravenou
incorporati
orporati
nt adducts 
t adducts 
maintenan
maintenan
Epi
Epigeneti
genetic
mediate 
mediat
e fir
fi


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
differentiation and have been found to be altered in specific ways in cancer.  Specifically, cancer 
cell genomes are typified by reduced methylation globally with focal areas of aberrant 
hypermethylation in the CpG islands of genes encoding known tumor suppressors such as PTEN 
and BRCA1 as well as genes encoding proteins required for apoptosis, including caspase 8, 
DAPK and Apaf-1.  DNA methylation-based gene silencing can thus contribute to the 
establishment and maintenance of the transformed state and limit the effectiveness of anticancer 
therapies.
CC-486 entered clinical testing in 2006 in subjects with MDS, CMMoL, and AML.  The AZA 
PH US 2007 CL 005 study has shown that CC-486 is bioavailable and a maximum tolerated dose 
(MTD) of 480 mg daily for 7 days of a 28-day cycle was defined based on dose-limiting diarrhea 
at the 600 mg dose (Garcia-Manero, 2011).  As expected, reversible and manageable 
myelosuppression was observed.  Pharmacodynamic activity (DNA hypomethylation) and 
clinical responses were observed with CC-486, although the cross-over design (with SC Vidaza 
administered during Cycle 1) confounded the interpretation of these responses in Part 1 of the 
study.
The second part of the AZA PH US 2007 CL 005 study explored both daily and twice daily 
extended dosing schedules of 14 and 21 days out of 28 days in a non-crossover design.  CC-486 
administered at 300 mg once daily (QD) for 14 or 21 days of a 28-day cycle produces cumulative 
exposures (area under the concentration-time curve [AUC] per cycle) that are approximately 
40% and 60% of the exposure achieved with the labeled dose and schedule of Vidaza, 
respectively.  Daily doses of 300 mg have proven to be tolerated on both the 14 and 21 out of 28-
day schedules with myelosuppression, gastrointestinal (GI) symptoms, and fatigue being the 
most common toxicities (Garcia-Manero, 2011).
In the AZA PH US 2007 CL 005 study, DNA methylation levels in blood were measured as a 
pharmacodynamic (PD) endpoint, to determine DNA hypomethylating activity of CC-486.  In 
summary, it was confirmed that CC-486 is biologically active, reducing DNA methylation when 
administered at low doses on extended schedules.
CC-486 is also under clinical investigation, either as monotherapy or in combination with other 
investigational products, for the treatment of lymphoma, multiple myeloma, and relapsed or 
refractory solid tumors (eg, urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra; 
pancreatic carcinoma; breast cancer; ovarian cancer; nasopharyngeal carcinoma; cervical 
carcinoma; anal carcinoma; and merkel cell carcinoma).  
 
  There are 2 ongoing studies evaluating 
PK of CC-486 (AZA-ST-001 and CC-223-NSCL-001). Part 1 of the AZA-ST-001 study 
assessed the impact (if any) of carboplatin or ABI-007 on the PK of CC-486 and the impact (if 
any) of CC-486 on the PK of carboplatin or ABI-007.  Preliminary results showed that in 
subjects from Arms A and B, following administration of CC-486 alone or in combination with 
carboplatin or ABI-007, azacitidine was rapidly absorbed and reached Tmax within approximately 
1.0 hour post-dose (median); azacitidine PK parameters (AUC, Cmax, t1/2, CL/F, and Vz/F) were 
comparable following administration of CC-486 alone or in combination.  Similarly, carboplatin 
and ABI-007 PK parameters were similar following administration of carboplatin or ABI-007 
alone or in combination with CC-486.  In subjects from the 3 arms (Arms A, B, and C, i.e., CC-
486 monotherapy), global genomic hypomethylation was observed in PBMCs, with maximum 
(AZA
(AZA-ST
ST 0
impact (if 
impact (if
C-486 on t
486 on t
ts fro
ts fr m Ar
Ar
bopl
oplatatin or 
in or 
1.0 hour po
.0 hour po
com
ompara
par
m
d A
d A
1(35235,(7$5<,1)250$7,21
dose
dos
diarrhea
arrhea
on) and 
n) and 
wi
with
th
i
SC Vi
SC Vi
h
s in Part 1 
s in Part 1 
daily and t
daily and 
n-crosso
rossove
8-day
da cycle
cl
y
er cy
er cycle) tha
cle) t
se and sch
e and sc
tolerated o
tolerated o
al (GI) sym
al (GI) sy
methylat
ethylatioio
mine DNA 
ine DNA
is bi
s biol
ologic
og
d schedule
d sched
est
estigat
igatioion
he treatmen
he treatme
, urothelial 
urothelia
reast cance
reast canc
no
noma
ma; and
; an
(1(


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
effect on Day 15.  A PK/PD (AUC/hypomethylation change on Day 15) correlation was noted (r 
> 0.5; p < 0.01).
1.3.1.
CC-486 Experience in Solid Tumors
A Phase 1 study of CC-486 in combination with carboplatin or nab-paclitaxel, or as a single 
agent in subjects with relapsed or refractory solid tumors (AZA-ST-001) was initiated on 30 Nov 
2011.  In Part 1 of this two-part study, CC-486 at escalating doses of 200 or 300 mg was 
administered on Days 1 to 14 of a 21-day cycle in three separate arms of the study (Arm A, Arm 
B, Arm C). 
In Arm A of AZA-ST-001, subjects received carboplatin (AUC = 4) on Day 8 of each cycle and 
in Arm B, subjects received nab-paclitaxel 100 mg/m2 beginning on Day 8.  For Arm A, both 
200 mg and 300 mg CC-486 were well tolerated with carboplatin AUC = 4.  For Arm B, 
initially, nab-paclitaxel was administered weekly starting on Cycle 1 Day 8 but dose-limiting 
neutropenia was encountered on this schedule at the first dose level of CC-486.  The protocol 
was amended to administer nab-paclitaxel on Days 8 and 15 of each cycle (ie, 2 out of 3 weeks) 
and this was well tolerated in combination with CC-486 at 200 mg.  When the CC-486 dose was 
escalated to 300 mg, dose-limiting neutropenia was again encountered, making the 200 mg the 
MTD of CC-486 in combination with nab-paclitaxel 100 mg/m2 on a 2- out of 3-week schedule.  
Arm C of study AZA-ST-001 assessed the safety of continuous administration of CC-486 on a 
21- out of 21-day schedule.  This schedule proved not to be tolerable, with profound 
granulocytopenia manifesting in 2 out of 6 subjects at the 300 mg dose level during Cycle 2.  
Single agent CC-486 was better tolerated in subjects when used at the dose of 300 mg daily for 
2- out of 3-week cycle with a manageable safety profile, and the recommended Phase 2 dose for 
Arm C was determined to be 300 mg on Days 1 to 14 of each 21-day cycle.
 
 
 
 
The most promising hints of activity in AZA-ST-001 were observed in Arm B.  Of 8 evaluable 
subjects with relapsed pancreatic carcinoma, 1 had a partial response (PR) and 3 others had 
stable disease (SD) > 16 weeks for a disease control rate (DCR) of 50%.  CC-486 has also shown 
promising efficacy in subjects with relapsed or refractory NSCLC (N = 20).  Although the 
efficacy data are not yet fully mature, objective responses were observed, including 2 PRs in 
NSCLC subjects. An additional 8 subjects with NSCLC had stable disease for periods ranging 
from 4 to 9 months. Furthermore, dramatic objective responses were observed in subjects with 
relapsed cervical and endometrial cancer.  These observations, although promising, do not 
provide conclusive evidence of an epigenetic modifying effect by CC-486.
Please refer to the Azacitidine IB for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and adverse event (AE) profile of 
the azacitidine/CC-486.
&(/*(1(3523
ctivit
ctivity y in A
in
reat
eatic carci
c carc
weeks for 
weeks fo
subjects w
subjects 
ot y
ot yet f
et fully
ully
f
s. An addit
s. An addit
months.
onths. Fur
Fur
ervical and
vical and
e concl
conclusiv
usiv
l
ase refer to
se refer to
pharmaco
pharmacol
he azac
e aza
5,(7$5<,1)250$7,21
m
ycle and 
le and 
A, both
A, both
Arm B, 
Arm B, 
dose
dose-limit
lim
86.  
6.  The pro
The p
e (ie, 2 out 
e (ie, 2 out 
hen the CC
hen the C
red, making
d, making
on a 2
 a - out
ou
s administ
s admin
e tolerable, 
tolerable
he 300 mg d
300 mg
when used 
when used
rofile, and 
rofile, and 
 to 14 of ea
to 14 of 
35,(
35
235


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
1.4.
Overview of Pembrolizumab
The programmed cell death protein-1 (PD-1) is an immune-checkpoint receptor expressed by T 
cells upon activation.  The normal function of PD-1 upon binding by its ligands, programmed 
death-ligand 1 (PD-L1) and PD-L2, is to moderate ongoing immune responses and prevent 
autoimmunity (Harvey, 2014).  Some tumor cells up-regulate the PD-1 ligands to evade active T-
cell immune surveillance. Pembrolizumab is a highly selective humanized monoclonal antibody 
(mAb) that binds to the PD-1 receptor and directly blocks the interaction between PD-1 and its 
ligands, thereby enhancing tumor regression and ultimately immune rejection (pembrolizumab
IB).  Pembrolizumab is being investigated in various oncology indications including melanoma, 
NSCLC, renal cell carcinoma (RCC), breast cancer, multiple myeloma (MM), microsatellite 
unstable tumors, and head and neck cancer. Pembrolizumab [Keytruda (US)],  is approved for 
treatment of melanoma in several countries; in the US it is indicated for the treatment of 
advanced, unresectable or metastatic malignant melanoma in patients with disease progression 
after prior treatment with ipilimumab and, for BRAF V600 mutation-positive patients, a BRAF 
inhibitor, while in the EU it is approved for the treatment of advanced (unresectable or 
metastatic) melanoma in adults. Pembrolizumab has also been granted approval in the US for the 
treatment of patients with metastatic NSCLC whose tumors express PD-L1 as determined by an 
FDA-approved test, and who have disease progression on or after platinum-containing 
chemotherapy.
1.4.1.
Pembrolizumab Experience in Solid Tumors and Safety
An open-label phase 1 trial (Keynote 001) is being conducted to evaluate the safety and clinical 
activity of single agent pembrolizumab. The dose escalation portion of this trial evaluated three 
dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered every 2 weeks, in subjects with 
advanced solid tumors. All 3 dose levels were well tolerated and no dose-limiting toxicities
(DLTs) were observed. Based on PK data showing a half-life of  21 days, the dosing frequency 
in the expansion cohort has been changed to every 3 weeks. 
The choice of the 200 mg every 3 weeks as an appropriate dose for the switch to fixed dosing is 
based on simulations performed using the population PK model of pembrolizumab showing that 
the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent 
with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient 
exposures in the exposure range established in melanoma as associated with maximal efficacy 
response and 3) will maintain individual patients exposure in the exposure range established in 
melanoma that are well tolerated and safe. 
The ongoing expansion cohort in Keynote 001 is enrolling subjects with NSCLC.
Keynote 001, Part C enrolled 495 subjects with NSCLC (adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma) to receive monotherapy pembrolizumab. The ORR was 
19.4% (18.0% in the 394 previously treated subjects and 24.8% in the 101 previously untreated 
subjects). The median PFS was 3.7 months, and the median OS was 12.0 months (Garon, 2015).
Pembrolizumab has been generally well-tolerated. The most common treatment related adverse 
events were fatigue (19.4%), pruritus (10.7%), and decreased appetite (10.5%). Adverse events 
of grade 3 or higher were reported in 47 of 495 patients (9.5%). The only treatment-related 
adverse events of an inflammatory or immune-mediated nature that occurred in more than 2% of 
&(/*
no
no
/*(1(35235,(7$5<,1)250$7,21
oma,
ma,
litite
roved for 
oved for 
ent of 
ent of 
ase progres
ase progres
e pati
e patients, a
ts, a
resectable o
resectable o
approval in
approval 
PD-
D-L1 as d
L1 as 
r platinum
platinum
rs s and Saf
and S
onducted to
onducted
escalat
escalatioion
administere
dminister
re well tol
re well tol
a showing a
a showing a
ged to ever
ged to ever
weeks
week as a
as
d using the 
using the
ery 3 week
ery 3 wee
the 2 mg/k
the 2 m
sure range e
ure range e
l maintain 
l maintain 
re well tole
re well tol
g ex
g expansio
pansio
x
n
e 001, Part C
 001, Part
ma, and 
ma, and
.4% (18.0%
.4% (18.0%
subjects)
ubjects)
mbr
mbr


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
patients were infusion-related reactions (in 15 patients [3.0%]), hypothyroidism (in 34 patients 
[6.9%]), and pneumonitis (in 18 patients [3.6%]). One infusion reaction led to treatment 
discontinuation. All the patients with hypothyroidism were successfully treated with medical 
therapy. Pneumonitis of grade 3 or greater was observed in 9 patients (1.8%), including 1 (0.2%) 
who died. At the time of this analysis, 2 cases of pneumonitis (both grade 1 or 2) were ongoing 
(Garon, 2015).
Please refer to the pembrolizumab IB for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and adverse event (AE) profile.
1.5.
Study Rationale
Both CC-486 and pembrolizumab have shown promising activity and acceptable tolerability in 
patients with relapsed or refractory NSCLC as detailed in Sections 1.3.1 and 1.4.1.
The reported response rate to second-line therapy in NSCLC has generally been less than 10% 
(NCCN, 2014), and many patients who do respond eventually develop resistance.  The limited 
availability of effective second-line therapy options call for the investigation of novel approaches 
to drug therapy in advanced NSCLC.  One potential strategy is the use of epigenetic agents, such 
as CC-486, to prime the tumor to become more responsive to immunotherapy. This approach is 
proposed by combining CC-486 with pembrolizumab in this trial.
Studies have shown that epigenetic events such as hypermethylation of the promoter sites on 
certain genes may play a role in tumor progression in lung cancer (Topaloglu, 2004).  
Importantly, unlike gene mutations, DNA methylation is reversible and can be inhibited by a 
DNMTi (Zeng, 2013).  There are currently 4 drugs targeting epigenetic changes that have been 
approved by the FDA for use in hematologic malignancies, i.e., 2 DNMT inhibitors for 
myelodysplastic syndrome (azacitidine and decitabine) and 2 histone deacetylase (HDAC) 
inhibitors for cutaneous T-cell lymphoma (vorinostat and romidepsin). A recent study using the 
combination epigenetic therapy of azacitidine and entinostat, an HDAC inhibitor, in subjects 
with recurrent metastatic NSCLC who had extensive prior systemic therapy yielded some 
interesting results (Juergens, 2011).  Though only two of the 65 subjects had robust and durable
RECIST criteria responses to this therapy, a group of these subjects were observed during 
follow-up to have responded to various subsequent therapeutic regimens (Juergens, 2011). Five 
of these subjects received 1 of 2 investigational immunotherapy drugs, anti-PD1 or anti-PD-L1
antibody.  Preliminary data revealed that 3 subjects experienced durable partial responses for 
over a year while the other two subjects had stable disease on therapy for more than 6 months 
(Brahmer, 2013).  
Previous PD-1 immune-checkpoint targeting monotherapy studies in subjects with advanced 
NSCLC who received previous systemic therapy reported only a 16 to 17% response rate 
(Brahmer, 2012; Topalian, 2012, Brahmer, 2013 abstract, Garon 2014). 
The results of the above study led to the hypothesis that azacitidine may prime the tumor to 
become more responsive to immunotherapy.  There are several possible mechanisms as to how 
this may occur (Brahmer 2013): 
!
Azacitidine induces the type I IFN pathway and subsequently upregulates suppressed 
antigen-presenting molecules, enhancing intratumoral inflammatory response.
&(/*(1(352
1
5235,(7$5<,1)250$7,21
rabili
rability
ty
i
in 
in 
.
en less than
en less tha
stanc
stance.  Th
e.  Th
ation of nov
n of n
se of epigen
e of epige
munotherapy
unotherap
alal.
ethylat
hylatioion o
n
ng cancer (
ng cancer
n is reversi
is reversi
s targeting 
s targeting 
alignancies
alignancie
decitabine) 
decitabine)
a (vorinosta
(vorinosta
cititididine and
ine and
who had ext
ho had ex
).  Thoug
).  Thoug
this therapy
this therap
ed to variou
d to vario
ed 1 of 2
ed 1 of 2 ini
ry data reve
data rev
y
the other tw
he other tw
).  
).  
D-1 immun
1 immun
who receiv
who recei
hmer, 2012
hmer, 201
he results 
he results 
beco
bec me
me
is m


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
Azacitidine reactivates the production of tumor antigens, such as cancer testes antigens, 
that are found in lung cancer.
!
Azacitidine activates silenced effector cytokine genes in anergized T cells.  
Further support for using CC-486 in combination with pembrolizumab is the fact that epigenetic 
treatment of NSCLC cell lines has been found to increase expression of PD-1 and PD-L1.  Co-
administration of a PD-1 pathway inhibitor would shift the balance in favor of the immune-
enhancing effects of epigenetic modulators on T cells (Brahmer, 2013).  Thus, the combination 
of azacitidine and a PD-1 pathway inhibitor would mechanistically complement each other for 
the purpose of cancer treatment.
Current treatment options for metastatic NSCLC patients who have progressed on first-line 
therapy are limited.  The use of epigenetic modifying agents such as CC-486 to overcome
immune resistance mechanisms of tumors is an interesting strategy.  Here we propose to evaluate
the ability of CC-486 to sensitize tumor cells to PD-1 inhibition with pembrolizumab.  
To explore the hypothesized mechanism of CC-486 priming to pembrolizumab efficacy, and 
potentially identify biomarkers to predict patients that would benefit from this therapeutic 
regimen, tissue samples will be collected from patients pre-therapy and during therapy for 
cellular and molecular analyses. Submission of archival or fresh tumor tissue pre-therapy is 
mandatory. Blood, serum and saliva will also be collected. 
 
 
&(/*(1(35235,(7$5<,1)250$7,21
r 
-line
line
rcom
rcome
opose to ev
opose to ev
izuma
izu
b.b.
zumab effic
mab effi
rom thi
this the
s th
and during
durin
tumor tissu
mor tiss
5<
$5<
7$5
(7$
(7


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
2.
STUDY OBJECTIVES
2.1.
Primary Objective
The primary objective of the study is:
!
To estimate the efficacy of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo based on PFS as measured using RECIST 1.1 criteria
2.2.
Secondary Objectives
The secondary objectives of the study are:
!
To estimate DCR of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo
!
To estimate OS of CC-486 plus pembrolizumab versus pembrolizumab plus placebo
!
To estimate ORR of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo
!
To evaluate safety and tolerability of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To evaluate the impact of pembrolizumab on the pharmacokinetics of CC-486
2.3.
Exploratory Objectives
The exploratory objectives of the study are:
!
To determine the preliminary efficacy (immune-related [ir] PFS, irDCR, irORR) of 
CC-486 plus pembrolizumab versus pembrolizumab plus placebo based on irRECIST
criteria 
!
To explore mechanism and biomarkers associated with efficacy of CC-486 plus 
pembrolizumab versus pembrolizumab plus placebo,
&(/*(1(35235,(7$5<,1)250$7,21
mab plus
mab plus
olizumab p
lizumab p
pembro
embrolizu
lizu
pembrolizu
pembrol
on the pharm
n the pharm
y efefficacy
ficacy
f
(i
ab
ab versus 
ver
ism and bi
m and b
versus pem
versus pe
( 3


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
3.
STUDY ENDPOINTS
3.1.
Primary Endpoint
!
PFS measured as time from randomization to progression according to RECIST 1.1 
(based on Investigator assessment) 
3.2.
Secondary Endpoints
!
Number (%) of subjects with SD for ≥ 18 weeks, complete response (CR) or PR 
(DCR). 
!
Overall survival.
!
Number (%) of subjects who achieve an objective CR or PR (ORR).
!
Safety to include the incidence of treatment-emergent adverse events (TEAEs), 
serious TEAEs, Grade 3-4 TEAEs, TEAEs of special interest, and laboratory 
abnormalities and other safety parameters.
!
Plasma PK parameters such as maximum observed concentration (Cmax), area under 
the concentration-time curve (AUC), time to maximum concentration (Tmax), terminal 
half-life (t1/2), apparent total body clearance (CL/F) and apparent volume of
distribution (Vz/F) for CC-486.
3.3.
Exploratory Endpoint(s)
!
Exploratory efficacy as measured by irPFS, irDCR, and irORR based on Investigator 
assessment using irRECIST.
!
 
!
!
DNA analyses, gene expression and soluble factors in blood.
&(/*(1(
alyses, gen
yses, gen
35235,(7$5<,1)250$7,21
PR
R).)
events (
events TE
estst, and lab
and lab
concentrati
oncen
ximum con
ximum con
L/F) and ap
L/F) and ap
d by
d by irirPFS,
PFS,
23
523
35
( 3


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
4.
OVERALL STUDY DESIGN
4.1.
Study Design
This is a Phase 2, multicenter, international, randomized, placebo controlled, double-blind study
to assess the safety and efficacy of CC-486 and pembrolizumab combination therapy versus 
pembrolizumab plus placebo in previously treated subjects with locally advanced or metastatic 
NSCLC who have received only one prior platinum-based chemotherapy regimen.
Approximately 90 subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or 
placebo plus pembrolizumab as follows:
!
Arm A: CC-486 300 mg administered orally daily on days 1-14 plus pembrolizumab
200 mg administered as a 30-minute IV infusion on day 1 of a 21-day cycle 
!
Arm B: Placebo administered orally daily on days 1-14 plus pembrolizumab 200 mg
administered as a 30-minute IV infusion on day 1 of a 21-day cycle 
A safety analysis will be performed in the first 10 subjects in each arm after the last enrolled 
subject has completed 1 cycle of treatment.
Randomization will be stratified between treatment arms by:
!
Histology (non-squamous versus squamous)
The decision to discontinue a subject, which will not be delayed or refused by the Sponsor, 
remains the responsibility of the treating physician. However, prior to discontinuing a subject, 
the Investigator may contact the medical monitor and forward appropriate supporting documents 
for review and discussion.
The study will be conducted in compliance with the International Council on Harmonisation 
(ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good 
Clinical Practice (GCP) and applicable regulatory requirements.
Primary analysis will be conducted when 70 PFS events have occurred.
&(/*(1(35235,(7$5<,1)250$7,21
b or 
o
embro
mbrolizum
lizum
ay cycle
cycle
y
mbrolizuma
mbrolizum
y cycle
cycle
y
rm afafter th
ter th
f
t be delaye
t be delay
n. Howeve
n. Howev
tor and forw
tor and for
ance wi
nce w th
th
i
tht
h
r Registrati
r Registr
cable regul
cable regu
ducted when
ducted whe


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Figure 1:
Overall Study Design
4.2.
Study Duration 
Enrollment is expected to take approximately 12 months to complete.  Completion of active 
treatment and post-treatment follow-up is expected to take an additional 12 months.  The entire 
study is expected to last approximately 2 years.
4.3.
End of Trial
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol, 
whichever is the later date.
&(/*(1(35235,(7$
12
12 months 
months 
xpecte
xpected to 
d to
years.
years.
either the d
ither the
r the date o
the date
condary
condary and
a
y
$7,21
date.
date.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
5.
TABLE OF EVENTS
Table 2:
Table of Events
Screening
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up 
Period
Day
-28 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Informed consent
X
Demographics
X
Prior cancer history
X
Prior cancer therapiesc
X
Complete medical history
X
Prior/ concomitant 
medication evaluationd
X (≤ 28d from 
screening)
Continuous, until 28 days after last dose
Prior/ concomitant 
procedures evaluatione
X (≤ 28d from 
screening)
Continuous, until 28 days after last dose
Inclusion/exclusion criteria
X
IRT registration
X
IRT randomization
Xf
Adverse event evaluation
Continuous after informed consent signature, until 30 days after discontinuation of either drug. See 
Section 11 for additional details on AE reporting timeframe
Physical examination 
(source documented only)
X
X
X
X
X
&(/*(
pri
prietet
nly)
ly)
*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
0$
0$
0$
0$
ent 
nt 
les
les
25
)2
1
)2
)2
)2
<
)2
<
5<
$ <
$5
7$
7$
7$
7$
7$
(7
5
C
5,
23
52
52
52
5
3
(
Continuous
Continuou
1(
X
*(
(/*
/


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 2:
Table of Events (Continued)
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up 
Period
Day
-28 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Weight
X
X
X
X
X
Height
X
Vital signs
X
X
X
X
X
ECOG performance status
X
X
X
X
X
Hematology laboratoryg
X
X
X
X
X
X
X
Coagulationh
X
HBV and HCV serologies 
(HBsAg, HBeAg, HBsAb, 
HBeAb, HBcAb, HCVAb)
X
X
Chemistry laboratoryi
X
X
X
X
X
X
X
Lipid panelj
X
Every 4th
cycle
X
Thyroid test
X
X
Cycle 3 Day 
1 then every 
6 weeks
Urinalysisk
X
X
X
X
X
12-lead electrocardiogram
X
X
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet
7,2
0$
0$
0$
0$
1
50
2
X
1)
,1
<
5<
$ <
X
$5
7$
7$
7$
7$
7$
(7
5
X
35
2 5
23
52
35
(
5
X
(1
X
*(
/*
/*
/*
/*


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 2:
Table of Events (Continued)
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up Period
Day
-28 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Serum β-hCG (for all 
FCBP)l
X
Serum or Urine β-hCG (for 
all FCBP)l
X
(w/in72 hours)
X
X
X
X
PK blood draws sampling
(See Section 6.5 for 
timepoints)
X
X
Tumor biopsy for 
Biomarker Analyses
X
(Mandatory –
archival or 
fresh tumor 
collection)
X
(Optional)
Blood for Biomarker DNA 
Analyses
X 
X
Blood for Biomarker RNA 
Analyses
X
X
X
Serum for Biomarker 
Analyses
X 
X
Xm
X
Saliva for Germline DNA 
Analysis
X
&(/*(
pri
prietet
*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
7,2
0$
Fo
Folll
0$
0$
0$
1
E
50
)2
1)
<
)
< ,
<
$5
7$
(7
2 5, 7
X
2
52
X
35
( 3
( 3
( 3
( 3
( 3
1(
*(


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 2:
Table of Events (Continued)
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up 
Period
Day
-28 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Tumor evaluation 
(CT/MRI)
X 
RECIST 1.1 algorithm: Every 6 weeks (± 5 days) from randomization for the first 24 
weeks then every 9 weeks until disease progression (for exceptions refer to 
Section 6.4.3) or start of a new anticancer treatment, or withdrawal of consent
The irRECIST will be evaluated as exploratory efficacy assessment. For additional 
details, see Sections 6.4.2 , 6.4.3 and Appendix B, Section 19.1
Bone Scan 
Only if clinically indicated
CT Scan of the Head or 
Brain MRI
X
Only if clinically indicated
Administer                    
CC-486/placebo
Daily on Days 1-14
Administer 
pembrolizumab
Xn
X
On Day 1 
only
IP accountability
X
X
X
X
Survival follow-up
Every 8 weeks 
(+/- 5 days)
Anticancer therapy since 
IP discontinuation
At every survival 
follow-up visit
Abbreviations:  β-hCG = beta human chorionic gonadotropin; C1D1 = Cycle 1 Day 1; CT = computed tomography; ECOG = Eastern Cooperative Oncology 
Group; EOT = End of Treatment; FCBP = females of child bearing potential; IP = investigational product; irRECIST = immune-related Response Evaluation 
Criteria in Solid Tumors; IRT = interactive response technology; MRI = magnetic resonance imaging; PK = pharmacokinetic; RECIST = Response Evaluation 
Criteria in Solid Tumors
a All visits have a ± 2-day window, except Cycle 1 Day 1 which must occur within 28 days from Informed Consent Form signature, and survival follow-up 
which has a ±5-day window.
&(/
pri
prietet
/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
7,2
0$
0$
0$
0$
1
E
50
)2
5 days) from
5 days) from
ease progre
se prog
nticancer tre
cancer tr
as explorat
as explor
6.4.2
6.4.2 , 6.4.
6.4
1)
y indicated
y indicated
$5
nly if clinica
ly if clinica
7$
Daily on D
Daily on 
,(
35
2 5
X
2
52
5
( 35
( 3
( 3
( 3
(1( 3
orionic gonad
rionic gonad
CBP = female
CBP = femal
nteractive res
teractive res
ndow, excep
ndow, excep
ow
ow.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
b Cycle 1 Day 1 evaluations can be omitted if Screening evaluations are performed within 72 hours of Cycle 1 Day 1.
c Prior cancer therapies include surgery, radiation, systemic or any other therapy (eg, hormonal, locoregional) for the subject's cancer
d Prior/concomitant medication evaluation ≤28 days before screening through 28 days after last dose.
e Prior/concomitant procedures evaluation ≤28 days before screening through 28 days after last dose.
f Prior to receiving first dose.
g Hematology includes complete blood count (CBC) with differential, including but not limited to red blood cell (RBC) count, hemoglobin, hematocrit, white 
blood cell (WBC) count with differential (neutrophil count including lymphocyte, monocyte, eosinophil, basophil counts and bands), absolute neutrophil count 
(ANC), and platelet count. ANC should be measured with automated count where available.
h Coagulation tests, including prothrombin time (PT), partial thromboplastin time (PTT), activated partial thromboplastin time (aPTT) and international 
normalized ration (INR)
I Chemistry includes (but is not limited to) sodium, potassium, calcium, phosphorus,  chloride, magnesium, bicarbonate, blood urea nitrogen (BUN) or urea, 
serum creatinine, fasting glucose, uric acid, albumin, total protein, alkaline phosphatase, lactate dehydrogenase, total bilirubin (indirect and direct), aspartate 
aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)
j Lipid Panel parameters include total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides
k Urinalysis (a urine dipstick may be used) at screening and D1 of each cycle if abnormal at baseline.
l Serum β-hCG (for all FCPB) performed at screening; remaining pregnancy tests may be serum or urine at the Investigator’s discretion. Pregnancy testing (for 
all FCPB) must be done within 72 hours prior to the first administration of IP and prior to dosing on Day 1 of every cycle.  If the serum screening pregnancy 
test is performed > 72 hours before first dose, a serum or urine pregnancy test should be performed (Investigator’s discretion).  The subject may not receive IP 
until the Investigator has verified that the result of the pregnancy test is negative.
m Day 1 of Cycle 3 and every third cycle thereafter (C6D1, C9D1, C12D1)
n On Cycle 1 Day 1, pembrolizumab will be administered after the 6 hour CC-486 PK sample collection. For all subsequent pembrolizumab administration, 
pembrolizumab will be co-administered with CC-486.
&(/*(1(35235,(7
pri
prietet
(7$5<,1)250$7,21
e Corpora
e Corpora
21
, hemoglobin
hemoglobi
and bands),
and bands),
astin t
stin time (aP
ime (
arbonate, blo
arbonate, blo
nase, total bi
se, total
m glutamic p
m glutamic p
glyce
glycerides
rides
e.
or urine at th
or urine a
sing on Day 
sing on Day 
erformed (In
erformed (In
PK sample c
PK sample c


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
6.
PROCEDURES
Any questions regarding the study should be directed to the Celgene medical monitor or 
designee. 
6.1.
Screening Period
Screening evaluations will be performed for all subjects to determine study eligibility. These 
evaluations must be completed within 28 days of first dosing unless noted below. Re-screening 
of patients is only allowed once per patient.
Waivers to the protocol will not be granted during the conduct of this trial, under any 
circumstances.
Safety laboratory analyses will be performed centrally. Decisions with respect to investigational 
product (IP) dosing can be made based on a local lab draw if the central lab results have not been 
received. Central labs should be drawn at all times specified within the protocol. Screening 
laboratory values must demonstrate subject eligibility, but may be repeated within the screening 
window if necessary.
The following will be performed at screening as specified in the Table of Events (Table 2), after
informed consent has been obtained:
!
Demographics 
!
Prior cancer history (including specific information regarding diagnosis, staging, and 
histology)
!
Prior cancer therapies: includes surgery, radiation, systemic or any other therapy for
the subject’s cancer
!
Complete medical history (all relevant medical conditions occurring ≥ 28 days before
Screening should be included)
!
Prior and concomitant medication evaluation (including those taken ≤28 days before
screening, except for those taken for cancer which are recorded as part of prior cancer 
therapy)
!
Prior and concomitant procedures (including all procedures occurring ≤ 28 days 
before screening)
!
Interactive response technology (IRT) for subject number 
!
Adverse event evaluation (begins after the subject signs the informed consent form 
[ICF])
!
Physical examination (source documented only), weight, height
!
Vital signs (including blood pressure, temperature, respiratory rate, and heart rate)
!
Eastern Cooperative Oncology Group (ECOG) performance status
&(/*(1(35235,(7$5<,1)250$7,21
ing
ng
to invest
investigi
b results hav
results ha
protocol.
otocol Sc
peated
eated wit
with
he Table of
he Table
informat
informatioio
surgery
rgery, rad
, ra
y (all
(all
y
releva
rele
l
ncluded)
ncluded)
tant m
tant medic
di
ept for thos
t for thos
nd concomi
nd concomi
re screening
re screenin
Interactive 
nteractive 
!
Advers
dvers
[ICF
[IC
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
Hematology panel: Complete blood count (CBC) with differential, including but not 
limited to red blood cell (RBC) count, hemoglobin, hematocrit, white blood cell 
(WBC) count with differential (neutrophil count including lymphocyte, monocyte, 
eosinophil, basophil counts and bands), absolute neutrophil count (ANC), and platelet 
count.
!
Coagulation tests including, prothrombin time (PT), partial thromboplastin time 
(PTT), activated partial thromboplastin time (aPTT), international normalized ratio 
(INR).
!
Chemistry panel including, but not limited to sodium, potassium, calcium, 
phosphorus,  chloride, magnesium, bicarbonate, blood urea nitrogen (BUN) or urea, 
serum creatinine, fasting glucose, uric acid, albumin, total protein, alkaline 
phosphatase, lactate dehydrogenase (LDH), total bilirubin (indirect and direct), 
aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), 
alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)
!
Lipid panel including total cholesterol, high-density lipoprotein, low-density 
lipoprotein, and triglycerides
!
Thyroid test
!
Hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies (hepatitis B surface 
antigen [HBsAg], hepatitis B e antigen [HBeAg], hepatitis B surface antibody 
[HBsAb], hepatitis B e antibody [HBeAb], hepatitis B core antibody [HBcAb], 
hepatitis C virus antibody [HCVAb]
!
Urinalysis (a urine dipstick may be used) at screening (and Day 1 of each cycle if 
abnormal at baseline).
!
12-lead electrocardiogram (ECG)
!
Pregnancy test is required for all female subjects of childbearing potential. Serum
beta subunit of human chorionic gonadotropin (β-hCG) pregnancy test will be 
performed at screening. Urine (or serum) pregnancy test will be performed to assess 
subject eligibility within 72 hours prior to the first administration of IP, if the serum 
pregnancy test did not already occur within 72 hours of dosing (negative results 
required for IP administration).
!
Submission of archival or newly obtained tumor biopsy specimen for biomarker 
analysis is mandatory.
!
Response assessment/tumor evaluation (see Section 6.4)
6.2.
Treatment Period
The subjects must start treatment within 28 days of signing the ICF. For all subsequent visits, an 
administrative window of ± 2 days is permitted.
Treatment cycles are 21 days in duration, and will occur as described in Section 8.2.
The following evaluations will be performed at the frequency specified in Table 2.  The 
evaluations should be performed prior to dosing on the visit day, unless otherwise specified:
&(/*(1(35235,(7$5<,1)250$7,21
or urea,
or urea,
e
d didirect),
rect),
i
e (AST/SG
(AST/S
ALT/S
ALT/SGPT
GP
tein, l
tein, low
ow-d
HCV) serolo
CV) serolo
Ag], hepat
g], hepa it
hepatit
hepatitis B
is B
used) at sc
sed) at sc
ECG)
CG)
ed for all fe
d for all f
n chorionic
n chorionic
ening. Urin
ening. Urin
ity y wi
with
th
i in 7
n 7
est did not a
est did not
or IP admi
or IP adm
f
missio
ission o
n of a
nalysis is m
alysis is m
Respons
Respons
.
Tr
Tr
The subje
The subje
dmini
dmini


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
IRT for subject randomization (prior to first dose)
!
Concomitant medications evaluation (continuously)
!
Concomitant procedures evaluation (continuously)
!
Adverse event evaluation (continuously)
!
Physical examination (source documented only) including weight
!
Vital signs: on-treatment vital sign measurements will be source documented only.  
However, if an abnormal (out of range) value is reported at any given visit, that
parameter should be collected in the case report form (CRF) at every subsequent
scheduled visit until it returns to normal, and as an AE if appropriate.
!
ECOG Performance status
!
Hematology panel
!
Chemistry panel
!
Lipid panel
!
Thyroid test
!
Urinalysis
!
Urine (or serum) pregnancy test (prior to dosing on Day 1 of each cycle)
!
PK sampling
!
Tumor biopsy for biomarker analyses [Optional, but strongly recommended]
!
Blood for biomarker analyses
!
Serum for biomarker analyses
!
Saliva for Germline DNA Analysis
!
Response assessment/tumor evaluation (see Section 6.4)
!
IP accountability
6.2.1.
End of Treatment
An end of treatment (EOT) evaluation should be performed for subjects who are withdrawn from
treatment for any reason as soon as possible after the decision to permanently discontinue
treatment has been made. Subjects must also be discontinued in the IRT system.
The following evaluations will be performed as specified in the Table 2:
!
Concomitant medications evaluation
!
Concomitant procedures evaluation
!
Adverse event evaluation (monitored through 30 days after the last dose of either 
study drug)
!
Physical examination including weight
&(/*(1(35235,(7$5<,1)250$7,21
entnt
sing on Day
ing on Da
es [Optiona
s [Option
ses
NA Analysi
A Analysi
ent/tumor e
ent/tumor 
ty
reatment
eatment
ment (EOT)
ment (EOT
any
any reason
reason
y
has been m
as been m
llo
llowing ev
wing ev
!
C
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
Vital signs
!
ECOG performance status
!
Hematology panel
!
Hepatitis B virus (HBV) and HCV serologies (HBsAg, HBeAg, HBsAb, HBeAb, 
HBcAb, HCVAb
!
Chemistry panel
!
Lipid panel
!
Urinalysis
!
12-lead ECG
!
Urine (or serum) β-hCG level for females of childbearing potential
!
Blood for biomarker analyses
!
Serum for biomarker analyses
!
Response assessment/tumor evaluation will be continued at the schedule defined in
Table 2, and does not need to be performed specifically for the EOT visit except as 
specified in Section 6.4.
!
IP accountability
6.3.
Follow-up Period
6.3.1.
Efficacy Follow-up
All subjects who discontinue treatment for reasons other than disease progression, start of new
anticancer therapy, or withdrawal of consent from the entire study will be followed for tumor
response assessments and subsequent anticancer therapies as specified in Section 6.4.
6.3.2.
Survival Follow-up
After the end of treatment (EOT) visit, all subjects will be followed every 8 weeks (± 5 days) for 
survival until withdrawal of consent, death, or lost to follow-up, whichever occurs first, or until 
the End of Trial. Subsequent anticancer therapies should be collected at the same schedule. New 
anticancer therapy includes (but is not limited to) any systemic or local medication, surgery, 
radiation, or any other therapy intended to treat the subject’s cancer.
Survival follow-up may be conducted by record review (including public records) and/or
telephone contact with the subject, family, or the subject’s treating physician.
6.4.
Response Assessments
Response assessments (tumor evaluations) should be performed at Screening within 28 days 
before the start of IPs, and every 6 weeks (± 5 days) from randomization for the first 24 weeks, 
then every 9 weeks thereafter until disease progression (for exceptions refer to Section 6.4.3), 
start of a new anticancer therapy, or withdrawal of consent from the entire study. Tumor 
assessments should also be performed at any time, if clinically indicated.  Subjects with 
&(/*(1(35235,(7$5<,1)250$7,21
ed at the sc
d at the s
ally for the
lly fo
for reasons 
or reason
onsent from
onsent 
ent ant
t a
ican
ican
up
up
t (
t EOT
OT) vi
wal
wal of
of
l
cons
ons
f
ubsequent a
ubsequent a
py
py i
y ncludes
nclude
any
ny other th
other th
y
follolow-up 
up
one contact
one contact
6.4.
.4.
R
Respon
Respon


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
historical tumor scans evaluable per RECIST 1.1 performed ≤ 28 days before the first dose need 
not repeat scans for the purposes of screening. Evaluation of response should be performed using 
RECIST 1.1 and irRECIST guidelines by Investigator assessment.  
6.4.1.
Assessment of Response According to RECIST Version 1.1
Response assessments include computed tomography (CT) scan or MRI.  The regions to be 
imaged are the chest, upper abdomen including whole liver and kidney and, if clinically 
indicated, pelvis. The pelvis scan should be performed only with MRI unless CT is the local 
standard of care at the site. In case of metastases to other organs not covered with these scans, 
the regions need to be included in the scans as well. If brain metastases are documented at 
baseline, brain imaging should be continued throughout the study. Bone scans will only be 
performed at baseline if clinically indicated. If at baseline, the bone scan is suggestive of bone 
lesions, CT or MRI will be used both at baseline and subsequent scans. Bone scans during the 
trial will only be performed if clinically indicated and if suggestive of new lesions, a CT or MRI 
will be performed to confirm the new lesion. Any skeletal lesions identified at baseline should be 
followed at the same schedule. The same mode of imaging for lesion evaluation at Screening 
must be used consistently throughout the study. Adherence to the planned imaging schedule is 
critical regardless of dose delays or unscheduled or missed assessments; scans must follow the 
calendar and not be adjusted for delays in treatment.
The CT imaging should include contrast unless medically contraindicated. Conventional CT 
should be performed with contiguous cuts of 5 mm or less in slice thickness. Spiral CT should be 
performed by use of a 5 mm contiguous reconstruction algorithm.
All subjects with evidence of objective tumor response (CR or PR) should have the response 
confirmed with repeat assessments at the next scheduled scan, but after no less than 4 weeks.  
6.4.2.
Assessment of Response According to irRECIST
Evaluation of response will also be performed using irRECIST guidelines as an exploratory 
assessment.  Additional details and definitions of irRECIST are found in Appendix B in Section
19.2.
6.4.3.
Assessment of Disease and Treatment after Initial Radiologic Progression
Immunotherapeutic agents such as pembrolizumab may produce antitumor effects by 
potentiating endogenous cancer-specific immune responses.  The response patterns seen with 
such an approach may extend beyond the typical time course of responses seen with cytotoxic 
agents, and can manifest as a clinical response after an initial increase in tumor burden or even 
the appearance of new lesions.  
If radiologic imaging shows PD by RECIST 1.1, tumor assessment should be repeated ≥4 weeks 
later in order to confirm PD (per irRECIST) with the option of continuing treatment per below 
while awaiting radiologic confirmation of progression.  If repeat imaging shows a reduction in 
the tumor burden compared to the initial scan demonstrating PD, treatment may be continued as 
per treatment calendar. A separate informed consent will be provided.  If repeat imaging 
confirms progressive disease, subjects will be discontinued from study therapy (exception noted
in Table 3).  In determining whether or not the tumor burden has increased or decreased, 
&(/*(1(35235,(7$5<,1)250$7,21
s, 
s, 
t
y be
y be
ve of bone 
ve of bone
ans during t
ns during 
ions, a CT 
a CT
d at baselin
at baselin
aluat
uatioion at 
n
nned imagi
nned imagi
ment
me s; scan
s; scan
contraindica
ntraindi
ss in slice t
s in slice
on algorithm
on algorithm
ponse (C
ponse (CR
scheduled 
scheduled 
cording to 
cording to
perform
erformed u
ed
d definit
d definitioi
f Disease a
f Disea
gents such 
gents suc
genous canc
enous canc
ch may
ch may ext
ext
y
can manifes
can manife
rance of ne
ce of ne
iolologigic ima
c im
er in order 
r in order 
while awa
while awa
he tum
e tum


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Investigators should consider all target lesions as well as non-target lesions. Refer to Appendix B
for additional information.
When feasible, subjects should not be discontinued until progression is confirmed; however, the 
decision to continue study treatment after the 1st evidence of disease progression is at the 
Investigator’s discretion based on the clinical status of the subject as described in Table 3.  
Subjects may receive study treatment while waiting for confirmation of PD if they are clinically 
stable as defined by the following criteria:
!
Absence of signs and symptoms indicating disease progression
!
No decline in ECOG performance status
!
Absence of rapid progression of disease
!
Absence of progressive tumor at critical anatomical sites (eg, cord compression) 
requiring urgent alternative medical intervention
Table 3:
Imaging and Treatment after Site-Assessed 1st Radiologic Evidence of PD
Clinically Stable
Clinically Unstable
Imaging
Treatment
Imaging
Treatment
Site based 
assessment 
indicates PD
Repeat imaging at 
≥4 weeks at site to 
confirm PD
May continue 
study treatment at 
the Investigator’s 
discretion while 
awaiting 
confirmatory scan 
by site
Repeat imaging at 
≥4 weeks to 
confirm PD per 
physician 
discretion only
Discontinue 
treatment
Repeat scan 
confirms PD
No additional 
imaging required
Exceptions as per 
note*
Discontinue
treatment
Exceptions as per 
note*
No additional 
imaging required
N/A
Repeat scan shows 
SD, PR or CR
Continue regularly 
scheduled imaging 
assessments
Continue study 
treatment at the 
Investigator’s 
discretion
Continue regularly 
scheduled imaging 
assessments
May restart study 
treatment if 
condition has 
improved and/or 
clinically stable 
per Investigator’s 
discretion
* Note:  If progression is confirmed per irRECIST, the subject remains clinically stable and per the Principal 
Investigator is achieving extraordinary clinical benefit, the Principal Investigator may discuss with the Sponsor to 
consider a potential exception.
6.5.
Pharmacokinetics
At specific sites, for the first 10-12 subjects randomized to each Arm, mandatory 
pharmacokinetics will be collected. Blood samples for CC-486 PK assessment will be collected 
on Day 1 of Cycle 1 and Cycle 2 prior to the dose administration of CC-486/placebo, known as 
predose, and over the 8-hour period following each dose administration of CC-486/placebo at 
mpressio
mpression)
n
ogic Eviden
gic Evide
Clinically 
Clinically
1)
Imaging
a
,1
lele
atory scan
tory scan
e
Repeat imag
Repeat ima
≥4 weeks
4 week
confirm
confir
phy
ph
d
5<
7$
er 
Discontinue
iscontinue
treatment
reatment
Excep
xcep
not
not
5,
52
 regularly
regularly
uled imagin
uled ima
essments
essme
5
*(
5
*(
*(
*(
5
progression i
gression
igator 
igato is achi
s achi
sider a poten
sider a poten
6.5.
6.
sp


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose (see Table 4).  These samples will be 
analyzed centrally.
Table 4:
Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase
Nominal Times
Acceptable Deviation Window
Predose
≤ 60 min
0.25 hr
± 3 min
0.5 hr
± 3 min
1 hr
± 3 min
1.5 hr
± 3 min
2 hr
± 3 min
2.5 hr
± 3 min
3 hr
± 3 min
3.5 hr
± 3 min
4 hr
± 3 min
6 hr
± 20 min
8 hr
± 20 min
6.6.
Biomarkers
Tumor, blood and serum will be collected to explore the hypothesized mechanism of CC-486 
priming to pembrolizumab efficacy, and potentially identify biomarkers to predict patients that 
would benefit from this therapeutic regimen. Fresh tumor biopsy is the preferred tissue for these 
analyses; however archival formalin fixed, paraffin embedded (FFPE) blocks may be provided 
instead. Archival or fresh tumor tissue is mandatory at screening, but it is optional at Cycle 2 
Day 14 -/+ 7 days. Blood, serum and saliva will also be collected at time point detailed in the 
schedule of events.
Details regarding the collection, storage, and shipment of the samples are provided in the 
Laboratory Manual. A separate consent will be provided.
6.7.
12-lead Electrocardiogram
Triplicate 12-lead ECGs will be recorded at screening and EOT and will be assessed locally. 
ECGs may be done more frequently and/or additional cardiac work-up may be performed, if 
clinically indicated by the investigator. The 12-lead ECGs (12-lead at 25 mm/sec reporting 
rhythm, ventricular rate, PR-interval, QRS complex, QT interval, and QTc interval) will be 
performed after the subject has been in the supine position for at least 5 minutes.
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$7
0$
50
25
min
min
)2
± 3 min
± 3 min
1)
± 3 mi
3 mi
,1
± ±
<
5<
$5
(7$
to explore t
to explore 
d potentiall
potentia
egimen. Fr
egimen. 
lin fixed, p
lin fixed, 
r tissue
tissue isis
erum
erum and sa
and
collect
collectioion
al. A separa
A separa
2-lead E
lead E
te 12
te 12-lead E
lead 
s m
s may be d
ay be 
inically ind
inically ind
rhy
hyth
y m,
m, ve
v
erform
erform


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
7.
STUDY POPULATION
7.1.
Number of Subjects and Sites
A total of approximately 90 adult subjects with locally advanced or metastatic NSCLC who have 
been treated with one prior platinum-based chemotherapy regimen will be randomized. The 
study will be conducted at sites globally.
7.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Subject is ≥ 18 years of age at the time of signing the informed consent form.
2. Subject has histologically or cytologically confirmed squamous or non-squamous 
NSCLC.
3. Subject has stage IIIB or IV NSCLC (American Joint Committee on Cancer [AJCC] 
Staging Manual, 7th edition [Edge, 2009]) and was pretreated with only 1 prior systemic
platinum based chemotherapy.
4. Subject has provided a formalin fixed tumor tissue sample from a biopsy of a tumor 
lesion either at the time of or after the diagnosis of metastatic disease has been made 
AND from a site not previously irradiated to assess for PD-L1 status. Fine needle 
aspirates, endobronchial ultrasound (EBUS) or cell blocks are not acceptable. Needle or 
excisional biopsies, or resected tissue is required.  Archival tissue may be acceptable.
Submission of formalin-fixed paraffin embedded tumor tissue sample blocks are 
preferred; if submitting unstained slides, the slides should be freshly cut and submitted to 
the testing laboratory within 14 days from site slide sectioning date otherwise a new 
specimen will be requested.
5. Subject has radiographically-documented measurable disease, as per RECIST 1.1.
6. Subject has an ECOG performance status of 0 to 1.
7. Subject has adequate organ functions, evidenced by the following:
a.
AST (SGOT), ALT (SGPT) ≤ 2.5 x upper limit of normal range (ULN), or ≤ 5 x ULN 
range if liver metastasis present
b. Total bilirubin ≤ 1.5 x ULN
c.
Serum creatinine ≤ 1.5 x ULN
d. Potassium within normal range, or correctable with supplements
8. Subject has adequate bone marrow function, evidenced by the following:
a.
Absolute neutrophil count ≥ 1.5 x 109 cells/L
b. Platelets ≥ 100 x 109 cells/L 
c.
Hemoglobin ≥ 9 g/dL
d. International normalized ratio (INR) or prothrombin time (PT) ≤1.5 x ULN unless 
subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic 
range of intended use of anticoagulants
&(/*(1(35235,(7$5<,1)250$7,21
m.
squamous
squamou
ee on Canc
ee on Can
d with
with onl
mple fro
mple from
metastati
etastatic
ess
ess fo
for PD
r PD
or cell bloc
or cell bl
equired.  Ar
quired.  A
embedded 
embedded 
ides, the sli
des, the sl
days from si
ays from
lly
lly-docum
docum
performan
performan
uate organ f
uate orga
OT), ALT (
OT), ALT
f liver meta
f liver meta
l bili
bili
l
rubin
rubin
i
erum
erum c
m reat
rea
Potassi
Potassiui
Subject h
Subject
a.a
A
b.b


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
e.
Activated partial thromboplastin time (aPTT) ≤1.5 x ULN unless subject is receiving 
anticoagulant therapy as long as PT or PTT is within therapeutic range of intended 
use of anticoagulants
9. Female of childbearing potential (FCBP) (defined as a sexually mature woman who 1) 
has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral 
oophorectomy (the surgical removal of both ovaries) or, 2) if ≥ 45 years old has not been 
naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any 
time during the preceding 24 consecutive months)) must:
a.
Have two negative pregnancy tests as verified by the Investigator prior to starting 
study therapy. She must agree to ongoing pregnancy testing during the course of the 
study, and after end of study treatment. This applies even if the subject practices true 
abstinence* from heterosexual contact.
b. Either commit to true abstinence* from heterosexual contact (which must be 
reviewed on a monthly basis) or agree to use, and be able to comply with two 
effective methods of contraception without interruption, 28 days prior to starting IP, 
during the study therapy (including dose interruptions), and for 120 days after 
discontinuation (or longer if required by local requirements) of study therapy. The 
two methods of contraception can either be two barrier methods or a barrier method 
plus a hormonal method to prevent pregnancy.
10. Male subjects must practice true abstinence* (which must be reviewed on a monthly 
basis) or agree to the use a condom during sexual contact with a pregnant female or a 
female of childbearing potential while participating in the study, during dose 
interruptions and for at least 3 months following investigational product discontinuation 
(or longer if required by local requirements), even if he has undergone a successful 
vasectomy. 
* True abstinence is acceptable when this is in line with the preferred and usual lifestyle 
of the subject. Note: Periodic abstinence (eg, calendar, ovulation, symptothermal, post-
ovulation  methods) and withdrawal are not acceptable methods of contraception.
11. Subject is willing to adhere to the study visit schedule and other protocol requirements.
12. Subject understands and voluntarily signs an informed consent document prior to any 
study related assessments/procedures are conducted.
7.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subject with non-squamous histology has known or unknown sensitizing EGFR and/or 
positive ALK mutation.
Note: Subjects with squamous histology and unknown EGFR and ALK mutational 
status are eligible.
2. Subject has received more than one line of therapy for stage IIIB or IV disease
3. Subject has been previously treated with azacitidine (any formulation), decitabine, or any 
other hypomethylating agent.
&(/*(1(35235,(7$5<,1)250$7,21
arting
arting
e of the
of the
actices true
actices true
which
whic must 
mus
mply
mply wi
wi
y
th
th
i
t
days prior to
ys prio
nd for 
d for 120 d
120 d
ments) of stu
ents) of st
ier method
er m
ich must b
ch must
xual contac
xual contac
cipat
ipa ing in
ing in
ollo
llowing in
wing i
ements), ev
ments), ev
le when thi
le when
dic ab
a stininen
d wi
with
th
i drawa
drawa
 adhere to 
adhere to
ands and 
ands and v
asses
assessmen
smen
clusion C
clusion 
nce of any o
ce of any 
Subject
Subject w
posi
posititi
i v


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
4. Subject has received prior therapy with any other anti-PD-1, or PD-L1 or PD-L2 agent or 
an antibody targeting other immuno-regulatory receptors or mechanism, including 
participation in any other pembrolizumab trial and treatment with pembrolizumab.
a.
Examples of such antibodies include (but are not limited to) antibodies against 
indoleamine 2,3-dioxygenase (IDO), PD-L1, IL-2R, glucocorticoid-induced 
tumor necrosis factor receptor (GITR).
5. Subject has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who 
has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to agents 
administered more than 4 weeks earlier.
6. Subject is currently participating and receiving study therapy or has participated in a 
study of an investigational agent and received study therapy or used an investigational 
device within 4 weeks prior to administration of pembrolizumab and CC-486
7. Subject has previous severe hypersensitivity reaction to another monoclonal antibody 
(mAb).
8. Subject has a known or suspected hypersensitivity to azacitidine, mannitol, or any other 
ingredient used in the manufacture of CC-486 (see the Azacitidine IB).
9. Subject has had radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks 
prior to starting IP, and/or from whom ≥ 30% of the bone marrow was irradiated.
10. Subject has received radiation therapy to the lung that is > 30 Gy within 6 months of the 
first dose of trial treatment
11. Subject has received a live-virus vaccination within 30 days of planned treatment start. 
Seasonal flu vaccines that do not contain live virus are permitted.
12. Subject has not recovered from the acute toxic effects of prior anticancer therapy, 
radiation, or major surgery/significant trauma.
13. Subject has an active infection requiring therapy.
14. Subject has had an allogenetic tissue/solid organ transplant.
15. Subject has active autoimmune disease that has required systemic treatment within the 
past 2 years (eg, with use of disease modifying agents, corticosteroids or 
immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic 
corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not 
considered a form of systemic treatment.
16. Subject has known active Hepatitis B, Hepatitis C or tuberculosis. Active Hepatitis B is 
defined as a known positive HBsAg result.  Active Hepatitis C is defined by a known 
positive Hep C Ab result and known quantitative HCV ribonucleic acid (RNA) results 
greater than the lower limits of detection of the assay.
17. Subject has had any other malignancy within 5 years prior to randomization, with the 
exception of adequately treated in situ carcinoma of the cervix, uterus, or non-
melanomatous skin cancer (all treatment of which should have been completed 6 months 
prior to enrollment).
d in a
d in a
tigat
igatioional
nal
486
486
oclonal ant
oclonal an
ne, m
ne, manni
anniti
cit
ci idine IB)
ine IB
radiat
radiatioi n 
bone marr
bone marr
ng that is > 
ng that is >
tion wi
n within
thin
i
ain live vir
ain live vir
e acute tox
e acute tox
nificant tra
nificant tra
tion requir
n requ
ogenet
ogenetic t
ic tisi
autoimmu
autoim
g, wi
w th
th
i
use e
h
pressive 
essive dru
dr
roi
roid repl
d replac
ac
ered a form
red a form
ubject has k
ect has k
defined as
defined as
posi
posititi
i ve
ve
grea
grea
17.
17.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
18. Subject has a history of inflammatory bowel disease (eg, Crohn’s disease, ulcerative 
colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other 
gastrointestinal disorder or defect that would interfere with the absorption, distribution, 
metabolism, or excretion of the IP and/or predispose the subject to an increased risk of 
gastrointestinal toxicity.
19. Subject has persistent diarrhea or clinically significant malabsorption syndrome or known 
sub-acute bowel obstruction ≥ Grade 2, despite medical management
20. Subject has significant active cardiac disease within the previous 6 months including 
unstable angina or angina requiring surgical or medical intervention, significant cardiac 
arrhythmia, or New York Heart Association (NYHA) class 3 or 4 congestive heart 
failure.
21. Subject has history of interstitial lung disease (ILD) OR a history of pneumonitis that has 
required oral or IV steroids. Subjects whose pneumonitis was solely as a result of 
radiation therapy for their NSCLC would not be excluded from the study unless they 
received oral/IV steroids to manage the pneumonitis.
22. Subject has a known history or current diagnosis of human immunodeficiency virus 
(HIV) infection, regardless of treatment status.
23. Subject has any other concurrent severe and/or uncontrolled medical condition that 
would, in the Investigator’s judgment, contraindicate patient participation in the clinical 
study (eg, chronic pancreatitis, etc.).
24. Subject with uncontrolled or symptomatic central nervous system (CNS) metastases
and/or carcinomatous meningitis
!
Subjects with controlled and asymptomatic CNS metastases may participate in this 
trial. The patient must have completed any prior treatment for CNS metastases (must 
include radiotherapy and/or surgery) ≥ 28 days (≥ 14 days for stereotactic 
radiosurgery). Patients must not be receiving corticosteroids for brain metastases.
25. Subject has not recovered from the acute toxic effects (Common Terminology Criteria for 
Adverse Events [CTCAE] grade ≤ 1) of prior anticancer therapy, radiation, or major 
surgery/significant trauma (except alopecia or other toxicities not considered a safety risk 
for the subject at the Investigator’s discretion).
26. Subject has an impaired ability to swallow oral medication.
27. Subject is pregnant or breast feeding.
28. Subject has any condition that confounds the ability to interpret data from the study.
29. Subject is or has an immediate family member (spouse or children) who is investigational 
site or sponsor staff directly involved with this trial, unless prospective Institutional 
Review Board (IRB) approval (by chair or designee) is given allowing exception to this 
criterion for a specific subject.
&(/*(1(35235,(7$5<,1)250$7,21
rdiac
diac
art 
umo
umonit
nitis tha
is th
s a result of
s a result o
study unle
study unle
mmunodef
munodef
trolled med
trolled me
ate patient 
ate patient 
entral
entral nerv
nerv
l
ymptomatic
mptomatic
om
ompleted a
pleted
m
or surgery
or surge
)y
must not be
ust not b
m
red fro
ed from 
m th
t
TCAE] grad
CAE] gra
nt trauma (e
nt trauma
at the I
at the Inve
n
as an impair
as an impai
ct is pregna
ct is pregn
ubject has a
ect has a
9.9. Subject 
Subject
sisite or
te o
i
Re
Re


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
8.
DESCRIPTION OF STUDY TREATMENTS
8.1.
Description of Investigational Products
Subjects will receive CC-486 plus pembrolizumab or pembrolizumab plus placebo during the 
study.  CC-486 and matching placebo will be double blind whereas pembrolizumab will be open 
label. CC-486 and pembrolizumab are designated as IPs.  All IPs must be stored in an area free 
of environmental extremes and a secured area to prevent unauthorized access, as directed on the 
package label. A temperature log must be maintained.
8.1.1.
CC-486 (Oral Azacitidine)/Placebo
The study sponsor, Celgene Corporation will supply CC-486 and placebo 150 and 200-mg 
tablets for oral administration. Sufficient quantities of IP will be supplied by Celgene and should 
be stored as directed on the label. All tablets will be packaged in blister packs. Each tablet is 
formulated using excipients that are generally regarded as safe and used in marketed drug 
products.  A list of excipients included in the formulations is provided in the azacitidine IB.  
8.1.2.
Pembrolizumab
Pembrolizumab (50 mg lyophilized powder in single-use vial for reconstitution) for IV 
administration will be sourced by the study sponsor (Celgene Corporation) from 
 
 and labeled for clinical trial use.  Sufficient quantities of IP will be supplied by 
Celgene and should be stored as directed on the label.  Pembrolizumab will be administered in 
the clinic.
The Pharmacy Manual contains specific instructions for pembrolizumab dose calculation, 
reconstitution, preparation of the infusion fluid, and administration.
8.2.
Treatment Administration and Schedule
Subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or pembrolizumab plus 
placebo. CC-486/placebo will be administered at a dose of 300 mg orally daily on days 1-14 of a 
21-day cycle.
During scheduled site visits the subjects must arrive to the clinic in the fasting state (ie, no food 
or drink [except water] for approximately 8 - 10 hours) for all predose safety laboratory 
evaluations. Dose administration should take place after all scheduled predose safety assessments 
are completed.
Subjects will ingest CC-486/placebo with approximately 240 mL (8 ounces) of room temperature 
water.  CC-486/placebo may be taken on an empty stomach or with food (a light breakfast or 
meal of up to approximately 600 calories).
If following CC-486/placebo administration an emesis event occurs, subjects should not take 
additional drug on that same day. It is recommended that the subject receives an antiemetic 30 
minutes prior to all subsequent CC-486 doses.
Pembrolizumab will be administered as a 30-minute IV infusion at a dose of 200 mg (4 x 50 mg 
vials) on Day 1 of a 21-day cycle. Sites should make every effort to target infusion timing to be 
&(/*(1(35235,(7$5<,1)250$7,21
the
d 200-
200-mg
mg
Celgene an
elgene an
cks. Each t
cks. Each t
in markete
n mark
d in the aza
d in the aza
al fo
for recon
r recon
gene Corpo
ene Cor
nt quant
nt quantititiei
el.  Pembro
el.  Pembr
tructions fo
tructions fo
fluid, and
fluid, and
tration a
ration 
1 to receive
 to receive
ll be admin
ll be adm
e visi
visits the 
ts th
i
water] for ap
ater] for ap
se adminis
se admi
ed.
ed.
s will inges
 will inge
.  CC
.  CC-486
-486/
eal of up to
eal of up to
If fof llow
didititi
i


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
as close to 30 minutes as possible. However, given the variability of infusion pumps from site to 
site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time of 24-40 minutes).
Pembrolizumab should be co-administered with CC-486.
For subjects enrolled in the PK population, the treatment administration on PK days (i.e., Day 1 
of Cycle 1 and Cycle 2) is described below:
!
After performing the required overnight fast, taking antiemetic premedication with 
240 mL of water for nausea and vomiting (eg, ondansetron), and completing the 
required predose assessments (including the predose PK sample), subjects will ingest 
CC-486/placebo with 240 mL of room temperature water in the clinic approximately 
30 minutes after antiemetic administration on each PK dosing day.  Each dose of   
CC-486/placebo should be given at approximately the same time each day.  The exact 
date and time of dosing will be recorded in the source documents and appropriate 
CRF.
!
On Day 1 of Cycle 1 only, pembrolizumab will be administered as described above, 
but administration will start after the 6 hour CC-486 PK sample collection time-point.
Dietary restrictions on PK days (i.e., Day 1 of Cycle 1 and Cycle 2): 
!
Subjects should be instructed to limit their coffee intake to one 8-ounce cup of black 
coffee (no cream or sugar) and to not consume alcohol, tea, chocolate, or cola 
beverages within 2 hours prior to collecting PK samples.
!
Subjects should not ingest food for a minimum of 8 hours prior and 2 hours after CC-
486/placebo is administered.  Water can be allowed as desired except for 1 hour 
before and after CC-486/placebo administration.  The only water permitted in the 1-
hour period before CC-486/placebo administration is the 240 mL of water for 
antiemetic ingestion.
8.2.1.
Dose Adjustment Guidelines
8.2.1.1.
CC-486 (oral azacitidine)/Placebo
For CC-486/placebo, a maximum of 1 dose reduction will be allowed from the original dose (eg, 
patients can dose reduce from 300 mg/placebo oral daily dose to 200 mg/placebo oral daily 
dose). Re-escalation to the higher dose is not permitted. If a subject requires more than 1 dose 
reduction for CC-486/placebo, they will be discontinued from CC-486/placebo, however, they 
may continue to receive pembrolizumab (and conversely, subjects who discontinue 
pembrolizumab may continue to receive CC-486/placebo) but must continue to undergo all 
safety and efficacy assessments as per Table 2.
CC-486/placebo may be withheld for up to 7 days between the end of 1 cycle and the start of the 
next cycle to allow hematologic criteria to recover sufficiently for the next cycle to begin.
The maximum number of days that a dose may be withheld without requiring a dose reduction is 
7 days.
The maximum number of days that a dose may be withheld due to unacceptable toxicity before a 
subject is permanently discontinued from CC-486 is 14 days.  For the purposes of dose 
adjustments, unacceptable toxicity will be defined as any AE that is deemed by the Investigator 
&(/*(1(35235,(7$5<,1)250$7,21
gest 
st
mately
mately
e of  
of  
y.  The exa
y.  The exa
appropriate
ppropriate
d as describ
as describ
mple co
mple collect
lle
:
take to one
ake to
cohol, tea, 
cohol, tea,
K samples.
K samples.
imum of 8 h
mum of 
n be allo
n be allowe
w
ministrati
ministratio
bo adminis
bo adminis
elines
lines
itidine)
idine)/P
/Pl
ximum of 
imum of 
e fro
 fr m 300
30
to the high
o the hig
486
86/placeb
/placeb
to receive p
o receive
mab may co
mab may c
d efficacy 
fficacy
86/
86 plpl
/ acebo
aceb
ext cy
ext cycle to
cle to
The m
The max
a
day


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
to be related to CC-486/placebo that poses a medical risk or substantial discomfort to the subject 
including, but not limited to, Grade 3 or 4 hematologic or non-hematologic toxicity. Subjects 
should be discontinued after the 3rd episode.
See Section 8.2.1.2 and Table 6 for dose modification guidelines for pembrolizumab drug-related 
adverse events for overlapping toxicity events for all IPs.
Please refer to Table 5 for the Dose Adjustment Guidelines.
Table 5:
CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity
Toxicity
Recommendation
Grade 2 hematologic toxicity causing delay to the 
planned start of a Cycle
Absolute Neutrophil Count (ANC) < 1.5 x 109/L
Platelets < 75 x 109/L
Hold CC-486/placebo until ANC & Platelets 
≤ Grade 1
Delay ≤ 7 days, resume CC-486/placebo at same 
dose
Delay 8 – 14 days, reduce CC-486/placebo by 100 
mg
Delay > 14 days, permanently discontinue from 
study
Grade 3 neutropenia or thrombocytopenia causing 
delay to the planned start of a Cycle ANC 0.5-0.99 
x 109/L
Platelets 25-49 x 109/L
Hold CC-486/placebo until ANC & Platelets 
recover to ≤Grade 1 (ANC ≥ 1.5 x 109/L, Platelets 
≥ 75 x 109/L)
Recovery in ≤ 7 days, resume CC-486/placebo at 
same dose
Recovery in 8–14 days, reduce CC-486/placebo by 
100 mg
No recovery by 14 days, permanently discontinue 
from study
Grade 4 neutropenia or thrombocytopenia causing 
delay to the planned start of a Cycle
ANC < 0.5 x 109/L
Platelets < 25 x 109/L
For ANC < 0.5 x 109/L
The initiation of G-CSF is left at the Investigator’s 
discretion. If initiated administer G-CSF per 
institutional practice or package insert and continue 
until ANC recovers to ≥ 2.0 x 109/L
Hold CC-486/placebo until ANC & Platelets 
recover to ≤Grade 1
(ANC ≥ 1.5 x 109/L, Platelets ≥ 75 x 109/L)
Recovery in ≤ 7 days, reduce CC-486/placebo by 
100 mg
No recovery by 7 days, permanently discontinue 
from study
&(/*(1(3523
enia causing
ia causin
e
CSF is left at
CSF is left a
ated 
ated admini
admini
actice or pac
ctice or pa
ecovers to
covers to ≥
235,(7$5<,1)250$7,21
$7
$7
$7
elets
elet
plac
placeb
ebo at s
CC
CC-486/
486/pla
pla
/
rmanently d
manently d
0$
6/6/placebo
placebo
/
un
≤Grade 1 
Grade 1
109/L)
/L)
covery in
covery in ≤ 
ame dose
ame dose
Recov
Recoverer
100 m
100 m
N
<
5,
23
/*


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 5:
CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity (Continued)
Toxicity
Recommendation
Grade 3 or 4 Nausea or Vomiting
Grade 3 or 4 Diarrhea
Grade 3 or 4 Fatigue/Asthenia
Hold until resolution to ≤ Grade 1 and provide 
optimal medical management
If response ≤72 hours (3 days), and recovery ≤ 7 
days, reintroduce CC-486/placebo at 200 mg
If event recurs after re-challenge at 200 mg, 
discontinue CC-486/placebo
If no recovery by 7 days, discontinue CC-
486/placebo
Grade 3 or 4 any other non-hematologic toxicity
Hold until resolution to ≤ Grade 1 and provide 
optimal medical management
If recovery ≤ 7 days, reintroduce CC-486/placebo 
at 200 mg
If event recurs after re-challenge at 200 mg, 
discontinue CC-486/placebo
If no recovery by 7 days, discontinue CC-
486/placebo
Renal dysfunction - For any unexplained 
reductions in serum bicarbonate levels to < 20 
mEq/L or unexplained elevations of BUN and/or 
serum creatinine (> 20%) from baseline
Hold until resolution to ≤ baseline level (+/- 20%) 
Reduce CC-486 dose in the next cycle of treatment 
to the next lower dose level 
If similar unexplained renal and/or electrolyte 
disturbances subsequently persist or recur, 
discontinue CC-486
ANC = absolute neutrophil count; ASCO = American Society of Clinical Oncology; BUN = blood urea nitrogen; ESMO =
European Society for Medical Oncology; G-CSF = granulocyte colony stimulating factor.
Note: The initiation of G-CSF is left at the Investigator’s discretion.
Note: Granulocyte colony stimulating factor (G-CSF) should only be utilized in accordance to ASCO or ESMO 
recommendations.
Note: If Grade 3 or 4 neutropenia associated with fever or Grade ≥ 3 thrombocytopenia with clinically significant bleeding 
occurs at any time, the dose adjustment guidelines for Grade 4 hematological toxicity should be enacted.
Note: If neutropenia is associated with fever and severe diarrhea, subject should be managed appropriately according to the local 
practice. In case of recurrence of the diarrhea with neutropenia and fever, the continuation of the subject in the study should be 
discussed on a case-by-case basis with the sponsor’s study monitor.
8.2.1.2.
Pembrolizumab
Adverse events associated with pembrolizumab exposure may represent an immunologic 
etiology.  These adverse events may occur shortly after the first dose or several months after the 
last dose of treatment. Pembrolizumab must be withheld for drug-related toxicities and severe or 
life-threatening AEs as per Table 6 below. Dose reductions are not permitted for pembrolizumab.
&(/
th
th
(/*(1(35235,(7$5<,1)250$7,21
$7
nd provide
nd provide
uce CC
uce C -486/
-486
challenge at
challenge 
placebo
placebo
7 days, dis
7 days, dis
0
l resolution 
resolution
e CC
CC-486 d
486 
he next low
he next lo
If similar un
If similar u
disturban
disturba
discon
discon
5<
5,
5
Society of Clin
ociety of Clin
= granulocyte c
granulocyte
igator
igator’s discre
’s d
G-CSF) should
CSF) shoul
ated with feve
ed with fev
ent guidelines
ent guideli
with fever and 
h fever and 
of the diarrhe
of the diarrh
 basis with th
basis with
rolizumab
rolizumab
ntnts s associat
associat
These adve
hese adv
se of treatm
se of treatm
reatening
reatening
h


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 6:
Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events
Toxicity
Hold 
Treatment 
For Grade
Timing for Restarting 
Treatment
Treatment Discontinuation
Diarrhea/Colitis
2-3
Toxicity resolves to 
Grade 0-1.
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
4
Permanently discontinue
Permanently discontinue
AST, ALT, or 
Increased Bilirubin
2
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose.
3-4
Permanently discontinue
(see exception below)1
Permanently discontinue
Type 1 diabetes 
mellitus (T1DM), if 
new onset, or 
Hyperglycemia
T1DM or
3-4
Hold pembrolizumab for 
new onset Type 1 
diabetes mellitus or 
Grade 3-4 hyperglycemia 
associated with evidence 
of beta cell failure.
Resume pembrolizumab when 
patients are clinically and 
metabolically stable.
Hypophysitis
2-4
Toxicity resolves to 
Grade 0-1. Therapy with 
pembrolizumab can be 
continued while 
endocrine replacement 
therapy is instituted
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
Hyperthyroidism 
3
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
4
Permanently discontinue
Permanently discontinue
Hypothyroidism
Therapy with 
pembrolizumab can be 
continued while thyroid 
replacement therapy is 
instituted
Therapy with pembrolizumab can be 
continued while thyroid replacement 
therapy is instituted.
Infusion Reaction
3-4
Permanently discontinue
Permanently discontinue
&(
Infusion R
nfusion R
&(/*(1(35235,(7$5<,1)250$7,21
t per 
per 
$7
e
0$
esolve withi
esolve withi
e.
50
tly discontin
y disco
)2
a 
nce
ce
Resume pem
Resum
patients a
patients 
metab
metab
,1
$5
ves to
ves to
Therapy wi
Therapy w
izumab can 
izumab can
nued while
ued while
docrine repl
ocrine rep
therapy is in
therapy is
7$
3
To
2
1
5
1(
(1
roidism
ism
(1
(1
(1
&(
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 6:
Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events (Continued)
Toxicity
Hold 
Treatment 
For Grade
Timing for Restarting 
Treatment
Treatment Discontinuation
Pneumonitis
2
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per
day within 12 weeks.
3-4
Permanently discontinue
Permanently discontinue
Renal Failure or 
Nephritis
2
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
3-4
Permanently discontinue
Permanently discontinue
All Other Drug-
Related Toxicity2
3 or Severe
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
4
Permanently discontinue
Permanently discontinue
Note: Permanently discontinue for any severe or Grade 3 (Grade 2 for pneumonitis) drug-related AE that recurs or 
any life-threatening event.
1 For patients with liver metastasis who begin treatment with Grade 2 AST or ALT, if AST or ALT increases by 
greater than or equal to 50% relative to baseline and lasts for at least 1 week then patients should be discontinued.
2 Patients with intolerable or persistent Grade 2 drug-related AE may hold IP at physician discretion.  Permanently 
discontinue IP for persistent Grade 2 adverse reactions for which treatment with IP has been held, that do not 
recover to Grade 0-1 within 12 weeks of the last dose.
After the first cycle, each drug may be given independently on a cyclical regimen according to 
the protocol-defined dose interruptions/delays for CC-486/placebo or pembrolizumab as defined 
in Section 8.2.1 above. Dosing interruptions are permitted in the case of medical / surgical events 
or logistical reasons not related to study therapy (eg, elective surgery, unrelated medical events, 
patient vacation, and/or holidays). Subjects should be placed back on study therapy within 3 
weeks of the scheduled interruption, unless otherwise discussed with the Sponsor. The reason for 
interruption should be documented in the patient's study record.
8.2.2.
Overdose
Overdose, as defined for this protocol, refers to blinded CC-486 and/or pembrolizumab. 
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 1,000 mg 
or greater (5 times the dose). No specific information is available on the treatment of overdose of 
pembrolizumab. In the event of overdose, the subject should be observed closely for signs of 
toxicity.  Appropriate supportive treatment should be provided if clinically indicated.
&(/*
ti
/*(1(35235,(7$5<,1)250$7,21
t per
per
$7
e
0$
resolve with
resolve with
se or inabili
or inabil
osteroid to 1
osteroid to 
dnisone or e
nisone
hin 12 week
hin 12 week
50
ma
manently d
ntly d
,1
Toxicity d
Toxicity
weeks o
weeks
redu
red
lele
<
$5
y discontinu
y discontin
(7
5,(
ade 3
de 3 (Grade 
(Grade 
treatment wit
eatment w
seline and la
seline and 
Grade 2 drug
rade 2 dru
 adverse reac
adverse reac
eeks of the la
eks of the la
drug may 
drug m
ose interrup
ose interrup
ve.e Dosing
Dosing
ons not rela
ons not re
on, and/or h
n, and/or 
he schedule
e schedule
on shoul
should
.2.2.
O
Overdose
Overdose
p


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
For CC-486, on a per dose basis, an overdose is defined as any amount over the protocol-
specified dose of blinded CC-486 assigned to a given subject, regardless of any associated 
adverse events or sequelae. On a schedule or frequency basis, an overdose is defined as anything 
more frequent than the protocol required schedule or frequency.
Complete data about drug administration, including any overdose, regardless of whether the 
overdose was accidental or intentional, should be reported in the case report form. See Section 
11.1 for the reporting of adverse events associated with overdose.
8.3.
Method of Treatment Assignment
Subjects who enter screening will be assigned the next available subject number. All eligible 
subjects will be randomized by IRT to receive CC-486 plus pembrolizumab or placebo plus 
pembrolizumab. Treatment assignment will be performed centrally.
All IP will be managed by the IRT system as a central subject number assignment and 
accountability tool only.
8.4.
Packaging and Labeling
The labels for IPs may include, but are not limited to, sponsor name, address and telephone 
number, the protocol number, IP name, dosage form and strength (where applicable), amount of 
IP per container, lot number, expiry date (where applicable), medication identification/kit 
number, dosing instructions, storage conditions, and required caution statements and/or 
regulatory statements as applicable. Additional information may be included on the label as 
applicable per local regulations.
8.5.
Investigational Product Accountability and Disposal 
Celgene (or designee) will review with the Investigator and relevant site personnel the process 
for Investigational Product return, disposal, and/or destruction including responsibilities for the 
site versus the responsibilities of Celgene (or designee).
8.6.
Investigational Product Compliance
Accurate recording of all IPs administered will be made in the appropriate section of the 
subject’s case report form (CRF) and source documents. The Investigator or designee is 
accountable for the compliance of all study-specific IPs either administered or in their custody 
during the course of the study.
&(/*(1(35235,(7$5<,1)250$7,21
gible
gible
bo plus
bo plus
ment and 
ment and
me, addres
e, addre
ngth (where
gth (whe
), medicat
medica i
uired caut
uired cau i
mati
ation may
n may
ccountabi
countabi
he Invest
he Investig
sposal, and/
sposal, a
Celgene (or
Celgene (or
al Produc
al Produc
l IP
I s admin
adm
form (
form (CRF
CR
e complian
 complian
se of the stu
se of the st


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
9.
CONCOMITANT MEDICATIONS AND PROCEDURES
9.1.
Permitted Concomitant Medications and Procedures
9.1.1.
CC-486 (oral azacitidine)
In general, the use of any concomitant medication/therapies deemed necessary for the care of the 
subject is permitted.
All concomitant treatments, including blood and blood products, must be reported on the CRF. 
Subjects may be administered supportive and palliative care (eg, pain control, anti-nausea, anti-
diarrheal) as clinically indicated throughout the study. 
Myeloid growth factors (granulocyte colony stimulating factor [G-CSF] and granulocyte 
macrophage colony-stimulating factor [GM-CSF]) should be administered according to 
American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology 
(ESMO) guidelines only for the treatment of neutropenic infections.
Antiemetic administration is encouraged during the study, and is required for subjects enrolled in 
the PK population; at the Investigator’s discretion, subjects not enrolled in the PK population
may receive prophylactic antiemetic therapy (eg, a serotonin [5-HT3] receptor antagonist such as  
ondansetron) approximately 30 minutes prior to each dose of CC-486.  
Treatment with antidiarrheal medications should be prescribed at the first sign of diarrhea.  Pre-
medication with antidiarrheal medication for subsequent doses of CC-486 may be appropriate at 
the Investigator’s discretion.
9.1.2.
Pembrolizumab Supportive Care
Subjects should receive appropriate supportive care measures as deemed necessary by the 
treating Investigator.  Suggested supportive care measures for the management of adverse events 
with potential immunologic etiology are outlined below. Where appropriate, these guidelines 
include the use of oral or intravenous treatment with corticosteroids as well as additional anti-
inflammatory agents if symptoms do not improve with administration of corticosteroids.  Note 
that several courses of steroid tapering may be necessary as symptoms may worsen when the 
steroid dose is decreased. For each disorder, attempts should be made to rule out other causes 
such as metastatic disease or bacterial or viral infection, which might require additional 
supportive care. The treatment guidelines are intended to be applied when the Investigator 
determines the events to be related to pembrolizumab. 
Note: if after the evaluation the event is determined not to be related, the Investigator does 
not need to follow the treatment guidance (as outlined below). Refer to Table 6 for dose 
modification guidelines for pembrolizumab. 
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event. 
&(/*(1(35235,(7$5<,1)250$7,21
CRF.
CRF.
usea, ant
sea, anti-i-
ranulocyte
anulocyte
according t
according 
or Medi
r Med cal
required
quired fo
fo
t enrolled in
enrolle
n [5
[5-HT3] r
HT3] r
se of CC
e of CC-48
prescribed a
prescribe
equent dos
equent do
Care
Care
upportive c
upportiv
upportive c
upportive c
lology
gy are ou
are ou
y
avenous
avenou tr
mptom
mptoms do
d
steroid tap
steroid tap
eased. For e
sed. For 
c disease o
c disease o
re. The trea
. The tre
the events 
the events
te: if after t
e: if after t
not need to
not need to
mo
modifica
dific
t m
t may b
ay 
t


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
9.1.2.1.
Management of pneumonitis
These guidelines may also be used for cases of pneumonitis that may not be related to 
pembrolizumab.
!
For Grade 2 events, treat with systemic corticosteroids. When symptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.
!
For Grade 3-4 events, immediately treat with intravenous steroids.  Administer 
additional anti-inflammatory measures, as needed.
!
Add prophylactic antibiotics for opportunistic infections in the case of prolonged 
steroid administration
9.1.2.2.
Management of Diarrhea/Colitis
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, 
abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such 
as peritoneal signs and ileus).  
!
All subjects who experience diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and 
electrolytes should be substituted via IV infusion.  For Grade 2 or higher diarrhea, 
consider GI consultation and endoscopy to confirm or rule out colitis.
!
For Grade 2 diarrhea/colitis, administer oral corticosteroids. 
!
For Grade 3 or 4 diarrhea/colitis, treat with intravenous steroids followed by high 
dose oral steroids.  
!
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
9.1.2.3.
Management of type 1 diabetes mellitus (if new onset, including diabetic 
ketoacidosis [DKA]) or ≥ Grade 3 Hyperglycemia, if associated with ketosis 
(ketonuria) or metabolic acidosis (DKA)
!
For type 1 diabetes mellitus (T1DM) or Grade 3-4 Hyperglycemia
o
Insulin replacement therapy is recommended for type 1 diabetes mellitus and 
for Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria.
o
Evaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglobin, and C-peptide.
9.1.2.4.
Management of hypophysitis
!
For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or 
less, steroid taper should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is tapered.
!
For Grade 3-4 events, treat with an initial dose of IV corticosteroids followed by oral 
corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be 
&(/*(1(35235,(7$5<,1)250$7,21
nged 
ed 
lit
litis (such 
is (such 
owel perfo
wel pe
advised to
dvised to
ake is not f
ake is no
n.  For Gra
.  For Gra
nfirm
nfirm or ru
or
m
oral cortico
oral cortic
at wi
t with
th
i
i
h ntn r
Grade 1 or 
Grade 1 
n 4 weeks.
4 wee
e 1 diabete
e 1 diabete
A]) or
A]) or ≥ G
≥G
metabolic
metabolic
didiabetes m
abetes m
Insulin rep
Insulin rep
fo
for Gra
r G
o
Eva
Ev
.2.4.
2.4.
M
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
started and continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.
9.1.2.5.
Management of hyperthyroidism or hypothyroidism
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated based 
on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
!
Grade 2 hyperthyroidism events (and Grade 2-4 hypothyroidism):
o
In hyperthyroidism, non-selective beta-blockers (eg, propranolol) are 
suggested as initial therapy.
o
In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine 
or liothyroinine, is indicated per standard of care.
!
Grade 3-4 hyperthyroidism 
o
Treat with an initial dose of IV corticosteroid followed by oral corticosteroids. 
When symptoms improve to Grade 1 or less, steroid taper should be started 
and continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.
9.1.2.6.
Management of hepatic abnormalities
!
For Grade 2 events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly).
o
Treat with IV or oral corticosteroids
!
For Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours. 
When symptoms improve to Grade 1 or less, a steroid taper should be started and continued over 
no less than 4 weeks.
9.1.2.7.
Management of renal failure or nephritis
!
For Grade 2 events, treat with corticosteroids.
!
For Grade 3-4 events, treat with systemic corticosteroids.
!
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
9.1.2.8.
Management of infusion reactions
Table 7 shows treatment guidelines for subjects who experience an infusion reaction associated 
with the administration of pembrolizumab.
&(/*(1(35235,(7$5<,1)250$7,21
levothy
levothyrox
rox
y
ed by
ed by oral
ora
y
l
oid taper sh
d taper sh
acement of
ement of
se is tapere
se is tap
n tests more
n tests m
osteroi
osteroids
ds
th intraven
th intraven
or less, a s
or less,
renal failu
renal failu
events, trea
vents, tr
e 3-4 event
4 even
n symptom
n symptom
ntinued ov
tinued ov
Manag
Manag
lele 7 shows
shows
wi
with
th
i
the adm
the adm
h


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 7:
Infusion Reactions
NCI CTCAE Grade
Treatment
Premedication at
Subsequent Dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicated
Increase monitoring of vital signs 
as medically indicated until the 
subject is deemed medically 
stable in the opinion of the 
Investigator.
None
Grade 2
Requires infusion interruption 
but responds promptly to 
symptomatic treatment (eg, 
antihistamines, NSAIDS, 
narcotics, IV fluids); 
prophylactic medications 
indicated for ≤ 24 hrs
Stop Infusion and monitor 
symptoms.
Additional appropriate medical 
therapy may include but is not 
limited to:
•
IV fluids
•
Antihistamines
•
NSAIDS
•
Acetaminophen
•
Narcotics
Increase monitoring of vital signs 
as medically indicated until the 
subject is deemed medically 
stable in the opinion of the 
Investigator.
If symptoms resolve within one 
hour of stopping drug infusion, 
the infusion may be restarted at 
50% of the original infusion rate 
(eg, from 100 mL/hr to 50 
mL/hr).  Otherwise dosing will 
be held until symptoms resolve 
and the subject should be 
premedicated for the next 
scheduled dose.
Subjects who develop Grade 2 
toxicity despite adequate 
premedication should be 
permanently discontinued 
from further trial treatment 
administration.
Subject may be premedicated 1.5 
hrs. (± 30 minutes) prior to 
infusion of pembrolizumab with:
Diphenhydramine 50 mg p.o. (or 
equivalent dose of 
antihistamine).
Acetaminophen 500-1000 mg 
p.o. (or equivalent dose of 
antipyretic).
&(/*(1(3
(/
35235,(7$5<
signs 
igns 
il the
l the
cally
cally
of the
of the
reso
esolve with
lve with
pping drug i
pping drug
sion may be
sion may be
of the origin
of the origin
g, from 100 
from 100
mL/hr).  Ot
mL/hr).  O
be
be held u
held
and th
nd 
pre
5<,1)250$7,21
$7
ated 1.5
ated 1.5
or to
zumab with
zumab with
e 50 mg p.o
50 mg p.
se of 
e of 
ne).
ne).
minophen 50
inophen 50
(or equivale
or equival
ntipyretic).
pyretic).
$7
$7
35
5<
$7


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 7:
Infusion Reactions (Continued)
NCI CTCAE Grade
Treatment
Premedication at
Subsequent Dosing
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial improvement; 
hospitalization indicated for 
other clinical sequelae (eg, renal 
impairment, pulmonary 
infiltrates)
Grade 4:
Life-threatening; pressor or 
ventilatory support indicated
Stop Infusion.
Additional appropriate medical 
therapy may include but is not 
limited to:
•
IV fluids
•
Antihistamines
•
NSAIDS
•
Acetaminophen
•
Narcotics
•
Oxygen
•
Pressors
•
Corticosteroids
•
Epinephrine
Increase monitoring of vital signs 
as medically indicated until the 
subject is deemed medically 
stable in the opinion of the 
Investigator.
Hospitalization may be indicated. 
Subject is permanently 
discontinued from further trial 
treatment administration.
No subsequent dosing
Appropriate resuscitation equipment should be available in the room and a physician readily available 
during the period of drug administration.
CTCAE = Common Terminology Criteria for Adverse Events;  hr = hour; IV = intravenous(ly); NCI = National 
Cancer Institute; NSAID = non-steroidal anti-inflammatory drug;  p.o. = oral(ly)
Appropriate resuscitation equipment should be available in the room and a physician readily available during the 
period of drug administration.
For Further information, please refer to CTCAE v4.0 at http://ctep.cancer.gov
9.2.
Prohibited Concomitant Medications and Procedures
The following concomitant medications are prohibited during the course of the study:
!
Cytotoxic, chemotherapeutic, targeted, hormonal, or investigational agents/therapies 
or any other anticancer treatment.
!
Vidaza (azacitidine injection), decitabine, or other demethylating agents.
!
Other PD-1 or PD-L1 inhibitors
!
Radiation therapy
o
Note:  Radiation therapy to a symptomatic solitary lesion or to the brain may 
be considered on an exceptional case by case basis after consultation with 
&(/*(1(35235,(7$5<,1)250$7,21
y
he
ay be indica
ay be indica
manently 
manently 
d from
d from furt
furt
m
t administr
administr
5<
$7
uld be availa
ld be availa
n.
35
52
eria for Adve
eria for Adve
roidal anti
roidal anti-i
ment should b
ent should 
n.n.
ease refer to 
ease refer to 
ibited Co
ibited Co
ng concomit
ng concomi
Cy
Cytotox
oto
y
or an
r a
!
V


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Sponsor.  The subject must have clear measurable disease outside the radiated 
field.  Administration of palliative radiation therapy will be considered 
clinical progression for the purposes of determining PFS.
!
Live vaccines within 30 days prior to the first dose of trial treatment and while 
participating in the trial.  Examples of live vaccines include, but are not limited to, the 
following: measles, mumps, rubella, chicken pox, yellow fever, seasonal flu, H1N1 
flu, rabies, bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza 
vaccines for injection are generally killed virus vaccines and are allowed. However, 
intranasal influenza vaccines (eg, Flu - Mist®) are live attenuated vaccines, and are 
not allowed.
!
Glucocorticoids for any purpose other than to modulate symptoms from an event of 
clinical interest (ECI), use as a pre-medication for chemotherapeutic agents specified 
in the protocol, or for use as a pre-medication in subjects with a known history of an 
IV contrast allergy administered as part of CT radiography. Replacement doses of 
steroids (for example, prednisone 5-7.5 mg daily) are permitted while on study. 
Subjects who, in the assessment by the Investigator, require the use of corticosteroids 
for any other clinical management should be discussed with medical monitor.
9.3.
Required Concomitant Medications and Procedures
Not applicable.
&(/*(1(35235,(7$5<,1)250$7,21
,
are
an event of 
an event of 
gents speci
ents spec
own history
wn histo
acement do
acement d
d while on
whil
e the use o
the use o
with medic
with med
Procedu
Proced


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
10.
STATISTICAL ANALYSES
10.1.
Overview
This is a placebo-controlled, double-blind, randomized, phase 2 trial designed to estimate the 
efficacy and safety/tolerability of CC-486 plus pembrolizumab and placebo plus pembrolizumab, 
in subjects with previously treated metastatic non-small cell lung cancer. The primary endpoint is 
PFS based on Investigator review. 
The sections below lay out the proposed statistical considerations and analyses. The detail
statistical analysis methods will be documented in the statistical analysis plan (SAP).
10.2.
Study Population Definitions
10.2.1.
Intent-To-Treat Population
The intent-to-treat (ITT) population will consist of all randomized subjects.  All efficacy 
analyses will be based on the ITT population, unless otherwise specified.  The efficacy analyses 
will be performed according to treatment assigned at randomization.
10.2.2.
Safety Population
The safety population will consist of any enrolled subjects who received at least 1 dose of IP.  
All safety analyses will be based on the Safety population, unless otherwise specified.  The 
treatment groups for the safety analyses are based on the treatment as received if different from 
the pre-planned randomization.
10.2.3.
PK Population
The PK analysis population will include all randomized subjects who have evaluable 
concentration data to determine the pharmacokinetic parameters from at least 1 dose of CC-486.
10.2.4.
Biomarker Population
The biomarker analysis population will include all randomized subjects who received at least 1
dose of IP, provided consent for exploratory biomarker studies, and had at least 1 predose 
biomarker tissue collected and deemed of adequate quality for biomarker analysis. 
10.3.
Sample Size and Power Considerations
The primary goal of this study is to provide estimates of the difference in efficacy and safety 
between CC-486 plus pembrolizumab and placebo plus pembrolizumab. 
Approximately 90 subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or 
placebo plus pembrolizumab. Primary analysis will be conducted when 70 PFS events occur.
Selected hypothetical scenarios are presented in Table 8 with confidence interval and power 
estimates, when approximately 70 PFS events have occurred.
The table below demonstrates the hypothetical power of testing the null hypothesis H0: λT/ λC=1, 
against the two sided alternative H0: λT/ λC≠1,assuming that time to PFS events in both treatment 
&(/*(1(35235,(7$5<,1)250$7,21
s s 
ects.  All ef
ects.  All 
ified.  The 
ed.  The 
on.n.
cts who rec
cts who re
atatioion, unl
n, un e
on the trea
on the tre
de all ran
de all r
d
e pharmaco
e pharmaco
lation
lation
populat
populatioi n w
onsent for 
onsent for 
ollected and
ollected and
ample Siz
ample Siz
mary goal
goal
y
of
of
l
en CC
en C -486
486
pproximate
pproximate
plplacebo p
acebo p
lect


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
arms follow exponential distributions, and λC is the monthly hazard rate of the survival 
distribution in the control arm, and  λT is the monthly hazard rate of the survival distribution in 
the experimental arm (CC-486+pembrolizumab).
Table 8:
Hypothetical Power and Resulting Two-sided 90% CI of Hazard Ratio
Combo Treatment Median PFS (month) 
5.5
5.0
4.6
Total PFS events
74
75
76
Power (%) w/two-sided α=0.10
1
82.4
71.7
59.4
HR with [two-sided 90% CI] 
0.55 [0.38,0.81]
0.60 [0.41,0.88]
0.65 [0.45,0.95]
1 These calculations assume the median PFS in pembrolizumab alone is 3.0 months (Garon, 2014). And lost to 
follow-up (to assess PFS events) rate is 10% at the end of study. 
The power calculations are conducted with East 5.4. 
10.4.
Background and Demographic Characteristics
Subjects’ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics, while gender, race and other categorical variables will be provided using frequency 
tabulations.  Medical history data will be summarized using frequency tabulations by system 
organ class and preferred term.
10.5.
Subject Disposition
Subject disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent for both treatment 
and follow-up phases.  A summary of subjects enrolled by site will be provided. Protocol 
deviations will be summarized using frequency tabulations.
10.6.
Efficacy Analysis
10.6.1.
Primary Efficacy Endpoint
The primary endpoint PFS will be defined as the time from the randomization date to disease 
progression assessed by Investigator according to RECIST version 1.1 guideline or death due to 
any cause, whichever occurs first.  
Subjects who are alive and progression-free at the cut-off date of the PFS analyses will be 
censored at the date of the last tumor evaluation.  If subjects  begin new anti-cancer therapy prior 
to documented progression, PFS will be censored at the last assessment prior to receiving the 
anti-cancer therapy. Subjects with 2 or more missing response assessments prior to a visit with 
documented disease progression (or death) will be censored at the last visit where the subject 
was documented to be PFS event-free.  A sensitivity analysis will be performed with censoring 
rules that follow the principles of assigning the date of event based on the time of the first 
evidence of objective progression or death regardless of violations, discontinuation of IP or 
change of therapy. 
PFS will be summarized by median progression-free survival time (including two-sided 90% 
confidence interval [CI]) for each treatment group and within each strata.  The hazard ratio and a 
&(/*
m
(/*(1(35235,(7$5<,1)250$7,21
7
$7
45,0.95]
,0.95]
$7
$7
0$7
d lost to
lost to
mmarized us
marized u
e provided 
provided
quency
quenc tabu
y
, entered, d
, entered, d
using frequ
using fre
ts enrolled 
ts enrolled
uency tabul
uency tabu
Endpoint
Endpoint
will be de
will be de
y Invest
nv
igat
iga
r occurs fir
occurs fi
e alive and 
e alive and
e date of th
date of t
nted progre
ted progre
ncer therapy
ncer therap
ented di
ented di
as docume
as docume
rulu es that 
that 
viden
viden


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
two-sided 90% CI will be estimated by using Cox proportional hazard model with treatment, and 
any stratification factors as model covariates.  The Kaplan-Meier curve for PFS will be presented
for each treatment group and strata.
10.6.2.
Secondary Endpoints
10.6.2.1.
Overall Survival
Overall survival (OS) will be defined as the time from the date of randomization to the date of 
death (any cause).  Subjects who are alive will be censored at the last time that the subject was 
known to be alive. The OS analysis may also be conducted at the time when 70 deaths occur, in 
addition to when the primary analysis is performed.
Medians of overall survival including two-sided 90% CI for each treatment group will be 
calculated.  The hazard ratio and a two-sided 90% CI will be estimated using Cox proportional 
hazard model with treatment, and all stratification factors in the model.  The Kaplan-Meier curve 
for survival will be presented for each strata and treatment group.
10.6.2.2.
Overall Response Rate (ORR)
Overall response rate is the percentage of subjects that achieve a confirmed complete or partial 
response as assessed by the Investigator using RECIST version 1.1 guideline. This rate will be 
presented for each treatment group and strata.  The 90% CI of the response rates will be 
provided.  A two-sided 90% CI of the Response rate differences between pembrolizumab plus 
placebo and pembrolizumab plus CC-486 arm, with each strata and overall will be provided.
10.6.2.3.
Disease Control Rate (DCR)
The percentage of disease control (i.e., confirmed SD, CR or PR) according to RECIST 1.1 will 
be analyzed in the same manner as ORR.  When SD is believed to be best response, it must meet 
the minimum duration of 18 weeks from randomization.
10.6.2.4.
irPFS, irORR and irDCR per irRECIST
Exploratory endpoints such as irPFS, irORR, and irDCR assessed by Investigator according to 
irRECIST will be analyzed using statistical methods described previously for similar primary or 
secondary endpoints.
10.6.3.
Subgroup Analysis
The effect of treatment on the efficacy variable OS, PFS, and DCR may be investigated within 
subgroups defined by selected baseline prognostic variables and any stratification factors.
The methods described in previous statistical analysis sections will be used for each subgroup 
separately. A forest plot may also be provided.
10.7.
Safety Analysis
Safety analysis will be performed using the safety population. Safety and tolerability will be 
monitored through continuous reporting of all AEs and SAEs, laboratory abnormalities, and 
incidence of subjects experiencing adverse events resulting in dose reductions, dose 
&(/*(1(35235,(7$5<,1)250$7,21
as
cur, in
ur, in
will
will be
be
ox proportio
ox proporti
Kaplan
Kapl
-Me
Me
confirmed
confirmed
on 1.1 guide
n 1.1 gui
of
of the
the
f
resp
re
fferences be
ferences b
ach strata 
ach stra
firirmed 
med SD,
SD,
.  When SD
.  When 
om 
m rando
rand m
rDCR per
DCR per
as 
as irirPFS, 
PFS, ir
ed using sta
ed using
roup Anal
roup Ana
f treatment 
f treatment
s defined b
defined b
methods des
ethods d
parately
arately. A
. A
10.7.
0.7.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
interruptions, and/or premature discontinuation of study drugs. TEAEs, TEAEs leading to death 
or discontinuation from treatment, events assessed as Grade 3 or Grade 4, events of clinical 
interest, vital signs, weight, clinical laboratory information, and concomitant 
medications/procedures will be tabulated and summarized.
Treatment-emergent adverse events will be coded according to MedDRA. All TEAEs will be 
summarized by MedDRA system organ class and preferred term, frequency, severity grade based 
on the CTCAE (Version 4.0) and relationship to treatment. Serious adverse events, events of 
clinical interest, and events leading to discontinuation or death will be listed separately.
10.8.
Pharmacokinetic Analysis
When appropriate, plasma PK samples collected will be analyzed for CC-486 concentration 
determination using a validated high-performance liquid chromatography/tandem mass 
spectrometric method.
10.8.1.
Plasma Concentrations
By-subject listing of pharmacokinetic blood sample collection times as well as derived sampling 
time deviations will be provided.  CC-486 plasma concentrations will be summarized using 
descriptive statistics (N, arithmetic mean, standard deviation, standard error, minimum, median, 
maximum, percent coefficient of variation, geometric mean, and geometric percent coefficient of 
variation) for each cycle, if/when appropriate.  Concentrations that are below the limit of 
quantitation (BLQ) will be treated as zero for the computation of descriptive statistics. Missing 
concentrations and concentrations from blood samples collected more than ± 10% of nominal 
time will be omitted from the calculation of descriptive statistics.
Individual subject concentration-time data and mean concentration-time data for each cycle will 
be graphically presented on linear and semi-logarithmic scales.
Following single dose administration, predose samples that are BLQ or missing will be assigned 
a numerical value of zero for the calculation of AUC.  Any anomalous concentration values 
observed at predose will be identified in the clinical study report (CSR) and used for the 
computation of AUC.  Pharmacokinetic parameters will be computed if the anomalous value is 
not greater than 5% of the Cmax.  If the anomalous value is greater than 5% of Cmax, the computed 
pharmacokinetic parameters for the given subject will be dropped from the pharmacokinetic 
analysis.  
Any other BLQ concentrations will be assigned a value of zero if they precede quantifiable 
samples in the initial portion of the profile.  A BLQ value that occurs between quantifiable data 
points, especially prior to Cmax, will be evaluated to determine if an assigned concentration of 
zero makes sense, or if reanalysis or exclusion of the data is warranted.  Following Cmax, BLQ 
values embedded between 2 quantifiable data points will be treated as missing when calculating 
AUC.  BLQ values occurring at the end of the collection interval (after the last quantifiable 
concentration) will be treated as missing data.  If consecutive BLQ concentrations are followed 
by quantifiable concentrations in the terminal portion of the concentration curve, these quantified 
values will be excluded from the pharmacokinetic analysis by assigning them a value of missing, 
unless otherwise warranted by the concentration-time profile.  For the purpose of analysis, these 
trailing BLQ values may be designated as zero in the dataset if the pharmacokinetic program 
&(/*(1(35235,(7$5<,1)250$7,21
tration
tration
mass
ass
as well as d
s well as d
will be sum
will be sum
andar
andard erro
and geome
and geom
tions that a
tions that a
putati
putation of
on of
les collecte
les collec
riptive stati
iptive stat
d mean co
d mean co
mi
mi-lologari
garithm
thm
i
predose sa
predos
lculat
cu
ioion o
n o
ntified in th
ntified in th
acokinetic
acokinetic
Cma
max.  If
.  
thth
f
meters for th
meters for t
concentrat
concentrat
e init
e initial po
ial po
pecially pri
cially pri
akes sense, 
kes sense,
es embedde
es embedd
AUC.  BLQ 
AUC.  BLQ
concentra
oncentra
y qua
y qua


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
used to do the analysis (such as WinNonlin®) will treat trailing zero values as missing when 
calculating AUC.
Actual sampling times will be used in the calculations of pharmacokinetic parameters that will be 
derived using noncompartmental methods with Phoenix™ WinNonlin® Professional Version 6.3, 
or higher, 
  Graphics may be prepared 
with SAS Version 9.1, or higher; or Excel 2007, or higher; Phoenix™ WinNonlin® Professional 
6.3, or higher; or S-Plus 8.2., or higher 
.
10.8.2.
Pharmacokinetic Parameters
The following PK parameters will be calculated for CC-486:
AUCinf
Area under the plasma concentration-time curve from Time 0 extrapolated 
to infinity, calculated as [AUCt + Ct/∀z].  Ct is the last quantifiable 
concentration. No AUC extrapolation will be performed with unreliable 
∀z.  If AUC %Extrap is ≥25%, AUCinf will not be reported
AUCt
Area under the plasma concentration-time curve from Time 0 to the time 
of the last quantifiable concentration, calculated by linear trapezoidal 
method when concentrations are increasing and the logarithmic 
trapezoidal method when concentrations are decreasing.
Cmax
Maximum observed plasma concentration, obtained directly from the 
observed concentration versus time data.
Tmax
Time to Cmax, obtained directly from the observed concentration versus 
time data.
t1/2
Terminal phase half-life in plasma, calculated as [(ln 2)/ ∀z].  t1/2 will only 
be calculated when a reliable estimate for ∀z can be obtained.  
CL/F
Apparent total clearance, calculated as [Dose/AUCinf]. 
Vz/F
Apparent volume of distribution, calculated as [(CL/F)/∀z ].
The following PK parameters for CC-486 will be calculated for diagnostic purposes and listed, 
but they will not be summarized:
∀z
Apparent terminal rate constant, calculated by linear regression of the 
terminal portion of the log-concentration versus time curve in plasma.  
Visual assessment will be used to identify the terminal linear phase of the 
concentration versus time profile.  A minimum of three data points will be 
used for calculation.  
∀z will not be estimated if the terminal phase of the log-concentration 
versus time profile does not exhibit a linear decline phase, or if the 
regression coefficient < 0.8.  
&(/*(1(35235,(7$5<,1)250$7,21
0 e
0 extxtrapol
rapol
uantifiable
antifiable
ed with unr
ed with unr
eported
eported
ve from
e from Ti
Ti
m
ulated by lin
ated by lin
sing and the
ing and
ons are dec
ons are dec
nc
ncentrati
entration
on
us t
s time data
ime da
directly fro
directly fro
e half
e half-f life i
li
d when a r
when a r
rent total cl
ent total cl
Apparent v
Apparent v
K parameter
parameter
ot be summ
t be sum


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
∀z lower
Lower limit of time (h) included in the calculation of ∀z. 
∀z N
Number of data points used in the calculation of ∀z.
∀z upper
Upper limit of time (h) included in the calculation of ∀z.
Rsq
Regression coefficient for calculation of ∀z.  
AUC % Extrap
Percentage of AUCinf due to extrapolation from the last quantifiable time 
point to infinity.
10.8.3.
PK Analyses
By-subject listing of pharmacokinetic parameters will be provided.  The pharmacokinetic 
parameters will also be summarized using descriptive statistics (N, arithmetic mean, standard 
deviation, standard error, minimum, median, maximum, percent coefficient of variation, 
geometric mean, and geometric percent coefficient of variation) for each cycle.  Also, when 
appropriate, graphical representations (i.e., scatter plots, box plots, etc) may be used to visualize
the results.
The effect of pembrolizumab on the PK of CC-486 will be assessed using graphic comparison 
and descriptive stats.
Exploratory analysis may be conducted to investigate the relationship between PK parameters 
and efficacy endpoints.
10.9.
Interim Analysis
No interim analysis of efficacy is planned for this study.
10.10.
Other Topics
10.10.1.
Data Monitoring Committee
An independent Data Monitoring Committee (iDMC) will be established and will include 
medical oncologists and a statistician, all of whom are not otherwise involved in the study 
conduct.  During the course of the study, the DMC will review the safety data regularly. The first 
DMC meeting will occur when 10 subjects in each arm have safety data from at least one cycle 
of treatment, with subsequent meetings approximately every 6 months or more often if requested 
by the DMC Chairman. The DMC will offer recommendations to continue, modify or stop the 
study based only on periodic evaluations of comparative safety data, in accordance with criteria 
outlined in the DMC Charter. An independent statistician will prepare the reports to the DMC 
members for each scheduled meeting. Operational details for the DMC will be detailed in the 
DMC charter.
10.10.2.
Steering Committee
The conduct of this trial will be overseen by a Steering Committee (SC), presided over by the 
coordinating principal Investigator and if possible the representative regional Investigators from 
&(/*(1(35235,(7$5<,1)250$7,21
me
acokinetic
acokineti
c m
c mean, sta
ean, s
nt of variat
nt of variat
ch cycle.  A
h cycle.  
etc) may be
etc) may be
ssessed usi
sessed us
the relat
the relatioi
d for this s
d for this
Committe
Committe
onitoring Co
nitoring
nd a stati
d a st
sti
he course of
e course of
will
will occur w
occur w
l
wi
with
th
i
subse
subse
h
MC Chairma
C Chairma
ased only o
ased only o
ned in the D
ned in the 
embers for
embers for
DMC cha
DMC cha


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
countries participating in this study.  The SC will serve in an advisory capacity to the Sponsor.  
Operational details for the SC will be detailed in a separate SC charter.
Note: The SC is separate from the DMC.
&(/*(1(35235,(7$5<,1)250$7,21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
11.
ADVERSE EVENTS
11.1.
Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study. It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subject’s health, including 
laboratory test values (as specified by the criteria in Section 11.3), regardless of etiology. Any 
worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-
existing condition) should be considered an AE.  A diagnosis or syndrome should be recorded on 
the AE page of the CRF rather than the individual signs or symptoms of the diagnosis or 
syndrome. 
Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an 
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be 
reported on the overdose CRF. (See Section 8.2.2 for the definition of overdose.) Any sequela 
of an accidental or intentional overdose of an investigational product should be reported as an 
AE on the AE CRF. If the sequela of an overdose is an SAE, then the sequela must be reported 
on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be 
identified as the cause of the event on the SAE report form and CRF but should not be reported 
as an SAE itself.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary. There is no known specific antidote for CC-486 and 
pembrolizumab overdose. Actual treatment should depend on the severity of the clinical situation 
and the judgment and experience of the treating physician.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or findings from 
other tests and/or procedures.
All AEs will be recorded by the Investigator from the time the subject signs informed consent 
until 30 days after the last dose of either study drug and those SAEs made known to the 
Investigator at any time thereafter that are suspected of being related to IP. Adverse events and 
SAEs will be recorded on the AE page of the CRF and in the subject’s source documents.  All 
SAEs must be reported to Celgene Drug Safety within 24 hours of the Investigator’s knowledge 
of the event by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.
In addition, events known as pembrolizumab Events of Clinical Interest (ECI) must also be 
recorded on the Adverse Event CRFs or Overdose CRF, depending on the event, and reported 
within 24 hours of the Investigator’s knowledge of the event, regardless of whether or not the 
Investigator considers the event related to the IP. If the event meets serious criteria (SAE), the 
event must also be reported to Celgene Drug Safety also within 24 hours by facsimile, or other 
appropriate method, using the SAE Report Form, or approved equivalent form as outlined in 
Section 11.5. 
&(/*(1(35235,(7$5<,1)250$7,21
y
pre
pre-
corded on
rded o
s or 
s or 
be reporte
be reporte
h an AE sh
h an AE sh
overdose.)
erdose
should be 
should be
n the sequel
the seque
lting 
ing in the
and CRF bu
nd CRF bu
ored as app
ored as app
wn specific
wn specifi
uld depend
uld depen
ing physici
ing physici
during the s
during the
ters:  the su
ters:  the
cal findings
findings
l
y the Invest
the Inve
y
st dose of e
t dose o
me thereafte
me therea
ded on the
ded on the
eported to 
eported to 
by
by f
y acsimil
acsimil
f
t form.
form.
dititioion,n, even
even
orded on th
rded on t
wi
within
thin
i
24 h
24 h
nvest
nvestigi


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
See Section 11.7 for detailed guidance on the reporting of pembrolizumab ECIs.  
11.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all adverse events as to: 
11.2.1.
Seriousness 
A serious adverse event (SAE) is any AE occurring at any dose that:
!
Results in death;
!
Is life-threatening (i.e., in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);
!
Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);
!
Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);
!
Is a congenital anomaly/birth defect;
!
Constitutes an important medical event.
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospitalizations for:
!
A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE. 
!
Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.
!
The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.
!
A procedure for protocol/disease-related investigations (eg, surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.
!
Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.
!
A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the CRF.  Hospitalization or 
prolonged hospitalization for a complication remains a reportable SAE.
&(/*(1(35235,(7$5<,1)250$7,21
mediate
ediate
zati
ation
on
ength of st
ngth of s
ant
antial 
ial disru
disru
 that may n
that may 
itity, but ma
y, but ma
ne of the ot
ne of the 
sed in decid
sed in dec
spitalizatio
pitalizatio
rotocol the
rotocol the
ation fo
for a 
r a 
nt or monito
nt or mon
n condit
n condi io
nistration o
nistration
ion.  Howe
n.  Howe
uch transfu
uch trans
A procedu
A procedu
endosc
endosc
hosp
os
r


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
An elective treatment of or an elective procedure for a pre-existing condition 
unrelated to the studied indication, that has not worsened from baseline. 
!
Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form 
must be completed.
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.
11.2.2.
Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity / intensity of the event. 
The severity / intensity of AEs will be graded based upon the subject’s symptoms according to 
the current active minor version of the Common Terminology Criteria for Adverse Events 
(CTCAE, Version 4.0); http://ctep.cancer.gov/protocolDevelopment/electronic_applications/
ctc.htm#ctc_40
Adverse events that are not defined in the CTCAE should be evaluated for severity / intensity 
according to the following scale:
!
Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!
Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!
Grade 3 = Severe – marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalization is possible
!
Grade 4 = Life threatening – extreme limitation in activity, significant assistance 
required; significant medical intervention/therapy required, hospitalization or hospice 
care probable
!
Grade 5 = Death - the event results in death
11.2.3.
Causality 
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected:
a causal relationship of the adverse event to IP administration is 
unlikely or remote, or other medications, therapeutic 
interventions, or underlying conditions provide a sufficient 
explanation for the observed event.
Suspected:
there is a reasonable possibility that the administration of IP 
caused the adverse event.  ‘Reasonable possibility’ means there 
is evidence to suggest a causal relationship between the IP and 
the adverse event.
&(/*(1(35235,(7$5<,1)250$7,21
event.
event
oms accord
ms accord
Adverse Ev
dverse Ev
ctronic_app
ronic_
uated for se
ated for s
no limitat
no limitati
limitat
limitatioion
vent
ventioion/the
n/the
atatioion n in ac
n ac
required, h
required, h
g g – extrem
extre
edical inte
edical int
h - th
the eve
e eve
y
must deter
must deter
an AE/SAE
n AE/SA
ot suspected
suspected
S


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Causality should be assessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes 
available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.
11.2.4.
Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
11.2.5.
Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(eg, discontinuation, interruption, or reduction of IP, as appropriate) and report if concomitant 
and/or additional treatments were given for the event. 
11.2.6.
Outcome
The Investigator will report the outcome of the event for both AEs and SAEs.
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered (returned to baseline), recovered with sequelae, or death (due to 
the SAE). 
11.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!
results in discontinuation from the study;
!
requires treatment, modification/ interruption of IP dose, or any other therapeutic 
intervention; or
!
is judged to be of significant clinical importance, eg, one that indicates a new disease 
process and/or organ toxicity, or is an exacerbation or worsening of an existing 
condition.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a 
part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE. If 
possible, the laboratory abnormality should be recorded as a medical term and not simply as an 
abnormal laboratory result (eg, record thrombocytopenia rather than decreased platelets).
11.4.
Pregnancy
All pregnancies, suspected pregnancies and lactation occurring in either a female subject of 
childbearing potential or partner of a male subject are immediately reportable events.
&(/*(1(35235,(7$5<,1)250$7,21
f the
he
E, as appli
E, as app
port if conc
port if conc
AEs and SA
Es an
e subject’s 
subject’
recovered w
ecovered
s
to be an A
to be an 
om 
m the stud
e stu
ificat
ic ion/ i
n/ i
of significan
f signific
or organ tox
or organ t
verit
erity y grade
grade
umented as
umented 
tory
ory abnorm
abnorm
y
rome shoul
rome shou
of a diagno
of a diagn
ossible, the
ossible, the
abnorm
bnormalal


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
69
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
11.4.1.
Females of Childbearing Potential
Pregnancies, suspected pregnancies (including elevated β-hCG or a positive pregnancy test in a 
female of childbearing potential regardless of age or disease state) and lactation of a female 
subject that occur during the trial or within 120 days of completing the trial (or longer if required 
by local requirements), or 30 days following cessation of treatment if the subject initiates new 
anticancer therapy, whichever is earlier, are considered immediately reportable events.  
Investigational product is to be discontinued immediately.  The pregnancy, suspected pregnancy, 
or positive pregnancy test, or lactation must be reported to Celgene Drug Safety immediately by 
facsimile, or other appropriate method, using the Pregnancy Initial Report Form, or approved 
equivalent form.  
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.
The female subject should be referred to an obstetrician-gynecologist, preferably one 
experienced in reproductive toxicity for further evaluation and counseling.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the Investigator 
should report the abnormal outcome as an AE.  If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by facsimile, or other appropriate 
method, within 24 hours of the Investigator’s knowledge of the event using the SAE Report 
Form, or approved equivalent form.
All neonatal deaths that occur within 30 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 30 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by 
facsimile, or other appropriate method, within 24 hours of the Investigator’s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
11.4.2.
Male Subjects
If a female partner of a male subject taking investigational product becomes pregnant while the 
subject is receiving investigational product or within 3 months of the last dose of IP, the male 
subject taking IP should notify the Investigator, and the pregnant female partner should be 
advised to call their healthcare provider immediately. The female partner should be referred to an 
obstetrician-gynecologist, preferably one experienced in reproductive toxicity for further 
evaluation and counseling.  Male subjects should avoid fathering a child until 3 months after the 
last dose of IP (or longer if required by local requirements). The ICF will address any country-
specific requirements, as needed.
11.5.
Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the CRF.  Any serious adverse event, or 
follow up to a serious adverse event, including death due to any cause other than progression of 
the cancer under study that occurs to any subject from the time the consent is signed through 90 
days following cessation of treatment, or 30 days following cessation of treatment if the subject 
initiates new anticancer therapy, whichever is earlier, whether or not related to the Sponsor's 
&(/*(1(35235,(7$5<,1)250$7,21
by
ved 
ed 
nd m
nd must
ust
m
her norm
er norma
d equivalen
d equivalen
ferably
ferably on
y
ing.
ng.
ortion
ortion), , th
th
outcome m
outcome m
y y by facsim
by facsi
of the even
e even
rth should b
rth should 
h afte
h after 30
r 30 d
uld also be 
uld also be 
ithin 24 hou
thin 24 hou
pproved eq
proved e
subject taki
subject tak
gatatioional pr
nal pr
d notify
d not
the
th
y
healt
ealthcare p
hcare
co
colologigist, pr
st, pr
counseling
counselin
IP
IP (or long
(or long
requiremen
uiremen
5.5.
Re
Re
Any AE th
Any AE t
ddi
ddititi
i o


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
70
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
product  must be reported to Celgene Drug Safety within 24 hours of the Investigator’s 
knowledge of the event by facsimile, or other appropriate method, using the SAE Report Form, 
or approved equivalent form.  This instruction pertains to initial SAE reports as well as any 
follow-up reports.
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to study drugs) that occur during 
the study (from the time the subject signs informed consent until 90 days after the last dose of 
either IP) or any SAE made known to the Investigator at anytime thereafter that are suspected of 
being related to IP.  SAEs occurring prior to treatment (after signing the ICF) will be captured.
The SAE report should provide a detailed description of the SAE and include a concise summary
of hospital records and other relevant documents.  If a subject died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data should be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the IRB/Ethics 
Committee (EC) of the SAE and providing them with all relevant initial and follow-up 
information about the event. The Investigator must keep copies of all SAE information on file 
including correspondence with Celgene and the IRB/EC.
11.5.1.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (eg, missing causality assessment) may be handled by phone.
11.6.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to CC-486 based on the Investigator Brochure.
In the United States, all suspected unexpected serious adverse reactions (SUSARs) will be 
reported in an expedited manner in accordance with 21 CFR 312.32.
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance 
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.
For the purpose of regulatory reporting in the EEA, Celgene Drug Safety will determine the 
expectedness of events suspected of being related to the other IP, pembrolizumab based on the 
Pembrolizumab Investigators Brochure for the product.
Events of  disease progression for the disease under study (including deaths due to disease 
progression for indications that are considered to be fatal) will be assessed as expected adverse 
events and will not be reported as expedited safety reports to regulatory authorities.
&(/*(1(35235,(7$5<,1)250$7,21
of 
of 
ed.d.
summary
summary
s b
s been
een
gene Drug 
ne Drug 
ed in a sub
ed in a su
Safet
Safety.y.
nforming th
orming
ialal and fo
and foll
all SAE in
all SAE in
m Celgene
Celgene
expect
expected to
ed to
essment) m
ssment) 
Adverse E
Adverse E
g, Cel
g, Celgene
g
o CC
CC-486
486 b
ted unexpe
ed unexpe
anner in acc
nner in ac
e European 
e European
eport in an 
port in an
erned, susp
erned, susp
2001/20/E
001/20/
n of adverse
of adverse
se (ENTR/C
(ENTR/
he purpose
e purpos
xpectedness
xpectedness
Pembroliz
Pembroliz
ent


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
71
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Celgene or its authorized representative shall notify the Investigator of the following 
information:
!
Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (i.e., SUSAR);
!
Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Sponsor and the IRB/EC.  (See Section 15.3 for record retention 
information).
Celgene Drug Safety Contact Information:
For Celgene Drug Safety contact information, please refer to the Serious Adverse Event Report 
Form Completion Guidelines or to the Pregnancy Report Form Completion Guidelines.
11.7.
Pembrolizumab Events of Clinical Interest
Selected non-serious and serious adverse events are also known as ECIs and must be reported to 
the Sponsor.
For the time period beginning when the consent form is signed until treatment 
allocation/randomization, any ECI, or follow up to an ECI, that occurs to any subject must be 
reported within 24 hours to the Sponsor if it causes the subject to be excluded from the trial, or is 
the result of a protocol-specified intervention, including but not limited to washout or 
discontinuation of usual therapy, diet, placebo treatment or a procedure.
For the time period beginning at treatment allocation/randomization through 30 days following 
cessation of treatment, any ECI, or follow up to an ECI, whether or not related to the Sponsor’s 
products, must be reported within 24 hours to the Sponsor, either by entering all ECIs of 
overdose on the Overdose CRF or by entering all other ECIs on the AE CRF within 24 hours of 
the Investigator’s knowledge of the event, regardless of whether or not the Investigator considers 
the event related to the IP. If the event meets serious criteria (SAE), the event must also reported 
to Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
Events of clinical interest for this trial include:
1. an overdose of pembrolizumab, as defined in Section 8.2.2 - Overdose, that is not 
associated with clinical symptoms or abnormal laboratory results. See Section 11.1 for a 
description of how overdoses of pembrolizumab are to be documented (with or without 
associated adverse events).
2. an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the 
upper limit of normal and, at the same time, an alkaline phosphatase lab value that is less 
than 2X the upper limit of normal, as determined by way of protocol-specified laboratory 
testing or unscheduled laboratory testing.*
&(/*(1(35235,(7$5<,1)250$7,21
n 
Adverse Ev
Adverse Ev
tion Guide
tion Guid
wn 
wn as ECIs
as EC
is signed u
s signed u
an ECI, th
an ECI, th
uses the sub
ses the su
n, including
n, including
ebo treatm
ebo treatm
ment allo
ment all ca
follo
l w up 
w up 
in 24 hours
in 24 hours
RF or by
RF or by en
y
dge of
of the e
the e
f
IP. If the e
IP. If the e
fety y wi
within 
thin
i
m, or approv
m, or approv
ical intere
cal intere
n overdose 
verdose 
associ
associated
ated
descrip
descrip
asso
asso
2.2.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
72
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
* Note:  These criteria are based upon available regulatory guidance documents. The 
purpose of the criteria is to specify a threshold of abnormal hepatic tests that may require 
an additional evaluation for an underlying etiology.
&(/*(1(35235,(7$5<,1)250$7,21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
73
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
12.
DISCONTINUATIONS
12.1.
Treatment Discontinuations
The following events are considered sufficient reasons for discontinuing a subject from the 
investigational product :
!
Adverse Event
!
Progressive Disease
!
Symptomatic deterioration (global deterioration of health status)
!
Physician decision
!
Withdrawal by subject
!
Death
!
Lost to follow-up
!
Protocol violation
!
Other (to be specified on CRF)
The reason for discontinuation of treatment should be recorded in the CRF and in the source 
documents.
The decision to discontinue a subject from treatment remains the responsibility of the treating 
physician, which will not be delayed or refused by the sponsor.  However, prior to discontinuing 
a subject, the Investigator may contact the Medical Monitor and forward appropriate supporting 
documents for review and discussion.
12.2.
Study Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
!
Adverse Event
!
Progressive disease
!
Withdrawal by subject
!
Death
!
Lost to follow-up
!
Protocol violation
!
Other
The reason for study discontinuation should be recorded in the CRF and in the source 
documents.
&(/*(1(35235,(7$5<,1)250$7,21
corded in th
orded in
ent
ent remain
remain
d by the sp
d by the sp
Medical Mo
Medical Mo
tion
on
idered suffi
dered suff
ntnt
sive disease
sive diseas
hdrawal by
hdrawal b
Death
Death
!
Lost t
ost t
!
P


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
74
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
13.
EMERGENCY PROCEDURES
13.1.
Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page).This global Emergency 
Call Center is available 24 hours a day and 7 days a week. The representatives are responsible 
for obtaining your call-back information and contacting the on call Celgene/contract research 
organization (CRO) Medical Monitor, who will then contact you promptly.
Note: The back-up 24-hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls. 
13.2.
Emergency Identification of Investigational Products
The blind must not be broken during the course of the study unless in the opinion of the 
Investigator, it is absolutely necessary to safely treat the subject. IF it is medically imperative to 
know what IP the subject is receiving, IP should be temporarily discontinued if, in the opinion of 
the Investigator, continuing IP can negatively affect the outcome of the subject’s treatment.
The decision to break the blind in emergency situations remains the responsibility of the treating 
physician, which will not be delayed or refused by the Sponsor. However, the Investigator may 
contact the Medical Monitor prior to breaking the blind to discuss unblinding, mainly in the 
interest of the subject.
The Investigator should ensure that the code is broken only in accordance with the protocol.  The 
Investigator should promptly notify the Medical Monitor of the emergency unblinding and the 
reason for breaking the blind, which should be clearly documented by the Investigator in the 
subject’s source documentation.
Emergency unblinding should only be performed by the Investigator through the IRT by using an 
emergency unblinding personal identification number (PIN), and the Investigator should call IRT 
for unblended dose information.
&(/*(1(35235,(7$5<,1)250$7,21
not be
ot b
ed on
d on
Emergency
Emergenc
esponsible
esponsible
ract researc
act resear
nly
nly b
y e used
e used
or or design
r or desig
nal Produ
nal Pro
dy
dy unless in
unless in
y
he subject. I
e subject. I
temporarily
temporari
fect the outc
ect the out
y situations 
y situations
fused by th
fused by th
reaking the
aking the
that the cod
that the cod
notify the 
notify the 
ind, which 
d, which 
mentation.
mentation.
ding s
ding shoul
hould
indi
inding pers
ng per
d dose info
dose info


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
75
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
14.
REGULATORY CONSIDERATIONS
14.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative, 
and Investigator abide by Good Clinical Practice (GCP), as described in International 
Conference on Harmonisation (ICH) Guideline E6 and in accordance with the general ethical 
principles outlined in the Declaration of Helsinki. The study will receive approval from an 
IRB/EC prior to commencement. The Investigator will conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.
14.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions, 
including obligations of confidentiality of Celgene information. The Investigator should maintain 
a list of Sub-investigators and other appropriately qualified persons to whom he or she has 
delegated significant study-related duties.
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.
The Investigator, or a designated member of the Investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The Investigator must ensure timely and accurate completion of CRFs and queries.
The information contained in the protocol and amendments (with the exception of the 
information provided by Celgene on public registry websites) is considered Celgene confidential 
information.  Only information that is previously disclosed by Celgene on a public registry 
website may be freely disclosed by the Investigator or its institution, or as outlined in the Clinical 
Trial Agreement.  Celgene protocol, amendment and IB information is not to be made publicly 
available (for example on the Investigator’s or their institution’s website) without express written 
approval from Celgene.  Information proposed for posting on the Investigator’s or their 
institution’s website must be submitted to Celgene for review and approval, providing at least 5 
business days for review.
At the time results of this study are made available to the public, Celgene will provide 
Investigators with a summary of the results that is written for the lay person.  The Investigator is 
responsible for sharing these results with the subject and/or their caregiver as agreed by the 
subject.
&(/*(1(35235,(7$5<,1)250$7,21
in 
authori
authorititi
i es
es
ical Practic
ical Practic
evaluate an
valuate
study
ud are a
re
y
study
study-relate
rel
ation. The I
. The
fied persons
fied person
ord of all su
rd of all su
study.  Subj
tudy.  Subj
documents.
ocuments
ber of the In
er of the I
olve querie
olve quer
ospital chart
spital cha
must ensur
must ensu
d in the pro
n the pro
y Celgene 
Celgene
y
nform
orm
f
ata ioion
reely disclo
reely disclo
ent.  Cel
nt.  Celgen
ge
for example
or example
from
om
f
Cel
Cel
m
g
utition’s web
on’s web
siness days
ness days
At
At the tim
the tim
vest
vest


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
76
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
14.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a subject and/or a subject’s legal representative 
prior to any study related procedures.
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original ICF signed and dated by the study subject and by the person 
consenting the study subject prior to the study subject’s entry into the study, must be maintained 
in the Investigator’s study files and a copy given to the study subject.  In addition, if a protocol is 
amended and it impacts on the content of the informed consent, the ICF must be revised.  Study 
subjects participating in the study when the amended protocol is implemented must be re-
consented with the revised version of the ICF.  The revised ICF signed and dated by the study 
subject and by the person consenting the study subject must be maintained in the Investigator’s 
study files and a copy given to the study subject.
14.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent). Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed ICF, it is the responsibility of the Investigator to obtain such permission in 
writing from the appropriate individual.
14.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, 
protocol number, study title and amendment number(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
14.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, ICF, and any other appropriate documents will 
be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is 
sought. If applicable, the documents will also be submitted to the authorities in accordance with 
local legal requirements.
IP can only be supplied to an Investigator by Celgene or its authorized representative after 
documentation on all ethical and legal requirements for starting the study has been received by 
&(/*(1(35235,(7$5<,1)250$7,21
ol is
ol is
Study
Study
re-
the study
the study
Invest
nvestigato
igato
privacy
ivacy an
an
y
d
ost stringen
st stringen
necessary, 
necessa
cords relev
cords relev
iver or auth
ver or au
Invest
Inve igato
iga
st be approv
t be app
endments w
ndments 
ned before
ned before
m the IRB/E
the IRB
m
tle and ame
and 
re do not re
e do not re
poses.
poses.
nstitution
nstitution
an
and App
d App
e the st
e the
art o
art o
submitted t
ubmitted t
dates of iss
dates of iss
sought. 
ought
al


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
77
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Celgene or its authorized representative. This documentation must also include a list of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue 
a statement confirming that the composition of the committee is in accordance with GCP. For 
example, the IRB General Assurance Number may be accepted as a substitute for this list. 
Formal approval by the IRB/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed. It must mention the date on which the decision was made and must be 
officially signed by a committee member. Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICF should also be revised.
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC. This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.
14.7.
Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:
!
Information on serious or unexpected adverse events as soon as possible; 
!
Periodic reports on the progress of the study;
!
Deviations from the protocol or anything that may involve added risk to subjects.
14.8.
Termination of the Study
Celgene reserves the right to terminate this study prematurely at any time for reasonable medical 
or administrative reasons. Any premature discontinuation  will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities, etc).
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!
Unsatisfactory enrollment;
!
GCP noncompliance;
!
Inaccurate or incomplete data collection;
!
Falsification of records;
!
Failure to adhere to the study protocol.
&(/*(1(35235,(7$5<,1)250$7,21
otocol
ocol
aluated to
aluated to
also be rev
also be rev
and, if app
and, if app
o applies to
applie
r, if applica
r, if applic
be reviewe
e revi
nal Revie
nal Revie
vestigator m
estigator 
pected adve
pected adv
gress of the
gress of the
otocol
otoco or a
or
l
of the Stu
of the S
ht to termin
ht to term
sons. Any
ons. Any p
y
requireme
requireme
e Invest
Investiga
ig
study
tudy f
y or m
or m
f
!
Unsat
Unsati
!
G
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
78
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
15.
DATA HANDLING AND RECORDKEEPING 
15.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed and 
retained.  Examples of source documents include: hospital records; clinic and office charts; 
laboratory notes; memoranda; subject’s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; X-ray film and reports; and records kept at the pharmacy, and 
the laboratories, as well as copies of CRFs or CD-ROM.
15.2.
Data Management
Data will be collected via CRF and entered into the clinical database per Celgene standard 
operating procedures (SOPs). This data will be electronically verified through use of 
programmed edit checks specified by the clinical team.  Discrepancies in the data will be brought 
to the attention of the clinical team, and investigational site personnel, if necessary.  Resolutions 
to these issues will be reflected in the database.  An audit trail within the system will track all 
changes made to the data.
15.3.
Record Retention
Essential documents must be retained by the Investigator according to the period of time outlined 
in the clinical trial agreement. The Investigator must retain these documents for the time period 
described above or according to local laws or requirements, whichever is longer. Essential 
documents include, but are not limited to, the following:
!
Signed informed consent documents for all subjects;
!
Subject identification code list, screening log (if applicable), and enrollment log;
!
Record of all communications between the Investigator and the IRB/EC;
!
Composition of the IRB/EC;
!
Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);
!
List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;
!
Copies of CRFs (if paper) and of documentation of corrections for all subjects;
!
IP accountability records;
!
Record of any body fluids or tissue samples retained;
!
All other source documents (subject records, hospital records, laboratory records, 
etc.); 
&(/*(1(35235,(7$5<,1)250$7,21
on as 
n as 
macy, and 
macy, and
elgene
elgene stan
stan
hrough use 
ugh us
es in the da
s in the d
nnel, if nece
nel, if nec
witithin the s
hin 
stigator acc
tigator acc
must retain
must reta
r requirem
r requirem
the follo
the follow
documents 
documen
code list, s
code list, 
mmu
mmunicati
nica o
of
of the IRB
e IR
f
f all co
all comm
mm
sentative(s)
sentative(s)
ist of Sub
ist of Sub
Invest
Investiga
iga
the stu
e stu
!
Co
Co
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
79
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
!
All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writing from Celgene prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements. Details of these arrangements should be 
documented. 
All study documents should be made available if required by relevant health authorities. 
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.
&(/*(1(35235,(7$5<,1)250$7,21
tion of 
tion of 


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
80
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
16.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative 
for compliance with applicable government regulations with respect to current GCP and SOPs.
16.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  All aspects of the study are reviewed with the Investigator and the staff at a study
initiation visit and/or at an Investigator meeting.  Prior to enrolling subjects into the study, a 
Celgene representative will review the protocol, CRFs, procedures for obtaining informed 
consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring will 
include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone.  During monitoring visits, the facilities, 
investigational product storage area, CRFs, subject’s source documents, and all other study 
documentation will be inspected/reviewed by the Celgene representative in accordance with the 
Study Monitoring Plan.
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the CRFs or via queries by the Investigator and/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
16.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs  to evaluate compliance with Good Clinical Practice 
guidelines and regulations.
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, CRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/IECs, regulatory authorities (eg, FDA, EMA, Health Canada) and 
company authorized representatives.  The Investigator should make every effort to be available 
for the audits and/or inspections.  If the Investigator is contacted by any regulatory authority 
regarding an inspection, he/she should contact Celgene immediately.
&(/*(1(35235,(7$5<,1)250$7,21
y
y, a
med 
med 
ring will
ring will
pri
priate
ate
the facilit
the facilitiei
nd all other 
d all other 
 in accorda
n acco
that i
ha s a di
a d
document
docume
r his/her sta
his/her st
ries by the 
ries by th
onsents, adh
onsents, adh
per recordin
er recordin
y-specific m
specific 
procedures
procedu
sentatives o
sentatives o
elgene SOP
lgene SOP
red to perm
red to pe
RFs and ap
RFs and a
ons by IRB
ns by IRB
rized repres
rized repre
s and/or ins
s and/or ins
an inspect
n inspect


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
81
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
17.
PUBLICATIONS
As described in Section 14.2 all protocol- and amendment-related information, with the 
exception of the information provided by Celgene on public registry websites, is considered 
Celgene confidential information and is not to be used in any publications.  Celgene protocol-
related information proposed for use in a publication must be submitted to Celgene for review 
and approval, and should not be utilized in a publication without express written approval from 
Celgene, or as described in the Clinical Trial Agreement.  
Celgene will ensure Celgene-sponsored studies are considered for publication in the scientific 
literature in a peer-reviewed journal, irrespective of the results.  At a minimum, this applies to 
results from all Phase 3 clinical studies, and any other study results of significant medical 
importance.  This also includes results relating to investigational medicines whose development 
programs have been discontinued.
Study results may also be presented at one or more medical congresses, and may be used for 
scientific exchange and teaching purposes.  Additionally, this study and its results may be 
submitted for inclusion in all appropriate health authority study registries, as well as publication 
on health authority study registry websites, as required by local health authority regulations.  
Eligibility for external authorship, as well as selection of first authorship, will be based on 
several considerations, including, but not limited to, contribution to protocol development, study 
recruitment, data quality, participation in data analysis, participation in study steering committee 
(when applicable) and contribution to abstract, presentation and/or publication development.
&(/*(1(35235,(7$5<,1)250$7,21
tific
ific
pplies to
plies to
edical
edical
se developm
se develop
nd may
nd may b
y e
d i
d its resul
ts resul
i
ts
l
stries, as w
ries, as w
healt
alth autho
uth
t authorshi
t authorsh
ibution to p
ibution to p
, part
 participati
icipat
entation an
entation a


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
82
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
18.
REFERENCES
Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs 
BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the 
primary outcome. Br J Cancer. 2000;83(4):447-453.
Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther 
Adv Med Oncol. 2011;3(6):279-291.
Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for 
the treatment of lung cancer. Cancer Immunol Res. 2013;1(2):85-91.
Brahmer JR, Horn L, Antonia SJ, et al. Survival and long-term follow-up of the phase I trial of 
nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated 
advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;(suppl; abstr 8030).
Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in 
patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for 
advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 
2006;32(8):583-587.
Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced 
non-small-cell lung cancer: a phase II trial. J Clin Oncol. 1999;17(7):2081-2085.
Edge SB, Byrd DR, Compton CC, et al. AJCC cancer Staging Manual. 7th Ed. Springer, 2009.
Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
revised RECIST guideline (version 1.1). Eur J Cancer. 45(2):228-247.
ESMO Clinical Practice Guidelines: Metastatic Non-Small-Cell Lung Cancer. Available at: 
www.esmo.org/Guidelines/Lung-Cancer/Metastatic-Non-Small-Cell-Lung-Cancer. Accessed 
11Feb2015.
Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus 
vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated 
with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18(12):2354-2362.
Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic 
syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 
2011;29(18):2521-2527.
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung 
cancer. N Engl J Med. 2015;372:2018-2028.
Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of pembrolizumab in 
previously treated patients (pts) with non-small cell lung cancer (NSCLC) [abstract]. In: 
Proceedings of the 2014 ASCO Annual Meeting; 2014 May 30-Jun 3; Chicago, IL. J Clin Oncol.
32:5s, 2014 (suppl; abstr 8020).
Gilotrif [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. 
Revised April 2014.
&(/*(1(35235,(7$5<,1)250$7,21
for 
or 
f
se I tri
se I trialal of
o
l
sly treated 
sly treated 
str 8030).
r 8030).
L1 antibod
L1 antibod
.
d line chem
d line che
ed trials.
ed tr
C
s second
second-li
ol.l. 1999;17
 1999;1
ncer Stagin
ncer Stagi
ew respons
ew respons
ur J Cancer
r J Cance
etastatic N
tastatic N
ancer/Meta
ncer/Met
r RN, et al.
r RN, et al
in pat
in patieients
ng chemot
ng chemot
Gore SD, C
Gore SD, 
onic myelo
onic myelo
:2521
:2521-2527
-2527
B, Ri
Rizvi
zvi NA
N
i
r. N Engl
r. N Engl J
Garon EB, L
Garon EB, 
previousl
previousl
rocee
rocee


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
83
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalance Worldwide in 2012. 
Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 11Feb2015
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus 
docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J 
Clin Oncol. 2004;22(15):1589-1597.
Harvey RD. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol 
Ther. 2014;96(2):214-223.
Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in 
patients with refractory advanced non small cell lung cancer. Cancer Discov. 2011;1(7):598-607.
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell 
lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809-1818.
Lang-Lazdunski L. Surgery for nonsmall cell lung cancer. Eur Respir Rev. 2013;22(129):382-
404.
Miranda RB, Jones PA. DNA methylation: the nuts and volts of repression. J Cell Physiol. 
2007;213(2):384-390.
NCCN Practice Guidelines in Oncology: Non-Small Cell Lung Cancer v.4.2014.  Available at: 
http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 11Feb2015.
Perol M, Ciuleanu TE, Arrieta O. REVEL: A randomized, double-blind, phase III study of 
docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the 
second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease 
progression after one prior platinum-based therapy. J Clin Oncol. 2014; 32 (5s): suppl; abstr 
LBA8006.
Peterson P, Park K, Fossella FV, et al. Is pemetrexed more effective in adenocarcinoma and 
large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III 
trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung 
cancer (NSCLC): P2-328 [abstract]. In: 12th World Conference on Lung Cancer. J of Thoracic 
Oncol 2007;2(8 suppl 4):S851.
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus 
placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 
3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2): 143-155.
Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second-line 
chemotherapy for non small cell lung cancer. Lung Cancer. 2000;29(1):67-73.
Shaw AT, Kimm D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-
positive lung cancer. N Engl J Med. 2013;368(25):2385-2394.
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best 
supportive care in patients with non-small-cell lung cancer previously treated with platinum-
based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-
cell lung cancer. N Engl J Med. 2005;353(2):123-132.
&(/*(1(35235,(7$5<,1)250$7,21
98
98-607.
607.
mall
mall-cell
cell
809
09-1818.
-1818.
13;22
3;22(129)
(129
sioion. J Cell
n. J Ce
Cancer v.4
Cancer v.4
f.f Accessed
Accesse
d, double-
, double b
B) versus D
B) versus 
ng cancer (
ng cancer 
apy. 
py. J Clin O
J Clin O
pemetrexe
pemetrexe
us cell carci
us cell carc
previously 
reviously
act]. In: 12t
act]. In: 12
1.1.
mgaard A, 
mgaard
h previ
prev
h
ous
ous
ndomised c
mised c
itte JJ, Berg
tte JJ, Be
py for non s
py for non 
T, Kimm D
T, Kimm D
ve
ve lung ca
lung c
Shepherd FA
hepherd F
supportiv
upportiv
sed
sed


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
84
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Speicher MR, Petersen S, Uhrig S, et al. Analysis of chromosomal alterations in non-small cell 
lung cancer by multiplex-FISH, comparative genomic hybridization, and multicolor bar coding. 
Lab Invest. 2000;80(7):1031-1041.
Tarceva [package insert]. OSI Pharmaceuticals, LLC, Northbrook, IL, USA an affiliate of 
Astellas Pharma US, Inc., 2012.
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated 
patients with refractory advanced non-small-cell lung cancer: results from a randomised, 
placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 
2005;366(9496):1527-1537.
Topalian SL. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J 
Med. 2012;366(26):2443-2454.
Topaloglu, O, Hoque, MO, Tokumaru, Y, et al. Detection of promoter hypermethylation of 
multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer 
Res. 2004;10(7):2284–2288.
Xalkori [package insert]. Pfizer Labs, New York, NY, USA, revised Aug, 2011.
Zeng L, Jarrett C, Brown K, et al. Insulin-like growth factor binding protein-3 (IGFBP-3) plays a 
role in the anti-tumorigenic effects of 5-Aza-2’-deoxycytidine (AZA) in breast cancer cells. Exp 
Cell Res. 2013;319(14):2282-2295.
&(/*(1(35235,(7$5<,1)250$7,21
N Engl J 
N Engl J 
thylat
thylatioion o
n
g cancer. Cl
g cancer. C
Aug,
Aug, 2011.
2011.
ing protein
g protein
(AZA) in b
(AZA) 


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
85
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
19.
APPENDICES
19.1.
Appendix A: RECIST 1.1
The following information is extracted/summarized from Eisenhauer, 2009, New response
evaluation criteria in solid tumors:  Revised RECIST guideline (version 1.1). Please refer to the 
primary reference for further information.
19.1.1.
Definitions
At screening, tumor lesions/lymph nodes will be categorized as measurable or non-measurable.
19.1.1.1.
Measurable Disease
Tumor Lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
!
10 mm by CT scan (CT scan slice thickness no greater than 5 mm)
!
10 mm caliper measurement by clinical exam (lesions which cannot be accurately 
measured with calipers should be recorded as non-measurable)
!
20 mm by chest X-ray
Malignant Lymph Nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis will 
be measured and followed.
19.1.2.
Tumor Response Evaluation
19.1.2.1.
Target Lesions
When more than one measurable tumor lesion is present at baseline all lesions up to a maximum 
of 5 lesions total (and a maximum of 2 lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline. Target 
lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements. Note that pathological nodes must meet the measurable 
criterion of a short axis of ≥ 15 mm by CT scan and only the short axis of these nodes will 
contribute to the baseline sum. All other pathological nodes (those with short axis ≥ 10 mm but 
< 15 mm) should be considered non-target lesions. Nodes that have a short axis < 10 mm are 
considered non-pathological and should not be recorded or followed. At baseline, the sum of the 
target lesions (longest diameter of tumor lesions plus short axis of lymph nodes:  overall 
maximum of 5) is to be recorded.
After baseline, a value should be provided on the CRF for all identified target lesions for each 
assessment, even if very small. If extremely small and faint lesions cannot be accurately 
measured but are deemed to be present, a default value of 5 mm may be used. If lesions are too 
small to measure and indeed are believed to be absent, a default value of 0 mm may be used.
&(/*(1(35235,(7$5<,1)250$7,21
surable.
surable.
est di
est d amete
mete
n 5 mm)
n 5 mm)
which cann
which cann
measurable)
measura
cally enlarg
cally enlarg
by
by CT scan
CT sca
y
aseline and
seline and
n
le tumor le
e tumor le
imum of 2
imum of
rget l
rget lesi
es ons
cted on the
ted on the
l invo
l involved 
lved 
peated meas
eated mea
short axis o
hort axis 
to the base
o the base
m) should b
m) should 
idered non
dered non
arget lesio
arget lesion
maximum
maximum
ter


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
86
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
19.1.2.2.
Non-target Lesions
All non-measurable lesions (or sites of disease) plus any measurable lesions over and above 
those listed as target lesions are considered non-target lesions. Measurements are not required 
but these lesions should be noted at baseline and should be followed as “present,” “absent,” or 
“unequivocal progression.”
19.1.2.3.
Response Criteria
Target and non-target lesions are evaluated for response separately, and then the tumor burden as 
a whole is evaluated as the overall response.
19.1.2.3.1. Target Lesion Response
Target lesions will be assessed as follows:
!
Complete Response (CR).  Disappearance of all target lesions. Any pathological 
lymph nodes (whether target or non-target) must have reduction in short axis to < 10 
mm.
!
Partial Response (PR).  At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters.
!
Progressive Disease (PD).  At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum 
if that is the smallest on study). In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at least 5 mm. (Note:  the appearance 
of one or more new lesions is also considered progression).
!
Stable Disease (SD).  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum of diameters while on 
study.
19.1.2.3.2. Non-target Lesion Response
Non-target lesions will be assessed as follows:
!
Complete Response (CR).  Disappearance of all non-target lesions and normalisation 
of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm 
short axis).
!
Non-CR/Non-PD.  Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal limits.
!
Progressive Disease (PD).  Unequivocal progression (see comments below) of 
existing non-target lesions. (Note: the appearance of one or more new lesions is also 
considered progression).
When the Subject Also Has Measurable Disease:  In this setting, to achieve “unequivocal 
progression” on the basis of the non-target disease, there must be an overall level of substantial 
worsening in non-target disease such that, even in presence of SD or PR in target disease, the 
overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest 
“increase” in the size of one or more non-target lesions is usually not sufficient to quality for 
&(/*(1(35235,(7$5<,1)250$7,21
as 
as 
ny patho
y pathololog
n in short a
in short a
um
u
of
of
m
diam
dia
f
rs.
se in the su
se in the su
on study
n study (th
(th
y
to the rel
to the rela
ase of at le
ase of at le
nsidered pr
nsidered pr
fficient shri
fficient shr
king as refe
king as refe
Response
Response
sessed as fo
sessed as f
sponse (CR
sponse (C
marker l
arker eve
ev
xis).
xis).
n-CR/Non
CR/Non
maintena
maintenanc
n
!
Progre
rogre
exis
exis
When t
When 


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
87
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
unequivocal progression status. The designation of overall progression solely on the basis of 
change in non-target disease in the face of SD or PR of target disease will therefore be extremely 
rare.
When the Subject Has Only Non-measurable Disease:  This circumstance arises in some 
Phase 3 trials when it is not a criterion of study entry to have measurable disease. The same 
general concepts apply here as noted above; however, in this instance there is no measurable 
disease assessment to factor into the interpretation of an increase in non-measurable disease 
burden. Because worsening in non-target disease cannot be easily quantified (by definition:  if all 
lesions are truly non-measurable) a useful test that can be applied when assessing subjects for 
unequivocal progression is to consider if the increase in overall disease burden based on the 
change in non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease: ie, an increase in tumor burden representing an 
additional 73% increase in “volume” (which is equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from “trace” to “large,” 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as “sufficient to require a change in therapy.” If “unequivocal progression” is seen, the 
subject should be considered to have had overall PD at that point. While it would be ideal to 
have objective criteria to apply to non-measurable disease, the very nature of that disease makes 
it impossible to do so: therefore, the increase must be substantial.
19.1.2.3.3. Overall Response
Overall response should be assessed according to Table 9 for subjects with target lesions, and
Table 10 for subjects with only non-target lesions.
Table 9:
Time Point Response: Subjects With Target (± Non-target) Disease
Target Lesions 
Response
Non-target Lesion Response
New Lesions
Overall Response
CR
CR
No
CR
CR
Non-CR/ non-PD
No
PR
CR
Not evaluated
No
PR
PR
Non-PD or not all evaluated
No
PR
SD1
Non-PD or not all evaluated
No
SD
Not all evaluated
Non-PD
No
NE
PD
Any
Yes or No
PD
Any
PD
Yes or No
PD
Any
Any
Yes
PD
CR = complete response, NE = inevaluable, PD = progressive disease, PR = partial response, SD = stable disease
&(/*(1(35235,(7$5<,1)250$7,21
all
all
or r 
he
he
uld be
ld be
esent
esenting an
ng an
meter in a
meter in a
trace” to “l
race” to “
be describe
e describe
progressio
progress
hile it wou
ile it wou
ry nature of
y nature o
al.
al.
lele 9 fo
for su
r su
ts With Ta
ts With Ta
Lesion Resp
sion Resp
5,
23
R/ non
R/ non-PD
PD
52
ot evaluated
evaluated
35
Non
Non-PD 
D
( 3
1(
Non
Non
1(
1(
1(
1(
d
N
(1
*(
/*
ny
(/
&(
CR = comp
CR = comp


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
88
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 10:
Time Point Response: Subjects With Non-target Disease Only
Non-target Lesion Response
New Lesions
Overall Response
CR
No
CR
Non-CR/ non-PD
No
Non-CR/non-PD1)
a
Not all evaluated
No
NE
Unequivocal PD
Yes or No
PD
Any
Yes
PD
CR = complete response, PD = progressive disease, NE =  inevaluable
a “Non-CR/non-PD” is preferred over “stable disease” for non-target disease since SD is increasingly used as 
endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is 
not advised.
19.1.2.4.
Symptomatic Deterioration
Subjects with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
‘symptomatic deterioration’. Every effort should be made to document objective progression 
even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an 
objective response: it is a reason for stopping study therapy. The objective response status of 
such subjects is to be determined by evaluation of target and non-target disease.
&(/*(1(35235,(7$5<,1)250$7,21
$7
$7
$7
0$7
$
used as 
ed as
e measured i
e measured i
uatioion of tre
n of
d be reporte
be report
ment objec
ment objec
tion is not 
on is 
 The objec
The objec
and non
nd non-tar


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
89
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
19.2.
Appendix B: irRECIST
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST
&(
pri
prietet
0$7,21
e Corpora
e Corpora
21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
90
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
pri
prietet
7,21
e Corpora
e Corpora
21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
91
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
92
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
93
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
94
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
95
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet
(/


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
96
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(
pri
prietet
7,21
e Corpora
e Corpora
21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
97
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(
pri
prietet
7,21
e Corpora
e Corpora
21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
98
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 11:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
99
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
19.3.
Appendix C: Table of Abbreviations
Table 12:
Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term
Explanation
AE
Adverse event
AIM
Azacitidine-induced immune
AJCC
American Joint Committee on Cancer
ALT
Alanine aminotransferase (SGPT)
ALK 
Anaplastic lymphoma kinase
AML
Acute myeloid leukemia
ANC
Absolute neutrophil count
aPTT
Activated partial thromboplastin time
ASCO
American Society of Clinical Oncology
AST
Aspartate aminotransferase (SGOT)
AUC
Area under the concentration-time curve
AZA
Azacitidine
β-hCG
Beta-subunit of human chorionic gonadotropin
BCG
Bacillus Calmette-Guerin
BLQ
Below the limit of quantitation
BSC
Best supportive care
BUN
Blood urea nitrogen
CBC
Complete blood count
CI
Confidence interval
CL/F
Apparent total body clearance
Cmax
Maximum plasma concentration of drug
CMMoL
Chronic myelomonocytic leukemia
CNS
Central nervous system
CR
Complete response
CRA
Clinical research associate
CRO
Contract research organization
CRF
Case report form
CSR
Clinical Study Report
CT
Computed tomography
&
F
&(
CRO
CR
&(/*(1(35235,(7$5<,1)250$7,21
$7
$7
$7
$7
0$
50
25
2
1)
,1
< ,
curve
urve
5<
$5
horionic gon
horionic gon
7$
uerin
rin
(7
of quantitati
of quantitati
5,(
tive care
ive car
35
urea nitrogen
a nitrogen
23
mplete bloo
mplete blo
52
Confidenc
Confidenc
35
(
Appar
Appar
( 3
1(
M
1(
1(
1(
(1
*(
/*
RA
(/
&(
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
100
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 12:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
CTCAE
Common Terminology Criteria for Adverse Events
DCR
Disease control rate
DIC
Disseminated Intravascular Coagulation
DILI
Drug-induced liver injury
DKA
Diabetic ketoacidosis
DLT
Dose-limiting toxicity
DNA
Deoxyribonucleic acid
DNMT1
DNA methyltransferase-1
DNMTi
DNA methyltransferase inhibitor
DMC
Data Monitoring Committee
EBUS
Endobronchial ultrasound
EC
Ethics Committee
ECI
Events of clinical interest
ECG
Electrocardiogram
ECOG
Eastern Cooperative Oncology Group
eCRF
Electronic case report form
EEA
European Economic Area
EGFR
Epidermal growth factor receptor
ESMO
European Society for Medical Oncology
EOT
End of treatment
EU
European Union
FFPE
Formalin fixed paraffin embedded
FAB
French American British
FDA
Food and Drug Administration
GCP
Good Clinical Practice
G-CSF
Granulocyte colony-stimulating factor
GM-CSF
Granulocyte macrophage colony-stimulating factor
GI
Gastrointestinal
GITR
Glucocorticoid-induced tumor necrosis factor receptor
HBV
Hepatitis B virus
&(
GM
GM
&(/*(1(3
Europe
Europ
35235,(7$5<,1)250$7,21
7
$7
$7
$7
$
0
5
2
)2
1
< ,
5<
$5
7$
Oncology G
ncology G
(7
eport form
port form
5,(
onomic Are
nomic Ar
35
al growth fa
growth f
23
opean Socie
pean Socie
52
End of trea
End of trea
35
3
(
Fo
Fo
(
1(
(1
*(
/*
CSF
SF
(/
-CSF
CSF
&(
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
101
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 12:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
HBcAb
Hepatitis B core antibody
HBeAb
Hepatitis B e antibody
HBeAg
Hepatitis B e antigen
HBsAg
Hepatitis B surface antigen
HBsAb
Hepatitis B surface antibody
HCl
Hydrochloride
HCV
Hepatitis C virus
HCVAb
Hepatitis C virus antibody
HDAC
Histone deacetylase
HIV
Human immunodeficiency virus
HR
Hazard ratio
HUS
Haemolytic Uraemic Syndrome
ICF
Informed consent form
IB
Investigator’s Brochure
ICH
International Conference on Harmonisation
iDMC
Independent Data Monitoring Committee
IDO
Indoleamine 2,3-dioxygenase
ILD
Interstitial lung disease
IND
Investigational New Drug
INR
International normalized ratio
IP
Investigational Product
IRB
Institutional Review Board
irAEs
Immune-related adverse events
irDCR
Immune-related disease control rate
irPFS
Immune-related progression-free survival
irRC
Immune-related response criteria
irRECIST
Immune-related Response Evaluation Criteria in Solid Tumors
irORR
Immune-related overall response rate
IRT
Interactive response technology
ITT
Intent-to-treat
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$7
0$
50
25
)2
1)
,1
5<
$5
7$
ce on Harm
e on Harm
(7
Monit
onitoring 
oring 
,(
,3,3-dioxygen
dioxyg
5
l lung disea
lung dise
23
tigational N
tigational N
2
nternational
nternatio
5
Investig
vest
3
(
Inst
Ins
(
1(
1(
1(
1(
(1
*(
/*
rRECIST
rRECIST
&(
ORR
ORR
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
102
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 12:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
ITP
Idiopathic (or immune) Thrombocytopenia Purpura
IV
Intravenous
LDH
Lactate dehydrogenase
LFT
Liver function test
mAb
Monoclonal antibody
MDS
Myelodysplastic syndrome
MM
Multiple myeloma
MedDRA
Medical Dictionary for Regulatory Activities
MRI
Magnetic resonance imaging
MTD
Maximum tolerated dose
NCCN
National Comprehensive Cancer Network
NCI
National Cancer Institute
NSCLC
Non-small cell lung cancer
NYHA
New York Heart Association
ORR
Overall response rate
OS
Overall survival
PD
Pharmacodynamics
PD
Progressive disease
PD-1
Programmed cell death protein-1
PD-L1
Programmed death-ligand 1
PE
Physical examination
PFS
Progression-free survival
PK
Pharmacokinetics
PR
Partial response
PT
Prothrombin time
PTT
Partial thromboplastin time
QD
Once daily
RBC
Red blood cell count
RCC
Renal cell carcinoma
RECIST
Response Evaluation Criteria in Solid Tumors
&
BC
BC
&(
QD
QD
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$7
0$
50
25
)2
1)
k
,1
5<
$5
n
7$
(7
,(
amics
amics
5
ve disease
ve disease
23
rammed cell
ammed cel
2
Programmed
Programm
5
Physical
ysic
3
(
Prog
Pro
(
1(
1(
1(
1(
(1
*(
/*
&(
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
103
CC-486-NSCL-001Amendment 1 Final: 14 Dec 2015
Table 12:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
RNA
Ribonucleic acid
SAE
Serious adverse event
SAP
Statistical analysis plan
SC
Steering Committee
SC
Subcutaneous
SD
Stable disease
SGOT
Serum glutamic oxaloacetic transaminase 
SGPT
Serum glutamic pyruvic transaminase
SOP
Standard operating procedure
SUSAR
Suspected unexpected serious adverse reaction
TEAE
Treatment-emergent adverse event
T1DM
Type 1 diabetes mellitus
T2DM
Type 2 diabetes mellitus
TKI
Tyrosine kinase inhibitor
TIL
Tumor-infiltrating lymphocyte
Tmax
Time to maximum concentration
TTP
Thrombotic Thrombocytopenic Purpura
t1/2
Terminal half-life
ULN
Upper limit of normal
US
United States 
Vz/F
Apparent volume of distribution
WBC
White blood cell count
WHO
World Health Organization
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$
0
5
2
)2
ion
ion
1
< ,
5<
$5
7$
mphocyte
mphocyte
(7
m concentra
m concentr
5,(
Thrombocyt
hrombocy
35
 half
a -f life
life
23
per limit of n
er limit of n
52
United Stat
United Sta
35
Appare
Appar
3
(
W
(
1(
(1
*(1


('06'RF1XPEHU
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature policies and procedures.
8VHU1DPH

7LWOH

'DWH0RQGD\'HFHPEHU30(DVWHUQ'D\OLJKW7LPH
0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\
                                                
&(/*(1(35235,(7$5<,1)250$7,21
H
  

Prot_000.pdf: 
 
 
 
 
 
Protocol Title: A Phase 2 Multicenter, Randomized, 
Placebo Controlled, Double-Blind Study To Assess 
The Safety And Efficacy Of CC-486 (Oral Azacitidine) 
In Combination With Pembrolizumab (Mk-3475) 
Versus Pembrolizumab Plus Placebo In Subjects 
With Previously Treated Locally Advanced Or 
Metastatic Non-Small Cell Lung Cancer 
 
NCT Number:  NCT02546986 
Original Protocol Date:  15 May 2015 


',6&/2685(
5('$&7('25,*,1$/35272&2/
&&16&/
$3+$6(08/7,&(17(55$1'20,=('3/$&(%2&21752//(''28%/(
%/,1'678'<72$66(667+(6$)(7<$1'()),&$&<2)&&25$/
$=$&,7,',1(,1&20%,1$7,21:,7+3(0%52/,=80$%0.9(5686
3(0%52/,=80$%3/863/$&(%2,168%-(&76:,7+35(9,286/<75($7('
/2&$//<$'9$1&('250(7$67$7,&12160$//&(///81*&$1&(5
㻌
7KHLQIRUPDWLRQFRQWDLQHGLQWKHDWWDFKHGUHSRUWLVWKHSURSHUW\RI&HOJHQHDQGVKRXOGQRWEHVKDUHGRU
XVHGIRUDQ\SXUSRVHRWKHUWKDQWKDWIRUZKLFKLWZDVSURYLGHG

&HOJHQHLVFRPPLWWHGWRSURYLGLQJLQIRUPDWLRQDERXWLWVFOLQLFDOWULDOVWRUHVHDUFKHUVDQGSDWLHQWVZLWKWKH
JRDORIIXUWKHULQJVFLHQFHDQGHQKDQFLQJKHDOWKFDUHZRUOGZLGH/DZVDQGUHJXODWLRQVUHTXLUHKRZHYHU
WKDW&HOJHQHSURWHFWVSDWLHQWSULYDF\7KHFRPSDQ\PD\IXUWKHUKDYHOHJDORUFRQWUDFWXDOREOLJDWLRQVQRW
WRGLVFORVHFRPPHUFLDORUWHFKQLFDOLQIRUPDWLRQSURYLGHGE\RUUHODWHGWRFHUWDLQSDUWQHUFRPSDQLHVRU
YHQGRUV

7KHDWWDFKHGUHSRUWLVSUHVHQWHGLQLWVRULJLQDOIRUPDWEXWFHUWDLQLQIRUPDWLRQKDVEHHQUHGDFWHGLQRUGHU
WRFRPSO\ZLWKWKHDIRUHPHQWLRQHGREOLJDWLRQVRUWRSURWHFW&HOJHQH¶VFRQILGHQWLDOFRPPHUFLDO
LQIRUPDWLRQ7KHUHGDFWLRQVDUHEDVHGRQWKHIROORZLQJSULQFLSOHV

x
5HGDFWHGLQIRUPDWLRQKDVEHHQUHSODFHGE\JUH\VSDFHPDLQWDLQLQJRULJLQDOVSDFLQJDQGSDJLQDWLRQ
x
$Q\LQIRUPDWLRQWKDWPLJKWDOORZWKHLGHQWLILFDWLRQRILQGLYLGXDOVKDVEHHQUHGDFWHGIRU
DQRQ\PL]DWLRQ
x
$WWDFKPHQWVWRWKLVUHSRUWWKDWFRQWDLQFRQILGHQWLDOLQIRUPDWLRQDUHQRWPDGHDYDLODEOH6XFK
DWWDFKPHQWVLQFOXGHWKRVHWKDWFRQWDLQLGHQWLILDEOHSDWLHQWLQIRUPDWLRQVXFKDVVXEMHFWOLVWLQJV
QDUUDWLYHVDQGSURILOHV7KH\DOVRPD\FRQWDLQFRQILGHQWLDOFRPPHUFLDOLQIRUPDWLRQVXFKDV
PHWKRGRORJLHVDQGK\SRWKHVLVJHQHUDWLQJDQGH[SORUDWRU\DQDO\VHV
x
&URVVUHIHUHQFHVWRWKHVHDWWDFKPHQWVVXFKDVOLQNVWRVXEMHFWOLVWLQJVLQ6HFWLRQDUHQRW
UHGDFWHGIURPWKHERG\RIWKHUHSRUW+RZHYHUWKHK\SHUOLQNVLQWKHHOHFWURQLFGRFXPHQWDUHQR
ORQJHUIXQFWLRQDO
x
,QIRUPDWLRQDERXW&HOJHQHYHQGRUVDQGWKHLUVHUYLFHVDUHUHGDFWHGEHFDXVHPDQ\FRQWUDFWVSURKLELW
GLVFORVXUHRIWKDWLQIRUPDWLRQ)XUWKHUODZVDQGUHJXODWLRQVSUHYHQWXVIURPGLVFORVLQJFHUWDLQ
LQIRUPDWLRQDERXWRXUYHQGRUVRUWKHLUVHUYLFHVEHFDXVHLWLVSURWHFWHGE\FRS\ULJKW

,QIRUPDWLRQDERXW&HOJHQH¶VUHGDFWLRQSROLFLHVDQGWKHDYDLODELOLW\RIDGGLWLRQDOGDWDIURPWKLVUHSRUWPD\
EHIRXQGDWKWWSZZZFHOJHQHFRPUHVHDUFKGHYHORSPHQWFOLQLFDOWULDOVFOLQLFDOWULDOVGDWDVKDULQJ


&(/*(1(35235,(7$5<,1)250$7,21
(
5686
5686
5($7('
5($7('
&$1&(5
&$1&(5
OGQRWEHVKD
OGQRWEHVK
HDUFKHUVDQG
HDUFKHUVDQ
GUHJXO
GUHJXODWLRQ
DWLR
OHJDORUF
JDORUFRQ
RQ
WHGWRFHUWDL
WHGWRFHU
FHUWDLQLQIRU
HUWDLQLQIRU
WHFW&HOJHQH
WHFW&HOJHQ
QJSULQFLSOH
QJSULQFLSOH
JUH\
JUH\ VSDFH
VSDFH
HQWLIL
HQWLILFDWLRQ
FDWL
QWDLQFRQILGH
DLQFRQILG
RQWDLQLGHQ
RQWDLQLGHQ
\DOVRPD\
\DOVRPD\
WKHVLVJHQHU
KHVLVJHQH
HVHDWWDFKPH
HVHDWWDFKP
RG\RIWKHU
RG\RIWKH
O
ERXW&HOJHQ
ERXW&HOJHQ
RIWKDWLQIRU
IWKDWLQIR
LRQDERXWR
LRQDERXWR
PDWLRQDERXW
PDWLRQDERXW
IRXQGDWKWWS
RXQGDWKWWS


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
1
CC-486-NSCL-001 Final: 15 May 2015
TITLE PAGE
A PHASE 2 MULTICENTER, RANDOMIZED, PLACEBO 
CONTROLLED, DOUBLE-BLIND STUDY TO ASSESS 
THE SAFETY AND EFFICACY OF CC-486 (ORAL 
AZACITIDINE) IN COMBINATION WITH 
PEMBROLIZUMAB (MK-3475) VERSUS 
PEMBROLIZUMAB PLUS PLACEBO IN SUBJECTS 
WITH PREVIOUSLY TREATED LOCALLY ADVANCED 
OR METASTATIC NON-SMALL CELL LUNG CANCER
PROTOCOL NUMBER:
CC-486-NSCL-001
DATE FINAL:
15 May 2015
EudraCT NUMBER:
2014-005614-29
IND NUMBER:
123160
SPONSOR NAME / ADDRESS:
Celgene Corporation
86 Morris Avenue
Summit, NJ 07901
United States
CONFIDENTIAL
This protocol is provided to you as an Investigator, potential Investigator, or consultant for review by 
you, your staff, and ethics committee/institutional review board.  The information contained in this 
document is regarded as confidential and, except to the extent necessary to obtain informed consent, 
may not be disclosed to another party unless such disclosure is required by law or regulations.  
Persons to whom the information is disclosed must be informed that the information is confidential 
and may not be further disclosed by them.
&(/*(1(35
provided to yo
provided to yo
aff, and ethic
f, and ethic
nt is regarded 
nt is regarded
ay not be disc
y not be disc
Persons to wh
ersons to wh
35235,(7$5<,1)250$7,21
CTS 
CTS 
VANCE
VANCE
G CANC
CAN
NSCL
C -001
01
ay
ay 2015
20
2014
2014-005
-005
1231
23
C
35
35
(/
(/
(/
(/
(/
(/
(/*


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
2
CC-486-NSCL-001 Final: 15 May 2015
MEDICAL MONITOR / EMERGENCY CONTACT INFORMATION 
Contact Information:
Name:
Title:
Address: Route de Perreux 1, 
Boudry, Switzerland  2017
Phone:
E-mail:
Note: The back-up 24-hour global emergency contact call center should only be used if you 
are not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls.
Back-up 24-hour Global Emergency Contact Call Center: 
&(/*(1(35235,(7$5<,1)250$7,21
0
50
2
1)
should only
should onl
dical Moni
ical Mon
er: 
5<
$5
$5<


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
3
CC-486-NSCL-001 Final: 15 May 2015
CELGENE THERAPEUTIC AREA HEAD SIGNATURE PAGE
{See appended electronic signature page}
Signature of Celgene Therapeutic Area Head
dd mmm yyyy
Printed Name of Celgene Therapeutic Area Head and Title
By my signature, I indicate I have reviewed this protocol and find its content to be 
acceptable.  
,1
,1)250$7,21
0$
0$
50
content to 
content to
,1


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
4
CC-486-NSCL-001 Final: 15 May 2015
SITE PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Site Principal Investigator
dd mmm yyyy
Printed Name of Site Principal Investigator
Institution Name:_______________________________________
By my signature, I agree to personally supervise the conduct of this study at my study 
site and to ensure its conduct is in compliance with the protocol, informed consent, 
Institutional Review Board (IRB)/Ethics Committee (EC) procedures, instructions from 
Celgene representatives, the Declaration of Helsinki, International Conference on 
Harmonisation (ICH) Good Clinical Practices Guidelines, and local regulations 
governing the conduct of clinical studies.
&(/*(1(35235,(7$5<,1)250$7,21
0$
0$
50
s study
s study at m
at
y
, informed 
nformed
ocedures, in
edures, i
national C
nationa
nes, and loc
s, and lo
7$
7$


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
5
CC-486-NSCL-001 Final: 15 May 2015
COORDINATING PRINCIPAL INVESTIGATOR SIGNATURE PAGE
Signature of Coordinating Principal Investigator
dd mmm yyyy
Printed Name of Coordinating Principal Investigator
Institution Name:_______________________________________
By my signature, I agree the protocol has been written to comply with ICH Good 
Clinical Practices guidelines and agree to offer guidance throughout the study as 
needed.
&(/*(1(35235,(7$5<
5<
5<,1)
wi
wi
1)250$7,21
0$
0$
50
th
th
i
ICH G
ICH 
h
ghout the st
out the st
5<


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
6
CC-486-NSCL-001 Final: 15 May 2015
PROTOCOL SUMMARY
Study Title
A Phase 2 multicenter, randomized, placebo controlled, double-blind study to assess the safety 
and efficacy of CC-486 (oral azacitidine) in combination with pembrolizumab (MK-3475) versus 
pembrolizumab plus placebo in subjects with previously treated locally advanced or metastatic 
non-small cell lung cancer
Indication  
Second-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC). 
Objectives
Primary Objective:
!
To estimate the efficacy of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo based on progression-free survival (PFS) as measured using Response 
Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria
Secondary Objectives:
!
To estimate disease control rate (DCR) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To estimate overall survival (OS) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To estimate overall response rate (ORR) of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To evaluate safety and tolerability of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To evaluate the impact of pembrolizumab on the pharmacokinetics of CC-486 
Exploratory Objectives:
!
To determine the preliminary efficacy (immune-related [ir] PFS, irDCR, irORR) of 
CC-486 in combination with pembrolizumab versus pembrolizumab plus placebo
based on irRECIST criteria 
!
To explore mechanism and biomarkers associated with efficacy of CC-486 in 
combination with pembrolizumab versus pembrolizumab plus placebo,
Study Design
This is a Phase 2, multicenter, international, randomized, placebo controlled double-blind study 
to assess the safety and efficacy of the combination therapy of CC-486 plus pembrolizumab
versus placebo plus pembrolizumab in previously treated subjects with locally advanced or 
metastatic NSCLC who have received one prior platinum-based chemotherapy regimen. 
&(/*(1(35235,(7$5<,1)250$7,21
SCLC
SCLC).
us s pembrol
pemb
ured using
red using R
ia
486 pl
6 plus 
us
l
pe
p
486 pl
486 plus
l
p
(ORR)
(ORR) of
of
erabilit
erability of
acebo
eb
mpact of pem
act of pe
mine the pre
ine the p
6 in combin
in combin
d on i
d on irREC
rREC
i
To expl
To explore
ore
combina
combin
Study De
Study D
(/*
(/


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
7
CC-486-NSCL-001 Final: 15 May 2015
Approximately 90 subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or 
placebo plus pembrolizumab. A safety analysis will be performed in the first 10 subjects in each 
arm after the completion of at least 1 cycle of treatment.
The randomization will be stratified by histology (non-squamous versus squamous).
An independent Data Monitoring Committee (iDMC) will be established to evaluate safety. 
Following the initial iDMC data review meeting, the iDMC will meet approximately every 6 
months per DMC charter (or more often if requested by the DMC Chairman) to assess safety 
data.  Details are outlined in the DMC charter.
The conduct of this trial will be overseen by a Steering Committee which will serve in an 
advisory capacity to the Sponsor.  
The study will be conducted in compliance with International Conference on Harmonisation 
(ICH) Good Clinical Practices (GCPs).
Study Population
Adult subjects with histologically confirmed diagnosis of locally advanced or metastatic 
NSCLC, lacking anaplastic lymphoma kinase (ALK) or endothelial growth factor receptor 
(EGFR) mutations, who have been treated with 1 prior platinum-based chemotherapy regimen
for locally advanced or metastatic disease.
Length of Study
Enrollment is expected to take approximately 12 months to complete.  The total length of this 
Phase 2 study with follow-up is estimated to be approximately 2 years. The primary analysis will 
be conducted when 70 PFS events have occurred. 
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol,
whichever is the later date.  
Study Treatments
CC-486/placebo will be administered at a dose of 300 mg orally daily on days 1-14 of a 21-day 
cycle. Pembrolizumab will be administered as a 30-minute intravenous (IV) infusion at a dose of 
200 mg (4 x 50 mg vials) on day 1 of a 21-day cycle. 
Subjects may remain on treatment until radiologic disease progression (for exceptions refer to 
Section 6.4.3 ), unacceptable toxicity, initiation of a new anticancer therapy, withdrawal of 
consent, subject refusal, physician decision, or death.
Overview of Efficacy Assessments
All subjects will be evaluated for tumor response and progression by Investigator assessment
according to RECIST 1.1 guidelines at screening and every 6 weeks (± 5 days) from 
randomization for the first 24 weeks, and every 9 weeks thereafter until documented disease 
progression (for exceptions refer to Section 6.4.3 ), start of new anticancer therapy, or 
withdrawal of consent. Subjects will also be evaluated according to irRECIST guidelines in cases 
of progressive disease (PD) per RECIST 1.1.
monisat
onisatioion n
nced 
ced or 
or met
m
growth fac
rowth fac
based 
as
chem
chem
ths to comp
ths to comp
proximately
proximatel
d. 
e of the last
e of the last
eceipt of th
eceipt of th
r explorato
r explorato
ministered 
ministered
will be adm
will be adm
ials)
als) on day
on d
main on tre
main on tre
), unaccept
unaccep
bject refusa
bject refus
iew of Effi
iew of Effi
subjects w
subjects w
acco
cc rding 
ding 
ando
andom


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
8
CC-486-NSCL-001 Final: 15 May 2015
Response assessments will include computed tomography (CT) scan or magnetic resonance 
imaging (MRI) of the chest and abdomen/pelvis. Bone scans will only be performed at baseline 
if clinically indicated. If the baseline bone scan is suggestive of metastasis, a CT or MRI should 
be performed and further follow-up of these lesions will follow the protocol schedule. Bone 
scans during the trial will only be performed if clinically indicated.  If suggestive of new lesions, 
a CT or MRI will be performed to confirm progression.
In the follow-up phase, anticancer treatment administered following the last dose of 
investigational product (IP) and survival will be followed every 8 weeks (± 5 days) until death, 
withdrawal of consent, or lost-to-follow-up, whichever occurs first, or the End of Trial.
Overview of Safety Assessments
All subjects will be monitored for adverse events, starting from the time the subject signs the 
informed consent form (ICF) until 30 days after the last dose of either study drug. A thorough 
evaluation of medical conditions will be conducted during screening for eligibility. Documented
physical examination (PE), vital signs, laboratory assessments, (eg, serum chemistry, 
hematology), 12-lead electrocardiogram (ECG), urinalysis, and Eastern Cooperative Oncology 
Group (ECOG) performance status will be monitored regularly. Preventative measures will be 
taken to avoid pregnancy in study subjects or their partners, and females of child-bearing 
potential will have regular pregnancy testing performed. The full schedule of assessments is 
described in Table 2 and Section 6.
Overview of Statistical Methods
This is a double-blind, placebo-controlled, randomized, phase 2 trial designed to evaluate the 
efficacy and safety/tolerability of  CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo, in subjects with previously treated locally advanced or metastatic non-small cell lung 
cancer. The primary endpoint is PFS based on Investigator review.
Sample Size
The primary goal of this study is to provide estimates of the difference in efficacy and safety 
between CC-486 + pembrolizumab and placebo + pembrolizumab. Approximately 90 subjects 
will be randomized 1:1 to receive CC-486 plus pembrolizumab or placebo plus pembrolizumab. 
Primary analysis will be conducted when 70 PFS events occur. In this particular setting, a formal 
power calculation was not conducted.
Efficacy Analysis
Efficacy analyses will be performed using the intent-to-treat (ITT) population.
The median PFS in each stratum and treatment arm will be calculated based on Kaplan-Meier 
estimates along with corresponding two-sided 90% confidence interval (CI).  In addition, the 
Cox proportional hazards regression model with treatment and any stratification factors will be 
performed to obtain the point estimate of hazard ratio (HR) and two-sided 90% CI.  
The secondary efficacy endpoint of OS will be analyzed similarly to PFS.  Other secondary 
endpoints of overall response rate (ORR), and disease control rate (DCR) will be evaluated as 
well. A two-sided 90% CI of the difference in ORR and DCR between the two treatment arms 
will be provided. 
&(/*(1(35235,(7$5<,1)250$7,21
signs the
signs the
g. A thorou
. A thorou
bilit
bility. Doc
oc
chemistry,
chemistry,
Cooperativ
oopera
entative me
ntative m
emales of c
males of c
ll schedule
l sch
zed, phase
zed, phase
embrolizum
embrolizu
cally advan
cally advan
on
on Investig
nvest
o provide es
rovide e
mab
mab and pla
and pla
eive CC
eive CC-4
onducted w
nducted w
not conduc
not condu
ses will be 
es will b
n PFS 
PFS in ea
in ea
s alo
s along wi
ng w
proportiona
proportion
erform
erformed to
ed to
The seco
The sec
dpo
d


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
9
CC-486-NSCL-001 Final: 15 May 2015
Safety Analysis
Safety analysis will be performed using the safety population. Safety and tolerability will be 
monitored through continuous reporting of adverse events (AEs) and serious adverse events 
(SAEs), laboratory abnormalities, and incidence of subjects experiencing adverse events 
resulting in dose reductions, dose interruptions, and/or premature discontinuation of study drugs. 
Treatment-emergent adverse events (TEAEs), TEAEs leading to death or discontinuation from 
treatment, events assessed as Grade 3 or Grade 4,  vital signs, weight, clinical laboratory 
information, and concomitant medications/procedures will be tabulated and summarized.
All AEs will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA). 
All TEAEs will be summarized by system organ class and preferred term, frequency, severity 
grade based on the Common Terminology Criteria for Adverse Events (CTCAE) (Version 4.0) 
and relationship to treatment. Serious TEAEs, TEAEs of interest, and TEAEs leading to 
discontinuation, dose reduction, or interruption, or death will be summarized/ listed separately.
DRA)
DRA).
verit
verity y 
ersion 4.0) 
ersion 4.0) 
ding to
ng to 
listed separ
isted sep


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
10
CC-486-NSCL-001 Final: 15 May 2015
TABLE OF CONTENTS
TITLE PAGE..............................................................................................................................1
PROTOCOL SUMMARY ..........................................................................................................6
1.
INTRODUCTION..................................................................................................18
1.1.
Disease Background ...............................................................................................18
1.2.
Treatment Options in Second-line Metastatic NSCLC ............................................18
1.3.
Overview of CC-486...............................................................................................20
1.3.1.
CC-486 Experience in Solid Tumors.......................................................................21
1.4.
Overview of Pembrolizumab ..................................................................................22
1.4.1.
Pembrolizumab Experience in Solid Tumors and Safety.........................................23
1.5.
Study Rationale ......................................................................................................24
2.
STUDY OBJECTIVES...........................................................................................26
2.1.
Primary Objective...................................................................................................26
2.2.
Secondary Objectives .............................................................................................26
2.3.
Exploratory Objectives ...........................................................................................26
3.
STUDY ENDPOINTS............................................................................................27
3.1.
Primary Endpoint....................................................................................................27
3.2.
Secondary Endpoints ..............................................................................................27
3.3.
Exploratory Endpoint(s)..........................................................................................27
4.
OVERALL STUDY DESIGN ................................................................................28
4.1.
Study Design ..........................................................................................................28
4.2.
Study Duration .......................................................................................................29
4.3.
End of Trial ............................................................................................................29
5.
TABLE OF EVENTS.............................................................................................30
6.
PROCEDURES......................................................................................................35
6.1.
Screening Period.....................................................................................................35
6.2.
Treatment Period ....................................................................................................36
6.2.1.
End of Treatment....................................................................................................37
6.3.
Follow-up Period....................................................................................................38
6.3.1.
Efficacy Follow-up.................................................................................................38
6.3.2.
Survival Follow-up.................................................................................................38
6.4.
Response Assessments............................................................................................38
&(/*(1(35235,(7$5<,1)250$7,21
8
....... 20
20
...........
.......... 21
2
.............
............
..............
............
.............
............
.............
.............
........
..
......
.....
.............
.........
..............
...
................
........
.............
.............
.............
.............
..............
........
IGN
IGN ......
..
..............
.............
..............
.........
.............
.........
OF EVENT
OF EVEN
CEDURES
CEDURES
Screening P
Screening P
Treatme
Treatm
.
End
En
.3.
.3.
.3.1.
.3.1.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
11
CC-486-NSCL-001 Final: 15 May 2015
6.4.1.
Assessment of Response According to RECIST Version 1.1...................................39
6.4.2.
Assessment of Response According to irRECIST ...................................................39
6.4.3.
Assessment of Disease and Treatment after Initial Radiologic Progression .............39
6.5.
Pharmacokinetics....................................................................................................40
6.6.
Biomarkers .............................................................................................................41
6.7.
12-lead Electrocardiogram......................................................................................41
7.
STUDY POPULATION.........................................................................................42
7.1.
Number of Subjects and Sites .................................................................................42
7.2.
Inclusion Criteria....................................................................................................42
7.3.
Exclusion Criteria...................................................................................................43
8.
DESCRIPTION OF STUDY TREATMENTS........................................................46
8.1.
Description of Investigational Products...................................................................46
8.1.1.
CC-486 (Oral Azacitidine)/Placebo.........................................................................46
8.1.2.
Pembrolizumab.......................................................................................................46
8.2.
Treatment Administration and Schedule .................................................................46
8.2.1.
Dose Adjustment Guidelines...................................................................................47
8.2.1.1.
CC-486 (oral azacitidine)/Placebo ..........................................................................47
8.2.1.2.
Pembrolizumab.......................................................................................................49
8.2.2.
Overdose ................................................................................................................51
8.3.
Method of Treatment Assignment...........................................................................52
8.4.
Packaging and Labeling..........................................................................................52
8.5.
Investigational Product Accountability and Disposal ..............................................52
8.6.
Investigational Product Compliance........................................................................52
9.
CONCOMITANT MEDICATIONS AND PROCEDURES....................................53
9.1.
Permitted Concomitant Medications and Procedures...............................................53
9.1.1.
CC-486 (oral azacitidine)........................................................................................53
9.1.2.
Pembrolizumab Supportive Care.............................................................................53
9.1.2.1.
Management of pneumonitis...................................................................................54
9.1.2.2.
Management of Diarrhea/Colitis.............................................................................54
9.1.2.3.
Management of type 1 diabetes mellitus (if new onset, including diabetic 
ketoacidosis [DKA]) or ≥ Grade 3 Hyperglycemia, if associated with ketosis 
(ketonuria) or metabolic acidosis (DKA) ................................................................54
9.1.2.4.
Management of hypophysitis ..................................................................................54
&(/*(1(35235,(7$5<,1)250$7,21
1
.......42
4
..........
.... 42
4
..............
...........
..............
............
.............
.............
..............
............
.............
......
.........
..... ....
..............
...........
..........
.............
.............
............
..............
..........
.............
..........
ignment
gnmen ..
ng...........
.........
oduct Acco
oduct Acc
al Product C
al Product C
MITANT M
ITANT
tted Conco
tted Conco
C-486 (ora
486 (ora
Pembrol
Pembro
1.1.
Man
Ma
.1.2.2.
.1.2.2.
9.1.2.3.
.1.2.3


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
12
CC-486-NSCL-001 Final: 15 May 2015
9.1.2.5.
Management of hyperthyroidism or hypothyroidism...............................................55
9.1.2.6.
Management of hepatic abnormalities.....................................................................55
9.1.2.7.
Management of renal failure or nephritis.................................................................55
9.1.2.8.
Management of infusion reactions ..........................................................................55
9.2.
Prohibited Concomitant Medications and Procedures..............................................55
9.3.
Required Concomitant Medications and Procedures................................................56
10.
STATISTICAL ANALYSES..................................................................................57
10.1.
Overview................................................................................................................57
10.2.
Study Population Definitions ..................................................................................57
10.2.1.
Intent-To-Treat Population .....................................................................................57
10.2.2.
Safety Population....................................................................................................57
10.2.3.
PK Population ........................................................................................................57
10.2.4.
Biomarker Population.............................................................................................57
10.3.
Sample Size and Power Considerations...................................................................57
10.4.
Background and Demographic Characteristics........................................................58
10.5.
Subject Disposition.................................................................................................58
10.6.
Efficacy Analysis....................................................................................................58
10.6.1.
Primary Efficacy Endpoint......................................................................................58
10.6.2.
Secondary Endpoints ..............................................................................................59
10.6.2.1.
Overall Survival .....................................................................................................59
10.6.2.2.
Overall Response Rate (ORR) ................................................................................59
10.6.2.3.
Disease Control Rate (DCR)...................................................................................59
10.6.2.4.
irPFS, irORR and irDCR per irRECIST..................................................................59
10.6.3.
Subgroup Analysis..................................................................................................59
10.7.
Safety Analysis.......................................................................................................59
10.8.
Pharmacokinetic Analysis.......................................................................................60
10.8.1.
Plasma Concentrations............................................................................................60
10.8.2.
Pharmacokinetic Parameters...................................................................................61
10.8.3.
PK Analyses...........................................................................................................62
10.9.
Interim Analysis .....................................................................................................62
10.10.
Other Topics...........................................................................................................62
10.10.1.
Data Monitoring Committee ...................................................................................62
10.10.2.
Steering Committee ................................................................................................62
6
.......57
5
..........
.... 57
5
..............
...........
..............
............
.............
.............
..............
............
.............
.............
.............
.....
..............
...........
.............
.............
.............
............
..............
..........
.............
..........
.............
....
e (ORR)
e (ORR) .
Rate (DCR)
Rate (DCR
and i
nd irDCR
rDCR
i
Analysis
Analysi
y y Analysis
Analysis
harmacokin
armacoki
Pl
P asma 
asma 
2.2.
Phar
Ph
0.8.3.
0.8.3.
10.9.
0.9.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
13
CC-486-NSCL-001 Final: 15 May 2015
11.
ADVERSE EVENTS..............................................................................................64
11.1.
Monitoring, Recording and Reporting of Adverse Events .......................................64
11.2.
Evaluation of Adverse Events.................................................................................65
11.2.1.
Seriousness.............................................................................................................65
11.2.2.
Severity / Intensity..................................................................................................66
11.2.3.
Causality ................................................................................................................66
11.2.4.
Duration .................................................................................................................67
11.2.5.
Action Taken..........................................................................................................67
11.2.6.
Outcome.................................................................................................................67
11.3.
Abnormal Laboratory Values..................................................................................67
11.4.
Pregnancy...............................................................................................................68
11.4.1.
Females of Childbearing Potential ..........................................................................68
11.4.2.
Male Subjects.........................................................................................................68
11.5.
Reporting of Serious Adverse Events......................................................................69
11.5.1.
Safety Queries ........................................................................................................69
11.6.
Expedited Reporting of Adverse Events..................................................................69
11.7.
Pembrolizumab Events of Clinical Interest .............................................................70
12.
DISCONTINUATIONS .........................................................................................72
12.1.
Treatment Discontinuations ....................................................................................72
12.2.
Study Discontinuation ............................................................................................72
13.
EMERGENCY PROCEDURES.............................................................................73
13.1.
Emergency Contact.................................................................................................73
13.2.
Emergency Identification of Investigational Products .............................................73
14.
REGULATORY CONSIDERATIONS...................................................................74
14.1.
Good Clinical Practice............................................................................................74
14.2.
Investigator Responsibilities...................................................................................74
14.3.
Subject Information and Informed Consent.............................................................75
14.4.
Confidentiality........................................................................................................75
14.5.
Protocol Amendments.............................................................................................75
14.6.
Institutional Review Board/Independent Ethics Committee Review and 
Approval ................................................................................................................75
14.7.
Ongoing Information for Institutional Review Board / Ethics Committee................76
14.8.
Termination of the Study ........................................................................................76
&(/*(1(35235,(7$5<,1)250$7,21
6
.......67
6
..........
.... 67
6
..............
...........
..............
............
.............
.............
..............
............
.............
......
..........
..... ...
..............
...........
.............
.............
rest
rest .......
...
..............
..........
.............
..........
.............
....
EDURES
DURE
ctct...........
......
entificati
tifica on
TORY CO
TORY C
Clinical Pr
Clinical P
nvest
estigator
igator
Subject 
Subject 
Con
Co
4.5.
4.5.
14.6.
4.6.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
14
CC-486-NSCL-001 Final: 15 May 2015
15.
DATA HANDLING AND RECORDKEEPING.....................................................77
15.1.
Data/Documents .....................................................................................................77
15.2.
Data Management...................................................................................................77
15.3.
Record Retention....................................................................................................77
16.
QUALITY CONTROL AND QUALITY ASSURANCE........................................79
16.1.
Study Monitoring and Source Data Verification......................................................79
16.2.
Audits and Inspections............................................................................................79
17.
PUBLICATIONS ...................................................................................................80
18.
REFERENCES.......................................................................................................81
19.
APPENDICES........................................................................................................84
19.1.
Appendix A: RECIST 1.1.......................................................................................84
19.1.1.
Definitions..............................................................................................................84
19.1.1.1.
Measurable Disease ................................................................................................84
19.1.2.
Tumor Response Evaluation ...................................................................................84
19.1.2.1.
Target Lesions........................................................................................................84
19.1.2.2.
Non-target Lesions .................................................................................................85
19.1.2.3.
Response Criteria....................................................................................................85
19.1.2.4.
Symptomatic Deterioration.....................................................................................87
19.2.
Appendix B: irRECIST...........................................................................................88
19.3.
Appendix C: Events of Clinical Interest (ECI) Guidance Document........................98
19.3.1.
Overview................................................................................................................98
19.3.1.1.
Dose Modification/Discontinuation ......................................................................100
19.3.2.
ECI Reporting Guidelines.....................................................................................100
19.3.3.
ECI Categories and Terms....................................................................................100
19.3.3.1.
Pneumonitis..........................................................................................................100
19.3.3.2.
Diarrhea/Colitis ....................................................................................................102
19.3.3.3.
Endocrine .............................................................................................................104
19.3.4.
Hematologic .........................................................................................................106
19.3.5.
Hepatic .................................................................................................................108
19.3.6.
Neurologic............................................................................................................109
19.3.7.
Ocular...................................................................................................................110
19.3.8.
Renal....................................................................................................................111
19.3.9.
Skin......................................................................................................................112
&(/*(1(35235,(7$5<,1)250$7,21
9
.......79
7
..........
.... 80
8
..............
...........
..............
............
.............
.............
..............
............
..........
......... .....
.............
.....
..............
...........
.............
.............
.............
............
..............
..........
.............
..........
inical Inter
inical Inter
.............
..........
n/Discont
/Discontini
g Guideline
g Guideline
gories and T
gories an
mo
monit
nitisis......
iarrhea/Co
arrhea/Co
Endocrin
Endocri
4.4.
Hem
He
9.3.5.
9.3.5.
19.3.6.
9.3.6.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
15
CC-486-NSCL-001 Final: 15 May 2015
19.3.9.1.
Immediate Evaluation for Potential Skin ECIs ......................................................113
19.3.10.
Other ....................................................................................................................114
19.3.11.
Infusion Reactions ................................................................................................115
19.3.12.
Follow-up to Resolution .......................................................................................117
19.3.13.
References............................................................................................................117
19.4.
Appendix D: Table of Abbreviations ....................................................................119
&(/*(1(35235,(7$5<,1)250$7,21
9


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
16
CC-486-NSCL-001 Final: 15 May 2015
LIST OF TABLES
Table 1:
Main Data in Pretreated NSCLC Subjects...............................................................19
Table 2:
Table of Events.......................................................................................................30
Table 3:
Imaging and Treatment after Site-Assessed 1st Radiologic Evidence of PD............40
Table 4:
Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase..........................................................................................41
Table 5:
CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity ...........................48
Table 6:
Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events.....................................................................................................................50
Table 7:
Hypothetical Power and Resulting Two-sided 90% CI of Hazard Ratio ..................58
Table 8:
Time Point Response: Subjects With Target (± Non-target) Disease .......................86
Table 9:
Time Point Response: Subjects With Non-target Disease Only ...............................87
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) 
RECIST..................................................................................................................88
Table 11:
Events of Clinical Interest.......................................................................................98
Table 12:
Infusion Reactions................................................................................................116
Table 13:
Abbreviations and Specialist Terms.....................................................................119
&(/*(1(35235,(7$5<,1)250$7,21
1
......48
.............
.......
5
o ...........
...
se
se ..........
.........
ly ...........
......
e-related (i
related (
.............
...........
..............
............
.............
..........
.............
...........


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
17
CC-486-NSCL-001 Final: 15 May 2015
LIST OF FIGURES
Figure 1:
Overall Study Design..............................................................................................29
&(/*(1(35235,(7$5<,1)250$7,21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
18
CC-486-NSCL-001 Final: 15 May 2015
1.
INTRODUCTION 
1.1.
Disease Background
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths in both men 
and women. Globally, approximately 1,825,000 new cases of lung cancer were diagnosed in
2012, and 1,590,000 deaths occurred due to this disease (Globocan, 2012). The World Health
Organization (WHO) divides lung cancer into 2 major classes based on its biology, therapy, and 
prognosis: NSCLC and small cell lung cancer. NSCLC accounts for more than 85% of all lung 
cancer cases and includes 2 major types: (1) non-squamous carcinoma (including 
adenocarcinoma, large-cell carcinoma, other cell types); and (2) squamous cell (epidermoid) 
carcinoma. Adenocarcinoma (40% of lung cancers) is the most common type of lung cancer seen 
in the United States (US) and is also the most frequently occurring cell type in nonsmokers 
(Speicher, 2000).
Cigarette smoking remains the most important risk factor for lung cancer, although 
approximately 15% of all lung cancers are diagnosed in patients who never smoked.
One reason for the high mortality rate of lung cancer is the advanced stage at diagnosis; only 25-
30% of new NSCLC cases are diagnosed with localized disease that is potentially curable with 
surgery (Fossella, 2000; Lang-Lazdunski, 2013). The majority of patients are diagnosed with 
locally advanced or metastatic disease and are not candidates for surgery.
1.2.
Treatment Options in Second-line Metastatic NSCLC
In patients with metastatic NSCLC who have experienced disease progression either during or 
after first-line therapy and have an Eastern Cooperative Oncology Group (ECOG) performance 
score of 0-2, single agent docetaxel, gemcitabine, or erlotinib is recommended if not previously 
given. Pemetrexed is another option for the non-squamous subtype of NSCLC (NCCN, 2014, 
ESMO, 2014).  
Docetaxel was shown to be superior to best supportive care (BSC), vinorelbine and ifosfamide; 
nevertheless, using either the weekly or three-weekly schedule in multiple randomized studies 
the observed response rate with docetaxel ranged from 3% to 12%, progression-free survival 
(PFS) from 1.9 to 3.4 months, and overall survival (OS) from 5.4 to 9.2 months (Shepherd, 2000; 
Fossella, 2000; Bria, 2006).
Recently, nintedanib, a triple angiokinase inhibitor, was approved in the European Union (EU) in 
combination with docetaxel as second-line therapy for NSCLC. The results showed that 
compared to docetaxel alone, nintedanib plus docetaxel significantly extended the median OS
from 10.3 to 12.6 months for patients with advanced adenocarcinoma, after first-line 
chemotherapy (P=0.0359; hazard ratio [HR]: 0.83) (Reck, 2014). In addition, ramucirumab was 
approved in the US in combination with docetaxel as second-line therapy. The phase 3 REVEL 
trial compared ramucirumab, a vascular endothelial growth factor (VEGFR)-2 antagonist, plus 
docetaxel with placebo plus docetaxel in NSCLC patients who experienced disease progression 
after treatment with platinum-based chemotherapy for locally advanced or metastatic disease.
Median OS was better in the ramucirumab group than in the placebo group (10.5 vs 9.1 months; 
&(/*(1(35235,(7$5<,1)250$7,21
nd
lung 
lung 
ermo
ermoid) 
id) 
ung cancer
ng cancer
nonsm
nonsmoker
ok
er, although
althou
never smo
never sm
nced stage a
ed stage 
se that is po
se that is
rity
ty
i
of
of
y
pat
pat
f
ie
dates for su
dates for 
ne Metas
Metas
experience
experience
Cooperativ
Cooperati
mcicitabine
tabine
i
, o
fofor the non
r the 
perior to be
perior to b
he weekly o
weekly
ate with doc
ate with d
months, an
months, 
a, 2006
, 2006).).
edanib
danib, a tr
a 
n wi
n with
th
i
doce
doce
h
d to doceta
o docet
10.3 to 12.
10.3 to 12
emotherapy
motherapy
approved i
pproved i
ririalal co
co
l


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
19
CC-486-NSCL-001 Final: 15 May 2015
HR, 0.857; P = .0235), as was median PFS (4.5 vs 3.0 months; HR, 0.762; P < .0001) (Perol,
2014).
Gemcitabine showed modest activity in a phase II study with a 6.2% partial response and 17 
weeks median duration of survival in advanced NSCLC subjects who progressed on first-line 
cisplatin-containing therapy (Sculier, 2000).  Another phase II study found a partial response in
19% of subjects treated with gemcitabine as a second-line agent, and a median duration of 
response of 29 weeks (Crino, 1999).  In a third trial evaluating gemcitabine plus BSC versus 
BSC alone, tumor response was seen in 19% of gemcitabine-treated subjects while response was 
not measured in subjects treated with BSC alone (Anderson, 2000).  There was no difference in 
OS (5.7 versus 5.9 months, respectively).   The difference in the results between the trials may be 
due to the percentage of stage III versus stage IV subjects included in the trials.  In the study by 
Sculier et al. 96% of subjects had stage IV disease compared to 59% and 40% in Crino et al. and 
Anderson et al., respectively.
Erlotinib has been proven to be superior to BSC with significantly improved survival (6.7 vs. 4.7 
months), PFS (2.2 vs. 1.8 months), and delayed time to symptom deterioration (Shepherd, 2005).
Gefitinib is approved in the EU for the treatment of advanced and metastatic NSCLC with 
activating mutations of endothelial growth factor receptor (EGFR) only. Although a higher 
response rate was in favor of gefitinib compared to placebo (8% vs. 1%), median time to 
progression (TTP) (3.0 vs. 2.6 months) and survival (5.6 vs. 5.1 months) were similar in the 2
groups (Thatcher, 2005). A non-inferiority trial compared gefitinib to docetaxel in NSCLC 
patients after 1 or 2 lines of chemotherapy (Kim, 2008). A similar median survival (7.6 vs. 8 
months) and TTP (2.2 vs. 2.7 months) were observed, but less toxicity and better quality of life 
favored the gefitinib arm.
Pemetrexed showed clinically equivalent efficacy outcomes but better tolerability when 
compared to docetaxel in patients with the non-squamous subtype of NSCLC (Hanna, 2004; 
Peterson, 2007). 
An overview of the published data with the above described agents are summarized in Table 1.
Table 1:
Main Data in Pretreated NSCLC Subjects
Compound
Line of 
treatment
Histology
N
RR (%)
Median 
TTP/PFS 
(months)
OS 
(months)
Docetaxel
2nd
All
2557
2.7-12.6
1.9-3.4
5.4-9.2
Gemcitabine
2nd
All
65
6.21
--
4.22
Erlotinib
2nd 3rd
All
806
6.2-9
1.7-2.2
6.7-9.2
Gefitinib
2nd 3rd
All
1862
8.0-9.1
2.2-3.0
5.6-7.6
Pemetrexed
2nd
All3
871
4.3-9.1
2.6-2.9
6.7-8.3
1 This value represents partial response.
2 This value represents median duration of survival.
3 A retrospective analysis found that pemetrexed only showed significantly higher survival when compared to docetaxel in the 
non-squamous subgroup.  Docetaxel had statistically better survival in the squamous cell subgroup
&(
Pemetrexed
emetrexed
&(/*(1(35235,(7$5<,1)250$7,21
as
as
e inin
may 
may be
be
e study
study by
by
y
ino et al. a
ino et al. a
d survival (
d survival 
ration (
ation (Shep
tastatic NS
tastatic N
) only
only. Alt
Alth
% vs. 1%), m
vs. 1
5.1
5.1 mo
m nth
d gefit
gefitinib t
inib t
). A s
). A simila
imila
ed, but less 
ed, but les
ficacy
ficacy ou
ou
y
tctc
u
e non
e non-squa
squa
a with the ab
with the a
Pretreated
retreate
f f 
ment
ment
H
35
(
2nd
nd
1(
2nd
(1
*
2n
*(
/*
inib
inib
/*
/*
/*
/*
&(
&
This va
This va
i


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
20
CC-486-NSCL-001 Final: 15 May 2015
Personalized treatment based on molecular characteristics of the tumor has also become the 
standard of care.  In addition to the above guidelines, patients whose tumors are positive for the 
EGFR and/or anaplastic lymphoma kinase (ALK) mutation(s) should receive targeted therapy.  
The EGFR mutation which results in the activation of the EGFR tyrosine kinase domain has 
been reported in about 20-25% of non-squamous NSCLC cases and less than 5% in tumors with 
squamous histology.  Erlotinib and afatinib are EGFR tyrosine kinase inhibitors (TKIs) indicated 
for first-line treatment of patients with metastatic NSCLC whose tumors have EGFR exon 19 
deletions or exon 21 (L858R) substitution mutations, the most commonly found mutations in 
NSCLC (Tarceva® Package Insert; Gilotrif® Package Insert; NCCN, 2014).  Patients who 
progress after first-line therapy are still recommended to be continued on erlotinib or afatinib as 
part of second-line therapy (NCCN, 2014).  Anaplastic lymphoma kinase translocation, another 
key driver mutation, occurs in roughly 5% of NSCLC cases (Shaw, 2013), and it is mostly 
associated with the adenocarcinoma subtype (Bang, 2011; Xalkori Package Insert).  Tumors with 
this mutation are amenable to treatment with crizotinib, an ALK, MET, and ROS1 tyrosine 
kinase inhibitor, and thus, crizotinib is used in first-line therapy for metastatic ALK-positive 
NSCLC patients.  For patients who progress after first-line therapy, crizotinib or the recently 
approved ALK inhibitor, ceritinib, is recommended as part of second-line therapy (NCCN, 
2014).  This trial will focus on second-line therapy for subjects who do not possess these 2 driver 
mutations.  Thus, EGFR-positive and ALK-positive subjects will be excluded from this trial.  
The reported response rate to second-line therapy has generally been less than 10% (NCCN, 
2014), and many patients who respond to second-line therapy eventually develop resistance.  The 
limited effective second-line therapy options available call for the investigation of novel 
approaches to drug therapy in advanced NSCLC.
1.3.
Overview of CC-486
CC-486 is an orally bioavailable formulation of azacitidine (AZA).  Azacitidine, an analog of the 
pyrimidine nucleoside cytidine, has effects on cell differentiation, gene expression, and 
deoxyribonucleic acid (DNA) synthesis and metabolism, and causes cytotoxicity.
Vidaza® (azacitidine injection) is approved by the US Food and Drug Administration (FDA) for 
five subtypes of the French American British (FAB) classification system of myelodysplastic 
syndrome (MDS) and chronic myelomonocytic leukemia (CMMoL). Vidaza is also approved by 
the European Commission for the treatment of adult MDS, acute myeloid leukemia (AML) and 
CMMoL patients who are not eligible for hematopoietic stem cell transplantation.  Vidaza can be 
administered by intravenous (IV) or subcutaneous (SC) routes as designated by country 
approval.
After its incorporation into a cell’s DNA during the S-phase of the cell cycle, AZA forms 
covalent adducts with DNA methyltransferase 1 (DNMT1) and depletes this enzyme required for 
the maintenance of DNA methylation patterns, thereby altering the epigenetic status of the cell.   
Epigenetic changes are covalent modifications of chromatin (DNA and histone proteins) that 
mediate the stable transmission of a gene’s transcriptional status through cell division.  One of 
the first recognized epigenetic alterations in cancer was DNA methylation.  The addition of a 
methyl group to cytosine in the dinucleotide CpG is catalyzed by DNA methyltransferases 
(DNMTs) and is associated with transcriptional suppresion of genes (Miranda, 2007). Genomic 
methylation patterns are precisely regulated during normal embryonic development and 
&(/*(1(35235,(7$5<,1)250$7,21
nib as 
nib as 
another 
another 
mostly
ostly
).  Tumors 
 Tumors
OS1 ty
S1 tyrosin
ros
y
tic ALK
tic ALK-po
p
tinib or the
inib or
line therap
line therap
o do not po
o do not p
ll be exclud
ll be exclud
ally been le
ally been le
erapy event
rapy eve
call for th
call for th
ioion of
of a
f za
fects on ce
fects on ce
hesis and m
sis and m
) is approve
approve
American B
American
ronic myelo
ronic my
sision f
on for the
h
f
who are not 
who are not 
intntravenou
ravenou
incorporati
orporati
nt adducts 
t adducts 
maintenan
maintenan
Epi
Epigeneti
genetic
mediate 
mediat
e fir
fi


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
21
CC-486-NSCL-001 Final: 15 May 2015
differentiation and have been found to be altered in specific ways in cancer.  Specifically, cancer 
cell genomes are typified by reduced methylation globally with focal areas of aberrant 
hypermethylation in the CpG islands of genes encoding known tumor suppressors such as PTEN 
and BRCA1 as well as genes encoding proteins required for apoptosis, including caspase 8, 
DAPK and Apaf-1.  DNA methylation-based gene silencing can thus contribute to the 
establishment and maintenance of the transformed state and limit the effectiveness of anticancer 
therapies.
CC-486 entered clinical testing in 2006 in subjects with MDS, CMMoL, and AML.  The AZA 
PH US 2007 CL 005 study has shown that CC-486 is bioavailable and a maximum tolerated dose 
(MTD) of 480 mg daily for 7 days of a 28-day cycle was defined based on dose-limiting diarrhea 
at the 600 mg dose (Garcia-Manero, 2011).  As expected, reversible and manageable 
myelosuppression was observed.  Pharmacodynamic activity (DNA hypomethylation) and 
clinical responses were observed with CC-486, although the cross-over design (with SC Vidaza 
administered during Cycle 1) confounded the interpretation of these responses in Part 1 of the 
study.
The second part of the AZA PH US 2007 CL 005 study explored both daily and twice daily 
extended dosing schedules of 14 and 21 days out of 28 days in a non-crossover design.  CC-486 
administered at 300 mg once daily (QD) for 14 or 21 days of a 28-day cycle produces cumulative 
exposures (area under the concentration-time curve [AUC] per cycle) that are approximately 
40% and 60% of the exposure achieved with the labeled dose and schedule of Vidaza, 
respectively.  Daily doses of 300 mg have proven to be tolerated on both the 14 and 21 out of 28-
day schedules with myelosuppression, gastrointestinal (GI) symptoms, and fatigue being the 
most common toxicities (Garcia-Manero, 2011).
In the AZA PH US 2007 CL 005 study, DNA methylation levels in blood were measured as a 
pharmacodynamic (PD) endpoint, to determine DNA hypomethylating activity of CC-486.  In 
summary, it was confirmed that CC-486 is biologically active, reducing DNA methylation when 
administered at low doses on extended schedules.
CC-486 is also under clinical investigation, either as monotherapy or in combination with other 
investigational products, for the treatment of lymphoma, multiple myeloma, and relapsed or 
refractory solid tumors (eg, urothelial carcinoma of the bladder, renal pelvis, ureter, or urethra; 
pancreatic carcinoma; breast cancer; ovarian cancer; nasopharyngeal carcinoma; cervical 
carcinoma; anal carcinoma; and merkel cell carcinoma).  
 
 There are 2 ongoing studies 
evaluating PK of CC-486 (AZA-ST-001 and CC-223-NSCL-001).
1.3.1.
CC-486 Experience in Solid Tumors
A Phase 1 study of CC-486 in combination with carboplatin or nab-paclitaxel, or as a single 
agent in subjects with relapsed or refractory solid tumors (AZA-ST-001) was initiated on 30 Nov 
2011.  In Part 1 of this two-part study, CC-486 at escalating doses of 200 or 300 mg was 
administered on Days 1 to 14 of a 21-day cycle in three separate arms of the study (Arm A, Arm 
B, Arm C). 
In Arm A of AZA-ST-001, subjects received carboplatin (AUC = 4) on Day 8 of each cycle and 
in Arm B, subjects received nab-paclitaxel 100 mg/m2 beginning on Day 8.  For Arm A, both 
&(/*(1
of CC
of CC-486 
48
CC
C -
1(35235,(7$5<,1)250$7,21
dose
dos
diarrhea
arrhea
on) and 
n) and 
wi
with
th
i
SC Vi
SC Vi
h
s in Part 1 
s in Part 1 
daily and t
daily and 
n-crosso
rossove
8-day
da cycle
cl
y
er cy
er cycle) tha
cle) t
se and sch
e and sc
tolerated o
tolerated o
al (GI) sym
al (GI) sy
methylat
ethylatioio
mine DNA 
ine DNA
is bi
s biol
ologic
og
d schedule
d sched
est
estigat
igatioion
he treatmen
he treatme
, urothelial 
urothelia
reast cance
reast canc
no
noma
ma; and
; an
486 E
486 E
ase 1 study
ase 1 study
ent in subje
nt in subje
2011.  In P
011.  In P
adminis
dmini
A
(1(


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
22
CC-486-NSCL-001 Final: 15 May 2015
200 mg and 300 CC-486 mg were well tolerated with carboplatin AUC = 4.  For Arm B, 
initially, nab-paclitaxel was administered weekly starting on Cycle 1 Day 8 but dose-limiting 
neutropenia was encountered on this schedule at the first dose level of CC-486.  The protocol 
was amended to administer nab-paclitaxel on Days 8 and 15 of each cycle (ie, 2 out of 3 weeks) 
and this was well tolerated in combination with CC-486 at 200 mg.  When the CC-486 dose was 
escalated to 300 mg, dose-limiting neutropenia was again encountered, making the 200 mg the 
MTD of CC-486 in combination with nab-paclitaxel 100 mg/m2 on a 2- out of 3-week schedule.  
Arm C of study AZA-ST-001 assessed the safety of continuous administration of CC-486 on a 
21- out of 21-day schedule.  This schedule proved not to be tolerable, with profound 
granulocytopenia manifesting in 2 out of 6 subjects at the 300 mg dose level during Cycle 2.  
Single agent CC-486 was better tolerated in subjects when used at the dose of 300 mg daily for 
2- out of 3-week cycle with a manageable safety profile, and the recommended Phase 2 dose for 
Arm C was determined to be 300 mg on Days 1 to 14 of each 21-day cycle.
 
 
 
 
The most promising hints of activity in AZA-ST-001 were observed in Arm B.  Of 8 evaluable
subjects with relapsed pancreatic carcinoma, 1 had a partial response (PR) and 3 others had 
stable disease (SD) > 16 weeks for a disease control rate (DCR) of 50%.  CC-486 has also shown 
promising efficacy in subjects with relapsed or refractory NSCLC (N = 20).  Although the 
efficacy data are not yet fully mature, objective responses were observed, including 2 PRs in 
NSCLC subjects. An additional 8 subjects with NSCLC had stable disease for periods ranging 
from 4 to 9 months. Furthermore, dramatic objective responses were observed in subjects with 
relapsed cervical and endometrial cancer.  These observations, although promissing, do not 
provide conclusive evidence of an epigenetic modifying effect by CC-486.
Please refer to the Azacitidine IB for detailed information concerning the available 
pharmacology, toxicology, drug metabolism, clinical studies, and adverse event (AE) profile of 
the azacitidine/CC-486.
1.4.
Overview of Pembrolizumab
The programmed cell death protein-1 (PD-1) is an immune-checkpoint receptor expressed by T 
cells upon activation.  The normal function of PD-1 upon binding by its ligands, programmed 
death-ligand 1 (PD-L1) and PD-L2, is to moderate ongoing immune responses and prevent 
autoimmunity (Harvey, 2014).  Some tumor cells up-regulate the PD-1 ligands to evade active T-
cell immune surveillance. Pembrolizumab is a highly selective humanized monoclonal antibody 
(mAb) that binds to the PD-1 receptor and directly blocks the interaction between PD-1 and its 
ligands, thereby enhancing tumor regression and ultimately immune rejection (pembrolizumab
IB).  Pembrolizumab is being investigated in various oncology indications including melanoma, 
NSCLC, renal cell carcinoma (RCC), breast cancer, multiple myeloma (MM), microsatellite 
unstable tumors, and head and neck cancer. Pembrolizumab was recently approved in the US for 
the treatment of advanced, unresectable or metastatic malignant melanoma, and for use in 
melanoma patients with disease progression after prior treatment with (a) ipilimumab or (b) a 
BRAF inhibitor, in the case of BRAF V600-mutant disease (Nishimura, 2000). It is the first anti-
&(/*(1(35235,(7$5<,1
ved in
d 
Ar
Arm
esponse (
esponse (PR
DCR) of 50
CR) of 5
ry NSCLC 
NSCLC
y
onses were 
onses we
SCLC had 
SCLC had
ectctivive resp
e resp
These ob
hese obser
ser
net
neticic mo
modify
dif
detailed 
detailed in
metabo
etab lism,
sm
f f Pembro
emb
l death prot
death pr
on.  The no
n.  The no
(PD
PD-L1
L1) an
y (
y (Harvey
Harvey
une surveill
e surveil
that 
a binds
inds
ands
nds, , th
thereb
ereb
B).) Pembr
embr
NSCLC,
NSCLC
stab
250$7,21
2.  
2.  
daily for 
daily for 
e 2 dose fo
e 2 dose fo
)25
1)2
1)


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
23
CC-486-NSCL-001 Final: 15 May 2015
PD-1 therapy to receive regulatory approval in the US, and pembrolizumab for the melanoma 
indication is currently under regulatory review in the EU.
1.4.1.
Pembrolizumab Experience in Solid Tumors and Safety
An open-label phase 1 trial (Keynote 001) is being conducted to evaluate the safety and clinical 
activity of single agent pembrolizumab. The dose escalation portion of this trial evaluated three 
dose levels, 1 mg/kg, 3 mg/kg, and 10 mg/kg, administered every 2 weeks, in subjects with 
advanced solid tumors. All 3 dose levels were well tolerated and no dose-limiting toxicities
(DLTs) were observed. Based on PK data showing a half-life of  21 days, the dosing frequency 
in the expansion cohort has been changed to every 3 weeks. 
The choice of the 200 mg every 3 weeks as an appropriate dose for the switch to fixed dosing is 
based on simulations performed using the population PK model of pembrolizumab showing that 
the fixed dose of 200 mg every 3 weeks will provide exposures that 1) are optimally consistent 
with those obtained with the 2 mg/kg dose every 3 weeks, 2) will maintain individual patient 
exposures in the exposure range established in melanoma as associated with maximal efficacy 
response and 3) will maintain individual patients exposure in the exposure range established in 
melanoma that are well tolerated and safe. 
The ongoing expansion cohort in Keynote 001 is enrolling subjects with NSCLC.
Keynote 001, Part C enrolled 38 subjects with NSCLC (adenocarcinoma, squamous cell 
carcinoma, and large cell carcinoma) who experienced progression of cancer after initiation of 
their second line of systemic therapy to receive monotherapy pembrolizumab. By Investigator-
assessed immune-related Evaluation Criteria in Solid Tumors (irRECIST), the overall response 
rate (ORR) (confirmed and unconfirmed) was 24%. Similar results were obtained using 
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, yielding an ORR (confirmed and 
unconfirmed) of 21%. Most responses by irRECIST were observed by the time of first planned 
assessment at Week 9. The median duration of response by irRECIST has not been reached with 
a median duration of follow-up of 62 weeks. The median OS for all 38 patients treated with 
pembrolizumab was 51 weeks.
Pembrolizumab has been generally well-tolerated in subjects with solid tumors at doses up to 10 
mg/kg every other week without DLTs.  Of the 479 subjects for which preliminary data was 
available, the most commonly reported treatment-emergent AEs experienced were fatigue 
(43.8%), nausea (26.7%), cough (25.3%), pruritus (24.6%), diarrhoea (22.3%), and rash (21.5%).   
466 subjects (97.3%) experienced treatment-emergent AEs of which 368 (76.8%) were 
considered drug-related. Serious adverse events (SAEs) were reported in 30.1% of patients, but 
SAEs that were attributed as potentially (possibly, probably, or definitely) drug-related by 
Investigators were reported in 6.7% of patients overall. Five patients died within 30 days of the 
last dose of pembrolizumab; none of the deaths were considered drug-related.
Preliminary results from Part C only (previously-treated NSCLC patients) reported the incidence 
of drug-related AEs to be 53%, usually Grade 1-2 in severity, and the AEs were most commonly 
rash (21.1%), pruritus (18.4%), fatigue (15.8%), diarrhea (13.2%), and arthralgia (10.5%). 
Serious AEs were reported in 34.2% of all NSCLC patients, but SAEs that were attributed as 
potentially drug-related by Investigators were reported in 2.6% of NSCLC patients. Most 
patients continued treatment in spite of adverse events; 21.1% discontinued due to an AE. The 
&(/*(1(35235,(7$5<,1)250$7,21
cy
cy
d dosing is
d dosing is
showing t
showing t
mally consi
mally con
ndividual p
ndividual 
ith maxima
th maxima
sure range e
ure range
ects with N
ects with N
enocarcino
nocarcin
rogression 
ogressio
therapy
therapy pem
pem
y
id Tum
id Tumors
ors
4%. Simila
4%. Simi
rs (RECIST
rs (RECIST
irRECIST
rRECIST
ation of res
tion of re
2 weeks. Th
weeks. 
nerally well
nerally well
ith
i out DLT
out DLT
mo
monly
n
rep
rep
y
.7%), coug
7%), coug
3%) experi
3%) experi
ug-related.
related
were attribu
were attribu
ators were r
s were
ose of pemb
ose of pem
reliminary
reliminary
of
of drug
drug
f
-rere
sh (2
sh (2


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
24
CC-486-NSCL-001 Final: 15 May 2015
incidence of Grade 3/4 drug related AEs was 2.6%. Thus, the overall AE summary suggests that 
pembrolizumab is generally tolerable and AEs are generally manageable in NSCLC patients
(pembrolizumab IB).
In Part C of the study, 2 patients developed pneumonitis and 1 patient was reported with steroid-
responsive pulmonary edema. Two cases were Grade 2; the case of pulmonary edema was Grade 
3. These cases began as early as 4 days after the first dose to several cycles (Week 18) after the 
first dose. It is not clear the role of prior thoracic radiation to the development of this AE. The 
Grade 3 episode responded to steroids, whereas the Grade 2 cases did not. The Grade 3
pulmonary edema and a case of Grade 2 pneumonitis were considered drug-related; the third 
case was considered not drug-related. All 3 patients died from malignant neoplasm.
1.5.
Study Rationale
Both CC-486 and pembrolizumab have shown promising activity and acceptable tolerability in 
patients with relapsed or refractory NSCLC as detailed in Sections 1.3.1 and 1.4.1.
The reported response rate to second-line therapy in NSCLC has generally been less than 10% 
(NCCN, 2014), and many patients who do respond eventually develop resistance.  The limited 
availability of effective second-line therapy options call for the investigation of novel approaches 
to drug therapy in advanced NSCLC.  One potential strategy is the use of epigenetic agents, such 
as CC-486, to prime the tumor to become more responsive to immunotherapy. This approach is 
proposed by combining CC-486 with pembrolizumab in this trial.
Studies have shown that epigenetic events such as hypermethylation of the promoter sites on 
certain genes may play a role in tumor progression in lung cancer (Topaloglu, 2004).  
Importantly, unlike gene mutations, DNA methylation is reversible and can be inhibited by a 
DNMTi (Zeng, 2013).  There are currently 4 drugs targeting epigenetic changes that have been 
approved by the FDA for use in hematologic malignancies, i.e., 2 DNMT inhibitors for 
myelodysplastic syndrome (azacitidine and decitabine) and 2 histone deacetylase (HDAC) 
inhibitors for cutaneous T-cell lymphoma (vorinostat and romidepsin).  A recent study using the 
combination epigenetic therapy of azacitidine and entinostat, an HDAC inhibitor, in subjects 
with recurrent metastatic NSCLC who had extensive prior systemic therapy yielded some 
interesting results (Juergens, 2011).  Though only two of the 65 subjects had robust and durable
RECIST criteria responses to this therapy, a group of these subjects were observed during 
follow-up to have responded to various subsequent therapeutic regimens (Juergens, 2011). Five 
of these subjects received 1 of 2 investigational immunotherapy drugs, anti-PD1 or anti-PD-L1
antibody.  Preliminary data revealed that 3 subjects experienced durable partial responses for 
over a year while the other two subjects had stable disease on therapy for more than 6 months 
(Brahmer, 2013).  
Previous PD-1 immune-checkpoint targeting monotherapy studies in subjects with advanced 
NSCLC who received previous systemic therapy reported only a 16 to 17% response rate 
(Brahmer, 2012; Topalian, 2012, Brahmer, 2013 abstract, Garon 2014). 
The results of the above study led to the hypothesis that azacitidine may prime the tumor to 
become more responsive to immunotherapy.  There are several possible mechanisms as to how 
this may occur (Brahmer 2013): 
(
&(/*(1(35235
a
35,(7$5<,1)250$7,21
d 
le tol
e tolerabil
erab
1.4.1
1.4.1.
lly y been les
been
op resistanc
p resistan
vest
es igat
gatioion
the use of 
e us
o immunot
immunot
his trial
his tria .
permethyla
permethyla
inin lung ca
lung ca
ylatio
ylation is r
is 
drugs targ
drugs targ
ogigic malign
c malign
nd decita
nd decit
pho
homa (vor
ma (vo
of azacit
of azacitididini
CLC who h
CLC who h
s, 2011
 201 ).  T
ses to this t
ses to this
sponded to 
ponded to
eceived 1 o
ceived 1 o
minary
minary dat
d
y
while the ot
while the o
r, 2013
013).  
).  
ous PD
ous PD-1 i
1
SCLC who
SCLC who
Brahmer,
Brahmer,
he re
he re


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
25
CC-486-NSCL-001 Final: 15 May 2015
!
Azacitidine induces the type I IFN pathway and subsequently upregulates suppressed 
antigen-presenting molecules, enhancing intratumoral inflammatory response.
!
Azacitidine reactivates the production of tumor antigens, such as cancer testes antigens, 
that are found in lung cancer.
!
Azacitidine activates silenced effector cytokine genes in anergized T cells.  
Further support for using CC-486 in combination with pembrolizumab is the fact that epigenetic 
treatment of NSCLC cell lines has been found to increase expression of PD-1 and PD-L1.  Co-
administration of a PD-1 pathway inhibitor would shift the balance in favor of the immune-
enhancing effects of epigenetic modulators on T cells (Brahmer, 2013).  Thus, the combination 
of azacitidine and a PD-1 pathway inhibitor would mechanistically complement each other for 
the purpose of cancer treatment.
Current treatment options for metastatic NSCLC patients who have progressed on first-line 
therapy are limited.  The use of epigenetic modifying agents such as CC-486 to overcome
immune resistance mechanisms of tumors is an interesting strategy.  Here we propose to evaluate
the ability of CC-486 to sensitize tumor cells to PD-1 inhibition with pembrolizumab.  
To explore the hypothesized mechanism of CC-486 priming to pembrolizumab efficacy, and 
potentially identify biomarkers to predict patients that would benefit from this therapeutic 
regimen, tissue samples will be collected from patients pre-therapy and during therapy for 
cellular and molecular analyses. Submission of archival or fresh tumor tissue pre-therapy is 
mandatory. Blood, serum and saliva will also be collected. 
 
 
&(/*(1(35235,(7$5<,1)250$7,21
natatioion n 
other
ther fo
for r 
on first
on first-lin
l
to overco
to overc
e we propo
we pro
pembro
pembrolizum
lizu
mbrolizu
mbrolizum
enefit fro
nefit f
m
herapy
erapy and
nd
r fresh tum
r fresh tum
ted.
ted.
7$5
(7$
,(7
5,(
35,


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
26
CC-486-NSCL-001 Final: 15 May 2015
2.
STUDY OBJECTIVES
2.1.
Primary Objective
The primary objective of the study is:
!
To estimate the efficacy of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo based on PFS as measured using RECIST 1.1 criteria
2.2.
Secondary Objectives
The secondary objectives of the study are:
!
To estimate DCR of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo
!
To estimate OS of CC-486 plus pembrolizumab versus pembrolizumab plus placebo
!
To estimate ORR of CC-486 plus pembrolizumab versus pembrolizumab plus 
placebo
!
To evaluate safety and tolerability of CC-486 plus pembrolizumab versus 
pembrolizumab plus placebo
!
To evaluate the impact of pembrolizumab on the pharmacokinetics of CC-486
2.3.
Exploratory Objectives
The exploratory objectives of the study are:
!
To determine the preliminary efficacy (immune-related [ir] PFS, irDCR, irORR) of 
CC-486 plus pembrolizumab versus pembrolizumab plus placebo based on irRECIST
criteria 
!
To explore mechanism and biomarkers associated with efficacy of CC-486 plus 
pembrolizumab versus pembrolizumab plus placebo,
mab plus
mab plus
olizumab p
lizumab p
pembro
embrolizu
lizu
pembrolizu
pembrol
on the pharm
n the pharm
y efefficacy
ficacy
f
(i
ab
ab versus 
ver
ism and bi
m and b
versus pem
versus pe
( 3


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
27
CC-486-NSCL-001 Final: 15 May 2015
3.
STUDY ENDPOINTS
3.1.
Primary Endpoint
!
PFS measured as time from randomization to progression according to RECIST 1.1 
(based on Investigator assessment) 
3.2.
Secondary Endpoints
!
Number (%) of subjects with SD for ≥ 18 weeks, complete response (CR) or PR 
(DCR). 
!
Overall survival.
!
Number (%) of subjects who achieve an objective CR or PR (ORR).
!
Safety to include the incidence of treatment-emergent adverse events (TEAEs), 
serious TEAEs, Grade 3-4 TEAEs, TEAEs of special interest, and laboratory 
abnormalities and other safety parameters.
!
Plasma PK parameters such as maximum observed concentration (Cmax), area under 
the concentration-time curve (AUC), time to maximum concentration (Tmax), terminal 
half-life (t1/2), apparent total body clearance (CL/F) and apparent volume of
distribution (Vz/F) for CC-486.
3.3.
Exploratory Endpoint(s)
!
Exploratory efficacy as measured by irPFS, irDCR, and irORR based on Investigator 
assessment using irRECIST.
 
!
DNA analyses, gene expression and soluble factors in blood.
&(/*(1(
alyses, gen
yses, gen
35235,(7$5<,1)250$7,21
PR
R).)
events (
events TE
estst, and lab
and lab
concentrati
oncen
ximum con
ximum con
L/F) and ap
L/F) and ap
d by
d by irirPFS,
PFS,
23
523
35
( 3


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
28
CC-486-NSCL-001 Final: 15 May 2015
4.
OVERALL STUDY DESIGN 
4.1.
Study Design
This is a Phase 2, multicenter, international, randomized, placebo controlled, double-blind study
to assess the safety and efficacy of CC-486 and pembrolizumab combination therapy versus 
pembrolizumab plus placebo in previously treated subjects with locally advanced or metastatic 
NSCLC who have received one prior platinum-based chemotherapy regimen.
Approximately 90 subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or 
placebo plus pembrolizumab as follows:
!
Arm A: CC-486 300 mg administered orally daily on days 1-14 plus pembrolizumab
200 mg administered as a 30-minute IV infusion on day 1 of a 21-day cycle 
!
Arm B: Placebo administered orally daily on days 1-14 plus pembrolizumab 200 mg
administered as a 30-minute IV infusion on day 1 of a 21-day cycle 
A safety analysis will be performed in the first 10 subjects in each arm after the last enrolled 
subject has completed 1 cycle of treatment.
Randomization will be stratified between treatment arms by:
!
Histology (non-squamous versus squamous)
The decision to discontinue a subject, which will not be delayed or refused by the Sponsor, 
remains the responsibility of the treating physician. However, prior to discontinuing a subject, 
the Investigator may contact the medical monitor and forward appropriate supporting documents 
for review and discussion.
The study will be conducted in compliance with the International Council on Harmonisation 
(ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use/Good 
Clinical Practice (GCP) and applicable regulatory requirements.
Primary analysis will be conducted when 70 PFS events have occurred.
&(/*(1(35235,(7$5<,1)250$7,21
b or 
o
embro
mbrolizum
lizum
ay cycle
cycle
y
mbrolizuma
mbrolizum
y cycle
cycle
y
rm afafter th
ter th
f
t be delaye
t be delay
n. Howeve
n. Howev
or and f
r and forw
or
f
ance wi
nce w th
th
i
tht
h
r Registrati
r Registr
cable regul
cable regu
ducted when
ducted whe


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
29
CC-486-NSCL-001 Final: 15 May 2015
Figure 1:
Overall Study Design
4.2.
Study Duration 
Enrollment is expected to take approximately 12 months to complete.  Completion of active 
treatment and post-treatment follow-up is expected to take an additional 12 months.  The entire 
study is expected to last approximately 2 years.
4.3.
End of Trial
The End of Trial is defined as either the date of the last visit of the last subject to complete the 
post-treatment follow-up, or the date of receipt of the last data point from the last subject that is 
required for primary, secondary and/or exploratory analysis, as pre-specified in the protocol, 
whichever is the later date.
&(/*(1(35235,(7$
12
12 months 
months 
xpecte
xpected to 
d to
years.
years.
either the d
either the
r the date o
the date
condary
condary and
a
y
$7,21
date.
date.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
30
CC-486-NSCL-001 Final: 15 May 2015
5.
TABLE OF EVENTS
Table 2:
Table of Events
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up 
Period
Day
-21 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Informed consent
X
Demographics
X
Prior cancer history
X
Prior cancer therapiesc
X
Complete medical history
X
Prior/ concomitant 
medication evaluationd
X (≤ 28d from 
screening)
Continuous, until 28 days after last dose
Prior/ concomitant 
procedures evaluatione
X (≤ 28d from 
screening)
Continuous, until 28 days after last dose
Inclusion/exclusion criteria
X
IRT registration
X
IRT randomization
Xf
Adverse event evaluation
Continuous after informed consent signature. See Section 11 for additional details on AE reporting 
timeframe
Physical examination 
(source documented only)
X
X
X
X
X
&(/*(
pri
prietet
nly)
ly)
*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
0$
0$
0$
0$
ent 
nt 
les
les
25
)2
1
)2
)2
)2
<
)2
<
5<
$ <
$5
7$
7$
7$
7$
7$
(7
5
C
5,
23
52
52
52
5
3
(
Continuous
Continuou
1(
X
*(
(/*
/


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
31
CC-486-NSCL-001 Final: 15 May 2015
Table 2:
Table of Events (Continued)
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up 
Period
Day
-21 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Weight
X
X
X
X
X
Height
X
Vital signs
X
X
X
X
X
ECOG performance status
X
X
X
X
X
Hematology laboratoryg
X
X
X
X
X
X
X
Coagulationh
X
HBV and HCV serologies 
(HBsAg, HBeAg, HBsAb, 
HBeAb, HBcAb, HCVAb)
X
X
Chemistry laboratoryi
X
X
X
X
X
X
X
Lipid panelj
X
Every 4th
cycle
X
Thyroid test
X
X
Cycle 3 Day 
1 then every 
6 weeks
Urinalysisk
X
X
X
X
X
12-lead electrocardiogram
X
X
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet
7,2
0$
0$
0$
0$
1
50
2
X
1)
,1
<
5<
$ <
X
$5
7$
7$
7$
7$
7$
(7
5
X
35
2 5
23
52
35
(
5
X
(1
X
*(
/*
/*
/*
/*


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
32
CC-486-NSCL-001 Final: 15 May 2015
Table 2:
Table of Events (Continued)
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up Period
Day
-21 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Serum β-hCG (for all 
FCBP)l
X
Serum or Urine β-hCG (for 
all FCBP)l
X
(w/in72 hours)
X
X
X
X
PK blood draws sampling
(See Section 6.5 for 
timepoints)
X
X
Tumor biopsy for 
Biomarker Analyses
X
(Mandatory –
archival or 
fresh tumor 
collection)
X
(Optional)
Blood for Biomarker DNA 
Analyses
X 
X
Blood for Biomarker RNA 
Analyses
X
X
X
Serum for Biomarker 
Analyses
X 
X
Xm
X
Saliva for Germline DNA 
Analysis
X
&(/*(
pri
prietet
*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
7,2
0$
Fo
Folll
0$
0$
0$
1
E
50
)2
1)
<
)
< ,
<
$5
7$
(7
2 5, 7
X
2
52
X
35
( 3
( 3
( 3
( 3
( 3
1(
*(


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
33
CC-486-NSCL-001 Final: 15 May 2015
Table 2:
Table of Events (Continued)
Screening 
Period
Treatment Perioda
Events
Screening
Cycle 1
Cycle 2
Subsequent 
cycles
Follow-up 
Period
Day
-21 to -1
1b
14
1
14
1
EOT
Disease 
Progression/ 
Survival
Tumor evaluation 
(CT/MRI)
X 
RECIST 1.1 algorithm: Every 6 weeks (± 5 days) from randomization for the first 24 
weeks then every 9 weeks until disease progression (for exceptions refer to Section 
6.4.3) or start of a new anticancer treatment, or withdrawal of consent
The irRECIST will be evaluated as exploratory efficacy assessment. For additional 
details, see Sections 6.4.2 , 6.4.3 and Appendix B, Section 19.1
Bone Scan 
Only if clinically indicated
CT Scan of the Head or 
Brain MRI
X
Only if clinically indicated
Administer                    
CC-486/placebo
Daily on Days 1-14
Administer 
pembrolizumab
Xn
X
On Day 1 
only
IP accountability
X
X
X
X
Survival follow-up
Every 8 weeks 
(+/- 5 days)
Anticancer therapy since 
IP discontinuation
At every survival 
follow-up visit
Abbreviations:  β-hCG = beta human chorionic gonadotropin; C1D1 = Cycle 1 Day 1; CT = computed tomography; ECOG = Eastern Cooperative Oncology 
Group; EOT = End of Treatment; FCBP = females of child bearing potential; IP = investigational product; irRECIST = immune-related Response Evaluation 
Criteria in Solid Tumors; IRT = interactive response technology; MRI = magnetic resonance imaging; PK = pharmacokinetic; RECIST = Response Evaluation 
Criteria in Solid Tumors
a All visits have a ± 2-day window, except Cycle 1 Day 1 which must occur within 21 days from Informed Consent Form signature, and survival follow-up 
which has a ±5-day window.
&(/
pri
prietet
/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
7,2
0$
0$
0$
0$
1
E
50
)2
5 days) from
5 days) from
progression
rogress
ncer treatme
er treatm
as explorat
as explor
6.4.2
6.4.2 , 6.4.
6.4
1)
y indicated
y indicated
$5
nly if clinica
ly if clinica
7$
Daily on D
Daily on 
,(
35
2 5
X
2
52
5
( 35
( 3
( 3
( 3
(1( 3
orionic gonad
rionic gonad
CBP = female
CBP = femal
nteractive res
teractive res
ndow, excep
ndow, excep
ow
ow.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
34
CC-486-NSCL-001 Final: 15 May 2015
b Cycle 1 Day 1 evaluations can be omitted if Screening evaluations are performed within 72 hours of Cycle 1 Day 1.
c Prior cancer therapies include surgery, radiation, systemic or any other therapy (eg, hormonal, locoregional) for the subject's cancer
d Prior/concomitant medication evaluation ≤28 days before screening through 28 days after last dose.
e Prior/concomitant procedures evaluation ≤28 days before screening through 28 days after last dose.
f Prior to receiving first dose.
g Hematology includes complete blood count (CBC) with differential, including but not limited to red blood cell (RBC) count, hemoglobin, hematocrit, white 
blood cell (WBC) count with differential (neutrophil count including lymphocyte, monocyte, eosinophil, basophil counts and bands), absolute neutrophil count 
(ANC), and platelet count. ANC should be measured with automated count where available.
h Coagulation tests, including prothrombin time (PT), partial thromboplastin time (PTT), activated partial thromboplastin time (aPTT) and international 
normalized ration (INR)
I Chemistry includes (but is not limited to) sodium, potassium, calcium, phosphorus,  chloride, magnesium, bicarbonate, blood urea nitrogen (BUN) or urea, 
serum creatinine, fasting glucose, uric acid, albumin, total protein, alkaline phosphatase, lactate dehydrogenase, total bilirubin (indirect and direct), aspartate 
aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)
j Lipid Panel parameters include total cholesterol, high-density lipoprotein, low-density lipoprotein, triglycerides
k Urinalysis (a urine dipstick may be used) at screening and D1 of each cycle if abnormal at baseline.
l Serum β-hCG (for all FCPB) performed at screening; remaining pregnancy tests may be serum or urine at the Investigator’s discretion. Pregnancy testing (for 
all FCPB) must be done within 72 hours prior to the first administration of IP and prior to dosing on Day 1 of every cycle.  If the serum screening pregnancy 
test is performed > 72 hours before first dose, a serum or urine pregnancy test should be performed (Investigator’s discretion).  The subject may not receive IP 
until the Investigator has verified that the result of the pregnancy test is negative.
m Day 1 of Cycle 3 and every third cycle thereafter (C6D1, C9D1, C12D1)
n On Cycle 1 Day 1, pembrolizumab will be administered after the 6 hour CC-486 PK sample collection. For all subsequent pembrolizumab administration, 
pembrolizumab will be co-administered with CC-486.
&(/*(1(35235,(7
pri
prietet
(7$5<,1)250$7,21
e Corpora
e Corpora
21
, he
hemoglobin
moglobi
and bands),
and bands),
astin t
stin time (aP
ime (
arbonate, blo
arbonate, blo
nase, total bi
se, total
m glutamic p
m glutamic p
glycerides
glycerides
e.
or urine at th
or urine a
sing on Day 
sing on Day
erformed (In
erformed (In
PK sample c
PK sample c


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
35
CC-486-NSCL-001 Final: 15 May 2015
6.
PROCEDURES
Any questions regarding the study should be directed to the Celgene medical monitor or 
designee. 
6.1.
Screening Period
Screening evaluations will be performed for all subjects to determine study eligibility. These 
evaluations must be completed within 21 days of first dosing unless noted below.
Waivers to the protocol will not be granted during the conduct of this trial, under any 
circumstances.
Safety laboratory analyses will be performed centrally. Decisions with respect to investigational 
product (IP) dosing can be made based on a local lab draw if the central lab results have not been 
received. Central labs should be drawn at all times specified within the protocol. Screening 
laboratory values must demonstrate subject eligibility, but may be repeated within the screening 
window if necessary.
The following will be performed at screening as specified in the Table of Events (Table 2), after
informed consent has been obtained:
!
Demographics 
!
Prior cancer history (including specific information regarding diagnosis, staging, and 
histology)
!
Prior cancer therapies: includes surgery, radiation, systemic or any other therapy for
the subject’s cancer
!
Complete medical history (all relevant medical conditions occurring ≥ 28 days before
Screening should be included)
!
Prior and concomitant medication evaluation (including those taken ≤28 days before
screening, except for those taken for cancer which are recorded as part of prior cancer 
therapy)
!
Prior and concomitant procedures (including all procedures occurring ≤ 28 days 
before screening)
!
Interactive response technology (IRT) for subject number 
!
Adverse event evaluation (begins after the subject signs the informed consent form 
[ICF])
!
Physical examination (source documented only), weight, height
!
Vital signs (including blood pressure, temperature, respiratory rate, and heart rate)
!
Eastern Cooperative Oncology Group (ECOG) performance status
!
Hematology panel: Complete blood count (CBC) with differential, including but not 
limited to red blood cell (RBC) count, hemoglobin, hematocrit, white blood cell 
&(/*(1(35235,(7$5<,1)250$7,21
invest
nvestigat
igati
sults have n
ults have
tocol.
ocol. Scree
Scre
ted wit
within t
h
Table of Ev
able of Ev
format
formatioion re
gery
gery, radi
, radia
all relevant 
relevan
l
uded)
uded)
nt m
nt medicat
edicati
for those ta
for those ta
concomitan
concomit
screening)
creening)
eractive res
ractive re
Adverse e
dverse e
[ICF])
ICF])
!
Ph
Ph
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
36
CC-486-NSCL-001 Final: 15 May 2015
(WBC) count with differential (neutrophil count including lymphocyte, monocyte, 
eosinophil, basophil counts and bands), absolute neutrophil count (ANC), and platelet 
count.
!
Coagulation tests including, prothrombin time (PT), partial thromboplastin time 
(PTT), activated partial thromboplastin time (aPTT), international normalized ratio 
(INR).
!
Chemistry panel including, but not limited to sodium, potassium, calcium, 
phosphorus,  chloride, magnesium, bicarbonate, blood urea nitrogen (BUN) or urea, 
serum creatinine, fasting glucose, uric acid, albumin, total protein, alkaline 
phosphatase, lactate dehydrogenase (LDH), total bilirubin (indirect and direct), 
aspartate aminotransferase/serum glutamic oxaloacetic transaminase (AST/SGOT), 
alanine aminotransferase/serum glutamic pyruvic transaminase (ALT/SGPT)
!
Lipid panel including total cholesterol, high-density lipoprotein, low-density 
lipoprotein, and triglycerides
!
Thyroid test
!
Hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies (hepatitis B surface 
antigen [HBsAg], hepatitis B e antigen [HBeAg], hepatitis B surface antibody 
[HBsAb], hepatitis B e antibody [HBeAb], hepatitis B core antibody [HBcAb], 
hepatitis C virus antibody [HCVAb]
!
Urinalysis (a urine dipstick may be used) at screening (and Day 1 of each cycle if 
abnormal at baseline).
!
12-lead electrocardiogram (ECG)
!
Pregnancy test is required for all female subjects of childbearing potential. Serum
beta subunit of human chorionic gonadotropin (β-hCG) pregnancy test will be 
performed at screening. Urine (or serum) pregnancy test will be performed to assess 
subject eligibility within 72 hours prior to the first administration of IP, if the serum 
pregnancy test did not already occur within 72 hours of dosing (negative results 
required for IP administration).
!
Submission of archival or newly obtained tumor biopsy specimen for biomarker 
analysis is mandatory.
!
Response assessment/tumor evaluation (see Section 6.4)
6.2.
Treatment Period
The subjects must start treatment within 21 days of signing the ICF. For all subsequent visits, an 
administrative window of ± 2 days is permitted.
Treatment cycles are 21 days in duration, and will occur as described in Section 8.2.
The following evaluations will be performed at the frequency specified in Table 2.  The 
evaluations should be performed prior to dosing on the visit day, unless otherwise specified:
!
IRT for subject randomization (prior to first dose)
&(/*(1(35235,(7$5<,1)250$7,21
ea,
ct),
T/SGOT),
T/SGOT),
SGPT)
GPT)
w-densit
nsi y
serologies (
rologies 
epat
epatititis B s
is
ititis B core 
is B core
at scr
at sc eenin
een
all female 
all female 
rionic gona
rionic gona
Urine
Urine (or s
(or 
hin 72 hou
in 72 hou
not already
not alread
administrat
dministra
of archiva
archiva
is mandato
is mandato
ponse asse
ponse ass
Treatm
Treatm
subject
subjects mu
m
ministrativ
nistrativ
Treatmen
Treatmen


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
37
CC-486-NSCL-001 Final: 15 May 2015
!
Concomitant medications evaluation (continuously)
!
Concomitant procedures evaluation (continuously)
!
Adverse event evaluation (continuously)
!
Physical examination (source documented only) including weight
!
Vital signs: on-treatment vital sign measurements will be source documented only.  
However, if an abnormal (out of range) value is reported at any given visit, that
parameter should be collected in the case report form (CRF) at every subsequent
scheduled visit until it returns to normal, and as an AE if appropriate.
!
ECOG Performance status
!
Hematology panel
!
Chemistry panel
!
Lipid panel
!
Thyroid test
!
Urinalysis
!
Urine (or serum) pregnancy test (prior to dosing on Day 1 of each cycle)
!
PK sampling
!
Tumor biopsy for biomarker analyses [Optional, but strongly recommended]
!
Blood for biomarker analyses
!
Serum for biomarker analyses
!
Saliva for Germline DNA Analysis
!
Response assessment/tumor evaluation (see Section 6.4)
!
IP accountability
6.2.1.
End of Treatment
An end of treatment (EOT) evaluation should be performed for subjects who are withdrawn from
treatment for any reason as soon as possible after the decision to permanently discontinue
treatment has been made. Subjects must also be discontinued in the IRT system.
The following evaluations will be performed as specified in the Table 2:
!
Concomitant medications evaluation
!
Concomitant procedures evaluation
!
Adverse event evaluation (monitored through 30 days after the last dose of either 
study drug)
!
Physical examination including weight
!
Vital signs
&(/*(1(35235,(7$5<,1)250$7,21
on Day
on Day 1
y
o
Optional, bu
Optional, b
Analysis
nalysi
umor evalu
umor evalu
ment
ment
(EOT) eva
EOT) ev
reason as s
reason as s
been made.
een mad
wing evalua
ng evalua
!
Conco
onco
!
C
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
38
CC-486-NSCL-001 Final: 15 May 2015
!
ECOG performance status
!
Hematology panel
!
Hepatitis B virus (HBV) and HCV serologies (HBsAg, HBeAg, HBsAb, HBeAb, 
HBcAb, HCVAb
!
Chemistry panel
!
Lipid panel
!
Urinalysis
!
12-lead ECG
!
Urine (or serum) β-hCG level for females of childbearing potential
!
Blood for biomarker analyses
!
Serum for biomarker analyses
!
Response assessment/tumor evaluation will be continued at the schedule defined in
Table 2, and does not need to be performed specifically for the EOT visit except as 
specified in Section 6.4.
!
IP accountability
6.3.
Follow-up Period
6.3.1.
Efficacy Follow-up
All subjects who discontinue treatment for reasons other than disease progression, start of new
anticancer therapy, or withdrawal of consent from the entire study will be followed for tumor
response assessments and subsequent anticancer therapies as specified in Section 6.4.
6.3.2.
Survival Follow-up
After the end of treatment (EOT) visit, all subjects will be followed every 8 weeks (± 5 days) for 
survival until withdrawal of consent, death, or lost to follow-up, whichever occurs first, or until 
the End of Trial. Subsequent anticancer therapies should be collected at the same schedule. New 
anticancer therapy includes (but is not limited to) any systemic or local medication, surgery, 
radiation, or any other therapy intended to treat the subject’s cancer.
Survival follow-up may be conducted by record review (including public records) and/or
telephone contact with the subject, family, or the subject’s treating physician.
6.4.
Response Assessments
Response assessments (tumor evaluations) should be performed at Screening within 21 days 
before the start of IPs, and every 6 weeks (± 5 days) from randomization for the first 24 weeks, 
then every 9 weeks thereafter until disease progression (for exceptions refer to Section 6.4.3), 
start of a new anticancer therapy, or withdrawal of consent from the entire study. Tumor 
assessments should also be performed at any time, if clinically indicated.  Subjects with 
historical tumor scans evaluable per RECIST 1.1 performed ≤ 21 days before the first dose need 
&(/*(1(35235,(7$5<,1)250$7,21
the schedu
the sched
for the EOT
for the E
easons othe
easons othe
nt from
nt from thth
m
nticancer t
icancer 
OT
OT) visit, a
visit, a
f consent, 
consent,
f
quent anti
quent antic
ncludes (but
cludes (bu
other therap
other therap
w-
w-up may
up may
contact wi
ontact witi
Res
Re
Response a
Response a
befo
bef re th
re 
n


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
39
CC-486-NSCL-001 Final: 15 May 2015
not repeat scans for the purposes of screening. Evaluation of response should be performed using 
RECIST 1.1 and irRECIST guidelines by Investigator assessment.  
6.4.1.
Assessment of Response According to RECIST Version 1.1
Response assessments include computed tomography (CT) scan or MRI.  The regions to be 
imaged are the chest and abdomen/pelvis, including whole liver and kidney. In case of 
metastases to other organs not covered with these scans, the regions need to be included in the 
scans as well. If brain metastases are documented at baseline, brain imaging should be continued 
throughout the study. Bone scans will only be performed at baseline if clinically indicated. If at 
baseline, the bone scan is suggestive of bone lesions, CT or MRI will be used both at baseline 
and subsequent scans. Bone scans during the trial will only be performed if clinically indicated 
and if suggestive of new lesions, a CT or MRI will be performed to confirm the new lesion. Any 
skeletal lesions identified at baseline should be followed at the same schedule. The same mode of 
imaging for lesion evaluation at Screening must be used consistently throughout the study. 
Adherence to the planned imaging schedule is critical regardless of dose delays or unscheduled 
or missed assessments; scans must follow the calendar and not be adjusted for delays in 
treatment.
The CT imaging should include contrast unless medically contraindicated. Conventional CT 
should be performed with contiguous cuts of 5 mm or less in slice thickness. Spiral CT should be 
performed by use of a 5 mm contiguous reconstruction algorithm.
All subjects with evidence of objective tumor response (CR or PR) should have the response 
confirmed with repeat assessments at the next scheduled scan, but after no less than 4 weeks.  
6.4.2.
Assessment of Response According to irRECIST
Evaluation of response will also be performed using irRECIST guidelines as an exploratory 
assessment.  Additional details and definitions of irRECIST are found in Appendix B in Section
19.2.
6.4.3.
Assessment of Disease and Treatment after Initial Radiologic Progression
Immunotherapeutic agents such as pembrolizumab may produce antitumor effects by 
potentiating endogenous cancer-specific immune responses.  The response patterns seen with 
such an approach may extend beyond the typical time course of responses seen with cytotoxic 
agents, and can manifest as a clinical response after an initial increase in tumor burden or even 
the appearance of new lesions.  
If radiologic imaging shows PD by RECIST 1.1, tumor assessment should be repeated ≥4 weeks 
later in order to confirm PD (per irRECIST) with the option of continuing treatment per below 
while awaiting radiologic confirmation of progression.  If repeat imaging shows a reduction in 
the tumor burden compared to the initial scan demonstrating PD, treatment may be continued as 
per treatment calendar.  If repeat imaging confirms progressive disease, subjects will be 
discontinued from study therapy (exception noted in Table 3).  In determining whether or not the 
tumor burden has increased or decreased, Investigators should consider all target lesions as well 
as non-target lesions. Refer to Appendix B for additional information.
&(/*(1(35235,(7$5<,1)250$7,21
ed d 
f ata
line
line
ndicated 
ndicated 
w l lesi
esion
on. An
A
he same m
e same m
out the stud
out the stud
elays or u
lays or uns
n
ed for del
d for d a
indicated. C
dicated. 
slice thickn
slice thic
orithm.
ithm.
(CR or PR
(CR or PR
duled scan,
uled scan
ng to irRE
ng to irRE
med using i
ed using 
nit
nitioions o
ns of i
ease and T
ase and T
such as pem
uch as pe
s cancer
s cancer-sp
s
y extend be
extend 
y
anifest as a
nifest as a
of new lesi
of new lesi
c imaging 
c imaging 
rder to con
r to co
await
awaiting r
ng
 tumor bur
tumor bur
per treatm
per treatm
disconti
scont


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
40
CC-486-NSCL-001 Final: 15 May 2015
When feasible, subjects should not be discontinued until progression is confirmed; however, the 
decision to continue study treatment after the 1st evidence of disease progression is at the 
Investigator’s discretion based on the clinical status of the subject as described in Table 3.  
Subjects may receive study treatment while waiting for confirmation of PD if they are clinically 
stable as defined by the following criteria:
!
Absence of signs and symptoms indicating disease progression
!
No decline in ECOG performance status
!
Absence of rapid progression of disease
!
Absence of progressive tumor at critical anatomical sites (eg, cord compression) 
requiring urgent alternative medical intervention
Table 3:
Imaging and Treatment after Site-Assessed 1st Radiologic Evidence of PD
Clinically Stable
Clinically Unstable
Imaging
Treatment
Imaging
Treatment
Site based 
assessment 
indicates PD
Repeat imaging at 
≥4 weeks at site to 
confirm PD
May continue 
study treatment at 
the Investigator’s 
discretion while 
awaiting 
confirmatory scan 
by site
Repeat imaging at 
≥4 weeks to 
confirm PD per 
physician 
discretion only
Discontinue 
treatment
Repeat scan 
confirms PD
No additional 
imaging required
Exceptions as per 
note*
Discontinue 
treatment
Exceptions as per 
note*
No additional 
imaging required
N/A
Repeat scan shows 
SD, PR or CR
Continue regularly 
scheduled imaging 
assessments
Continue study 
treatment at the 
Investigator’s 
discretion
Continue regularly 
scheduled imaging 
assessments
May restart study 
treatment if 
condition has 
improved and/or 
clinically stable 
per Investigator’s 
discretion
* Note:  If progression is confirmed per irRECIST, the subject remains clinically stable and per the Principal 
Investigator is achieving extraordinary clinical benefit, the Principal Investigator may discuss with the Sponsor to 
consider a potential exception.
6.5.
Pharmacokinetics
At specific sites, for the first 10-12 subjects randomized to each Arm, mandatory 
pharmacokinetics will be collected. Blood samples for CC-486 PK assessment will be collected 
on Day 1 of Cycle 1 and Cycle 2 prior to the dose administration of CC-486/placebo, known as 
predose, and over the 8-hour period following each dose administration of CC-486/placebo at 
0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, and 8 hours post-dose (see Table 4).  These samples will be 
analyzed centrally.
&(
t
(/*(1(35235,(7$5<,1)250$7,21
ion) 
n) 
dence of P
dence of P
ally Unstab
ally Unstab
25
g
)2
)2
1)2
an
an
maging at 
aging a
eeks to
k
nfirm PD pe
nfirm PD
physician
physician
discretio
discretio
1
7$
1
nue
nue
ent
ent
xceptions as
xceptions as
note
not *
(7
2
7
ly 
aging
aging
s
Contin
Contin
trea
trea
I
23
1
52
ion is confirm
ion is confirm
achieving ex
chieving ex
otential exce
otential exce
Phar
har
specific s
specific s
pharmaco
pharmaco
n Day
n Day


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
41
CC-486-NSCL-001 Final: 15 May 2015
Table 4:
Schedule of Pharmacokinetic Blood Sample Collection in the 
Pharmacokinetics Phase
Nominal Times
Acceptable Deviation Window
Predose
≤ 60 min
0.25 hr
± 3 min
0.5 hr
± 3 min
1 hr
± 3 min
1.5 hr
± 3 min
2 hr
± 3 min
2.5 hr
± 3 min
Nominal Times
Acceptable Deviation Window
3 hr
± 3 min
3.5 hr
± 3 min
4 hr
± 3 min
6 hr
± 20 min
8 hr
± 20 min
6.6.
Biomarkers
Tumor, blood and serum will be collected to explore the hypothesized mechanism of CC-486 
priming to pembrolizumab efficacy, and potentially identify biomarkers to predict patients that 
would benefit from this therapeutic regimen. Fresh tumor biopsy is the preferred tissue for these 
analyses; however archival formalin fixed, paraffin embedded (FFPE) blocks may be provided 
instead. Archival or fresh tumor tissue is mandatory at screening, but it is optional at Cycle 2 
Day 14 -/+ 7 days. Blood, serum and saliva will also be collected at time point detailed in the 
schedule of events.
Details regarding the collection, storage, and shipment of the samples are provided in the 
Laboratory Manual. A separate consent will be provided.
6.7.
12-lead Electrocardiogram
Triplicate 12-lead ECGs will be recorded at screening and EOT and will be assessed locally.  
The 12-lead ECGs (12-lead at 25 mm/sec reporting rhythm, ventricular rate, PR-interval, QRS 
complex, QT interval, and QTc interval) will be performed after the subject has been in the 
supine position for at least 5 minutes.
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$7
0$
50
ion Window
ion Wind
25
min
min
)2
± 3 min
± 3 min
1)
± 3 m
< ,1
±
5<
$5
7$
explore the 
explore the
otentially id
otentially i
men. Fresh
men. Fre
fixed, para
fixed, pa
ssue
ssue is man
m
m and saliv
and saliv
llect
llection, sto
n, s
A separate 
A separat
lead E
ead Elec
lec
12-lead EC
lead EC
lead ECGs 
lead ECGs
plex, QT int
plex, QT in
pine p
pine posi
osititi
i


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
42
CC-486-NSCL-001 Final: 15 May 2015
7.
STUDY POPULATION
7.1.
Number of Subjects and Sites
A total of approximately 90 adult subjects with locally advanced or metastatic NSCLC who have 
been treated with one prior platinum-based chemotherapy regimen will be randomized. The 
study will be conducted at sites globally.
7.2.
Inclusion Criteria
Subjects must satisfy the following criteria to be enrolled in the study:
1. Subject is ≥ 18 years of age at the time of signing the informed consent form.
2. Subject has histologically or cytologically confirmed squamous or non-squamous 
NSCLC.
3. Subject has stage IIIB or IV NSCLC (American Joint Committee on Cancer [AJCC] 
Staging Manual, 7th edition [Edge, 2009])  and was pretreated with 1 prior systemic
platinum based chemotherapy.
4. Subject has provided a formalin fixed tumor tissue sample from a biopsy of a tumor 
lesion either at the time of or after the diagnosis of metastatic disease has been made 
AND from a site not previously irradiated to assess for PD-L1 status. Fine needle 
aspirates, endobronchial ultrasound (EBUS) or cell blocks are not acceptable. Needle or 
excisional biopsies, or resected tissue is required.  Archival tissue may be acceptable. 
Submission of formalin-fixed paraffin embedded tumor tissue sample blocks are 
preferred; if submitting unstained slides, the slides should be freshly cut and submitted to 
the testing laboratory within 14 days from site slide sectioning date otherwise a new 
specimen will be requested.
5. Subject has radiographically-documented measurable disease, as per RECIST 1.1.
6. Subject has an ECOG performance status of 0 to 1.
7. Subject has adequate organ functions, evidenced by the following:
a.
AST (SGOT), ALT (SGPT) ≤ 2.5 x upper limit of normal range (ULN), or ≤ 5 x ULN 
range if liver metastasis present
b. Total bilirubin ≤ 1.5 x ULN
c.
Serum creatinine ≤ 1.5 x ULN
d. Potassium within normal range, or correctable with supplements
8. Subject has adequate bone marrow function, evidenced by the following:
a.
Absolute neutrophil count ≥ 1.5 x 109 cells/L
b. Platelets ≥ 100 x 109 cells/L 
c.
Hemoglobin ≥ 9 g/dL
d. International normalized ratio (INR) or prothrombin time (PT) ≤1.5 x ULN unless 
subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic 
range of intended use of anticoagulants
&(/*(1(35235,(7$5<,1)250$7,21
m.
squamous
squamou
ee on Canc
ee on Can
ed with
with 1 p
mple fro
mple from
metastati
etastatic
ess
ess fo
for PD
r PD
or cell bloc
or cell bl
equired.  Ar
quired.  A
embedded 
embedded 
ides, the sli
des, the sl
days from si
ays from
lly
lly-docum
docum
performan
performan
uate organ f
uate orga
OT), ALT (
OT), ALT
f liver meta
f liver meta
l bili
bili
l
rubin
rubin
i
erum
erum c
m reat
rea
Potassi
Potassiui
Subject h
Subject
a.a
A
b.b


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
43
CC-486-NSCL-001 Final: 15 May 2015
e.
Activated partial thromboplastin time (aPTT) ≤1.5 x ULN unless subject is receiving 
anticoagulant therapy as long as PT or PTT is within therapeutic range of intended 
use of anticoagulants
9. Female of childbearing potential (FCBP) (defined as a sexually mature woman who 1) 
has not undergone a hysterectomy (the surgical removal of the uterus) or bilateral 
oophorectomy (the surgical removal of both ovaries) or, 2) if ≥ 45 years old has not been 
naturally postmenopausal for at least 24 consecutive months (ie, has had menses at any 
time during the preceding 24 consecutive months)) must:
a.
Have two negative pregnancy tests as verified by the Investigator prior to starting 
study therapy. She must agree to ongoing pregnancy testing during the course of the 
study, and after end of study treatment. This applies even if the subject practices true 
abstinence* from heterosexual contact.
b. Either commit to true abstinence* from heterosexual contact (which must be 
reviewed on a monthly basis) or agree to use, and be able to comply with two 
effective methods of contraception without interruption, 28 days prior to starting IP, 
during the study therapy (including dose interruptions), and for 120 days after 
discontinuation (or longer if required by local requirements) of study therapy. The 
two methods of contraception can either be two barrier methods or a barrier method 
plus a hormonal method to prevent pregnancy.
10. Male subjects must practice true abstinence* (which must be reviewed on a monthly 
basis) or agree to the use a condom during sexual contact with a pregnant female or a 
female of childbearing potential while participating in the study, during dose 
interruptions and for at least 3 months following investigational product discontinuation 
(or longer if required by local requirements), even if he has undergone a successful 
vasectomy. 
* True abstinence is acceptable when this is in line with the preferred and usual lifestyle 
of the subject. Note: Periodic abstinence (eg, calendar, ovulation, symptothermal, post-
ovulation  methods) and withdrawal are not acceptable methods of contraception.
11. Subject is willing to adhere to the study visit schedule and other protocol requirements.
12. Subject understands and voluntarily signs an informed consent document prior to any 
study related assessments/procedures are conducted.
7.3.
Exclusion Criteria
The presence of any of the following will exclude a subject from enrollment:
1. Subject has known sensitizing EGFR and/or positive ALK mutation.
2. Subject has been previously treated with azacitidine (any formulation), decitabine, or any 
other hypomethylating agent.
3. Subject has received prior therapy with any other anti-PD-1, or PD-L1 or PD-L2 agent or 
an antibody targeting other immuno-regulatory receptors or mechanism, including 
participation in any other pembrolizumab trial and treatment with pembrolizumab.
&(/*(1(35235,(7$5<,1)250$7,21
arting
arting
e of the
of the
actices true
actices true
which must 
which mus
mply wit
mply with h t
days prior to
ys prio
nd for 
d for 120 d
120 d
ments) of stu
ents) of st
ier method
er m
hich must b
ch must
xual contac
xual contac
cipat
ipa ing in
ing in
ollo
llowing in
wing i
ements), ev
ments), ev
le when thi
le when
dic abstin
abstinen
d wi
with
th
i drawa
drawa
 adhere to 
adhere to
ands and vo
ands and v
asses
assessmen
smen
clusion C
clusion 
nce of any o
ce of any 
Subject 
Subject h
2.2. Subje
Subje
oth
oth
3


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
44
CC-486-NSCL-001 Final: 15 May 2015
a.
Examples of such antibodies include (but are not limited to) antibodies against 
indoleamine 2,3-dioxygenase (IDO), PD-L1, IL-2R, glucocorticoid-induced 
tumor necrosis factor receptor (GITR).
4. Subject has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who 
has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to agents 
administered more than 4 weeks earlier.
5. Subject is currently participating and receiving study therapy or has participated in a 
study of an investigational agent and received study therapy or used an investigational 
device within 4 weeks prior to administration of pembrolizumab and CC-486
6. Subject has previous severe hypersensitivity reaction to another monoclonal antibody 
(mAb).
7. Subject has a known or suspected hypersensitivity to azacitidine, mannitol, or any other 
ingredient used in the manufacture of CC-486 (see the Azacitidine IB).
8. Subject has had radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks 
prior to starting IP, and/or from whom ≥ 30% of the bone marrow was irradiated.
9. Subject has received radiation therapy to the lung that is > 30 Gy within 6 months of the 
first dose of trial treatment
10. Subject has received a live-virus vaccination within 30 days of planned treatment start. 
Seasonal flu vaccines that do not contain live virus are permitted.
11. Subject has not recovered from the acute toxic effects of prior anticancer therapy, 
radiation, or major surgery/significant trauma.
12. Subject has an active infection requiring therapy.
13. Subject has had an allogenetic tissue/solid organ transplant.
14. Subject has active autoimmune disease that has required systemic treatment within the 
past 2 years (eg, with use of disease modifying agents, corticosteroids or 
immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic 
corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not 
considered a form of systemic treatment.
15. Subject has known active Hepatitis B, Hepatitis C or tuberculosis. Active Hepatitis B is 
defined as a known positive HBsAg result.  Active Hepatitis C is defined by a known 
positive Hep C Ab result and known quantitative HCV ribonucleic acid (RNA) results 
greater than the lower limits of detection of the assay.
16. Subject has had any other malignancy within 5 years prior to randomization, with the 
exception of adequately treated in situ carcinoma of the cervix, uterus, or non-
melanomatous skin cancer (all treatment of which should have been completed 6 months 
prior to enrollment).
17. Subject has a history of inflammatory bowel disease (eg, Crohn’s disease, ulcerative 
colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other 
gastrointestinal disorder or defect that would interfere with the absorption, distribution, 
&(/*(1(35235,(7$5<,1)250$7,21
tibody
ibody
ol
ol, or any
, or an
B).
B).
fo
for palliat
r pal
i
row was ir
row was ir
> 30 Gy
30 Gy wi
wi
y
ti
n 30 days o
n 30 days 
rus are perm
rus are per
xic effects 
xic effects
auma.
auma.
ring therap
ring therap
ssue/so
ssue/solid o
lid
une disease
ne diseas
of disease 
of disease
rugs). Repl
rugs). Rep
cement the
ement th
m of sys
m of system
te
known acti
nown acti
s a known p
s a known 
ve Hep C A
Hep C A
ater than th
ter than th
Subject ha
Subject ha
excepti
excepti
mela
mel
p
1


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
45
CC-486-NSCL-001 Final: 15 May 2015
metabolism, or excretion of the IP and/or predispose the subject to an increased risk of 
gastrointestinal toxicity.
18. Subject has persistent diarrhea or clinically significant malabsorption syndrome or known 
sub-acute bowel obstruction ≥ Grade 2, despite medical management
19. Subject has significant active cardiac disease within the previous 6 months including 
unstable angina or angina requiring surgical or medical intervention, significant cardiac 
arrhythmia, or New York Heart Association (NYHA) class 3 or 4 congestive heart 
failure.
20. Subject has history of interstitial lung disease (ILD) OR a history of pneumonitis that has 
required oral or IV steroids. Subjects whose pneumonitis was solely as a result of 
radiation therapy for their NSCLC would not be excluded from the study unless they 
received oral/IV steroids to manage the pneumonitis.
21. Subject has a known history or current diagnosis of human immunodeficiency virus 
(HIV) infection, regardless of treatment status.
22. Subject has any other concurrent severe and/or uncontrolled medical condition that 
would, in the Investigator’s judgment, contraindicate patient participation in the clinical 
study (eg, chronic pancreatitis, etc.).
23. Subject with uncontrolled or symptomatic central nervous system (CNS) metastases
and/or carcinomatous meningitis
!
Subjects with controlled and asymptomatic CNS metastases may participate in this 
trial. The patient must have completed any prior treatment for CNS metastases (must 
include radiotherapy and/or surgery) ≥ 28 days (≥ 14 days for stereotactic 
radiosurgery) and, if on corticosteroid therapy, should be receiving a stable dose of no 
greater than 4 mg/d dexamethasone (or equivalent anti-inflammatory potency of 
another corticosteroid) for at least 14 days before start of study treatment
24. Subject has not recovered from the acute toxic effects (Common Terminology Criteria for 
Adverse Events [CTCAE] grade ≤ 1) of prior anticancer therapy, radiation, or major 
surgery/significant trauma (except alopecia or other toxicities not considered a safety risk 
for the subject at the Investigator’s discretion).
25. Subject has an impaired ability to swallow oral medication.
26. Subject is pregnant or breast feeding.
27. Subject has any condition that confounds the ability to interpret data from the study.
28. Subject is or has an immediate family member (spouse or children) who is investigational 
site or sponsor staff directly involved with this trial, unless prospective Institutional 
Review Board (IRB) approval (by chair or designee) is given allowing exception to this 
criterion for a specific subject.
hat has
hat has
of 
of 
less they
less they
eficienc
eficiency y v
medica
edical con
l con
nt participa
t particip
ervous syst
rvous sy
tic CNS me
tic CNS m
d any
any pri
pri
y
or 
or
y) )y ≥ 28 day
≥ 28 day
teroid thera
eroid thera
hasone (or e
hasone (o
at least 14
at least
fro
from the a
e 
AE] grade 
AE] grade ≤
rauma (exc
auma (ex
the I
th
nvest
nve i
an impaired
n impaire
s pregnant 
s pregnant
ect has any
ect has any
Subject i
Subject is o
s 
sisite or sp
te or s
i
Revie
Revie
cri
cri


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
46
CC-486-NSCL-001 Final: 15 May 2015
8.
DESCRIPTION OF STUDY TREATMENTS
8.1.
Description of Investigational Products
Subjects will receive CC-486 plus pembrolizumab or pembrolizumab plus placebo during the 
study.  CC-486 and matching placebo will be double blind whereas pembrolizumab will be open 
label. CC-486 and pembrolizumab are designated as IPs.  All IPs must be stored in an area free 
of environmental extremes and a secured area to prevent unauthorized access, as directed on the 
package label. A temperature log must be maintained.
8.1.1.
CC-486 (Oral Azacitidine)/Placebo
The study sponsor, Celgene Corporation will supply CC-486 and placebo 150 and 200-mg 
tablets for oral administration. Sufficient quantities of IP will be supplied by Celgene and should 
be stored as directed on the label. All tablets will be packaged in blister packs. Each tablet is 
formulated using excipients that are generally regarded as safe and used in marketed drug 
products.  A list of excipients included in the formulations is provided in the azacitidine IB.  
8.1.2.
Pembrolizumab
Pembrolizumab (50 mg lyophilized powder in single-use vial for reconstitution) for IV 
administration will be sourced by the study sponsor (Celgene Corporation) from 
 
 and labeled for clinical trial use.  Sufficient quantities of IP will be supplied by 
Celgene and should be stored as directed on the label.  Pembrolizumab will be administered in 
the clinic.
The Pharmacy Manual contains specific instructions for pembrolizumab dose calculation, 
reconstitution, preparation of the infusion fluid, and administration.
8.2.
Treatment Administration and Schedule
Subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or pembrolizumab plus 
placebo. CC-486/placebo will be administered at a dose of 300 mg orally daily on days 1-14 of a 
21-day cycle.
During scheduled site visits the subjects must arrive to the clinic in the fasting state (ie, no food 
or drink [except water] for approximately 8 - 10 hours) for all predose safety laboratory 
evaluations. Dose administration should take place after all scheduled predose safety assessments 
are completed.
Subjects will ingest CC-486/placebo with approximately 240 mL (8 ounces) of room temperature 
water.  CC-486/placebo may be taken on an empty stomach or with food (a light breakfast or 
meal of up to approximately 600 calories).
If following CC-486/placebo administration an emesis event occurs, subjects should not take 
additional drug on that same day. It is recommended that the subject receives an antiemetic 30 
minutes prior to all subsequent CC-486 doses.
Pembrolizumab will be administered as a 30-minute IV infusion at a dose of 200 mg (4 x 50 mg 
vials) on Day 1 of a 21-day cycle. Sites should make every effort to target infusion timing to be 
&(/*(1(35235,(7$5<,1)250$7,21
the
d 200-
200-mg
mg
Celgene an
elgene an
cks. Each t
cks. Each t
in markete
mark
d in the aza
d in the aza
al fo
for recon
r recon
gene Corpo
ene Cor
nt quant
nt quantititiei
el.  Pembro
el.  Pembr
tructions fo
tructions fo
fluid, and
fluid, and
tration a
ration 
1 to receive
 to receive
ll be admin
ll be adm
e visits the 
visits th
water] for ap
ter] for ap
se adminis
se admi
ed.
ed.
s will inges
 will inge
.  CC
.  CC-486
86/
eal of up to
eal of up to
If fof llow
didititi
i


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
47
CC-486-NSCL-001 Final: 15 May 2015
as close to 30 minutes as possible. However, given the variability of infusion pumps from site to 
site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time of 24-40 minutes).
Pembrolizumab should be co-administered with CC-486.
For subjects enrolled in the PK population, the treatment administration on PK days (i.e., Day 1 
of Cycle 1 and Cycle 2) is described below:
!
After performing the required overnight fast, taking antiemetic premedication with 
240 mL of water for nausea and vomiting (eg, ondansetron), and completing the 
required predose assessments (including the predose PK sample), subjects will ingest 
CC-486/placebo with 240 mL of room temperature water in the clinic approximately 
30 minutes after antiemetic administration on each PK dosing day.  Each dose of   
CC-486/placebo should be given at approximately the same time each day.  The exact 
date and time of dosing will be recorded in the source documents and appropriate 
CRF.
!
On Day 1 of Cycle 1 only, pembrolizumab will be administered as described above, 
but administration will start after the 6 hour CC-486 PK sample collection time-point.
Dietary restrictions on PK days (i.e., Day 1 of Cycle 1 and Cycle 2): 
!
Subjects should be instructed to limit their coffee intake to one 8-ounce cup of black 
coffee (no cream or sugar) and to not consume alcohol, tea, chocolate, or cola 
beverages within 2 hours prior to collecting PK samples.
!
Subjects should not ingest food for a minimum of 8 hours prior and 2 hours after CC-
486/placebo is administered.  Water can be allowed as desired except for 1 hour 
before and after CC-486/placebo administration.  The only water permitted in the 1-
hour period before CC-486/placebo administration is the 240 mL of water for 
antiemetic ingestion.
8.2.1.
Dose Adjustment Guidelines
8.2.1.1.
CC-486 (oral azacitidine)/Placebo
For CC-486/placebo, a maximum of 1 dose reduction will be allowed from the original dose (eg, 
patients can dose reduce from 300 mg/placebo oral daily dose to 200 mg/placebo oral daily 
dose). Re-escalation to the higher dose is not permitted. If a subject requires more than 1 dose 
reduction for CC-486/placebo, they will be discontinued from CC-486/placebo, however, they 
may continue to receive pembrolizumab (and conversely, subjects who discontinue 
pembrolizumab may continue to receive CC-486/placebo) but must continue to undergo all 
safety and efficacy assessments as per  Table 2.
CC-486/placebo may be withheld for up to 7 days between the end of 1 cycle and the start of the 
next cycle to allow hematologic criteria to recover sufficiently for the next cycle to begin.
The maximum number of days that a dose may be withheld without requiring a dose reduction is 
7 days.
The maximum number of days that a dose may be withheld due to unacceptable toxicity before a 
subject is permanently discontinued from CC-486 is 14 days.For the purposes of dose 
adjustments, unacceptable toxicity will be defined as any AE that is deemed by the Investigator 
&(/*(1(35235,(7$5<,1)250$7,21
gest 
st
mately
mately
e of  
of  
y.  The exa
y.  The exa
app
ppropri
ropriate
ate
d as describ
as describ
mple co
mple collect
lle
:
take to one
ake to
cohol, tea, 
cohol, tea,
K samples.
K samples.
imum of 8 h
mum of 
n be allo
n be allowe
w
ministrati
ministratio
bo adminis
bo adminis
elines
lines
itidine)
idine)/P
/Pl
ximum of 
imum of 
e fro
 fr m 300
30
to the high
o the hig
486
86/placeb
/placeb
o receiv
o receive p
e
mab may co
mab may c
d efficacy 
fficacy
86/
86 plpl
/ acebo
aceb
ext cy
ext cycle to
cle to
The m
The max
a
day


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
48
CC-486-NSCL-001 Final: 15 May 2015
to be related to CC-486/placebo that poses a medical risk or substantial discomfort to the subject 
including, but not limited to, Grade 3 or 4 hematologic or non-hematologic toxicity. Subjects 
should be discontinued after the 3rd episode.
See Section 8.2.1.2 and Table 6 for dose modification guidelines for pembrolizumab drug-related 
adverse events for overlapping toxicity events for all IPs.
Please refer to Table 5 for the Dose Adjustment Guidelines.
Table 5:
CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity
Toxicity
Recommendation
Grade 2 hematologic toxicity causing delay to the 
planned start of a Cycle
Absolute Neutrophil Count (ANC) < 1.5 x 109/L
Platelets < 75 x 109/L
Hold CC-486/placebo until ANC & Platelets 
≤ Grade 1
Delay ≤ 7 days, resume CC-486/placebo at same 
dose
Delay 8 – 14 days, reduce CC-486/placebo by 100 
mg
Delay > 14 days, permanently discontinue from 
study
Grade 3 neutropenia or thrombocytopenia causing 
delay to the planned start of a Cycle ANC 0.5-0.99 
x 109/L
Platelets 25-49 x 109/L
Hold CC-486/placebo until ANC & Platelets 
recover to ≤Grade 1 (ANC ≥ 1.5 x 109/L, Platelets 
≥ 75 x 109/L)
Recovery in ≤ 7 days, resume CC-486/placebo at 
same dose
Recovery in 8–14 days, reduce CC-486/placebo by 
100 mg
No recovery by 14 days, permanently discontinue 
from study
Grade 4 neutropenia or thrombocytopenia causing 
delay to the planned start of a Cycle
ANC < 0.5 x 109/L
Platelets < 25 x 109/L
For ANC < 0.5 x 109/L
The initiation of G-CSF is left at the Investigator’s 
discretion. If initiated administer G-CSF per 
institutional practice or package insert and continue 
until ANC recovers to ≥ 2.0 x 109/L
Hold CC-486/placebo until ANC & Platelets 
recover to ≤Grade 1
(ANC ≥ 1.5 x 109/L, Platelets ≥ 75 x 109/L)
Recovery in ≤ 7 days, reduce CC-486/placebo by 
100 mg
No recovery by 7 days, permanently discontinue 
from study
&(/*(1(3523
enia causing
ia causin
e
CSF is left at
CSF is left a
ated admini
ated admini
235,(7$5<,1)250$7,21
$7
$7
$7
elets
elet
placebo at s
placebo at s
CC-486/
CC-486/pla
pla
/
rmanently d
manently d
0$
6/6/placebo
placebo
/
un
≤Grade 1 
Grade 1
109/L)
/L)
covery in
covery in ≤ 
ame dose
ame dose
Recov
Recoverer
100 m
100 m
N
<
5,
actice or pac
ctice or pa
ecovers to
covers to ≥
23
/*


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
49
CC-486-NSCL-001 Final: 15 May 2015
Table 5:
CC-486/Placebo Dose Adjustment and Dose Delays for Toxicity (Continued)
Toxicity
Recommendation
Grade 3 or 4 Nausea or Vomiting
Grade 3 or 4 Diarrhea
Grade 3 or 4 Fatigue/Asthenia
Hold until resolution to ≤ Grade 1 and provide 
optimal medical management
If response ≤72 hours (3 days), and recovery ≤ 7 
days, reintroduce CC-486/placebo at 200 mg
If event recurs after re-challenge at 200 mg, 
discontinue CC-486/placebo
If no recovery by 7 days, discontinue CC-
486/placebo
Grade 3 or 4 any other non-hematologic toxicity
Hold until resolution to ≤ Grade 1 and provide 
optimal medical management
If recovery ≤ 7 days, reintroduce CC-486/placebo 
at 200 mg
If event recurs after re-challenge at 200 mg, 
discontinue CC-486/placebo
If no recovery by 7 days, discontinue CC-
486/placebo
Renal dysfunction - For any unexplained 
reductions in serum bicarbonate levels to < 20 
mEq/L or unexplained elevations of BUN and/or 
serum creatinine (> 20%) from baseline
Hold until resolution to ≤ baseline level (+/- 20%) 
Reduce CC-486 dose in the next cycle of treatment 
to the next lower dose level 
If similar unexplained renal and/or electrolyte 
disturbances subsequently persist or recur, 
discontinue CC-486
ANC = absolute neutrophil count; ASCO = American Society of Clinical Oncology; BUN = blood urea nitrogen; ESMO =
European Society for Medical Oncology; G-CSF = granulocyte colony stimulating factor.
Note: The initiation of G-CSF is left at the Investigator’s discretion.
Note: Granulocyte colony stimulating factor (G-CSF) should only be utilized in accordance to ASCO or ESMO 
recommendations.
Note: If Grade 3 or 4 neutropenia associated with fever or Grade ≥ 3 thrombocytopenia with clinically significant bleeding 
occurs at any time, the dose adjustment guidelines for Grade 4 hematological toxicity should be enacted.
Note: If neutropenia is associated with fever and severe diarrhea, subject should be managed appropriately according to the local 
practice. In case of recurrence of the diarrhea with neutropenia and fever, the continuation of the subject in the study should be 
discussed on a case-by-case basis with the sponsor’s study monitor.
8.2.1.2.
Pembrolizumab
Adverse events associated with pembrolizumab exposure may represent an immunologic 
etiology.  These adverse events may occur shortly after the first dose or several months after the 
last dose of treatment. Pembrolizumab must be withheld for drug-related toxicities and severe or 
life-threatening AEs as per Table 6 below. Dose reductions are not permitted for pembrolizumab.
&(/*(1(35235,(7$5<,1)250$7,21
C-
$7
 1 and prov
1 and pro
troduce CC
roduce 
re-challeng
challe
486/6 placebo
eb
/
ry by 7 days
ry by 7 day
bo
5
until resolu
until resolu
educe CC
educe CC-4
to the next
to the next
If simil
If simi
distu
dist
d
$5
235,
American So
American So
gy
gy; G
; G-CSF = 
CSF =
at the
at th Investig
Invest
ting factor (G
acto
f
penia associat
penia associ
dose adjustme
dose adjustme
associated
associated w
of recurrence o
f recurrence
case
case-by-
-by-case 
ase 
Pembr
Pembr
verse eve
erse even
etitiol
ology
ogy.  T
.  T
last dose
ast dos
th


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
50
CC-486-NSCL-001 Final: 15 May 2015
Table 6:
Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events
Toxicity
Hold 
Treatment 
For Grade
Timing for Restarting 
Treatment
Treatment Discontinuation
Diarrhea/Colitis
2-3
Toxicity resolves to 
Grade 0-1.
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
4
Permanently discontinue
Permanently discontinue
AST, ALT, or 
Increased Bilirubin
2
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose.
3-4
Permanently discontinue
(see exception below)1
Permanently discontinue
Type 1 diabetes 
mellitus (T1DM), if 
new onset, or 
Hyperglycemia
T1DM or
3-4
Hold pembrolizumab for 
new onset Type 1 
diabetes mellitus or 
Grade 3-4 hyperglycemia 
associated with evidence 
of beta cell failure.
Resume pembrolizumab when 
patients are clinically and 
metabolically stable.
Hypophysitis
2-4
Toxicity resolves to 
Grade 0-1. Therapy with 
pembrolizumab can be 
continued while 
endocrine replacement 
therapy is instituted
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
Hyperthyroidism 
3
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
4
Permanently discontinue
Permanently discontinue
Hypothyroidism
Therapy with 
pembrolizumab can be 
continued while thyroid 
replacement therapy is 
instituted
Therapy with pembrolizumab can be 
continued while thyroid replacement 
therapy is instituted.
Infusion Reaction
3-4
Permanently discontinue
Permanently discontinue
&(
Infusion R
nfusion R
&(/*(1(35235,(7$5<,1)250$7,21
t per 
per 
$7
e
0$
esolve withi
esolve withi
e.
50
tly discontin
y disco
)2
a 
nce
ce
Resume pem
Resum
patients a
patients 
metab
metab
,1
$5
ves to
ves to
Therapy wi
Therapy w
izumab can 
izumab can
nued while
ued while
docrine repl
ocrine rep
therapy is in
therapy is
7$
3
To
2
1
5
1(
(1
roidism
ism
(1
(1
(1
&(
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
51
CC-486-NSCL-001 Final: 15 May 2015
Table 6:
Dose Modification Guidelines for Pembrolizumab Drug-Related Adverse 
Events (Continued)
Toxicity
Hold 
Treatment 
For Grade
Timing for Restarting 
Treatment
Treatment Discontinuation
Pneumonitis
2
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per
day within 12 weeks.
3-4
Permanently discontinue
Permanently discontinue
Renal Failure or 
Nephritis
2
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
3-4
Permanently discontinue
Permanently discontinue
All Other Drug-
Related Toxicity2
3 or Severe
Toxicity resolves to 
Grade 0-1
Toxicity does not resolve within 12 
weeks of last dose or inability to 
reduce corticosteroid to 10 mg or 
less of prednisone or equivalent per 
day within 12 weeks.
4
Permanently discontinue
Permanently discontinue
Note: Permanently discontinue for any severe or Grade 3 drug-related AE that recurs or any life-threatening event.
1 For patients with liver metastasis who begin treatment with Grade 2 AST or ALT, if AST or ALT increases by 
greater than or equal to 50% relative to baseline and lasts for at least 1 week then patients should be discontinued.
2 Patients with intolerable or persistent Grade 2 drug-related AE may hold IP at physician discretion.  Permanently 
discontinue IP for persistent Grade 2 adverse reactions for which treatment with IP has been held, that do not 
recover to Grade 0-1 within 12 weeks of the last dose.
After the first cycle, each drug may be given independently on a cyclical regimen according to 
the protocol-defined dose interruptions/delays for CC-486/placebo or pembrolizumab as defined 
in Section 8.2.1 above. Dosing interruptions are permitted in the case of medical / surgical events 
or logistical reasons not related to study therapy (eg, elective surgery, unrelated medical events, 
patient vacation, and/or holidays). Subjects should be placed back on study therapy within 3 
weeks of the scheduled interruption, unless otherwise discussed with the Sponsor. The reason for 
interruption should be documented in the patient's study record.
8.2.2.
Overdose
Overdose, as defined for this protocol, refers to blinded CC-486 and/or pembrolizumab. 
For purposes of this trial, an overdose of pembrolizumab will be defined as any dose of 1,000 mg 
or greater.
For CC-486, on a per dose basis, an overdose is defined as the following amount over the 
protocol-specified dose of blinded CC-486 assigned to a given subject, regardless of any 
&(/*(1(35235,(7$5<,1)250$7,21
t per
per
$7
ue
ue
0$
resolve with
resolve with
se or inabili
or inabil
osteroid to 1
osteroid to 
dnisone or e
nisone
hin 12 week
in 12 week
50
ma
manently d
ntly d
,1
Toxicity d
Toxicity
weeks o
weeks
redu
red
lele
<
$5
y discontinu
y discontin
(7
5,(
de 3 drug
de 3 drug-rere
atment with G
atment with G
ine and lasts 
ne and lasts
de 2 drug
de 2 drug-rel
dverse reactio
verse reac
s of the last 
s of the last 
rug m
ug may be 
ay b
e interrupti
e interrup
. Dosing in
Dosing in
s not relate
s not relate
, and/or hol
, and/or ho
scheduled 
scheduled 
n shoul
should b
d b
.
Ove
Ov
Overdose, a
Overdose, a
For pur
or pur


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
52
CC-486-NSCL-001 Final: 15 May 2015
associated adverse events or sequelae. On a schedule or frequency basis, an overdose is defined 
as anything more frequent than the protocol required schedule or frequency.
Complete data about drug administration, including any overdose, regardless of whether the 
overdose was accidental or intentional, should be reported in the case report form. See Section 
11.1 for the reporting of adverse events associated with overdose.
8.3.
Method of Treatment Assignment
Subjects who enter screening will be assigned the next available subject number. All eligible 
subjects will be randomized by IRT to receive CC-486 plus pembrolizumab or placebo plus 
pembrolizumab. Treatment assignment will be performed centrally.
All IP will be managed by the IRT system as a central subject number assignment and 
accountability tool only.
8.4.
Packaging and Labeling
The labels for IPs may include, but are not limited to, sponsor name, address and telephone 
number, the protocol number, IP name, dosage form and strength (where applicable), amount of 
IP per container, lot number, expiry date (where applicable), medication identification/kit 
number, dosing instructions, storage conditions, and required caution statements and/or 
regulatory statements as applicable. Additional information may be included on the label as 
applicable per local regulations.
8.5.
Investigational Product Accountability and Disposal 
Celgene (or designee) will review with the Investigator and relevant site personnel the process 
for Investigational Product return, disposal, and/or destruction including responsibilities for the 
site versus the responsibilities of Celgene (or designee).
8.6.
Investigational Product Compliance
Accurate recording of all IPs administered will be made in the appropriate section of the 
subject’s case report form (CRF) and source documents. The Investigator or designee is 
accountable for the compliance of all study-specific IPs either administered or in their custody 
during the course of the study.
&(/*(1(35235,(7$5<,1)250$7,21
s 
nd 
nd 
ddress and 
ddress and
where appli
ere appli
dicatation idid
caut
cautioion sta
n s
n may be in
may be i
ntability a
ntability a
est
estigator a
igator a
, and/or des
and/or de
ne (or desig
e (or des
oduct Com
oduct Com
administere
administer
CRF) and 
CRF) and
pliance of a
pliance o
he study
he study.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
53
CC-486-NSCL-001 Final: 15 May 2015
9.
CONCOMITANT MEDICATIONS AND PROCEDURES
9.1.
Permitted Concomitant Medications and Procedures
9.1.1.
CC-486 (oral azacitidine)
In general, the use of any concomitant medication/therapies deemed necessary for the care of the 
subject is permitted.
All concomitant treatments, including blood and blood products, must be reported on the CRF. 
Subjects may be administered supportive and palliative care (eg, pain control, anti-nausea, anti-
diarrheal) as clinically indicated throughout the study. 
Myeloid growth factors (granulocyte colony stimulating factor [G-CSF] and granulocyte 
macrophage colony-stimulating factor [GM-CSF]) should be administered according to 
American Society of Clinical Oncology (ASCO) and European Society for Medical Oncology 
(ESMO) guidelines only for the treatment of neutropenic infections.
Antiemetics are not required during the study, except for subjects enrolled in the PK population; 
at the Investigator’s discretion, subjects not enrolled in the PK population may also receive 
prophylactic antiemetic therapy (eg, a serotonin [5-HT3] receptor antagonist such as  
ondansetron) approximately 30 minutes prior to each dose of CC-486.  
Treatment with antidiarrheal medications should be prescribed at the first sign of diarrhea.  Pre-
medication with antidiarrheal medication for subsequent doses of CC-486 may be appropriate at 
the Investigator’s discretion.
9.1.2.
Pembrolizumab Supportive Care
Subjects should receive appropriate supportive care measures as deemed necessary by the 
treating Investigator.  Suggested supportive care measures for the management of adverse events 
with potential immunologic etiology are outlined below and in greater detail in the events of 
clinical interest (ECI) guidance in Appendix C. Where appropriate, these guidelines include the 
use of oral or intravenous treatment with corticosteroids as well as additional anti-inflammatory 
agents if symptoms do not improve with administration of corticosteroids.  Note that several 
courses of steroid tapering may be necessary as symptoms may worsen when the steroid dose is 
decreased. For each disorder, attempts should be made to rule out other causes such as metastatic 
disease or bacterial or viral infection, which might require additional supportive care. The
treatment guidelines are intended to be applied when the Investigator determines the events to be 
related to pembrolizumab. 
Note: if after the evaluation the event is determined not to be related, the Investigator is 
instructed to follow the ECI reporting guidance but does not need to follow the treatment 
guidance (as outlined in the ECI guidance). Refer to Table 6 for dose modification guidelines 
for pembrolizumab. 
It may be necessary to perform conditional procedures such as bronchoscopy, endoscopy, or skin 
photography as part of evaluation of the event. Suggested conditional procedures, as appropriate, 
can be found in the ECI guidance.
&(/*(1(35235,(7$5<,1)250$7,21
CRF.
CRF.
usea, ant
sea, anti-i-
ranulocyte
anulocyte
according t
according 
or Medi
r Med cal
enro
n
lled in
led in
populat
popula ion
ceptor antag
eptor anta
se of CC
e of CC-48
prescribed a
prescribe
equent dos
equent do
Care
Care
upportive c
upportiv
upportive c
upportive c
lology
gy are ou
are ou
y
nce
nce inin Appe
Appe
treatm
atment w
t
not improv
not impro
apering
ering ma
ma
ach disorde
ach disorde
teri
erial or vi
al or vi
guiuidelines a
delines a
o pembroli
o pembrol
Note: if aft
Note: if aft
instructe
instruct
guiuida
d
fofo


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
54
CC-486-NSCL-001 Final: 15 May 2015
9.1.2.1.
Management of pneumonitis
These guidelines may also be used for cases of pneumonitis that may not be related to 
pembrolizumab.
!
For Grade 2 events, treat with systemic corticosteroids. When symptoms improve to 
Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.
!
For Grade 3-4 events, immediately treat with intravenous steroids.  Administer 
additional anti-inflammatory measures, as needed.
!
Add prophylactic antibiotics for opportunistic infections in the case of prolonged 
steroid administration
9.1.2.2.
Management of Diarrhea/Colitis
Subjects should be carefully monitored for signs and symptoms of enterocolitis (such as diarrhea, 
abdominal pain, blood or mucus in stool, with or without fever) and of bowel perforation (such 
as peritoneal signs and ileus).  
!
All subjects who experience diarrhea/colitis should be advised to drink liberal 
quantities of clear fluids.  If sufficient oral fluid intake is not feasible, fluid and 
electrolytes should be substituted via IV infusion.  For Grade 2 or higher diarrhea, 
consider GI consultation and endoscopy to confirm or rule out colitis.
!
For Grade 2 diarrhea/colitis that persists greater than 3 days, administer oral 
corticosteroids. 
!
For Grade 3 or 4 diarrhea/colitis that persists > 1 week, treat with intravenous steroids 
followed by high dose oral steroids.  
!
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
9.1.2.3.
Management of type 1 diabetes mellitus (if new onset, including diabetic 
ketoacidosis [DKA]) or ≥ Grade 3 Hyperglycemia, if associated with ketosis 
(ketonuria) or metabolic acidosis (DKA)
!
For type 1 diabetes mellitus (T1DM) or Grade 3-4 Hyperglycemia
o
Insulin replacement therapy is recommended for type 1 diabetes mellitus and 
for Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria.
o
Evaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglobin, and C-peptide.
9.1.2.4.
Management of hypophysitis
!
For Grade 2 events, treat with corticosteroids. When symptoms improve to Grade 1 or 
less, steroid taper should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is tapered.
nged 
ed 
lit
litis (such 
is (such 
owel perfo
wel pe
advised to
dvised to
ake is not f
ake is no
n.  For Gra
.  For Gra
nfirm
nfirm or ru
or
m
greater th
greater than
hat persi
hat persists
sts
roids. 
roids. 
to Grade 1 
to Grad
han 4 week
an 4 wee
ype 1 diab
ype 1 diab
DKA]) or
KA]) or ≥
or metabo
or metab
e 1 di
 1 diabetes
abetes
o
Insulin 
Insul
fo
for G
r G
o
9.1.2.4.
9.1.2.4.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
55
CC-486-NSCL-001 Final: 15 May 2015
!
For Grade 3-4 events, treat with an initial dose of IV corticosteroids followed by oral
corticosteroids. When symptoms improve to Grade 1 or less, steroid taper should be 
started and continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.
9.1.2.5.
Management of hyperthyroidism or hypothyroidism
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated based 
on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
!
Grade 2 hyperthyroidism events (and Grade 3-4 hypothyroidism):
o
In hyperthyroidism, non-selective beta-blockers (eg, propranolol) are 
suggested as initial therapy.
o
In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine 
or liothyroinine, is indicated per standard of care.
!
Grade 3-4 hyperthyroidism 
o
Treat with an initial dose of IV corticosteroid followed by oral corticosteroids. 
When symptoms improve to Grade 1 or less, steroid taper should be started 
and continued over no less than 4 weeks. Replacement of appropriate 
hormones may be required as the steroid dose is tapered.
9.1.2.6.
Management of hepatic abnormalities
!
For Grade 2 events, monitor liver function tests more frequently until returned to 
baseline values (consider weekly).
o
Treat with IV or oral corticosteroids
!
For Grade 3-4 events, treat with intravenous corticosteroids for 24 to 48 hours. 
!
When symptoms improve to Grade 1 or less, a steroid taper should be started and 
continued over no less than 4 weeks.
9.1.2.7.
Management of renal failure or nephritis
!
For Grade 2 events, treat with corticosteroids.
!
For Grade 3-4 events, treat with systemic corticosteroids.
!
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
9.1.2.8.
Management of infusion reactions
See Appendix C for guidelines for subjects who experience an infusion reaction associated with 
administration of pembrolizumab.
9.2.
Prohibited Concomitant Medications and Procedures
The following concomitant medications are prohibited during the course of the study:
&(/*(1(35235,(7$5<,1)250$7,21
) are
are
 with levot
with lev
ollolowed by
ed by
s, steroid 
s, steroid ta
. Replacem
Replacem
oid dose is 
d dose 
unction test
nction tes
y).).
corti
corticoster
cost
eat with int
at with in
mprove to G
prove to G
o less than 
o less tha
ent of rena
nt of rena
ade 2 event
de 2 event
Grade 3
Grade 3-4
When sym
When sym
contntinu
inu
1.2.8.
1.2.8.
M
See
See App
Ap
min


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
56
CC-486-NSCL-001 Final: 15 May 2015
!
Cytotoxic, chemotherapeutic, targeted, hormonal, or investigational agents/therapies 
or any other anticancer treatment.
!
Vidaza (azacitidine injection), decitabine, or other demethylating agents.
!
Other PD-1 or PD-L1 inhibitors
!
Radiation therapy
o
Note:  Radiation therapy to a symptomatic solitary lesion or to the brain may 
be considered on an exceptional case by case basis after consultation with 
Sponsor.  The subject must have clear measurable disease outside the radiated 
field.  Administration of palliative radiation therapy will be considered 
clinical progression for the purposes of determining PFS.
!
Live vaccines within 30 days prior to the first dose of trial treatment and while 
participating in the trial.  Examples of live vaccines include, but are not limited to, the 
following: measles, mumps, rubella, chicken pox, yellow fever, seasonal flu, H1N1 
flu, rabies, bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza 
vaccines for injection are generally killed virus vaccines and are allowed. However, 
intranasal influenza vaccines (eg, Flu - Mist®) are live attenuated vaccines, and are 
not allowed.
!
Glucocorticoids for any purpose other than to modulate symptoms from an event of 
clinical interest, use as a pre-medication for chemotherapeutic agents specified in the 
protocol, or for use as a pre-medication in subjects with a known history of an IV 
contrast allergy administered as part of CT radiography. Replacement doses of 
steroids (for example, prednisone 5-7.5 mg daily) are permitted while on study. 
Subjects who, in the assessment by the Investigator, require the use of corticosteroids 
for any other clinical management should be discussed with medical monitor.
9.3.
Required Concomitant Medications and Procedures
Not applicable.
&(/*(1(35235,(7$5<,1)250$7,21
adiated 
diated 
ed 
and while
and while
re not limit
re not limit
, seasonal f
seasonal f
ccine.
ne. Seas
Se
and are allo
nd are all
attenuated 
ttenuated
modulate sy
dulate s
chem
emoth
othera
e
n subjects w
subject
f CT radi
CT radiog
o
7.5 m
7.5 mg dai
g da
m
by
by the I
the I
y
nve
nve
ment shoul
ment should
tant Med
ant Med


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
57
CC-486-NSCL-001 Final: 15 May 2015
10.
STATISTICAL ANALYSES
10.1.
Overview
This is a placebo-controlled, double-blind, randomized, phase 2 trial designed to estimate the 
efficacy and safety/tolerability of CC-486 plus pembrolizumab and placebo plus pembrolizumab, 
in subjects with previously treated metastatic non-small cell lung cancer. The primary endpoint is 
PFS based on Investigator review. 
The sections below lay out the proposed statistical considerations and analyses. The detail
statistical analysis methods will be documented in the statistical analysis plan (SAP).
10.2.
Study Population Definitions
10.2.1.
Intent-To-Treat Population
The intent-to-treat (ITT) population will consist of all randomized subjects.  All efficacy 
analyses will be based on the ITT population, unless otherwise specified.  The efficacy analyses 
will be performed according to treatment assigned at randomization.
10.2.2.
Safety Population
The safety population will consist of any enrolled subjects who received at least 1 dose of IP.  
All safety analyses will be based on the Safety population, unless otherwise specified.  The 
treatment groups for the safety analyses are based on the treatment as received if different from 
the pre-planned randomization.
10.2.3.
PK Population
The PK analysis population will include all randomized subjects who have evaluable 
concentration data to determine the pharmacokinetic parameters from at least 1 dose of CC-486.
10.2.4.
Biomarker Population
The biomarker analysis population will include all randomized subjects who received at least 1
dose of IP, provided consent for exploratory biomarker studies, and had at least 1 predose 
biomarker tissue collected and deemed of adequate quality for biomarker analysis. 
10.3.
Sample Size and Power Considerations
The primary goal of this study is to provide estimates of the difference in efficacy and safety 
between CC-486 plus pembrolizumab and placebo plus pembrolizumab. 
Approximately 90 subjects will be randomized 1:1 to receive CC-486 plus pembrolizumab or 
placebo plus pembrolizumab. Primary analysis will be conducted when 70 PFS events occur.
Selected hypothetical scenarios are presented in Table 7 with confidence interval and power 
estimates, when approximately 70 PFS events have occurred.
The table below demonstrates the hypothetical power of testing the null hypothesis H0: λT/ λC=1, 
against the two sided alternative H0: λT/ λC≠1,assuming that time to PFS events in both treatment 
&(/*(1(35235,(7$5<,1)250$7,21
s s 
ects.  All e
ects.  All f
ified.  The 
ed.  The 
on.n.
cts who r
cts who rec
e
atatioion, unle
n, un
on the trea
on the tre
de all ran
de all r
d
e pharmaco
e pharmaco
lation
lation
populat
populatioi n w
onsent for 
onsent for 
ollected and
ollected and
ample Siz
ample Siz
mary goal
goal
y
of
of
l
en CC
en C -486
486
pproximate
pproximate
plplacebo p
acebo p
lect


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
58
CC-486-NSCL-001 Final: 15 May 2015
arms follow exponential distributions, and λC is the monthly hazard rate of the survival 
distribution in the control arm, and  λT is the monthly hazard rate of the survival distribution in 
the experimental arm (CC-486+pembrolizumab).
Table 7:
Hypothetical Power and Resulting Two-sided 90% CI of Hazard Ratio
Combo Treatment Median PFS (month) 
5.5
5.0
4.6
Total PFS events
74
75
76
Power (%) w/two-sided α=0.10
1
82.4
71.7
59.4
HR with [two-sided 90% CI] 
0.55 [0.38,0.81]
0.60 [0.41,0.88]
0.65 [0.45,0.95]
1 These calculations assume the median PFS in pembrolizumab alone is 3.0 months (Garon, 2014). And lost to 
follow-up (to assess PFS events) rate is 10% at the end of study. 
The power calculations are conducted with East 5.4. 
10.4.
Background and Demographic Characteristics
Subjects’ age, height, weight, and baseline characteristics will be summarized using descriptive 
statistics, while gender, race and other categorical variables will be provided using frequency 
tabulations.  Medical history data will be summarized using frequency tabulations by system 
organ class and preferred term.
10.5.
Subject Disposition
Subject disposition (analysis population allocation, entered, discontinued, along with primary 
reason for discontinuation) will be summarized using frequency and percent for both treatment 
and follow-up phases.  A summary of subjects enrolled by site will be provided. Protocol 
deviations will be summarized using frequency tabulations.
10.6.
Efficacy Analysis
10.6.1.
Primary Efficacy Endpoint
The primary endpoint PFS will be defined as the time from the randomization date to disease 
progression assessed by Investigator according to RECIST version 1.1 guideline or death due to 
any cause, whichever occurs first.  
Subjects who are alive and progression-free at the cut-off date of the PFS analyses will be 
censored at the date of the last tumor evaluation.  If subjects  begin new anti-cancer therapy prior 
to documented progression, PFS will be censored at the last assessment prior to receiving the 
anti-cancer therapy. Subjects with 2 or more missing response assessments prior to a visit with 
documented disease progression (or death) will be censored at the last visit where the subject 
was documented to be PFS event-free.  A sensitivity analysis will be performed with censoring 
rules that follow the principles of assigning the date of event based on the time of the first 
evidence of objective progression or death regardless of violations, discontinuation of IP or 
change of therapy. 
PFS will be summarized by median progression-free survival time (including two-sided 90% 
confidence interval [CI]) for each treatment group and within each strata.  The hazard ratio and a 
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
45,0.95]
,0.95]
$7
$7
0$7
d lost to
lost to
mmarized us
marized u
e provided 
provided
quen
quency
c tabu
y
, entered, d
entered, d
using frequ
using fre
ts enrolled 
ts enrolled
uency tabul
uency tabu
Endpoint
Endpoint
will be de
will be de
y Invest
nv
igat
iga
r occurs fir
occurs fi
e alive and 
e alive and
e date of th
date of t
nted progre
ted progre
ncer therapy
ncer therap
mented di
ented di
as docume
as docume
rulu es that 
that 
viden
viden


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
59
CC-486-NSCL-001 Final: 15 May 2015
two-sided 90% CI will be estimated by using Cox proportional hazard model with treatment, and 
any stratification factors as model covariates.  The Kaplan-Meier curve for PFS will be presented
for each treatment group and strata.
10.6.2.
Secondary Endpoints
10.6.2.1.
Overall Survival
Overall survival (OS) will be defined as the time from the date of randomization to the date of 
death (any cause).  Subjects who are alive will be censored at the last time that the subject was 
known to be alive. The OS analysis may also be conducted at the time when 70 deaths occur, in 
addition to when the primary analysis is performed.
Medians of overall survival including two-sided 90% CI for each treatment group will be 
calculated.  The hazard ratio and a two-sided 90% CI will be estimated using Cox proportional 
hazard model with treatment, and all stratification factors in the model.  The Kaplan-Meier curve 
for survival will be presented for each strata and treatment group.
10.6.2.2.
Overall Response Rate (ORR)
Overall response rate is the percentage of subjects that achieve a confirmed complete or partial 
response as assessed by the Investigator using RECIST version 1.1 guideline. This rate will be 
presented for each treatment group and strata.  The 90% CI of the response rates will be 
provided.  A two-sided 90% CI of the Response rate differences between pembrolizumab plus 
placebo and pembrolizumab plus CC-486 arm, with each strata and overall will be provided.
10.6.2.3.
Disease Control Rate (DCR)
The percentage of disease control (i.e., confirmed SD, CR or PR) according to RECIST 1.1 will 
be analyzed in the same manner as ORR.  When SD is believed to be best response, it must meet 
the minimum duration of 18 weeks from randomization.
10.6.2.4.
irPFS, irORR and irDCR per irRECIST
Exploratory endpoints such as irPFS, irORR, and irDCR assessed by Investigator according to 
irRECIST will be analyzed using statistical methods described previously for similar primary or 
secondary endpoints.
10.6.3.
Subgroup Analysis
The effect of treatment on the efficacy variable OS, PFS, and DCR may be investigated within 
subgroups defined by selected baseline prognostic variables and any stratification factors.
The methods described in previous statistical analysis sections will be used for each subgroup 
separately. A forest plot may also be provided.
10.7.
Safety Analysis
Safety analysis will be performed using the safety population. Safety and tolerability will be 
monitored through continuous reporting of all AEs and SAEs, laboratory abnormalities, and 
incidence of subjects experiencing adverse events resulting in dose reductions, dose 
&(/*(1(35235,(7$5<,1)250$7,21
as
cur, in
ur, in
will
will be
be
ox proportio
ox proporti
Kaplan
Kapl
-Me
Me
confirmed
confirmed
on 1.1 guide
n 1.1 gui
of
of the
the
f
resp
re
fferences be
ferences b
ach
ach strata 
tra
firirmed 
med SD,
SD,
.  When SD
.  When 
om 
m rando
rand m
rDCR per
DCR per
as 
as irirPFS, 
PFS, ir
ed using sta
ed using
roup Anal
roup Ana
f treatment 
f treatment
s defined b
defined b
methods des
ethods d
parately
arately. A
. A
10.7.
0.7.


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
60
CC-486-NSCL-001 Final: 15 May 2015
interruptions, and/or premature discontinuation of study drugs. TEAEs, TEAEs leading to death 
or discontinuation from treatment, events assessed as Grade 3 or Grade 4,  vital signs, weight, 
clinical laboratory information, and concomitant medications/procedures will be tabulated and 
summarized.
Treatment-emergent adverse events will be coded according to MedDRA. All TEAEs will be 
summarized by MedDRA system organ class and preferred term, frequency, severity grade based 
on the CTCAE (Version 4.0) and relationship to treatment. Serious adverse events, events of 
interest, and events leading to discontinuation or death will be listed separately.
10.8.
Pharmacokinetic Analysis
When appropriate, plasma PK samples collected will be analyzed for CC-486 concentration 
determination using a validated high-performance liquid chromatography/tandem mass 
spectrometric method.
10.8.1.
Plasma Concentrations
By-subject listing of pharmacokinetic blood sample collection times as well as derived sampling 
time deviations will be provided.  CC-486 plasma concentrations will be summarized using 
descriptive statistics (N, arithmetic mean, standard deviation, standard error, minimum, median, 
maximum, percent coefficient of variation, geometric mean, and geometric percent coefficient of 
variation) for each cycle, if/when appropriate.  Concentrations that are below the limit of 
quantitation (BLQ) will be treated as zero for the computation of descriptive statistics. Missing 
concentrations and concentrations from blood samples collected more than ± 10% of nominal 
time will be omitted from the calculation of descriptive statistics.
Individual subject concentration-time data and mean concentration-time data for each cycle will 
be graphically presented on linear and semi-logarithmic scales.
Following single dose administration, predose samples that are BLQ or missing will be assigned 
a numerical value of zero for the calculation of AUC.  Any anomalous concentration values 
observed at predose will be identified in the clinical study report (CSR) and used for the 
computation of AUC.  Pharmacokinetic parameters will be computed if the anomalous value is
not greater than 5% of the Cmax.  If the anomalous value is greater than 5% of Cmax, the computed 
pharmacokinetic parameters for the given subject will be dropped from the pharmacokinetic 
analysis.  
Any other BLQ concentrations will be assigned a value of zero if they precede quantifiable 
samples in the initial portion of the profile.  A BLQ value that occurs between quantifiable data 
points, especially prior to Cmax, will be evaluated to determine if an assigned concentration of 
zero makes sense, or if reanalysis or exclusion of the data is warranted.  Following Cmax, BLQ 
values embedded between 2 quantifiable data points will be treated as missing when calculating 
AUC.  BLQ values occurring at the end of the collection interval (after the last quantifiable 
concentration) will be treated as missing data.  If consecutive BLQ concentrations are followed 
by quantifiable concentrations in the terminal portion of the concentration curve, these quantified 
values will be excluded from the pharmacokinetic analysis by assigning them a value of missing, 
unless otherwise warranted by the concentration-time profile.  For the purpose of analysis, these 
trailing BLQ values may be designated as zero in the dataset if the pharmacokinetic program 
&(/*(1(35235,(7$5<,1)250$7,21
tration
tration
mass 
ass 
as well as d
s well as d
will be sum
will be sum
andard erro
andard erro
and geome
and geom
tions that a
tions that a
putation of 
putation of 
les collecte
les collec
riptive stati
iptive stat
d mean co
d mean co
mi
mi-lologari
garithm
thm
i
predose sa
predos
lculat
cu
ioion o
n o
ntified in th
ntified in th
acokinetic
acokinetic
Cma
max.  If
.  
thth
f
meters for th
meters for t
concentrat
concentrat
e init
e initial po
ial po
pecially pri
cially pri
akes sense, 
kes sense,
es embedde
es embedd
AUC.  BLQ
AUC.  BLQ
concentra
oncentra
y qua
y qua


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
61
CC-486-NSCL-001 Final: 15 May 2015
used to do the analysis (such as WinNonlin®) will treat trailing zero values as missing when 
calculating AUC.
Actual sampling times will be used in the calculations of pharmacokinetic parameters that will be 
derived using noncompartmental methods with Phoenix™ WinNonlin® Professional Version 6.3, 
or higher, 
  Graphics may be prepared 
with SAS Version 9.1, or higher; or Excel 2007, or higher; Phoenix™ WinNonlin® Professional 
6.3, or higher; or S-Plus 8.2., or higher 
.
10.8.2.
Pharmacokinetic Parameters
The following PK parameters will be calculated for CC-486:
AUCinf
Area under the plasma concentration-time curve from Time 0 extrapolated 
to infinity, calculated as [AUCt + Ct/∀z].  Ct is the last quantifiable 
concentration. No AUC extrapolation will be performed with unreliable 
∀z.  If AUC %Extrap is ≥25%, AUCinf will not be reported
AUCt
Area under the plasma concentration-time curve from Time 0 to the time 
of the last quantifiable concentration, calculated by linear trapezoidal 
method when concentrations are increasing and the logarithmic 
trapezoidal method when concentrations are decreasing.
Cmax
Maximum observed plasma concentration, obtained directly from the 
observed concentration versus time data.
Tmax
Time to Cmax, obtained directly from the observed concentration versus 
time data.
t1/2
Terminal phase half-life in plasma, calculated as [(ln 2)/ ∀z].  t1/2 will only 
be calculated when a reliable estimate for ∀z can be obtained.  
CL/F
Apparent total clearance, calculated as [Dose/AUCinf]. 
Vz/F
Apparent volume of distribution, calculated as [(CL/F)/∀z ].
The following PK parameters for CC-486 will be calculated for diagnostic purposes and listed, 
but they will not be summarized:
∀z
Apparent terminal rate constant, calculated by linear regression of the 
terminal portion of the log-concentration versus time curve in plasma.  
Visual assessment will be used to identify the terminal linear phase of the 
concentration versus time profile.  A minimum of three data points will be 
used for calculation.  
∀z will not be estimated if the terminal phase of the log-concentration 
versus time profile does not exhibit a linear decline phase, or if the 
regression coefficient < 0.8.  
&(/*(1(35235,(7$5<,1)250$7,21
0 extrapola
0 extrapola
uantif
antifiable
iable
f
ed with unr
ed with unr
eported
eported
ve from Ti
e from T
ulated by lin
ated by lin
sing and the
ing and
ons are dec
ons are dec
ncentration
ncentration
us t
s time data
ime da
directly fro
directly fro
e half
e half-f life i
li
d when a r
when a r
rent 
ent total
tota cl
l
Apparent v
Apparent v
K parameter
parameter
ot be summ
t be sum


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
62
CC-486-NSCL-001 Final: 15 May 2015
∀z lower
Lower limit of time (h) included in the calculation of ∀z. 
∀z N
Number of data points used in the calculation of ∀z.
∀z upper
Upper limit of time (h) included in the calculation of ∀z.
Rsq
Regression coefficient for calculation of ∀z.  
AUC % Extrap
Percentage of AUCinf due to extrapolation from the last quantifiable time 
point to infinity.
10.8.3.
PK Analyses
By-subject listing of pharmacokinetic parameters will be provided.  The pharmacokinetic 
parameters will also be summarized using descriptive statistics (N, arithmetic mean, standard 
deviation, standard error, minimum, median, maximum, percent coefficient of variation, 
geometric mean, and geometric percent coefficient of variation) for each cycle.  Also, when 
appropriate, graphical representations (i.e., scatter plots, box plots, etc) may be used to visualize
the results.
The effect of pembrolizumab on the PK of CC-486 will be assessed using graphic comparison 
and descriptive stats.
Exploratory analysis may be conducted to investigate the relationship between PK parameters 
and efficacy endpoints.
10.9.
Interim Analysis
No interim analysis of efficacy is planned for this study.
10.10.
Other Topics
10.10.1.
Data Monitoring Committee
An independent Data Monitoring Committee (iDMC) will be established and will include 
medical oncologists and a statistician, all of whom are not otherwise involved in the study 
conduct.  During the course of the study, the DMC will review the safety data regularly. The first 
DMC meeting will occur when 10 subjects in each arm have safety data from at least one cycle 
of treatment, with subsequent meetings approximately every 6 months or more often if requested 
by the DMC Chairman. The DMC will offer recommendations to continue, modify or stop the 
study based only on periodic evaluations of comparative safety data, in accordance with criteria 
outlined in the DMC Charter. An independent statistician will prepare the reports to the DMC 
members for each scheduled meeting. Operational details for the DMC will be detailed in the 
DMC charter.
10.10.2.
Steering Committee
The conduct of this trial will be overseen by a Steering Committee (SC), presided over by the 
coordinating principal Investigator and if possible the representative regional Investigators from 
&(/*(1(35235,(7$5<,1)250$7,21
me
acokinetic
acokineti
c m
c mean, sta
ean, s
nt of variat
nt of variat
ch cycle.  A
h cycle.  
etc) may be
etc) may be
ssessed usi
ssessed us
the relat
the relatioi
d for this s
d for this
Committe
Committe
onitoring Co
nitoring
nd a stati
d a st
sti
he course of
e course of
will
will occur w
occur w
l
wi
with
th
i
subse
subse
h
MC Chairma
C Chairma
ased only o
ased only o
ned in the D
ned in the 
embers for
embers for
DMC cha
DMC cha


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
63
CC-486-NSCL-001 Final: 15 May 2015
countries participating in this study.  The SC will serve in an advisory capacity to the Sponsor.  
Operational details for the SC will be detailed in a separate SC charter.
Note: The SC is separate from the DMC.
&(/*(1(35235,(7$5<,1)250$7,21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
64
CC-486-NSCL-001 Final: 15 May 2015
11.
ADVERSE EVENTS
11.1.
Monitoring, Recording and Reporting of Adverse Events
An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen 
in a subject during the course of a study. It may be a new intercurrent illness, a worsening 
concomitant illness, an injury, or any concomitant impairment of the subject’s health, including 
laboratory test values (as specified by the criteria in Section 11.3), regardless of etiology. Any 
worsening (i.e., any clinically significant adverse change in the frequency or intensity of a pre-
existing condition) should be considered an AE.  A diagnosis or syndrome should be recorded on 
the AE page of the CRF rather than the individual signs or symptoms of the diagnosis or 
syndrome. 
Abuse, withdrawal, sensitivity or toxicity to an investigational product should be reported as an 
AE. Overdose, accidental or intentional, whether or not it is associated with an AE should be 
reported on the overdose CRF. (See Section 8.2.2 for the definition of overdose.) Any sequela 
of an accidental or intentional overdose of an investigational product should be reported as an 
AE on the AE CRF. If the sequela of an overdose is an SAE, then the sequela must be reported 
on an SAE report form and on the AE CRF. The overdose resulting in the SAE should be 
identified as the cause of the event on the SAE report form and CRF but should not be reported 
as an SAE itself.
In the event of overdose, the subject should be monitored as appropriate and should receive 
supportive measures as necessary. There is no known specific antidote for CC-486 and 
pembrolizumab overdose. Actual treatment should depend on the severity of the clinical situation 
and the judgment and experience of the treating physician.
All subjects will be monitored for AEs during the study.  Assessments may include monitoring 
of any or all of the following parameters:  the subject’s clinical symptoms, laboratory, 
pathological, radiological or surgical findings, physical examination findings, or findings from 
other tests and/or procedures.
All AEs will be recorded by the Investigator from the time the subject signs informed consent 
until 30 days after the last dose of either study drug and those SAEs made known to the 
Investigator at any time thereafter that are suspected of being related to IP. Adverse events and 
SAEs will be recorded on the AE page of the CRF and in the subject’s source documents.  All 
SAEs must be reported to Celgene Drug Safety within 24 hours of the Investigator’s knowledge 
of the event by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form.
In addition, adverse events known as pembrolizumab Events of Clinical Interest (ECI) must also 
be recorded on the Adverse Event CRFs and reported within 5 days of the Investigator’s 
knowledge of the event, regardless of whether or not the Investigator considers the event related 
to the IP. If the event meets serious criteria (SAE), the event must also reported to Celgene Drug 
Safety within 24 hours by facsimile, or other appropriate method, using the SAE Report Form, or 
approved equivalent form as outlined in Section 11.5. This includes the reporting of  any 
pembrolizumab ECIs that become known to the investigator > 30 days to ≤90 days after the last 
&(/*(1(35235,(7$5<,1)250$7,21
y
pre
pre-
corded on
rded o
s or 
s or 
be reporte
be reporte
th an AE sh
h an AE sh
overdose.)
erdose
should be 
should be
n the sequel
the seque
lting 
ing in the
and CRF bu
nd CRF b
ored as app
ored as app
wn specific
wn specifi
ould depend
uld depen
ing physici
ing physici
during the s
during the
ters:  the su
ters:  the
cal findings
findings
l
y the Invest
the Inve
y
st dose of e
t dose o
me thereafte
me therea
rded on the
ded on the
eported to 
eported to 
by
by f
y acsimil
acsimil
f
t form.
form.
ditio
ition, 
n, adve
adv
recorded o
ecorded o
knowl
knowledge
edge
o the
o the IP
I


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
65
CC-486-NSCL-001 Final: 15 May 2015
dose of pembrolizumab, or 30 days after the last dose of pembrolizumab if the subject initiates a 
new anticancer therapy, whichever is earlier, whether or not related to pembrolizumab. 
See Section 11.5.1 (or Section 11.7) as well as Appendix C for detailed guidance on the 
reporting of pembrolizumab ECIs.  
11.2.
Evaluation of Adverse Events
A qualified Investigator will evaluate all adverse events as to: 
11.2.1.
Seriousness 
A serious adverse event (SAE) is any AE occurring at any dose that:
!
Results in death;
!
Is life-threatening (i.e., in the opinion of the Investigator, the subject is at immediate 
risk of death from the AE);
!
Requires inpatient hospitalization or prolongation of existing hospitalization 
(hospitalization is defined as an inpatient admission, regardless of length of stay);
!
Results in persistent or significant disability/incapacity (a substantial disruption of the 
subject’s ability to conduct normal life functions);
!
Is a congenital anomaly/birth defect;
!
Constitutes an important medical event.
Important medical events are defined as those occurrences that may not be immediately life 
threatening or result in death, hospitalization, or disability, but may jeopardize the subject or 
require medical or surgical intervention to prevent one of the other outcomes listed above.  
Medical and scientific judgment should be exercised in deciding whether such an AE should be 
considered serious.
Events not considered to be SAEs are hospitalizations for:
!
A standard procedure for protocol therapy administration.  However, hospitalization 
or prolonged hospitalization for a complication of therapy administration will be 
reported as an SAE. 
!
Routine treatment or monitoring of the studied indication not associated with any 
deterioration in condition.
!
The administration of blood or platelet transfusion as routine treatment of studied 
indication.  However, hospitalization or prolonged hospitalization for a complication 
of such transfusion remains a reportable SAE.
!
A procedure for protocol/disease-related investigations (eg, surgery, scans, 
endoscopy, sampling for laboratory tests, bone marrow sampling).  However, 
hospitalization or prolonged hospitalization for a complication of such procedures 
remains a reportable SAE.
!
Hospitalization or prolongation of hospitalization for technical, practical, or social 
reasons, in absence of an AE.
&(/*(1(35235,(7$5<,1)250$7,21
ct is at imm
is at imm
g g hospi
hospitaliz
ta
i
ardldless of l
ess of l
ity y (a subst
(a subst
;
ccurrences 
ccurrences 
or disabili
or disabili
prevent on
prevent on
d be exercis
be exerci
Es are hosp
Es are hosp
edure for pr
dure for 
hospi
hospitalizat
tal
i
an SAE.
an SAE
ne treatmen
e treatmen
ririorati
oration in
on
The admin
The admin
indicat
ndicati
of
of su
s
f
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
66
CC-486-NSCL-001 Final: 15 May 2015
!
A procedure that is planned (i.e., planned prior to starting of treatment on study); 
must be documented in the source document and the CRF.  Hospitalization or 
prolonged hospitalization for a complication remains a reportable SAE.
!
An elective treatment of or an elective procedure for a pre-existing condition 
unrelated to the studied indication, that has not worsened from baseline. 
!
Emergency outpatient treatment or observation that does not result in admission, 
unless fulfilling other seriousness criteria above.
If an AE is considered serious, both the AE page/screen of the CRF and the SAE Report Form 
must be completed.
For each SAE, the Investigator will provide information on severity, start and stop dates, 
relationship to IP, action taken regarding IP, and outcome.
11.2.2.
Severity / Intensity
For both AEs and SAEs, the Investigator must assess the severity / intensity of the event. 
The severity / intensity of AEs will be graded based upon the subject’s symptoms according to 
the current active minor version of the Common Terminology Criteria for Adverse Events 
(CTCAE, Version 4.0); 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_40
Adverse events that are not defined in the CTCAE should be evaluated for severity / intensity 
according to the following scale:
!
Grade 1 = Mild – transient or mild discomfort; no limitation in activity; no medical 
intervention/therapy required
!
Grade 2 = Moderate – mild to moderate limitation in activity, some assistance may be 
needed; no or minimal medical intervention/therapy required
!
Grade 3 = Severe – marked limitation in activity, some assistance usually required; 
medical intervention/therapy required, hospitalization is possible
!
Grade 4 = Life threatening – extreme limitation in activity, significant assistance 
required; significant medical intervention/therapy required, hospitalization or hospice 
care probable
!
Grade 5 = Death - the event results in death
11.2.3.
Causality 
The Investigator must determine the relationship between the administration of IP and the 
occurrence of an AE/SAE as Not Suspected or Suspected as defined below:
Not suspected:
a causal relationship of the adverse event to IP administration is 
unlikely or remote, or other medications, therapeutic 
interventions, or underlying conditions provide a sufficient 
explanation for the observed event.
rm
ates,
ates,
sity
ty
i
of
of the e
t
f
t’s symptom
s sympto
teria f
er
or A
or A
f
licat
icatioions/ct
ns/ct
ld be evalu
ld be eval
sco
scomfo
mfort; n
rt; n
moderate 
moderate 
dical interv
dical interv
arked limita
rked limi
n/therapy r
/therapy r
threatening
hreatening
gnificant me
gnificant m
able
ble
e 5 = Death
e 5 = Deat
Causality 
Causality
vestigator m
vestigator m
urrence of a
urrence of 
No
No


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
67
CC-486-NSCL-001 Final: 15 May 2015
Suspected:
there is a reasonable possibility that the administration of IP 
caused the adverse event.  ‘Reasonable possibility’ means there 
is evidence to suggest a causal relationship between the IP and 
the adverse event.
Causality should be assessed and provided for every AE/SAE based on currently available 
information.  Causality is to be reassessed and provided as additional information becomes 
available.
If an event is assessed as suspected of being related to a comparator, ancillary or additional IP 
that has not been manufactured or provided by Celgene, please provide the name of the 
manufacturer when reporting the event.
11.2.4.
Duration
For both AEs and SAEs, the Investigator will provide a record of the start and stop dates of the 
event.
11.2.5.
Action Taken
The Investigator will report the action taken with IP as a result of an AE or SAE, as applicable 
(eg, discontinuation, interruption, or reduction of IP, as appropriate) and report if concomitant 
and/or additional treatments were given for the event. 
11.2.6.
Outcome
The Investigator will report the outcome of the event for both AEs and SAEs.
All SAEs that have not resolved upon discontinuation of the subject’s participation in the study 
must be followed until recovered (returned to baseline), recovered with sequelae, or death (due to 
the SAE). 
11.3.
Abnormal Laboratory Values
An abnormal laboratory value is considered to be an AE if the abnormality:
!
results in discontinuation from the study;
!
requires treatment, modification/ interruption of IP dose, or any other therapeutic 
intervention; or
!
is judged to be of significant clinical importance, eg, one that indicates a new disease 
process and/or organ toxicity, or is an exacerbation or worsening of an existing 
condition.
Regardless of severity grade, only laboratory abnormalities that fulfill a seriousness criterion 
need to be documented as a serious adverse event.  
If a laboratory abnormality is one component of a diagnosis or syndrome, then only the diagnosis 
or syndrome should be recorded on the AE page/screen of the CRF.  If the abnormality was not a 
part of a diagnosis or syndrome, then the laboratory abnormality should be recorded as the AE. If 
&(/*(1(35235,(7$5<,1)250$7,21
IP 
P 
nd stop dat
nd stop da
of an AE o
of an A
opriate)
opriate an
an
event for bo
event for 
ntntinuatio
inuation
ed to baseli
ed to baseli
ratory Va
ratory Va
ue is consid
ue is cons
cont
con inuat
uatio
treatm
eatment,
ent
vent
entioion; or
n; or
s s judged to
judged to
process a
process a
condi
ondi
egardless o
egardless o
need to be
need to be
a lal


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
68
CC-486-NSCL-001 Final: 15 May 2015
possible, the laboratory abnormality should be recorded as a medical term and not simply as an 
abnormal laboratory result (eg, record thrombocytopenia rather than decreased platelets).
11.4.
Pregnancy
All pregnancies, suspected pregnancies and lactation occurring in either a female subject of 
childbearing potential or partner of a male subject are immediately reportable events.
11.4.1.
Females of Childbearing Potential
Pregnancies, suspected pregnancies (including elevated β-hCG or a positive pregnancy test in a 
female of childbearing potential regardless of age or disease state) and lactation of a female 
subject that occur during the trial or within 120 days of completing the trial (or longer if required 
by local requirements), or 30 days following cessation of treatment if the subject initiates new 
anticancer therapy, whichever is earlier, are considered immediately reportable events.  
Investigational product is to be discontinued immediately.  The pregnancy, suspected pregnancy, 
or positive pregnancy test, or lactation must be reported to Celgene Drug Safety immediately by 
facsimile, or other appropriate method, using the Pregnancy Initial Report Form, or approved 
equivalent form.  
The Investigator will follow the female subject until completion of the pregnancy, and must 
notify Celgene Drug Safety immediately about the outcome of the pregnancy (either normal or 
abnormal outcome) using the Pregnancy Follow-up Report Form, or approved equivalent form.
The female subject should be referred to an obstetrician-gynecologist, preferably one 
experienced in reproductive toxicity for further evaluation and counseling.
If the outcome of the pregnancy was abnormal (eg, spontaneous abortion), the Investigator 
should report the abnormal outcome as an AE.  If the abnormal outcome meets any of the serious 
criteria, it must be reported as an SAE to Celgene Drug Safety by facsimile, or other appropriate 
method, within 24 hours of the Investigator’s knowledge of the event using the SAE Report 
Form, or approved equivalent form.
All neonatal deaths that occur within 30 days of birth should be reported, without regard to 
causality, as SAEs.  In addition, any infant death after 30 days that the Investigator suspects is 
related to the in utero exposure to the IP should also be reported to Celgene Drug Safety by 
facsimile, or other appropriate method, within 24 hours of the Investigator’s knowledge of the 
event using the SAE Report Form, or approved equivalent form.
11.4.2.
Male Subjects
If a female partner of a male subject taking investigational product becomes pregnant while the 
subject is receiving investigational product or within 3 months of the last dose of IP, the male 
subject taking IP should notify the Investigator, and the pregnant female partner should be 
advised to call their healthcare provider immediately. The female partner should be referred to an 
obstetrician-gynecologist, preferably one experienced in reproductive toxicity for further 
evaluation and counseling.  Male subjects should avoid fathering a child until 3 months after the 
last dose of IP (or longer if required by local requirements). The ICF will address any country-
specific requirements, as needed.
&(/*(1(35235,(7$5<,1)250$7,21
in a 
n a 
ale
r if required
r if require
nititiates new
iates ne
events. 
events. 
suspected p
suspected 
g Saf
Safetet
f y y im
eport Form
port Form
n of the pr
n of the
of
of the preg
the pre
f
ort Form, o
rt Form,
cian
ian-gynec
gyne
valaluat
uat
l
ion an
n a
al (e
al (eg,g, spon
spon
AE
AE.  .  If the
If the
o Cel
o Celgene 
gene
stigator’s kn
igator’s
m.
within 30
within 30
itioion, any i
n, any 
xposure to 
xposure to
ppropri
propriate m
te
AE Report 
AE Report 
Male Subje
Male Subje
ale partner 
ale partner
ct i
t is receiv
s recei
bject taking
bject taking
advised to
dvised to
bstetri
bstetr


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
69
CC-486-NSCL-001 Final: 15 May 2015
11.5.
Reporting of Serious Adverse Events
Any AE that meets any criterion for an SAE requires the completion of an SAE Report Form in 
addition to being recorded on the AE page/screen of the CRF.  Any serious adverse event, or 
follow up to a serious adverse event, including death due to any cause other than progression of 
the cancer under study that occurs to any subject from the time the consent is signed through 90 
days following cessation of treatment, or 30 days following cessation of treatment if the subject 
initiates new anticancer therapy, whichever is earlier, whether or not related to the Sponsor's 
product  must be reported to Celgene Drug Safety within 24 hours of the Investigator’s 
knowledge of the event by facsimile, or other appropriate method, using the SAE Report Form, 
or approved equivalent form.  This instruction pertains to initial SAE reports as well as any 
follow-up reports.
The Investigator is required to ensure that the data on these forms is accurate and consistent.  
This requirement applies to all SAEs (regardless of relationship to study drugs) that occur during 
the study (from the time the subject signs informed consent until 90 days after the last dose of 
either IP) or any SAE made known to the Investigator at anytime thereafter that are suspected of 
being related to IP.  SAEs occurring prior to treatment (after signing the ICF) will be captured.
The SAE report should provide a detailed description of the SAE and include a concise summary
of hospital records and other relevant documents.  If a subject died and an autopsy has been 
performed, copies of the autopsy report and death certificate are to be sent to Celgene Drug 
Safety as soon as these become available.  Any follow-up data should be detailed in a subsequent 
SAE Report Form, or approved equivalent form, and sent to Celgene Drug Safety.  
Where required by local legislation, the Investigator is responsible for informing the IRB/Ethics 
Committee (EC) of the SAE and providing them with all relevant initial and follow-up 
information about the event. The Investigator must keep copies of all SAE information on file 
including correspondence with Celgene and the IRB/EC.
11.5.1.
Safety Queries
Queries pertaining to SAEs will be communicated from Celgene Drug Safety to the site via 
facsimile or electronic mail.  The response time is expected to be no more than five (5) business 
days.  Urgent queries (eg, missing causality assessment) may be handled by phone.
11.6.
Expedited Reporting of Adverse Events
For the purpose of regulatory reporting, Celgene Drug Safety will determine the expectedness of 
events suspected of being related to CC-486 based on the Investigator Brochure.
In the United States, all suspected unexpected serious adverse reactions (SUSARs) will be 
reported in an expedited manner in accordance with 21 CFR 312.32.
For countries within the European Economic Area (EEA), Celgene or its authorized 
representative will report in an expedited manner to Regulatory Authorities and Ethics 
Committees concerned, suspected unexpected serious adverse reactions (SUSARs) in accordance 
with Directive 2001/20/EC and the Detailed Guidance on collection, verification and 
presentation of adverse reaction reports arising from clinical trials on investigational products for 
human use (ENTR/CT3) and also in accordance with country-specific requirements.
&(/*(1(35235,(7$5<,1)250$7,21
orm, 
m,
any
consistent.
onsistent
) that occur
that occu
er th
er the l
e last 
ast
fter that are 
er that 
he ICF)
he ICF) wi
wi
and includ
nd includ
died and an
died an
e are to be s
are to be s
p data shou
data sh
sent to Celg
sent to Celg
tor is respo
tor is resp
m wit
m with all r
h all 
or must kee
or must kee
and the IRB
and the IRB
l be co
be commu
mmu
The respo
The respo
missing ca
missing ca
ited Repo
ed Repo
of regulato
of regulato
cted of bein
cted of bein
nited States
d State
ted in an ex
ted in an ex
or countri
or countrie
represent
epresent
omm
omm


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
70
CC-486-NSCL-001 Final: 15 May 2015
For the purpose of regulatory reporting in the EEA, Celgene Drug Safety will determine the 
expectedness of events suspected of being related to the other IP, pembrolizumab based on the 
Pembrolizumab Investigators Brochure for the product.
Events of  disease progression for the disease under study (including deaths due to disease 
progression for indications that are considered to be fatal) will be assessed as expected adverse 
events and will not be reported as expedited safety reports to regulatory authorities.
Celgene or its authorized representative shall notify the Investigator of the following 
information:
!
Any AE suspected of being related to the use of IP in this study or in other studies 
that is both serious and unexpected (i.e., SUSAR);
!
Any finding from tests in laboratory animals that suggests a significant risk for 
human subjects including reports of mutagenicity, teratogenicity, or carcinogenicity.
Where required by local legislation, the Investigator shall notify his/her IRB/EC promptly of 
these new serious and unexpected AE(s) or significant risks to subjects.
The Investigator must keep copies of all pertinent safety information on file including 
correspondence with Sponsor and the IRB/EC.  (See Section 15.3 for record retention 
information).
Celgene Drug Safety Contact Information:
For Celgene Drug Safety contact information, please refer to the Serious Adverse Event Report 
Form Completion Guidelines or to the Pregnancy Report Form Completion Guidelines.
11.7.
Pembrolizumab Events of Clinical Interest
Selected adverse events are also known as Events of Clinical Interest (ECI) and must be recorded 
as such on the Adverse Event CRFs and reported within 5 days of the Investigator’s knowledge 
of the event, regardless of whether or not the Investigator considers the event related to the IP. If
the event meets serious criteria (SAE), the event must also reported to Celgene Drug Safety 
within 24 hours by facsimile, or other appropriate method, using the SAE Report Form, or 
approved equivalent form as outlined in Section 11.5.  
Events of clinical interest for this trial include, but are not limited to :
1. an overdose of pembrolizumab, as defined in Section 8.2.2 - Overdose, that is not 
associated with clinical symptoms or abnormal laboratory results. See Section 11.1 for a 
description of how overdoses of pembrolizumab are to be documented (with or without 
associated adverse events).
2. an elevated AST or ALT lab value that is greater than or equal to 3X the upper limit of 
normal and an elevated total bilirubin lab value that is greater than or equal to 2X the upper 
limit of normal and, at the same time, an alkaline phosphatase lab value that is less than 2X 
the upper limit of normal, as determined by way of protocol-specified laboratory testing or 
unscheduled laboratory testing.*
&(/*(1(35235,(7$5<,1)250$7,21
didies 
e
t risk for 
risk for 
carcinogen
carcinog
B/EC prom
B/EC prom
n on file inc
on file inc
fo
for record
cor
refer to the
refer to the
Report F
Report For
Clinical I
Clinical I
as Events o
as Events o
nd reported
nd reported
or not the I
r not the 
(SAE), the 
(SAE), the 
or other ap
or other ap
as outlined
 outlined
rest fo
est for thi
se of pembr
se of pemb
wi
with
th
i
clinica
clini
h
on of how 
n of how
iated adver
ed adver
an eleva
an elev
norm
normalal an
an
l
limit o
mit o
th
the


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
71
CC-486-NSCL-001 Final: 15 May 2015
*Note:  These criteria are based upon available regulatory guidance documents. The purpose 
of the criteria is to specify a threshold of abnormal hepatic tests that may require an 
additional evaluation for an underlying etiology.  
There are additional ECIs identified in the Appendix C guidance document which also need to be 
reported to the Sponsor within 5 days of the Investigator’s knowledge of the event by data entry 
into the Adverse Event eCRF, regardless of whether or not the Investigator considers the event 
related to the IP, and if deemed serious (SAE), also reported to Celgene Drug Safety within 24 
hours by facsimile, or other appropriate method, using the SAE Report Form, or approved 
equivalent form as outlined in Section 11.5.
Subjects should be assessed for possible ECIs prior to each dose.  Lab results should be 
evaluated and subjects should be asked for signs and symptoms suggestive of an immune-related 
event.  Subjects who develop an ECI thought to be immune-related should have additional 
testing to rule out other etiologic causes.  If lab results or symptoms indicated a possible 
immune-related ECI then additional testing should be performed to rule out other etiologic 
causes.  If no other cause was found, then it is assumed to be immune-related.
In addition, any pembrolizumab ECIs that become known to the investigator >30 days to ≤90 
days after the last dose of pembrolizumab, or 30 days after the last dose of pembrolizumab if the 
subject initiates a new anticancer therapy, whichever is earlier, whether or not related to 
pembrolizumab, must be reported to the sponsor within 5 days of the Investigator’s knowledge 
of the event by data entry into the Adverse Event eCRF. If the event is deemed serious (SAE), it 
must also be reported to Celgene Drug Safety within 24 hours by facsimile, or other appropriate 
method, using the SAE Report Form, or approved equivalent form as outlined in Section 11.5.
&(/*(1(35235,(7$5<,1)250$7,21
mune
mune-rel
relate
ate
ddidititi onal
onal
a possible
possible
other eti
other etiol
o
ated.
ated.
stigator >3
igator >
t dose of pe
dose of p
whether or
wheth
ys
ys of
of the In
the In
f
f th
t e event
e event
4 hours by
4 hours by
quivalent f
quivalent 


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
72
CC-486-NSCL-001 Final: 15 May 2015
12.
DISCONTINUATIONS
12.1.
Treatment Discontinuations
The following events are considered sufficient reasons for discontinuing a subject from the 
investigational product :
!
Adverse Event
!
Progressive Disease
!
Symptomatic deterioration (global deterioration of health status)
!
Physician decision
!
Withdrawal by subject
!
Death
!
Lost to follow-up
!
Protocol violation
!
Other (to be specified on CRF)
The reason for discontinuation of treatment should be recorded in the CRF and in the source 
documents.
The decision to discontinue a subject from treatment remains the responsibility of the treating 
physician, which will not be delayed or refused by the sponsor.  However, prior to discontinuing 
a subject, the Investigator may contact the Medical Monitor and forward appropriate supporting 
documents for review and discussion.
12.2.
Study Discontinuation
The following events are considered sufficient reasons for discontinuing a subject from the 
study:
!
Adverse Event
!
Progressive disease
!
Withdrawal by subject
!
Death
!
Lost to follow-up
!
Protocol violation
!
Other
The reason for study discontinuation should be recorded in the CRF and in the source 
documents.
&(/*(1(35235,(7$5<,1)250$7,21
corded in th
orded in
ent
ent remain
remain
d by the sp
d by the sp
Medical Mo
Medical Mo
tion
on
idered suffi
dered suff
ntnt
sive disease
sive diseas
hdrawal by
hdrawal b
Death
Death
!
Lost t
ost t
!
P


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
73
CC-486-NSCL-001 Final: 15 May 2015
13.
EMERGENCY PROCEDURES
13.1.
Emergency Contact
In emergency situations, the Investigator should contact the responsible Clinical Research 
Physician/Medical Monitor or designee by telephone at the number(s) listed on the Emergency 
Contact Information page of the protocol (after title page).
In the unlikely event that the Clinical Research Physician/Medical Monitor or designee cannot be 
reached, please contact the global Emergency Call Center by telephone at the number listed on 
the Emergency Contact Information page of the protocol (after title page).This global Emergency 
Call Center is available 24 hours a day and 7 days a week. The representatives are responsible 
for obtaining your call-back information and contacting the on call Celgene/contract research 
organization (CRO) Medical Monitor, who will then contact you promptly.
Note: The back-up 24-hour global emergency contact call center should only be used if you are 
not able to reach the Clinical Research Physician(s) or Medical Monitor or designee for 
emergency calls. 
13.2.
Emergency Identification of Investigational Products
The blind must not be broken during the course of the study unless in the opinion of the 
Investigator, it is absolutely necessary to safely treat the subject. IF it is medically imperative to 
know what IP the subject is receiving, IP should be temporarily discontinued if, in the opinion of 
the Investigator, continuing IP can negatively affect the outcome of the subject’s treatment.
The decision to break the blind in emergency situations remains the responsibility of the treating 
physician, which will not be delayed or refused by the Sponsor. However, the Investigator may 
contact the Medical Monitor prior to breaking the blind to discuss unblinding, mainly in the 
interest of the subject.
The Investigator should ensure that the code is broken only in accordance with the protocol.  The 
Investigator should promptly notify the Medical Monitor of the emergency unblinding and the 
reason for breaking the blind, which should be clearly documented by the Investigator in the 
subject’s source documentation.
Emergency unblinding should only be performed by the Investigator through the IRT by using an 
emergency unblinding personal identification number (PIN), and the Investigator should call IRT 
for unblended dose information.
&(/*(1(35235,(7$5<,1)250$7,21
not be
ot b
ed on
d on
Em
Emergency
ergenc
esponsible
esponsible
ract researc
act resear
nly
nly b
y e used
e used
or or design
r or desig
nal Produ
nal Pro
dy
dy unless in
unless in
y
he subject. I
e subject. I
temporarily
temporari
fect the outc
ect the out
y situations 
y situations
fused by th
fused by th
reaking the
aking the
that the cod
that the cod
y notify the 
notify the 
ind, which 
d, which 
mentat
mentation.
ding s
ding shoul
hould
inding pers
inding per
d dose info
dose info


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
74
CC-486-NSCL-001 Final: 15 May 2015
14.
REGULATORY CONSIDERATIONS
14.1.
Good Clinical Practice
The procedures set out in this study protocol pertaining to the conduct, evaluation, and 
documentation of this study are designed to ensure that Celgene, its authorized representative, 
and Investigator abide by Good Clinical Practice (GCP), as described in International 
Conference on Harmonisation (ICH) Guideline E6 and in accordance with the general ethical 
principles outlined in the Declaration of Helsinki. The study will receive approval from an 
IRB/EC prior to commencement. The Investigator will conduct all aspects of this study in 
accordance with applicable national, state, and local laws of the pertinent regulatory authorities.
14.2.
Investigator Responsibilities
Investigator responsibilities are set out in the ICH Guideline for Good Clinical Practice and in 
the local regulations.  Celgene staff or an authorized representative will evaluate and approve all 
Investigators who in turn will select their staff.
The Investigator should ensure that all persons assisting with the study are adequately informed 
about the protocol, amendments, study treatments, as well as study-related duties and functions, 
including obligations of confidentiality of Celgene information. The Investigator should maintain 
a list of Sub-investigators and other appropriately qualified persons to whom he or she has 
delegated significant study-related duties.
The Investigator is responsible for keeping a record of all subjects who sign an informed consent 
document and are screened for entry into the study.  Subjects who fail screening must have the 
reason(s) recorded in the subject’s source documents.
The Investigator, or a designated member of the Investigator’s staff, must be available during 
monitoring visits to review data, resolve queries and allow direct access to subject records (eg, 
medical records, office charts, hospital charts, and study-related charts) for source data 
verification.  The Investigator must ensure timely and accurate completion of CRFs and queries.
The information contained in the protocol and amendments (with the exception of the 
information provided by Celgene on public registry websites) is considered Celgene confidential 
information.  Only information that is previously disclosed by Celgene on a public registry 
website may be freely disclosed by the Investigator or its institution, or as outlined in the Clinical 
Trial Agreement.  Celgene protocol, amendment and IB information is not to be made publicly 
available (for example on the Investigator’s or their institution’s website) without express written 
approval from Celgene.  Information proposed for posting on the Investigator’s or their 
institution’s website must be submitted to Celgene for review and approval, providing at least 5 
business days for review.
At the time results of this study are made available to the public, Celgene will provide 
Investigators with a summary of the results that is written for the lay person.  The Investigator is 
responsible for sharing these results with the subject and/or their caregiver as agreed by the 
subject.
&(/*(1(35235,(7$5<,1)250$7,21
in 
authori
authorititi
i es
es
ical Practic
cal Practic
evaluate an
valuate
study are a
udy are 
study
study-relate
rel
ation. The I
. The
fied persons
fied person
ord of all su
rd of all su
study.  Subj
tudy.  Subj
documents.
ocuments
ber of the In
er of the I
olve querie
olve quer
ospital chart
spital cha
must ensur
must ensu
d in the pro
n the pro
y Celgene 
Celgene
y
nform
orm
f
ata ioion
reely disclo
reely disclo
ent.  Cel
nt.  Celgen
ge
for example
or example
from
om
f
Cel
Cel
m
g
utition’s web
on’s web
siness days
ness days
At
At the tim
the tim
vest
vest


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
75
CC-486-NSCL-001 Final: 15 May 2015
14.3.
Subject Information and Informed Consent
The Investigator must obtain informed consent of a subject and/or a subject’s legal representative 
prior to any study related procedures.
Documentation that informed consent occurred prior to the study subject’s entry into the study 
and of the informed consent process should be recorded in the study subject’s source documents 
including the date.  The original ICF signed and dated by the study subject and by the person 
consenting the study subject prior to the study subject’s entry into the study, must be maintained 
in the Investigator’s study files and a copy given to the study subject.  In addition, if a protocol is 
amended and it impacts on the content of the informed consent, the ICF must be revised.  Study 
subjects participating in the study when the amended protocol is implemented must be re-
consented with the revised version of the ICF.  The revised ICF signed and dated by the study 
subject and by the person consenting the study subject must be maintained in the Investigator’s 
study files and a copy given to the study subject.
14.4.
Confidentiality
Celgene affirms the subject's right to protection against invasion of privacy and to be in 
compliance with ICH and other local regulations (whichever is most stringent). Celgene requires 
the Investigator to permit Celgene's representatives and, when necessary, representatives from 
regulatory authorities, to review and/or copy any medical records relevant to the study in 
accordance with local laws.
Should direct access to medical records require a waiver or authorization separate from the 
subject’s signed ICF, it is the responsibility of the Investigator to obtain such permission in 
writing from the appropriate individual.
14.5.
Protocol Amendments
Any amendment to this protocol must be approved by the Celgene Clinical Research 
Physician/Medical Monitor.  Amendments will be submitted to the IRB/EC for written approval.  
Written approval must be obtained before implementation of the amended version occurs.  The 
written signed approval from the IRB/EC should specifically reference the Investigator name, 
protocol number, study title and amendment number(s) that is applicable. Amendments that are 
administrative in nature do not require IRB/IEC approval but will be submitted to the IRB/IEC 
for information purposes.
14.6.
Institutional Review Board/Independent Ethics Committee Review 
and Approval
Before the start of the study, the study protocol, ICF, and any other appropriate documents will 
be submitted to the IRB/EC with a cover letter or a form listing the documents submitted, their 
dates of issue, and the site (or region or area of jurisdiction, as applicable) for which approval is 
sought. If applicable, the documents will also be submitted to the authorities in accordance with 
local legal requirements.
IP can only be supplied to an Investigator by Celgene or its authorized representative after 
documentation on all ethical and legal requirements for starting the study has been received by 
&(/*(1(35235,(7$5<,1)250$7,21
ol is
ol is
Study
Study
re-
the study
the study
Invest
nvestigato
igato
privacy
ivacy an
an
y
d
ost stringen
st stringen
necessary, 
necessa
cords relev
cords relev
iver or auth
ver or au
Invest
Inve igato
iga
st be approv
t be app
endments w
ndments 
ned before
ned before
m 
m th
the IRB/E
e IRB
tle and ame
and 
re do not re
e do not re
poses.
poses.
nstitution
nstitution
an
and App
d App
e the start o
e the start o
submitted t
ubmitted t
dates of iss
dates of iss
sought. 
ought
al


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
76
CC-486-NSCL-001 Final: 15 May 2015
Celgene or its authorized representative. This documentation must also include a list of the 
members of the IRB/EC and their occupation and qualifications. If the IRB/EC will not disclose 
the names, occupations and qualifications of the committee members, it should be asked to issue 
a statement confirming that the composition of the committee is in accordance with GCP. For 
example, the IRB General Assurance Number may be accepted as a substitute for this list. 
Formal approval by the IRB/EC should mention the protocol title, number, amendment number 
(if applicable), study site (or region or area of jurisdiction, as applicable), and any other 
documents reviewed. It must mention the date on which the decision was made and must be 
officially signed by a committee member. Before the first subject is enrolled in the study, all 
ethical and legal requirements must be met.
The IRB/EC and, if applicable, the authorities, must be informed of all subsequent protocol 
amendments in accordance with local legal requirements. Amendments must be evaluated to 
determine whether formal approval must be sought and whether the ICF should also be revised.
The Investigator must keep a record of all communication with the IRB/EC and, if applicable, 
between a Coordinating Investigator and the IRB/EC. This statement also applies to any 
communication between the Investigator (or Coordinating Investigator, if applicable) and 
regulatory authorities.
Any advertisements used to recruit subjects for the study must be reviewed by Celgene and the 
IRB/EC prior to use.
14.7.
Ongoing Information for Institutional Review Board / Ethics 
Committee
If required by legislation or the IRB/EC, the Investigator must submit to the IRB/EC:
!
Information on serious or unexpected adverse events as soon as possible; 
!
Periodic reports on the progress of the study;
!
Deviations from the protocol or anything that may involve added risk to subjects.
14.8.
Termination of the Study
Celgene reserves the right to terminate this study prematurely at any time for reasonable medical 
or administrative reasons. Any premature discontinuation  will be appropriately documented 
according to local requirements (eg, IRB/EC, regulatory authorities, etc).
In addition, the Investigator or Celgene has the right to discontinue a single site at any time 
during the study for medical or administrative reasons such as:
!
Unsatisfactory enrollment;
!
GCP noncompliance;
!
Inaccurate or incomplete data collection;
!
Falsification of records;
!
Failure to adhere to the study protocol.
&(/*(1(35235,(7$5<,1)250$7,21
otocol
ocol
aluated to
aluated to
also be rev
also be rev
and, if app
and, if app
o applies to
applie
r, if applica
r, if applic
be reviewe
e revi
na
nal Revie
l Revie
vestigator m
estigator 
pected adve
pected adv
gress of the
gress of the
otocol
otoco or a
or
l
of the Stu
of the S
ht to termin
ht to term
sons. Any
ons. Any p
y
requireme
requireme
e Invest
Investiga
ig
study
tudy f
y or m
or m
f
!
Unsat
Unsati
!
G
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
77
CC-486-NSCL-001 Final: 15 May 2015
15.
DATA HANDLING AND RECORDKEEPING 
15.1.
Data/Documents
The Investigator must ensure that the records and documents pertaining to the conduct of the 
study and the distribution of the investigational product are complete, accurate, filed and 
retained.  Examples of source documents include: hospital records; clinic and office charts; 
laboratory notes; memoranda; subject’s diaries or evaluation checklists; dispensing records; 
recorded data from automated instruments; copies or transcriptions certified after verification as 
being accurate copies; microfiche; X-ray film and reports; and records kept at the pharmacy, and 
the laboratories, as well as copies of CRFs or CD-ROM.
15.2.
Data Management
Data will be collected via CRF and entered into the clinical database per Celgene standard 
operating procedures (SOPs). This data will be electronically verified through use of
programmed edit checks specified by the clinical team.  Discrepancies in the data will be brought 
to the attention of the clinical team, and investigational site personnel, if necessary.  Resolutions 
to these issues will be reflected in the database.  An audit trail within the system will track all 
changes made to the data.
15.3.
Record Retention
Essential documents must be retained by the Investigator according to the period of time outlined 
in the clinical trial agreement. The Investigator must retain these documents for the time period 
described above or according to local laws or requirements, whichever is longer. Essential 
documents include, but are not limited to, the following:
!
Signed informed consent documents for all subjects;
!
Subject identification code list, screening log (if applicable), and enrollment log;
!
Record of all communications between the Investigator and the IRB/EC;
!
Composition of the IRB/EC;
!
Record of all communications between the Investigator, Celgene, and their authorized 
representative(s);
!
List of Sub-investigators and other appropriately qualified persons to whom the 
Investigator has delegated significant study-related duties, together with their roles in 
the study, curriculum vitae, and their signatures;
!
Copies of CRFs (if paper) and of documentation of corrections for all subjects;
!
IP accountability records;
!
Record of any body fluids or tissue samples retained;
!
All other source documents (subject records, hospital records, laboratory records, 
etc.); 
&(/*(1(35235,(7$5<,1)250$7,21
on as 
n as 
macy, and 
cy, and
elgene
elgene stan
stan
hrough use 
ugh us
es in the da
s in the d
nnel, if nece
nel, if nec
with
th
i in the s
in 
stigator acc
tigator acc
must retain
must reta
r requirem
r requirem
the follo
the follow
documents 
documen
code
code list, s
list, 
mmu
mmunicati
nica o
of
of the IRB
e IR
f
f all co
all comm
mm
sentative(s
sentative(s)
ist of Sub
ist of Sub
Invest
Investiga
iga
the stu
e stu
!
Co
Co
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
78
CC-486-NSCL-001 Final: 15 May 2015
!
All other documents as listed in Section 8 of the ICH consolidated guideline on GCP 
(Essential Documents for the Conduct of a Clinical Trial).
The Investigator must notify Celgene if he/she wishes to assign the essential documents to 
someone else, remove them to another location or is unable to retain them for a specified period.  
The Investigator must obtain approval in writing from Celgene prior to destruction of any 
records. If the Investigator is unable to meet this obligation, the Investigator must ask Celgene 
for permission to make alternative arrangements. Details of these arrangements should be 
documented. 
All study documents should be made available if required by relevant health authorities. 
Investigator/Institution should take measures to prevent accidental or premature destruction of 
these documents.
&(/*(1(35235,(7$5<,1)250$7,21
tion
tion of
of


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
79
CC-486-NSCL-001 Final: 15 May 2015
16.
QUALITY CONTROL AND QUALITY ASSURANCE
All aspects of the study will be carefully monitored by Celgene or its authorized representative 
for compliance with applicable government regulations with respect to current GCP and SOPs.
16.1.
Study Monitoring and Source Data Verification
Celgene ensures that appropriate monitoring procedures are performed before, during and after 
the study.  All aspects of the study are reviewed with the Investigator and the staff at a study
initiation visit and/or at an Investigator meeting.  Prior to enrolling subjects into the study, a 
Celgene representative will review the protocol, CRFs, procedures for obtaining informed 
consent, record keeping, and reporting of AEs/SAEs with the Investigator.  Monitoring will 
include on-site visits with the Investigator and his/her staff as well as any appropriate 
communications by mail, email, fax, or telephone.  During monitoring visits, the facilities, 
investigational product storage area, CRFs, subject’s source documents, and all other study 
documentation will be inspected/reviewed by the Celgene representative in accordance with the 
Study Monitoring Plan.
Accuracy will be checked by performing source data verification that is a direct comparison of 
the entries made onto the CRFs against the appropriate source documentation.  Any resulting 
discrepancies will be reviewed with the Investigator and/or his/her staff.  Any necessary 
corrections will be made directly to the CRFs or via queries by the Investigator and/or his/her 
staff. Monitoring procedures require that informed consents, adherence to inclusion/exclusion 
criteria and documentation of SAEs and their proper recording be verified.  Additional 
monitoring activities may be outlined in a study-specific monitoring plan.
16.2.
Audits and Inspections
In addition to the routine monitoring procedures, a Good Clinical Practice Quality Assurance 
unit exists within Celgene.  Representatives of this unit will conduct audits of clinical research 
activities in accordance with Celgene SOPs  to evaluate compliance with Good Clinical Practice 
guidelines and regulations.
The Investigator is required to permit direct access to the facilities where the study took place, 
source documents, CRFs and applicable supporting records of study subject participation for 
audits and inspections by IRB/IECs, regulatory authorities (eg, FDA, EMA, Health Canada) and 
company authorized representatives.  The Investigator should make every effort to be available 
for the audits and/or inspections.  If the Investigator is contacted by any regulatory authority 
regarding an inspection, he/she should contact Celgene immediately.
&(/*(1(35235,(7$5<,1)250$7,21
y
y, a
med 
med 
ing will
ng will
i
pri
priate
ate
the facilit
the facilitiei
nd all other 
d all other 
e in accorda
n acco
that i
ha s a di
a d
document
docume
r his/her sta
his/her st
ries by the 
ries by th
onsents, adh
onsents, adh
per recordin
er recordin
y-speci
specific m
fic 
procedures
procedu
sentatives o
sentatives o
elgene SOP
lgene SOP
red to perm
red to pe
RFs and ap
RFs and a
ons by IRB
ns by IRB
rized repres
rized repre
s and/or ins
s and/or ins
an inspect
n inspect


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
80
CC-486-NSCL-001 Final: 15 May 2015
17.
PUBLICATIONS
As described in Section 14.2 all protocol- and amendment-related information, with the 
exception of the information provided by Celgene on public registry websites, is considered 
Celgene confidential information and is not to be used in any publications.  Celgene protocol-
related information proposed for use in a publication must be submitted to Celgene for review 
and approval, and should not be utilized in a publication without express written approval from 
Celgene, or as described in the Clinical Trial Agreement.  
Celgene will ensure Celgene-sponsored studies are considered for publication in the scientific 
literature in a peer-reviewed journal, irrespective of the results.  At a minimum, this applies to 
results from all Phase 3 clinical studies, and any other study results of significant medical 
importance.  This also includes results relating to investigational medicines whose development 
programs have been discontinued.
Study results may also be presented at one or more medical congresses, and may be used for 
scientific exchange and teaching purposes.  Additionally, this study and its results may be 
submitted for inclusion in all appropriate health authority study registries, as well as publication 
on health authority study registry websites, as required by local health authority regulations.  
Eligibility for external authorship, as well as selection of first authorship, will be based on 
several considerations, including, but not limited to, contribution to protocol development, study 
recruitment, data quality, participation in data analysis, participation in study steering committee 
(when applicable) and contribution to abstract, presentation and/or publication development.
&(/*(1(35235,(7$5<,1)250$7,21
tific
ific
pplies to
plies to
edical
edical
se developm
se develop
nd may
nd may b
y e
d i
d its resul
ts resul
i
ts
l
stries, as w
ries, as w
ealalth
tl
autho
uth
h
t authorshi
t authorsh
ibution to p
ibution to p
, participati
 participat
entation an
entation a


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
81
CC-486-NSCL-001 Final: 15 May 2015
18.
REFERENCES
Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs 
BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the 
primary outcome. Br J Cancer. 2000;83(4):447-453.
Bang YJ. The potential for crizotinib in non-small cell lung cancer: a perspective review. Ther 
Adv Med Oncol. 2011;3(6):279-291.
Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: making immunotherapy a reality for 
the treatment of lung cancer. Cancer Immunol Res. 2013;1(2):85-91.
Brahmer JR, Horn L, Antonia SJ, et al. Survival and long-term follow-up of the phase I trial of 
nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated 
advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 2013;(suppl; abstr 8030).
Brahmer JR, Tykodi SS, Chow LQM, et al. Safety and activity of anti-PD-L1 antibody in 
patients with advanced cancer. N Engl J Med. 2012;366(26):2455-2465.
Bria E, Cuppone F, Ciccarese M, et al. Weekly docetaxel as second line chemotherapy for 
advanced non-small-cell lung cancer: meta-analysis of randomized trials. Cancer Treat Rev. 
2006;32(8):583-587.
Crino L, Mosconi AM, Scagliotti G, et al. Gemcitabine as second-line treatment for advanced 
non-small-cell lung cancer: a phase II trial. J Clin Oncol. 1999;17(7):2081-2085.
Edge SB, Byrd DR, Compton CC, et al. AJCC cancer Staging Manual. 7th Ed. Springer, 2009.
Eisenhauer E, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors: 
revised RECIST guideline (version 1.1). Eur J Cancer. 45(2):228-247.
ESMO Clinical Practice Guidelines: Metastatic Non-Small-Cell Lung Cancer. Available at: 
www.esmo.org/Guidelines/Lung-Cancer/Metastatic-Non-Small-Cell-Lung-Cancer. Accessed 
11Feb2015.
Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus 
vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated 
with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18(12):2354-2362.
Garcia-Manero G, Gore SD, Cogle C, et al. Phase I study of oral azacitidine in myelodysplastic 
syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol. 
2011;29(18):2521-2527.
Garon EB, Leighl NB, Rizvi NA, et al. Safety and clinical activity of pembrolizumab in 
previously treated patients (pts) with non-small cell lung cancer (NSCLC) [abstract]. In: 
Proceedings of the 2014 ASCO Annual Meeting; 2014 May 30-Jun 3; Chicago, IL. J Clin Oncol.
32:5s, 2014 (suppl; abstr 8020).
Gilotrif [package insert]. Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA. 
Revised April 2014.
Globocan 2012: Estimated Cancer Incidence, Mortality and Prevalance Worldwide in 2012. 
Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Accessed 11Feb2015
&(/*(1(35235,(7$5<,1)250$7,21
for 
or 
f
se I tri
se I trialal of
o
l
sly treated 
sly treated 
str 8030).
r 8030).
L1 antibod
L1 antibod
.
d line chem
d line che
ed tri
tr als. C
s second
second-li
ol.l. 1999;17
1999;1
ncer Stagin
ncer Stagi
ew respons
ew respons
ur J Cancer
r J Cance
etastati
tastat c N
ancer/Meta
ncer/Met
2
r RN, et al.
r RN, et al
in pat
in patieients
ng chemot
ng chemot
Gore SD, C
Gore SD, 
onic myelo
onic myelo
:2521
:2521-2527
2527
B, Leighl N
Leighl 
ously treate
ously treate
oceedings o
ceedings o
32:5s, 201
2:5s, 201
ilotri
ilotri


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
82
CC-486-NSCL-001 Final: 15 May 2015
Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus 
docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J 
Clin Oncol. 2004;22(15):1589-1597.
Harvey RD. Immunologic and clinical effects of targeting PD-1 in lung cancer. Clin Pharmacol 
Ther. 2014;96(2):214-223.
Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in 
patients with refractory advanced non small cell lung cancer. Cancer Discov. 2011;1(7):598-607.
Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell 
lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372(9652):1809-1818.
Lang-Lazdunski L. Surgery for nonsmall cell lung cancer. Eur Respir Rev. 2013;22(129):382-
404.
Miranda RB, Jones PA. DNA methylation: the nuts and volts of repression. J Cell Physiol. 
2007;213(2):384-390.
NCCN Practice Guidelines in Oncology: Non-Small Cell Lung Cancer v.4.2014.  Available at: 
http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 11Feb2015.
Nishimura H, Honjo T, Minato N. Facilitation of β selection and modification of positive 
selection in the thymus of PD-1-deficient mice. J Exp Med 2000;191(5):891-898.
Perol M, Ciuleanu TE, Arrieta O. REVEL: A randomized, double-blind, phase III study of 
docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the 
second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease 
progression after one prior platinum-based therapy. J Clin Oncol. 2014; 32 (5s): suppl; abstr 
LBA8006.
Peterson P, Park K, Fossella FV, et al. Is pemetrexed more effective in adenocarcinoma and 
large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III 
trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung 
cancer (NSCLC): P2-328 [abstract]. In: 12th World Conference on Lung Cancer. J of Thoracic 
Oncol 2007;2(8 suppl 4):S851.
Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus 
placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 
3, double-blind, randomised controlled trial. Lancet Oncol. 2014;15(2): 143-155.
Sculier JP, Lafitte JJ, Berghmans T, et al. A phase II trial testing gemcitabine as second-line 
chemotherapy for non small cell lung cancer. Lung Cancer. 2000;29(1):67-73.
Shaw AT, Kimm D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-
positive lung cancer. N Engl J Med. 2013;368(25):2385-2394.
Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best 
supportive care in patients with non-small-cell lung cancer previously treated with platinum-
based chemotherapy. J Clin Oncol. 2000;18(10):2095-2103.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-
cell lung cancer. N Engl J Med. 2005;353(2):123-132.
&(/*(1(35235,(7$5<,1)250$7,21
ellll
8.8.
29)
29):382
:382-
Cell Physio
ell Physi
v.4.2014.  
v.4.2014
ssed 11Feb
ed 11Feb
modificat
odificat
000;191(5)
000;191(5
d, double-
, double b
B) versus D
B) versus 
ng cancer (
ng cancer 
apy. J Clin O
py. J Clin O
pemetrexe
pemetrexe
us cell carci
us cell carc
previously 
reviously
act]. In: 12t
act]. In: 12
1.1.
mgaard A, 
mgaard
h previ
prev
h
ous
ous
ndomised c
mised c
itte JJ, Berg
tte JJ, Be
py for non s
py for non 
T, Kimm D
T, Kimm D
ve
ve lung ca
lung c
Shepherd FA
hepherd F
supportiv
upportiv
sed
sed


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
83
CC-486-NSCL-001 Final: 15 May 2015
Speicher MR, Petersen S, Uhrig S, et al. Analysis of chromosomal alterations in non-small cell 
lung cancer by multiplex-FISH, comparative genomic hybridization, and multicolor bar coding. 
Lab Invest. 2000;80(7):1031-1041.
Tarceva [package insert]. OSI Pharmaceuticals, LLC, Northbrook, IL, USA an affiliate of 
Astellas Pharma US, Inc., 2012.
Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated 
patients with refractory advanced non-small-cell lung cancer: results from a randomised, 
placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 
2005;366(9496):1527-1537.
Topalian SL. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J 
Med. 2012;366(26):2443-2454.
Topaloglu, O, Hoque, MO, Tokumaru, Y, et al. Detection of promoter hypermethylation of 
multiple genes in the tumor and bronchoalveolar lavage of patients with lung cancer. Clin Cancer 
Res. 2004;10(7):2284–2288.
Xalkori [package insert]. Pfizer Labs, New York, NY, USA, revised Aug, 2011.
Zeng L, Jarrett C, Brown K, et al. Insulin-like growth factor binding protein-3 (IGFBP-3) plays a 
role in the anti-tumorigenic effects of 5-Aza-2’-deoxycytidine (AZA) in breast cancer cells. Exp 
Cell Res. 2013;319(14):2282-2295.
&(/*(1(35235,(7$5<,1)250$7,21
N Engl J 
N Engl J 
thylat
thylatioion o
n
g cancer. Cl
g cancer. C
Aug,
Aug, 2011.
2011.
ing protein
g protein
(AZA) in b
(AZA) 


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
84
CC-486-NSCL-001 Final: 15 May 2015
19.
APPENDICES
19.1.
Appendix A: RECIST 1.1
The following information is extracted/summarized from Eisenhauer, 2009, New response
evaluation criteria in solid tumors:  Revised RECIST guideline (version 1.1). Please refer to the 
primary reference for further information.
19.1.1.
Definitions
At screening, tumor lesions/lymph nodes will be categorized as measurable or non-measurable.
19.1.1.1.
Measurable Disease
Tumor Lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
!
10 mm by CT scan (CT scan slice thickness no greater than 5 mm)
!
10 mm caliper measurement by clinical exam (lesions which cannot be accurately 
measured with calipers should be recorded as non-measurable)
!
20 mm by chest X-ray
Malignant Lymph Nodes: To be considered pathologically enlarged and measurable, a lymph 
node must be ≥ 15 mm in short axis when assessed by CT scan (CT scan slice thickness 
recommended to be no greater than 5 mm). At baseline and in follow-up, only the short axis will 
be measured and followed.
19.1.2.
Tumor Response Evaluation
19.1.2.1.
Target Lesions
When more than one measurable tumor lesion is present at baseline all lesions up to a maximum 
of 5 lesions total (and a maximum of 2 lesions per organ) representative of all involved organs 
should be identified as target lesions and will be recorded and measured at baseline. Target
lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements. Note that pathological nodes must meet the measurable 
criterion of a short axis of ≥ 15 mm by CT scan and only the short axis of these nodes will 
contribute to the baseline sum. All other pathological nodes (those with short axis ≥ 10 mm but 
< 15 mm) should be considered non-target lesions. Nodes that have a short axis < 10 mm are 
considered non-pathological and should not be recorded or followed. At baseline, the sum of the 
target lesions (longest diameter of tumor lesions plus short axis of lymph nodes:  overall 
maximum of 5) is to be recorded.
After baseline, a value should be provided on the CRF for all identified target lesions for each 
assessment, even if very small. If extremely small and faint lesions cannot be accurately 
measured but are deemed to be present, a default value of 5 mm may be used. If lesions are too 
small to measure and indeed are believed to be absent, a default value of 0 mm may be used.
&(/*(1(35235,(7$5<,1)250$7,21
surab
surable.
le.
est di
est d amete
mete
n 5 mm)
n 5 mm)
which cann
which cann
measurable)
measura
cally enlarg
cally enlarg
by
by CT scan
CT sca
y
aseline and
seline and
n
le tumor le
e tumor le
imum of 2
imum of
rget l
rget lesi
es ons
cted on the
ted on the
l invo
l involved 
lved 
peated meas
eated mea
short axis o
hort axis 
to the base
o the base
m) should b
m) should 
idered non
dered non
arget lesio
arget lesion
maximum
maximum
ter


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
85
CC-486-NSCL-001 Final: 15 May 2015
19.1.2.2.
Non-target Lesions
All non-measurable lesions (or sites of disease) plus any measurable lesions over and above 
those listed as target lesions are considered non-target lesions. Measurements are not required 
but these lesions should be noted at baseline and should be followed as “present,” “absent,” or 
“unequivocal progression.”
19.1.2.3.
Response Criteria
Target and non-target lesions are evaluated for response separately, and then the tumor burden as 
a whole is evaluated as the overall response.
19.1.2.3.1. Target Lesion Response
Target lesions will be assessed as follows:
!
Complete Response (CR).  Disappearance of all target lesions. Any pathological 
lymph nodes (whether target or non-target) must have reduction in short axis to < 10 
mm.
!
Partial Response (PR).  At least a 30% decrease in the sum of diameters of target 
lesions, taking as reference the baseline sum diameters.
!
Progressive Disease (PD).  At least a 20% increase in the sum of diameters of target 
lesions, taking as reference the smallest sum on study (this includes the baseline sum 
if that is the smallest on study). In addition to the relative increase of 20%, the sum 
must also demonstrate an absolute increase of at least 5 mm. (Note:  the appearance 
of one or more new lesions is also considered progression).
!
Stable Disease (SD).  Neither sufficient shrinkage to qualify for PR nor sufficient 
increase to qualify for PD, taking as reference the smallest sum of diameters while on 
study.
19.1.2.3.2. Non-target Lesion Response
Non-target lesions will be assessed as follows:
!
Complete Response (CR).  Disappearance of all non-target lesions and normalisation 
of tumor marker level. All lymph nodes must be non-pathological in size (< 10 mm 
short axis).
!
Non-CR/Non-PD.  Persistence of one or more non-target lesion(s) and/or 
maintenance of tumor marker level above the normal limits.
!
Progressive Disease (PD).  Unequivocal progression (see comments below) of 
existing non-target lesions. (Note: the appearance of one or more new lesions is also 
considered progression).
When the Subject Also Has Measurable Disease:  In this setting, to achieve “unequivocal 
progression” on the basis of the non-target disease, there must be an overall level of substantial 
worsening in non-target disease such that, even in presence of SD or PR in target disease, the 
overall tumor burden has increased sufficiently to merit discontinuation of therapy. A modest 
“increase” in the size of one or more non-target lesions is usually not sufficient to quality for 
&(/*(1(35235,(7$5<,1)250$7,21
as 
as 
ny patho
y pathololog
n in short a
in short a
um of diam
um of dia
rs.
se in the su
se in the su
on study
n study (th
(th
y
to the rel
to the rela
ase of at le
ase of at le
nsidered pr
nsidered pr
fficient shri
fficient shr
king as refe
king as refe
Response
Response
sessed as fo
sessed as f
sponse (CR
sponse (C
marker l
arker eve
ev
xis).
xis).
n-CR/Non
CR/Non
maintenanc
maintenan
!
Progre
rogre
exis
exis
When t
When 


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
86
CC-486-NSCL-001 Final: 15 May 2015
unequivocal progression status. The designation of overall progression solely on the basis of 
change in non-target disease in the face of SD or PR of target disease will therefore be extremely
rare.
When the Subject Has Only Non-measurable Disease:  This circumstance arises in some 
Phase 3 trials when it is not a criterion of study entry to have measurable disease. The same 
general concepts apply here as noted above; however, in this instance there is no measurable 
disease assessment to factor into the interpretation of an increase in non-measurable disease 
burden. Because worsening in non-target disease cannot be easily quantified (by definition:  if all 
lesions are truly non-measurable) a useful test that can be applied when assessing subjects for 
unequivocal progression is to consider if the increase in overall disease burden based on the 
change in non-measurable disease is comparable in magnitude to the increase that would be 
required to declare PD for measurable disease: ie, an increase in tumor burden representing an 
additional 73% increase in “volume” (which is equivalent to a 20% increase diameter in a 
measurable lesion). Examples include an increase in a pleural effusion from “trace” to “large,” 
an increase in lymphangitic disease from localized to widespread, or may be described in 
protocols as “sufficient to require a change in therapy.” If “unequivocal progression” is seen, the 
subject should be considered to have had overall PD at that point. While it would be ideal to 
have objective criteria to apply to non-measurable disease, the very nature of that disease makes 
it impossible to do so: therefore, the increase must be substantial.
19.1.2.3.3. Overall Response
Overall response should be assessed according to Table 8 for subjects with target lesions, and
Table 9 for subjects with only non-target lesions.
Table 8:
Time Point Response: Subjects With Target (± Non-target) Disease
Target Lesions 
Response
Non-target Lesion Response
New Lesions
Overall Response
CR
CR
No
CR
CR
Non-CR/ non-PD
No
PR
CR
Not evaluated
No
PR
PR
Non-PD or not all evaluated
No
PR
SD1
Non-PD or not all evaluated
No
SD
Not all evaluated
Non-PD
No
NE
PD
Any
Yes or No
PD
Any
PD
Yes or No
PD
Any
Any
Yes
PD
CR = complete response, NE = inevaluable, PD = progressive disease, PR = partial response, SD = stable disease
&(/
ny
(/*(1(3
Non
Non-PD 
D
35235,(7$5<,1)250$7,21
all
all
or r 
the
he
uld be
ld be
esent
esenting an
ng an
meter in a
meter in a
trace” to “
ace” to “
be describe
e describe
progressio
progress
hile it wou
ile it wou
ry nature of
y nature o
al.
al.
lele 8 fo
for su
r su
ts With Ta
ts With Ta
Lesion Resp
sion Resp
5,
23
R/ non
R/ non-PD
PD
52
ot evaluated
evaluated
35
( 3
1(
Non
Non
1(
1(
1(
1(
d
N
(1
*(
/*
(/
&(
CR = comp
CR = comp


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
87
CC-486-NSCL-001 Final: 15 May 2015
Table 9:
Time Point Response: Subjects With Non-target Disease Only
Non-target Lesion Response
New Lesions
Overall Response
CR
No
CR
Non-CR/ non-PD
No
Non-CR/non-PD1)
a
Not all evaluated
No
NE
Unequivocal PD
Yes or No
PD
Any
Yes
PD
CR = complete response, PD = progressive disease, NE =  inevaluable
a “Non-CR/non-PD” is preferred over “stable disease” for non-target disease since SD is increasingly used as 
endpoint for assessment of efficacy in some trials so to assign this category when no lesions can be measured is 
not advised.
19.1.2.4.
Symptomatic Deterioration
Subjects with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression at that time should be reported as 
‘symptomatic deterioration’. Every effort should be made to document objective progression 
even after discontinuation of treatment. Symptomatic deterioration is not a descriptor of an 
objective response: it is a reason for stopping study therapy. The objective response status of 
such subjects is to be determined by evaluation of target and non-target disease.
&(/*(1(35235,(7$5<,1)250$7,21
$7
$7
$7
0$7
$
used as 
ed as
e measured i
e measured i
uatioion of 
n of tr
d be reporte
be report
ment objec
ment objec
tion is
on is not 
 The objec
The objec
and non
nd non-tar


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
88
CC-486-NSCL-001 Final: 15 May 2015
19.2.
Appendix B: irRECIST
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST
&(
pri
prietet
0$7,21
e Corpora
e Corpora
21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
89
CC-486-NSCL-001 Final: 15 May 2015
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(
pri
prietet
7,21
e Corpora
e Corpora
21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
90
CC-486-NSCL-001 Final: 15 May 2015
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
91
CC-486-NSCL-001 Final: 15 May 2015
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
92
CC-486-NSCL-001 Final: 15 May 2015
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
93
CC-486-NSCL-001 Final: 15 May 2015
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
94
CC-486-NSCL-001 Final: 15 May 2015
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet
(/


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
95
CC-486-NSCL-001 Final: 15 May 2015
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
pri
prietet
7,21
e Corpora
e Corpora
21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
96
CC-486-NSCL-001 Final: 15 May 2015
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(
pri
prietet
7,21
e Corpora
e Corpora
21


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
97
CC-486-NSCL-001 Final: 15 May 2015
Table 10:
Imaging Guidance for Standard RECIST 1.1 and Immune-related (ir) RECIST (Continued)
&(/*(1(35235,(7$5<,1)250$7,21
e Corpora
e Corpora
21
pri
prietet


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
98
CC-486-NSCL-001 Final: 15 May 2015
19.3.
Appendix C: Events of Clinical Interest (ECI) Guidance Document
19.3.1.
Overview
The purpose of this appendix is to provide study sites with guidance on the identification and 
management of ECIs associated with pembrolizumab.
Based on the literature review, and consideration of mechanism of action of pembrolizumab, 
potential immune-related adverse events (irAEs) are the primary Event of ECI. Immune-related 
AEs are adverse events associated with the treatment of patients with immunotherapy treatments 
that appear to be associated with the immune therapy’s mechanism of action. Based on these 
potential irAEs, the Sponsor has defined a list of specific adverse event terms (ECIs) that are 
selected adverse experiences that must be reported to Sponsor within 5 days from the time the 
Investigator/physician is aware of such an occurrence, regardless of whether or not the 
Investigator/physician considers the event to be related to IP. ECIs may be identified through 
spontaneous patient report and/or upon review of subject data. Table 11 provides the list of terms 
and reporting requirements for AEs that must be reported as ECIs.  
Given that the current list of events of clinical interest is not comprehensive for all potential 
immune-related events, it is possible that AEs other than those listed in this document may be 
observed in patients receiving pembrolizumab. Therefore any Grade 3 or higher event that the 
Investigator/physician considers to be immune-related should be reported as an ECI regardless of 
whether the specific event term is in Table 11 and reported to Sponsor within 5 days from the 
time the Investigator/physician is aware of such an occurrence. Adverse events that are both an 
SAE and an ECI should be reported on both the eCRF and also reported to Celgene Drug Safety 
within 24 hours by facsimile, or other appropriate method, using the SAE Report Form, or 
approved equivalent form as outlined in Section 11.5.
Table 11:
Events of Clinical Interest
Pneumonitis (reported as ECI if  ≥ Grade 2)
Acute interstitial pneumonitis
Interstitial lung disease
Pneumonitis
Colitis (reported as ECI if ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to 
treat the AE)
Intestinal Obstruction
Colitis
Colitis microscopic
Enterocolitis
Enterocolitis hemorrhagic
Gastrointestinal perforation
Necrotizing colitis
Diarrhea
Endocrine (reported as ECI if  ≥ Grade 3 or ≥ Grade 2 and resulting in dose modification or use of systemic 
steroids to treat the AE)
Adrenal Insufficiency
Hyperthyroidism
Hypophysitis
Hypopituitarism
Hypothyroidism
Thyroid disorder
Thyroiditis
Hyperglycemia, if ≥Grade 3 and associated with ketosis or 
metabolic acidosis (DKA)
&
hy
hyro
ro
y idid
&(/*
nal Insufficie
nal Insufficie
/*(1(35235,(7$5<,1)250$7,21
ments
ents
ese 
ese
hat are
hat are
m th
the time t
e time 
ot the
ot the
ent
entified thro
ified thr
ovides the l
ovides the 
ehensive fo
ensive fo
sted in this 
d in this
Gr
Grade 3 or
ade 3
uld be re
d be repo
p
rted to
rted to Spo
Sp
currence.
currenc
A
CRF and al
CRF and al
ate method
te method
ioion n 11.5
11.5.
est
est
de 2)
2)
23
Int
Int
52
52
52
52
ade 2 or any
ade 2 or a
35
( 3
1(
s
(1
reported as 
eported as 
o treat the A
eat the A
*(
/*
Hypopituitari
Hypopituitari
(/
&(


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
99
CC-486-NSCL-001 Final: 15 May 2015
Table 11:
Events of Clinical Interest (Continued)
Endocrine (reported as ECI)
Type 1 diabetes mellitus (if new onset)
Hematologic (reported as ECI if  ≥ Grade 3 or any grade resulting in dose modification or use of systemic 
steroids to treat the AE)
Autoimmune hemolytic anemia 
Aplastic anemia 
Thrombotic Thrombocytopenic 
Purpura (TTP)
Idiopathic (or immune) Thrombocytopenia 
Purpura  (ITP)
Disseminated Intravascular 
Coagulation (DIC)
Haemolytic Uraemic Syndrome 
(HUS)
Any Grade 4 anemia regardless of underlying mechanism
Hepatic (reported as ECI if  ≥ Grade 2, or any grade resulting in dose modification or use of systemic steroids 
to treat the AE)
Hepatitis 
Autoimmune hepatitis 
Transaminase elevations (ALT 
and/or AST)
Infusion Reactions (reported as ECI for any grade)
Allergic reaction
Anaphylaxis
Cytokine release syndrome
Serum sickness
Infusion reactions
Infusion-like reactions
Neurologic (reported as ECI for any grade)
Autoimmune neuropathy
Guillain-Barre syndrome
Demyelinating polyneuropathy
Myasthenic syndrome
Ocular (report as ECI if  ≥ Grade 2 or any grade resulting in dose modification or use of systemic steroids to 
treat the AE)
Uveitis
Iritis
Renal (reported as ECI if  ≥ Grade 2)
Nephritis
Nephritis autoimmune
Renal Failure
Renal failure acute
Creatinine elevations (report as ECI if ≥Grade 3 or any grade 
resulting in dose modification or use of systemic steroids to treat the 
AE)
Skin (reported as ECI for any grade)
Dermatitis exfoliative
Erythema multiforme
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Skin (reported as ECI if ≥ Grade 3)
Pruritus
Rash
Rash generalized
Rash maculo-papular
Any rash considered clinically significant in the physician’s judgment 
Other (reported as ECI for any grade)
Myocarditis
Pancreatitis
Pericarditis
Any other Grade 3 event which is considered immune-related by the physician
&(/
h maculo
maculo-pa
pa
(/*(1(35235,
tis
tis
5,(7$5<,1)250$7,21
7
ome
me
7
$7
0$
systemic ste
ystemic st
50
inase elevatio
nase elevati
AST)
AST)
25
1)
Cytokine 
okine
y
,1
<
Infusi
In
<
5<
5<
5<
5<
ndrome
ndrome
$5
7$
ulting in dos
ting in do
(7
5,
35
Neph
ep
23
52
C
52
52
52
52
or any grade
or any gra
( 3
1(
necrolysis
ecrolysis
(1
ted as ECI i
d as ECI i
*(
/*
(/
Any
An rash co
sh co
y
&(
her
h
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
100
CC-486-NSCL-001 Final: 15 May 2015
Each of the events above is described within this guidance document, along with site 
requirements for reporting these events to the Sponsor.  In addition, the guidelines include 
recommendations on the management of these ECIs. These guidelines are intended to be applied 
when the Investigator determines the events to be related to pembrolizumab. Note: if after the 
evaluation the event is determined not to be related, the Investigator is instructed to follow the 
ECI reporting guidance but does not need to follow the treatment guidance (below). Therefore, 
these recommendations should be seen as guidelines and the treating physician should exercise 
individual clinical judgment based on the patient.  For any question of dose modification or other 
treatment options, the specific language in the protocol should be followed.  Any questions 
pertaining to the collection of this information or management of ECIs should be directed to your 
local Sponsor contact. 
19.3.1.1.
Dose Modification/Discontinuation
The treatment guidance provides specific direction when to hold and/or discontinue 
pembrolizumab for each immune-related adverse event.  Of note, when the guidance states to 
“discontinue” pembrolizumab this is the permanent discontinuation of treatment with 
pembrolizumab. “Hold” means to stop treating with pembrolizumab but resumption of treatment 
may be considered assuming the patient meets the criteria for resumption of treatment.
19.3.2.
ECI Reporting Guidelines
Events of clinical interest are selected non-serious and serious adverse experiences that must be 
reported to Sponsor within 5 days for NON-SERIOUS events regardless of attribution to study 
treatment.  The AEs listed in this document and any event that meets the ECI criteria (as noted) 
in Table 11 or in the respective protocol (event term and Grade) must be reported regardless of 
physician-determined causality with IP and whether or not considered immune-related by the 
physician (unless otherwise specified).   Physicians/study coordinators/designated site personnel 
are required to record these experiences as ECIs on the Adverse Event CRF and to provide 
supplemental information (such as medical history, concomitant medications, investigations, 
etc.) about the event.  
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be 
reported to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate 
method, using the SAE Report Form, or approved equivalent form as outlined in Section 
11.5.
!
Please refer to the CRF Completion Guidelines. 
!
Please refer to protocol for details on reporting timelines and reporting of overdose 
19.3.3.
ECI Categories and Terms
This section describes the ECI categories and outlines subject management guidelines when an 
ECI is reported.
19.3.3.1.
Pneumonitis
The following AE terms, if considered ≥ Grade 2, are considered ECIs and should be reported to 
the Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
r r 
to y
to your 
our 
ntinue
in
guidance s
guidance 
eatment w
atmen
but resump
ut resump
mpt
mp ion o
n of t
rious adve
ous adv
US events
US events
7$
y event tha
y event tha
term and G
erm and 
whether or n
whether or n
5,
hy
hysicians/s
sicians/s
s as ECIs o
as ECIs 
medical hist
edical hi
ets the crit
ets the crit
Drug Safet
rug Safet
E Report F
E Report 
e refer to t
e refer to t
Pl
Please refer
ease refer
ECI C
CI C
is sect
s section n 
ECI i
EC
s rep
s rep
3


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
101
CC-486-NSCL-001 Final: 15 May 2015
!
Pneumonitis
!
Interstitial lung disease
!
Acute interstitial pneumonitis 
If symptoms indicate possible new or worsening cardiac abnormalities additional testing and/or a 
cardiology consultation should be considered. 
All attempts should be made to rule out other causes such as metastatic disease, bacterial or viral 
infection.  It is important that patients with a suspected diagnosis of pneumonitis be 
managed as per the guidance below until treatment-related pneumonitis is excluded.  
Treatment of both a potential infectious etiology and pneumonitis in parallel may be 
warranted.  Management of the treatment of suspected pneumonitis with steroid treatment 
should not be delayed for a therapeutic trial of antibiotics.  If an alternative diagnosis is 
established, the patient does not require management as below; however the AE should be 
reported regardless of etiology.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
Course of Action
Grade 2 events:
!
Report as ECI
!
Hold pembrolizumab
!
Consider pulmonary consultation with bronchoscopy and biopsy/bronchoalveolar 
lavage (BAL)
!
Consider infectious disease (ID) consult
!
Conduct an in person evaluation approximately twice per week
!
Consider frequent chest X-ray as part of monitoring
!
Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg/day prednisone or 
equivalent.  When symptoms improve to Grade 1 or less, steroid taper should be 
started and continued over no less than 4 weeks.  
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.   
!
Second episode of pneumonitis – discontinue pembrolizumab if upon re-challenge the 
patient develops a second episode of Grade 2 or higher pneumonitis.
Grade 3 and 4 events:
!
Report as ECI
!
Discontinue pembrolizumab
!
Hospitalize patient
&(/*(1(35235,(7$5<,1)250$7,21
be
d treatmen
d treatmen
agnosis 
gnosis isis
E should be
E should 
SAE), mus
AE), m
propriate m
ropriate m
tioion 11.5
11.5
wi
with
th
i
bronc
bronc
h
e (
e (ID
ID) cons
evaluat
evaluation
chest X
hest X-r
stemic cort
stemic co
.  When sym
.  When 
and continu
and continu
manent
anently 
ly d
prednisone 
prednisone
!
Second
Second
pati
pati
Grade 3 an
Grade 3 an


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
102
CC-486-NSCL-001 Final: 15 May 2015
!
Bronchoscopy with biopsy and/or BAL is recommended.
!
Immediately treat with intravenous steroids (methylprednisolone 125 mg IV). When 
symptoms improve to Grade 1 or less, a high dose oral steroid (prednisone 1 to 2 
mg/kg once per day or dexamethasone 4 mg every 4 hours) taper should be started 
and continued over no less than 4 weeks.
!
If IV steroids followed by high dose oral steroids does not reduce initial symptoms 
within 48 to 72 hours, treat with additional anti-inflammatory measures. Discontinue 
additional anti-inflammatory measures upon symptom relief and initiate a prolonged 
steroid taper over 45 to 60 days. If symptoms worsen during steroid reduction, initiate 
a retapering of steroids starting at a higher dose of 80 or 100 mg followed by a more 
prolonged taper and administer additional anti-inflammatory measures, as needed.
!
Add prophylactic antibiotics for opportunistic infections.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.3.2.
Diarrhea/Colitis
The following AE terms, if considered ≥ Grade 2 or resulting in dose modification or use of 
systemic steroids to treat the AE, are considered ECIs and should be reported to the Sponsor on 
the Adverse Event CRF within 5 days if determined to be a non-serious event:
!
Colitis 
!
Colitis microscopic
!
Enterocolitis
!
Enterocolitis hemorrhagic 
!
Gastrointestinal perforation
!
Intestinal obstruction 
!
Necrotizing colitis
!
Diarrhea
All attempts should be made to rule out other causes such as metastatic disease, bacterial or 
parasitic infection, viral gastroenteritis, or the first manifestation of an inflammatory bowel 
disease by examination for stool leukocytes, stool cultures, a Clostridium difficile titer and 
endoscopy.   However the AE should be reported regardless of etiology.
Course of Action
Grade 2 Diarrhea/Colitis (4-6 stools/day over baseline, dehydration requiring IV fluids < 24 
hours, abdominal pain, mucus or blood in stool):  
!
Report as ECI
!
Hold pembrolizumab
&(/*(1(35235,(7$5<,1)250$7,21
ged 
ed 
ini
in titi
i ate
ate
y a m
y
ore
ore
s needed
s needed.
E), must be 
), must be
riate metho
iate m
11.5
11.5.
g in dose m
in dose m
d should be
d should be
be a non
be a non-s
ration
ration
ion
ion
coli
ol ti
i s
oululd be mad
d be ma
ctioion, viral
n, viral
examinat
aminatioi
opy
op .   How
 How
urse of Ac
urse of Ac
Grade 2 D
Grade 2 D
ours, 
ours,


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
103
CC-486-NSCL-001 Final: 15 May 2015
!
Symptomatic Treatment
!
For Grade 2 diarrhea that persists for greater than 3 days, and for diarrhea with blood 
and/or mucus, 
o
Consider GI consultation and endoscopy to confirm or rule out colitis 
o
Administer oral corticosteroids (prednisone 1-2 mg/kg once daily or 
equivalent)
!
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.   
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
!
If symptoms worsen or persist > 3 days treat as Grade 3
Grade 3 Diarrhea/Colitis (or Grade 2 diarrhea that persists for > 1 week):
!
Report as ECI
!
Hold pembrolizumab
!
Rule out bowel perforation.  Imaging with plain films or CT can be useful
!
Recommend consultation with gastroenterologist and confirmation biopsy with 
endoscopy
!
Treat with intravenous steroids (methylprednisolone 125 mg) followed by high-dose 
oral steroids (prednisone 1 to 2 mg/kg once per day or dexamethasone 4 mg every 4 
hours).  When symptoms improve to Grade 1 or less, steroid taper should be started 
and continued over no less than 4 weeks.  Taper over 6 to 8 weeks in patients with 
diffuse and severe ulceration and/or bleeding.
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
!
If IV steroids followed by high-dose oral steroids does not reduce initial symptoms 
within 48 to 72 hours, consider treatment with additional anti-inflammatory measures 
as described in the literature (Topalian, 2012). Discontinue additional anti-
inflammatory measures upon symptom relief and initiate a prolonged steroid taper 
over 45 to 60 days. If symptoms worsen during steroid reduction, initiate a retapering 
of steroids starting at a higher dose of 80 or 100 mg followed by a more prolonged 
taper and administer additional anti-inflammatory measures as needed. 
Grade 4 events: 
!
Report as ECI
!
Permanently discontinue pembrolizumab
!
Manage as per Grade 3
&(/*(1(35235,(7$5<,1)250$7,21
g or l
g or less of
ess o
ms or CT c
ms or C
gist and con
ist and con
predniso
prednisolo
kg once per
g once pe
e to Grade 
e to Grade 
n 4 weeks. 
n 4 weeks
n and/or bl
and/or b
ue for inabi
for inabi
alent per da
alent per da
llolowed by h
wed by
72 hours, co
72 hours,
ed in the lit
ed in the 
matory
matory m
y
ea
45 to 60 d
45 to 60 d
steroi
steroi
f
ds st
ds s
taper and
aper and
4 events:
4 events:
!
R


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
104
CC-486-NSCL-001 Final: 15 May 2015
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.  
19.3.3.3.
Endocrine
The following AE terms, if considered ≥Grade 3 or if ≥Grade 2 and require 
holding/discontinuation/ modification of pembrolizumab dosing, are considered ECIs and should 
be reported to the Sponsor on the Adverse Event CRF within 5 days if determined to be a non-
serious event:
!
Adrenal insufficiency
!
Hyperthyroidism
!
Hypophysitis
!
Hypopituitarism 
!
Hypothyroidism
!
Thyroid disorder 
!
Thyroiditis 
All attempts should be made to rule out other causes such as brain metastases, sepsis and/or 
infection.  However the AE should be reported regardless of etiology.
Hypophysitis or other symptomatic endocrinopathy other than hypo- or hyperthyroidism
Grade 2-4 events:
!
Report as ECI if appropriate
!
Hold pembrolizumab
!
Rule out infection and sepsis with appropriate cultures and imaging.
!
Monitor thyroid function or other hormonal level tests and serum chemistries more 
frequently until returned to baseline values.
!
Pituitary gland imaging should be considered (MRIs with gadolinium and selective 
cuts of the pituitary can show enlargement or heterogeneity and confirm the 
diagnosis).
!
Treat with prednisone 40 mg orally or equivalent per day.  When symptoms improve 
to Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.  Replacement of appropriate hormones may be required as the steroid dose is 
tapered. 
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks. 
!
Hypophysitis with clinically significant adrenal insufficiency and hypotension, 
dehydration, and electrolyte abnormalities (such as hyponatremia and hyperkalemia) 
constitutes adrenal crisis.
&(/*(1(35235,(7$5<,1)250$7,21
as brain m
as brain m
ess of etio
ess of etiolol
athy other 
athy other
(7
sepsis wit
sepsis wi h
nct
nctioion or o
n or 
returned to
eturned t
and imagin
and imagin
he pituitary
he pituitary
nosis).
osis).
reat wi
reat with
th
i
p
h
to Grade 
o Grade
weeks
eeks
tap
tap
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
105
CC-486-NSCL-001 Final: 15 May 2015
!
Consultation with an endocrinologist may be considered.
Hyperthyroidism and Hypothyroidism
Thyroid disorders can occur at any time during treatment. Monitor patients for changes in 
thyroid function (at the start of treatment, periodically during treatment, and as indicated based 
on clinical evaluation) and for clinical signs and symptoms of thyroid disorders.
Grade 2 hyperthyroidism, Grade 2-4 hypothyroidism events:
!
Report as ECI if appropriate (see Table 11)
!
Monitor thyroid function or other hormonal level tests and serum chemistries more 
frequently until returned to baseline values.
!
Thyroid hormone and/or steroid replacement therapy to manage adrenal insufficiency.
!
Therapy with pembrolizumab can be continued while treatment for the thyroid 
disorder is instituted. 
!
In hyperthyroidism, non-selective beta-blockers (eg, propranolol) are suggested as 
initial therapy. 
!
In hypothyroidism, thyroid hormone replacement therapy, with levothyroxine or 
liothyroinine, is indicated per standard of care. 
!
Consultation with an endocrinologist may be considered.
Grade 3 hyperthyroidism events:
!
Report as ECI
!
Hold pembrolizumab
!
Rule out infection and sepsis with appropriate cultures and imaging.
!
Treat with an initial dose of methylprednisolone 1 to 2 mg/kg intravenously followed 
by oral prednisone 1 to 2 mg/kg per day.  When symptoms improve to Grade 1 or 
less, steroid taper should be started and continued over no less than 4 weeks. 
Replacement of appropriate hormones may be required as the steroid dose is tapered.
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 hyperthyroidism events:
!
Report as ECI
!
Discontinue pembrolizumab
!
Manage as per Grade 3
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.  
&(/*(1(35235,(7$5<,1)250$7,21
more
more
al insufficie
insuffici
r the thy
r the thyroi
ro
y
nolo
nolol)l) are s
are
erapy, with
rapy,
considered
onsider
s wit
with appr
h app
e of m
of methy
ethy
to 2 mg/kg
to 2 mg/kg
should be
should be
f appropria
appropria
ly disconti
ly discon
one or equi
one or equi
thy
hyroi
roi
y
dism
dism
Report as 
Report as 
!
Disco
sco
!
M
NOTE:  
NOTE
the
h


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
106
CC-486-NSCL-001 Final: 15 May 2015
Type 1 diabetes mellitus (if new onset) and ≥ Grade 3 Hyperglycemia
The following AE terms are considered ECIs and should be reported to the Sponsor on the 
Adverse Event CRF within 5 days if determined to be a non-serious event:
!
Type 1 diabetes mellitus (T1DM), if new onset, including diabetic ketoacidosis 
(DKA) 
!
Grade 3 or higher hyperglycemia, if associated with ketosis (ketonuria) or metabolic 
acidosis (DKA).
Immune-mediated diabetes may present as new onset of type 1 diabetes or an abrupt worsening 
of pre-existing diabetes associated with laboratorial evidence of beta cell failure. All attempts 
should be made to rule out other causes such as type 2 diabetes mellitus (T2DM), T2DM 
decompensation, steroid-induced diabetes, physiologic stress-induced diabetes, or poorly 
controlled pre-existing diabetes (either T1DM or T2DM), but events meeting the above criteria 
should be reported as ECIs regardless of etiology. The patients may present with hyperglycemia 
(abrupt onset or abrupt decompensation) with clinical evidence of diabetic ketoacidosis or 
laboratory evidence of insulin deficiency, such as ketonuria, laboratory evidence of metabolic 
acidosis, or low or undetected c-peptide.
Course of Action
T1DM should be immediately treated with insulin.
Type 1 diabetes mellitus or Grade 3-4 hyperglycemia events:
!
Report as ECI if appropriate (see Table 11)
!
Hold pembrolizumab for new onset type 1 diabetes mellitus or Grade 3-4 
hyperglycemia associated with evidence of beta cell failure, and resume 
pembrolizumab when patients are clinically and metabolically stable. 
!
Insulin replacement therapy is recommended for type 1 diabetes mellitus and for 
Grade 3-4 hyperglycemia associated with metabolic acidosis or ketonuria. 
!
Evaluate patients with serum glucose and a metabolic panel, urine ketones, 
glycosylated hemoglobin, and C-peptide. 
!
Consultation with an endocrinologist is recommended.
!
Consider local testing for islet cell antibodies and antibodies to GAD, IA-2, ZnT8, 
and insulin may be obtained.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.  
19.3.4.
Hematologic
The following AE term, if considered Grade ≥3 or requiring dose modification or use of 
systemic steroids to treat the AE, are considered an ECI and should be reported to the Sponsor on 
the Adverse Event CRF within 5 days if determined to be a non-serious event:
&(/*(1(35235,(7$5<,1)250$7,21
ic
worsening
orsening
l attempts
l attempts
, T2DM 
, T2DM 
s, or poorly
s, or poorly
ng the abov
ng the abov
sent wi
nt with
ti
hy
h
bet
betic ketoa
ic ketoa
atory
to
evide
evid
y
mia events:
mia events:
able
ble 11
11)
nset t
nset type 1
ype
ith
th
i
evidenc
eviden
h
tients are cl
ients are
therap
therapy y is r
is r
lycemia ass
lycemia ass
ents with se
ents with
ed hemoglo
ed hemog
ltat
tatioion wi
with
th
i
onsider loc
onsider loc
and insuli
and insuli
E:  Any eve
E:  Any eve
he Celgene
he Celgene
SAE Repor
SAE Repor
.3.4
3 4


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
107
CC-486-NSCL-001 Final: 15 May 2015
!
Autoimmune hemolytic anemia
!
Aplastic anemia
!
Disseminated Intravascular Coagulation (DIC)
!
Haemolytic Uraemic Syndrome (HUS)
!
Idiopathic (or immune) Thrombocytopenia Purpura (ITP)
!
Thrombotic Thrombocytopenic Purpura (TTP)
!
Any Grade 4 anemia regardless of underlying mechanism
All attempts should be made to rule out other causes such as metastases, sepsis and/or infection.   
Relevant diagnostic studies such as peripheral blood smear, reticulocyte count, LDH, 
haptoglobin, bone marrow biopsy or Coomb’s test, etc., should be considered to confirm the 
diagnosis. However the AE should be reported regardless of etiology.
Course of Action
Grade 2 events:
!
Report as ECI
!
Hold pembrolizumab
!
Prednisone 1-2 mg/kg daily may be indicated
!
Consider hematology consultation.
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 3 events:
!
Report as ECI
!
Hematology consultation. 
!
Hold pembrolizumab   Discontinuation should be considered as per specific protocol 
guidance.
!
Treat with methylprednisolone 125 mg iv or prednisone 1-2 mg/kg orally (or 
equivalent) as appropriate
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events:
!
Report as ECI
!
Hematology consultation
!
Discontinue pembrolizumab for all solid tumor indications; refer to protocol for 
hematologic malignancies.
&(/*(1(35235,(7$5<,1)250$7,21
infect
nfectioion. 
n.
H, 
H, 
confirm th
confirm th
y y to reduce
to reduc
wi
with
th
i in 12 w
in 12 w
tition. 
on.
mab   Disc
mab   Di
h m
h
ethylpr
ethylp
alent) as app
alent) as ap
rmanent
anentlyly
prednison
prednison
4 events:
4 events:
!
R


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
108
CC-486-NSCL-001 Final: 15 May 2015
!
Treat with methylprednisolone 125 mg iv or prednisone 1-2 mg/kg orally (or 
equivalent) as appropriate
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.5.
Hepatic
The following AE terms, if considered ≥ Grade 2 or greater (or any grade with dose modification 
or use of systemic steroids to treat the AE), are considered ECIs and should be reported to the 
Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!
Autoimmune hepatitis 
!
Hepatitis 
!
Transaminase elevations
All attempts should be made to rule out other causes such as metastatic disease, infection or 
other hepatic diseases. However the AE should be reported regardless of etiology.
Drug-induced Liver Injury (DILI)
In addition, the event must be reported as a drug-induced liver injury (DILI) ECI, if the patient 
meets the laboratory criteria for potential DILI defined as: 
!
An ALT or AST lab value that is greater than or equal to three times (3X) the upper 
limit of normal (ULN) and 
!
An elevated total bilirubin lab value that is greater than or equal to two times (2X) 
ULN and
!
At the same time, an alkaline phosphatase lab value that is less than 2X ULN,
!
As a result of within-protocol-specific testing or unscheduled testing.
Note that any hepatic immune ECI meeting DILI criteria should only be reported once as a DILI 
event.  
Course of Action
Grade 2 events:
!
Report as ECI
!
Hold pembrolizumab when AST or ALT > 3.0 to 5.0 times ULN and/or total bilirubin 
> 1.5 to 3.0 times ULN.
!
Monitor liver function tests (LFTs) more frequently until returned to baseline values 
(consider weekly).
o
Treat with 0.5-1 mg/kg/day methylprednisolone or oral equivalent and when 
LFT returns to Grade 1 or baseline, taper steroids over at least 1 month, 
&(/*(1(35235,(7$5<,1)250$7,21
ion 
on
the
nt:
disease, in
disease, 
ss of etio
of etiolol
ver i
er injury
njury (D
(
y
:
than or equ
han or e
ue that is gr
ue that is g
ne phospha
ne phospha
rotocol
rotoco -spe
sp
ECI meet
ECI meet
s:
Report as
Report as
!
Holold
>
!


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
109
CC-486-NSCL-001 Final: 15 May 2015
consider prophylactic antibiotics for opportunistic infections, and resume 
pembrolizumab per protocol.
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
!
Permanently discontinue pembrolizumab for patients with liver metastasis who begin 
treatment with Grade 2 elevation of AST or ALT, and AST or ALT increases ≥50% 
relative to baseline and lasts ≥1 week.
Grade 3 events:
!
Report as ECI
!
Discontinue pembrolizumab when AST or ALT > 5.0 times ULN and/or total 
bilirubin > 3.0 times ULN.  
!
Consider appropriate consultation and liver biopsy to establish etiology of hepatic 
injury, if necessary
!
Treat with high-dose intravenous glucocorticosteroids for 24 to 48 hours.  When 
symptoms improve to Grade 1 or less, a steroid taper with dexamethasone 4 mg every 
4 hours or prednisone at 1 to 2 mg/kg should be started and continued over no less 
than 4 weeks. 
!
If serum transaminase levels do not decrease 48 hours after initiation of systemic 
steroids, oral mycophenolate mofetil 500 mg every 12 hours may be given. Infliximab 
is not recommended due to its potential for hepatotoxicity.
!
Several courses of steroid tapering may be necessary as symptoms may worsen when 
the steroid dose is decreased.
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events: 
!
Report as ECI
!
Permanently discontinue pembrolizumab
!
Manage patient as per Grade 3 above
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.6.
Neurologic
The following AE terms, regardless of grade, are considered ECIs and should be reported to the 
Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!
Autoimmune neuropathy
!
Demyelinating polyneuropathy
&(/*(1(35235,(7$5<,1)250$7,21
total
total
ioiolology
gy of
of
y
h
f
24 to 48 ho
24 to 48 h
with dexame
th dexam
ted and con
ed an
48 hours a
8 hours
mg every 1
mg every
for hepato
or hepato
f
may be ne
may be ne
r inabilit
inabil y y
t per day w
per day w
y discontin
y discontin
e patient as
e patient as
event that m
vent that 
ene Drug S
ne Drug S
port Form, 
t Form
3.6.
.6.
Ne
Ne
The fo
The follo
llo
pon
pons


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
110
CC-486-NSCL-001 Final: 15 May 2015
!
Guillain-Barre syndrome
!
Myasthenic syndrome
All attempts should be made to rule out other causes such as metastatic disease, other 
medications or infectious causes. However the AE should be reported regardless of etiology.
Course of Action
Grade 2 events:
!
Report as ECI
!
Moderate (Grade 2) – consider withholding pembrolizumab. 
!
Consider treatment with prednisone 1-2 mg/kg orally daily as appropriate
!
Consider neurology consultation. Consider biopsy for confirmation of diagnosis.
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 3 and 4 events:
!
Report as ECI
!
Discontinue pembrolizumab
!
Obtain neurology consultation.  Consider biopsy for confirmation of diagnosis.
!
Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equivalent 
once per day. If condition worsens consider intravenous immunoglobulin (IVIG) or 
other immunosuppressive therapies as per local guidelines
When symptoms improve to Grade 1 or less, steroid taper should be started and continued over 
no less than 4 weeks.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.7.
Ocular
The following AE terms, if considered Grade ≥2 or requiring dose modification or use of 
systemic steroids to treat the AE, is considered an ECI and should be reported to the Sponsor on 
the Adverse Event CRF within 5 days if determined to be a non-serious event:
!
Uveitis
!
Iritis 
All attempts should be made to rule out other causes such as metastatic disease, infection or 
other ocular disease (eg, glaucoma or cataracts). However the AE should be reported regardless 
of etiology.
Course of Action
Grade 2 events: 
&(/*(1(35235,(7$5<,1)250$7,21
e
of diagnosi
of diagno
ose to 10 m
se to 10 m
opsy for co
opsy for c
dose of 1 t
dose of 1 t
onsider 
onsider int
in
es as per 
es as per lolo
less, steroid
ess, steroid
criteria for
criteria fo
hinin 24 hou
24 hou
ved equiva
ved equiv
term
terms, if co
s, if c
ds to treat t
ds to treat t
Event CRF
Event CRF
Uveit
Uveitisis
!
Iri
Irititi
All
All attem
attemp
m
other oc
ther o
t


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
111
CC-486-NSCL-001 Final: 15 May 2015
!
Evaluation by an ophthalmologist is strongly recommended.
!
Treat with topical steroids such as 1% prednisolone acetate suspension and 
iridocyclitics.
!
Discontinue pembrolizumab as per protocol if symptoms persist despite treatment 
with topical immunosuppressive therapy.
Grade 3 events:
!
Evaluation by an ophthalmologist is strongly recommended 
!
Hold pembrolizumab and consider permanent discontinuation as per specific protocol 
guidance.
!
Treat with systemic corticosteroids such as prednisone at a dose of 1 to 2 mg/kg per 
day.  When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events: 
!
Evaluation by an ophthalmologist is strongly recommended 
!
Permanently discontinue pembrolizumab
!
Treat with corticosteroids as per Grade 3 above
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.8.
Renal
The following AEs if ≥ Grade 2 are considered ECIs and should be reported to the Sponsor on 
the Adverse Event CRF within 5 days if determined to be a non-serious event:
!
Nephritis
!
Nephritis autoimmune
!
Renal failure
!
Renal failure acute
Creatinine elevations ≥ Grade 3 or any grade with dose modification or use of systemic steroids 
to treat the AE.
All attempts should be made to rule out other causes such as obstructive uropathy, progression of 
disease, or injury due to other chemotherapy agents.  A renal consultation is recommended. 
However the AE should be reported regardless of etiology.
Course of Action
Grade 2 events:
&(/*(1(35235,(7$5<,1)250$7,21
protocol
rotocol
o 2 m
2 mg/kg p
g/kg 
m
uld be start
uld be sta
d dose to 1
dose to
ommended 
ommended
 above
 above
ERIOUS ad
RIOUS a
by facsimil
by facsimil
t form as o
t form as o
are conside
are consid
in 5 days if
n 5 days if
autoimmun
autoimmu
l failure
failure
Renal
Renal failur
failur
ne elevat
levatioio
at the AE.
at the AE
All
All attem
attempts
pt
m
&
didisease, 
sease, 
owe


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
112
CC-486-NSCL-001 Final: 15 May 2015
!
Hold pembrolizumab
!
Treatment with prednisone 1-2 mg/kg orally daily.
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 3-4 events: 
!
Discontinue pembrolizumab
!
Renal consultation with consideration of ultrasound and/or biopsy as appropriate
!
Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone IV or 
equivalent once per day.  
When symptoms improve to Grade 1 or less, steroid taper should be started and continued over 
no less than 4 weeks.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.9.
Skin
Rash and Pruritus
The following AEs should be considered as ECIs, if ≥ Grade 3 and should be reported to the 
Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!
Pruritus
!
Rash
!
Rash generalized
!
Rash maculo-papular
!
In addition to CTCAE Grade 3 rash, any rash that is considered clinically significant, 
in the physician's judgment, should be treated as an ECI. Clinical significance is left 
to the physician to determine, and could possibly include rashes such as the 
following: 
o
rash with a duration > 2 weeks; OR 
o
rash that is > 10% body surface area; OR 
o
rash that causes significant discomfort not relieved by topical medication or 
temporary cessation of IP.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
&(/*(1(35235,(7$5<,1)250$7,21
or 
continued o
continued 
AE), m
AE), must b
t b
m
opriate me
opriate m
on 11.5
11.5.
Grade 3 an
Grade 3 a
f determine
f determin
CAE Grade
CAE Grade
n's judgmen
 judgmen
cian to dete
ian to det
:
rash wit
rash with
o
rash 
rash
o
NOTE:  Any
NOTE:  An
to the Ce
o the Ce
AE R
AE R


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
113
CC-486-NSCL-001 Final: 15 May 2015
Other Skin ECIs
The following AEs should always be reported as ECIs, regardless of grade, and should be 
reported to the Sponsor on the Adverse Event CRF within 5 days if determined to be a non-
serious event:
!
Dermatitis exfoliative
!
Erythema multiforme
!
Stevens-Johnson syndrome
!
Toxic epidermal necrolysis
Please note, the AE should be reported regardless of etiology.
Course of Action
Grade 2 events:
!
Symptomatic treatment should be given such as topical glucocorticosteroids (eg, 
betamethasone 0.1% cream or hydrocortisone 1%) or urea-containing creams in 
combination with oral anti-pruritics (eg, diphenhydramine hydrochloride [HCl] or 
hydroxyzine HCl). 
!
Treatment with oral steroids is at physician’s discretion for Grade 2 events.
Grade 3 events:
!
Hold pembrolizumab.
!
Consider dermatology consultation and biopsy for confirmation of diagnosis.
!
Treatment with oral steroids is recommended, starting with 1 mg/kg prednisone or 
equivalent once per day or dexamethasone 4 mg four times orally daily.  When 
symptoms improve to Grade 1 or less, steroid taper should be started and continued 
over no less than 4 weeks.
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks.
Grade 4 events:
!
Permanently discontinue pembrolizumab.
!
Dermatology consultation and consideration of biopsy and clinical dermatology 
photograph.
!
Initiate steroids at 1 to 2 mg/kg prednisone or equivalent.  When symptoms improve 
to Grade 1 or less, steroid taper should be started and continued over no less than 4 
weeks.
19.3.9.1.
Immediate Evaluation for Potential Skin ECIs
A. Photographs:
&(/*(1(35235,(7$5<,1)250$7,21
ocorticoster
ortico
co
contntaining
aining
ine
n hydroch
hydro
creti
cretion f
on for
f
and biopsy
nd biopsy
recommen
ecommen
exam
examethas
etha
ade 1 or les
ade 1 or 
eks.
eks.
ontinue for 
ontinue for 
equivalent p
uivalent p
nent
ently disc
ly disc
rmatol
atology
ogy
photograp
photograp
!
Initi iat
iat
to G
to G
.3.9
3 9


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
114
CC-486-NSCL-001 Final: 15 May 2015
Every attempt should be made to get a photograph of the actual ECI skin lesion or rash as soon 
as possible. 
!
Take digital photographs of: 
o
the head (to assess mucosal or eye involvement), 
o
the trunk and extremities, and 
o
a close-up of the skin lesion/rash.
!
If possible, a ruler should be placed alongside the site of a skin occurrence as a fixed 
marker of distance. 
!
The time/date stamp should be set in the 'ON' position for documentation purposes. 
!
Photographs should be stored with the subject’s study records. 
!
The Sponsor may request copies of photographs. The local study contact (eg, clinical 
research associate [CRA]) will provide guidance to the site, if needed. 
B. Past Medical History:
Collect past medical history relevant to the event. Any pre-existing conditions not previously 
reported (eg, drug allergy) should be entered into the Medical History electronic case report form 
(eCRF). 
C. Vitals Signs and Standard Laboratory Tests:
Measure vital signs and record on the Vital Signs CRF.  Perform standard laboratory tests (CBC 
with differential and serum chemistry panel, including LFTs). 
D. Dermatology Consult
Refer the subject to a dermatologist as soon as possible. 
!
For a “severe rash”, the subject must be seen within 1-2 days of reporting the event. 
!
For clinically significant rash, the subject should be seen within 3-5 days. 
The dermatologist should submit a biopsy sample to a certified dermatopathology laboratory or 
to a pathologist experienced in reviewing skin specimens. 
The site should provide the dermatologist with all relevant case history, including copies of 
clinical photographs and laboratory test results.
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.10.
Other
The following AEs, regardless of grade, are considered ECIs and should be reported to the 
Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!
Myocarditis
!
Pericarditis
&(/*(1(35235,(7$5<,1)250$7,21
xed 
xed 
purposes. 
purposes. 
contact (eg
contact (
needed.
needed.
ng condi
condititi
i o
History
History ele
RF.  Perfo
RF.  Perfo
luding LFT
luding LFT
oon as poss
oon as po
subject mu
ubject mu
icant rash, t
cant rash, t
ubmi
bmit a bi
t a bi
i
nced in revi
nced in re
vide th
de the der
e de
phs and lab
phs and lab
event that 
event that 
gene Drug 
ne Drug 
eport Form
eport Form
9.3.10.
.3.10.
O
The fo
The follo
l
ons


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
115
CC-486-NSCL-001 Final: 15 May 2015
!
Pancreatitis
!
Any additional Grade 3 or higher event which the physician considers to be immune 
related
All attempts should be made to rule out other causes.  Therapeutic specialists should be 
consulted as appropriate. However the AE should be reported regardless of etiology.
Course of Action
Grade 2 events or Grade 1 events that do not improve with symptomatic treatment:
!
Withhold pembrolizumab.  
!
Systemic corticosteroids may be indicated. 
!
Consider biopsy for confirmation of diagnosis.
!
If pembrolizumab held and corticosteroid required, manage as per Grade 3 below.
Grade 3 events:
!
Hold pembrolizumab
!
Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equivalent 
once per day.  
!
When symptoms improve to Grade 1 or less, steroid taper should be started and 
continued over no less than 4 weeks.  
!
Permanently discontinue for inability to reduce corticosteroid dose to 10 mg or less of 
prednisone or equivalent per day within 12 weeks. Otherwise, pembrolizumab 
treatment may be restarted and the dose modified as specified in the protocol
Grade 4 events:
!
Treat with systemic corticosteroids at a dose of 1 to 2 mg/kg prednisone or equivalent 
once per day.  
!
Discontinue pembrolizumab
NOTE:  Any event that meets the criteria for SERIOUS adverse event (SAE), must be reported 
to the Celgene Drug Safety within 24 hours by facsimile, or other appropriate method, using the 
SAE Report Form, or approved equivalent form as outlined in Section 11.5.
19.3.11.
Infusion Reactions
Signs and symptoms usually develop during or shortly after drug infusion and generally resolve 
completely within 24 hours of completion of infusion.
The following AE terms, regardless of grade, are considered ECIs and should be reported to the 
Sponsor on the Adverse Event CRF within 5 days if determined to be a non-serious event:
!
Allergic reaction
!
Anaphylaxis
!
Cytokine release syndrome
&(/*(1(35235,(7$5<,1)250$7,21
r G
r Grade 3 b
rade 3
2 mg/kg pr
2 mg/kg pr
steroid tap
teroid ta
o reduce c
o reduce 
ith
i in 12 we
in 12 we
he dose mo
he dose mo
ticosteroids
costeroid
mbrolizuma
brolizum
meets the c
meets the
Safet
Safety y wi
with
i
m, or approv
m, or approv
nfusion Re
nfusion R
nd symptom
nd symptom
pletely wi
letely withti
he fo
he follo
llowin
wi
Sponsor
Sponsor


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
116
CC-486-NSCL-001 Final: 15 May 2015
!
Serum sickness
!
Infusion reactions
!
Infusion-like reactions
Please note, the AE should be reported regardless of etiology.
Course of Action
Table 12 shows treatment guidelines for subjects who experience an infusion reaction associated 
with the administration of pembrolizumab.
Table 12:
Infusion Reactions
NCI CTCAE Grade
Treatment
Premedication at 
Subsequent Dosing
Grade 1
Mild reaction; infusion 
interruption not indicated; 
intervention not indicated
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the Investigator.
None
Grade 2
Requires infusion 
interruption but responds 
promptly to symptomatic 
treatment (eg, 
antihistamines, NSAIDS, 
narcotics, IV fluids); 
prophylactic medications 
indicated for ≤24 hrs
Stop Infusion.
Additional appropriate medical therapy may 
include but is not limited to:
! IV fluids
! Antihistamines
! NSAIDS
! Acetaminophen
! Narcotics
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the Investigator.
If symptoms resolve within one hour of 
stopping drug infusion, the infusion may be 
restarted at 50% of the original infusion rate 
(eg, from 100 mL/hr to 50 mL/hr).  Otherwise 
dosing will be held until symptoms resolve and 
the subject should be premedicated for the next 
scheduled dose.
Subjects who develop Grade 2 toxicity 
despite adequate premedication should be 
permanently discontinued from further trial 
treatment administration.
Subject may be 
premedicated 1.5 hrs.
(± 30 minutes) prior to 
infusion of 
pembrolizumab with:
Diphenhydramine 50 mg 
p.o. (or equivalent dose of 
antihistamine).
Acetaminophen 500-1000 
mg p.o. (or equivalent 
dose of antipyretic).
&(/*(1(35235,(7$5<,1)250$7,21
d d 
dication at
dication at
equent Dos
equent Dos
0
e
25
,1
y may
y may
toring of vit
toring of 
ntil the
til the subje
bj
the opinion
he opinion
mptoms reso
mptoms reso
opping drug 
opping drug
restarted at 
started a
(eg, from
fr
dosin
dos
the
the
Sub
Su
,1
,1
,1
(/
1(
,1


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
117
CC-486-NSCL-001 Final: 15 May 2015
Table 12:
Infusion Reactions (Continued)
NCI CTCAE Grade
Treatment
Premedication at 
Subsequent Dosing
Grades 3 or 4
Grade 3:
Prolonged (i.e., not rapidly 
responsive to symptomatic 
medication and/or brief 
interruption of infusion); 
recurrence of symptoms 
following initial 
improvement; 
hospitalization indicated 
for other clinical sequelae 
(eg, renal impairment, 
pulmonary infiltrates)
Grade 4:
Life-threatening; pressor 
or ventilatory support 
indicated
Stop Infusion.
Additional appropriate medical therapy may 
include but is not limited to:
•
IV fluids
•
Antihistamines
•
NSAIDS
•
Acetaminophen
•
Narcotics
•
Oxygen
•
Pressors
•
Corticosteroids
•
Epinephrine
Increase monitoring of vital signs as medically 
indicated until the subject is deemed medically 
stable in the opinion of the Investigator.
Hospitalization may be indicated. Subject is 
permanently discontinued from further trial 
treatment administration.
No subsequent dosing
CTCAE = Common Terminology Criteria for Adverse Events;  hr = hour; IV = intravenous(ly); NCI = National 
Cancer Institute; NSAID = non-steroidal anti-inflammatory drug;  p.o. = oral(ly)
Appropriate resuscitation equipment should be available in the room and a physician readily available during the 
period of drug administration.
For Further information, please refer to CTCAE v4.0 at http://ctep.cancer.gov
19.3.12.
Follow-up to Resolution
Subjects should be followed to resolution. The Adverse Event CRF should be updated with 
information regarding duration and clinical course of the event. Information obtained from the 
consulting specialist, including diagnosis, should be recorded in the appropriate AE fields. 
Any treatments administered for the event should also be entered in the Concomitant Medication 
eCRF.
19.3.13.
References
Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, et al. Safety and Activity of Anti–PD-L1 
Antibody in Patients with Advanced Cancer.  N Engl J Med 2012; 366:2455-2465.
Bristol-Myers Squibb: YERVOY (ipilimumab): Serious and fatal immune-mediated adverse 
reactions—YERVOY Risk Evaluation and Mitigation Strategy (REMS). 
http://www.yervoy.com/hcp/rems.aspx
Bristol-Myers Squibb: YERVOY (ipilimumab) prescribing information revised March 2011. 
http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/125377s0000lbl.pdf
y y
all
a y 
bject is
bject is
further tri
urther tr
7$
,1
$7
vents; 
vents; hr = h
hr = 
matory drug
matory drug
ilable in the r
able in the r
AE v4.0
E v4.0 at ht
tion
tion
to resol
to resolut
l io
ration and c
ration an
ncluding di
ncluding d
ministered 
ministered 
Referenc
Referenc
mer JR, Ty
mer JR, Tyk
ibody
ibody i
y n P
n P
Bri
Br stolol-M
eacti
eactio


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
118
CC-486-NSCL-001 Final: 15 May 2015
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, et al. Improved Survival with 
Ipilimumab in Patients with Metastatic Melanoma. N Engl J Med 363:711-723, 2010.
Lemech C and Arkenau HT. Novel Treatments for Metastatic Cutaneous Melanoma and the 
Management of Emergent Toxicities. Clinical Medicine Insights: Oncology 2012:6 53–66.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.  Nature Reviews 
Cancer 2012; 12:252-264.
Phan GQ, Weber JS, and Sondak VK.  CTLA-4 Blockade with Monoclonal Antibodies in 
Patients with Metastatic Cancer: Surgical Issues. Annals of Surgical Oncology 15(11):3014–
3021.
Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, 
Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer. N Engl J Med 2012; 
366:2443-2454.
Weber J, Thompson JA, Hamid O, et al: A randomized, double-blind, placebo-controlled, phase 
II study comparing the tolerability and efficacy of ipilimumab administered with or without 
prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 
15:5591-5598, 2009.
Weber JS Practical Management of Immune-Related Adverse Events from Immune Checkpoint 
Protein Antibodies for the Oncologist. American Society of Clinical Oncology 2012; 1092-
9118/10/1-10.
Weber JS, Kahler KC, and Hauschild A. Management of Immune-Related Adverse Events and 
Kinetics of Response With Ipilimumab. J Clin Oncol 30. 2012. 
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2012.41.6750.
&(/*(1(35235,(7$5<,1)250$7,21
014–
al. Safety,
al. Safety,
Med 2012; 
Med 2012
plplacebo
acebo-con
c
nistered wit
stered wi
IV melano
V melano
erse Events
erse Event
y y of
of Clinic
Clini
f
ement of Im
ement of Im
n Oncol 30
n Oncol 30
O.2012.41
O.2012.41


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
119
CC-486-NSCL-001 Final: 15 May 2015
19.4.
Appendix D: Table of Abbreviations
Table 13:
Abbreviations and Specialist Terms
Abbreviation or 
Specialist Term
Explanation
AE
Adverse event
AIM
Azacitidine-induced immune
AJCC
American Joint Committee on Cancer
ALT
Alanine aminotransferase (SGPT)
ALK 
Anaplastic lymphoma kinase
AML
Acute myeloid leukemia
ANC
Absolute neutrophil count
aPTT
Activated partial thromboplastin time
ASCO
American Society of Clinical Oncology
AST
Aspartate aminotransferase (SGOT)
AUC
Area under the concentration-time curve
AZA
Azacitidine
β-hCG
Beta-subunit of human chorionic gonadotropin
BCG
Bacillus Calmette-Guerin
BLQ
Below the limit of quantitation
BSC
Best supportive care
BUN
Blood urea nitrogen
CBC
Complete blood count
CI
Confidence interval
CL/F
Apparent total body clearance
Cmax
Maximum plasma concentration of drug
CMMoL
Chronic myelomonocytic leukemia
CNS
Central nervous system
CR
Complete response
CRA
Clinical research associate
CRO
Contract research organization
CRF
Case report form
CSR
Clinical Study Report
CT
Computed tomography
F
&(
CRO
CR
&(/*(1(35235,(7$5<,1)250$7,21
$7
$7
$7
$7
0$
50
25
2
1)
,1
< ,
curve
urve
5<
$5
horionic gon
horionic gon
7$
uerin
rin
(7
of quantitati
of quantitati
5,(
tive care
ive car
35
urea nitrogen
a nitrogen
23
mplete bloo
mplete blo
52
Confidenc
Confidenc
35
(
Appar
Appar
( 3
1(
M
1(
1(
1(
(1
*(
/*
RA
(/
&(
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
120
CC-486-NSCL-001 Final: 15 May 2015
Table 13:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
CTCAE
Common Terminology Criteria for Adverse Events
DCR
Disease control rate
DIC
Disseminated Intravascular Coagulation
DILI
Drug-induced liver injury
DKA
Diabetic ketoacidosis
DLT
Dose-limiting toxicity
DNA
Deoxyribonucleic acid
DNMT1
DNA methyltransferase-1
DNMTi
DNA methyltransferase inhibitor
DMC
Data Monitoring Committee
EBUS
Endobronchial ultrasound
EC
Ethics Committee
ECI
Events of clinical interest
ECG
Electrocardiogram
ECOG
Eastern Cooperative Oncology Group
eCRF
Electronic case report form
EEA
European Economic Area
EGFR
Endothelial growth factor receptor
ESMO
European Society for Medical Oncology
EOT
End of treatment
EU
European Union
FFPE
Formalin fixed paraffin embedded
FAB
French American British
FDA
Food and Drug Administration
GCP
Good Clinical Practice
G-CSF
Granulocyte colony-stimulating factor
GM-CSF
Granulocyte macrophage colony-stimulating factor
GI
Gastrointestinal
GITR
Glucocorticoid-induced tumor necrosis factor receptor
HBV
Hepatitis B virus
&(
GM
GM
&(/*(1(3
Europe
Europ
35235,(7$5<,1)250$7,21
7
$7
$7
$7
$
0
5
2
)2
1
< ,
5<
$5
7$
Oncology G
ncology G
(7
eport form
port form
5,(
onomic Are
nomic Ar
35
ialal growth 
owth
23
opean Socie
pean Socie
52
End of trea
End of trea
35
3
(
Fo
Fo
(
1(
(1
*(
/*
CSF
SF
(/
-CSF
CSF
&(
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
121
CC-486-NSCL-001 Final: 15 May 2015
Table 13:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
HBcAb
Hepatitis B core antibody
HBeAb
Hepatitis B e antibody
HBeAg
Hepatitis B e antigen
HBsAg
Hepatitis B surface antigen
HBsAb
Hepatitis B surface antibody
HCl
Hydrochloride
HCV
Hepatitis C virus
HCVAb
Hepatitis C virus antibody
HDAC
Histone deacetylase
HIV
Human immunodeficiency virus
HR
Hazard ratio
HUS
Haemolytic Uraemic Syndrome
ICF
Informed consent form
IB
Investigator’s Brochure
ICH
International Conference on Harmonisation
iDMC
Independent Data Monitoring Committee
IDO
Indoleamine 2,3-dioxygenase
ILD
Interstitial lung disease
IND
Investigational New Drug
INR
International normalized ratio
IP
Investigational Product
IRB
Institutional Review Board
irAEs
Immune-related adverse events
irDCR
Immune-related disease control rate
irPFS
Immune-related progression-free survival
irRC
Immune-related response criteria
irRECIST
Immune-related Response Evaluation Criteria in Solid Tumors
irORR
Immune-related overall response rate
IRT
Interactive response technology
ITT
Intent-to-treat
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$7
0$
50
25
)2
1)
,1
5<
$5
7$
ce on Harm
e on Harm
(7
Monit
onitoring 
oring 
,(
,3,3-dioxygen
dioxyg
5
l lung disea
lung dise
23
tigational N
tigational N
2
nternational
nternatio
5
Investig
vest
3
(
Inst
Ins
(
1(
1(
1(
1(
(1
*(
/*
rRECIST
rRECIST
&(
ORR
ORR
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
122
CC-486-NSCL-001 Final: 15 May 2015
Table 13:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
ITP
Idiopathic (or immune) Thrombocytopenia Purpura
IV
Intravenous
LDH
Lactate dehydrogenase
LFT
Liver function test
mAb
Monoclonal antibody
MDS
Myelodysplastic syndrome
MM
Multiple myeloma
MedDRA
Medical Dictionary for Regulatory Activities
MRI
Magnetic resonance imaging
MTD
Maximum tolerated dose
NCCN
National Comprehensive Cancer Network
NCI
National Cancer Institute
NSCLC
Non-small cell lung cancer
NYHA
New York Heart Association
ORR
Overall response rate
OS
Overall survival
PD
Pharmacodynamics
PD
Progressive disease
PD-1
Programmed cell death protein-1
PD-L1
Programmed death-ligand 1
PE
Physical examination
PFS
Progression-free survival
PK
Pharmacokinetics
PR
Partial response
PT
Prothrombin time
PTT
Partial thromboplastin time
QD
Once daily
RBC
Red blood cell count
RCC
Renal cell carcinoma
RECIST
Response Evaluation Criteria in Solid Tumors
&
BC
BC
&(
QD
QD
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$7
0$
50
25
)2
1)
k
,1
5<
$5
n
7$
(7
,(
amics
amics
5
ve disease
ve disease
23
rammed cell
ammed cel
2
Programmed
Programm
5
Physical
ysic
3
(
Prog
Pro
(
1(
1(
1(
1(
(1
*(
/*
&(
&


('06'RF1XPEHU
CC-486
Protocol CC-486-NSCL-001
Celgene Corporation
Confidential and Proprietary
123
CC-486-NSCL-001 Final: 15 May 2015
Table 13:
Abbreviations and Specialist Terms (Continued)
Abbreviation or 
Specialist Term
Explanation
RNA
Ribonucleic acid
SAE
Serious adverse event
SAP
Statistical analysis plan
SC
Steering Committee
SC
Subcutaneous
SD
Stable disease
SGOT
Serum glutamic oxaloacetic transaminase 
SGPT
Serum glutamic pyruvic transaminase
SOP
Standard operating procedure
SUSAR
Suspected unexpected serious adverse reaction
TEAE
Treatment-emergent adverse event
T1DM
Type 1 diabetes mellitus
T2DM
Type 2 diabetes mellitus
TKI
Tyrosine kinase inhibitor
TIL
Tumor-infiltrating lymphocyte
Tmax
Time to maximum concentration
TTP
Thrombotic Thrombocytopenic Purpura
t1/2
Terminal half-life
ULN
Upper limit of normal
US
United States 
Vz/F
Apparent volume of distribution
WBC
White blood cell count
WHO
World Health Organization
&(/*(1(35235,(7$5<,1)250$7,21
7
$7
$7
$7
$
0
5
2
)2
ion
ion
1
< ,
5<
$5
7$
mphocyte
mphocyte
(7
m concentra
m concentr
5,(
Thrombocyt
hrombocy
35
 half
a -f life
life
23
per limit of n
er limit of n
52
United Stat
United Sta
35
Appare
Appar
3
(
W
(
1(
(1
*(1


('06'RF1XPEHU
Celgene Signing Page
This is a representation of an electronic record that was signed electronically in Livelink.
This page is the manifestation of the electronic signature(s) used in compliance with
the organizations electronic signature policies and procedures.
8VHU1DPH

7LWOH

'DWH)ULGD\0D\30(DVWHUQ'D\OLJKW7LPH
0HDQLQJ$SSURYHGQRFKDQJHVQHFHVVDU\
                                                
&(/*(1(35235,(7$5<,1)250$7,21